# PHIL > PHIL is a digital hub and direct-to-patient platform for pharmaceutical brands. It connects patients, prescribers, and pharmacies in one workflow so people can start and stay on prescribed therapy, and so brands can improve coverage, adherence, and commercial performance. PHIL, Inc. is a healthcare technology company headquartered in Scottsdale, Arizona. It provides digital access, direct-to-patient services, an integrated pharmacy network, prior authorization, financial assistance, and data solutions for retail and specialty-lite pharmaceutical brands in the United States. This file contains the text of every indexable page on phil.us, generated from the production build. For a curated overview with key links, see https://phil.us/llms.txt. --- # PHIL — Medication Access, Simplified. Source: https://phil.us/ ## The Simple Path to Affordable Medication Access PHIL is the digital hub and direct-to-patient platform that helps pharma brands maximize starts, coverage, adherence, and commercial performance. For Pharma Improve patient outcomes and commercial performance for your retail and specialty-lite brands Brand Experience → For Patients Get affordable medications delivered right to your door with PHILRx Patient Experience → For Providers Improve patient care with in-workflow prescribing and PA tools through PHILRx Provider Experience → Helping Pharma Brands Grow 2X+ Patient Starts vs. Traditional Channels 2X+ Covered Dispenses vs. Traditional Channels 3X+ Refill Adherence vs. Traditional Channels 4.9/5.0 Patient Satisfaction Score Trustpilot ### Maximize Patient Outcomes and Commercial Performance We help retail and specialty-lite brands break through access barriers to improve commercial performance. Our end-to-end digital hub and direct-to-patient platform delivers strong results through human-first care, innovative technology, and AI-supported outcomes. PHIL is helping pharma lead the way: Digital Access PA & Coverage Dispense Network Data & Insights PHILRx Today at 12pm Hi Sarah! Dr. Jones sent your Adaptrex® prescription to the PHILRx pharmacy. Tap below to get started. Enroll in minutes Fast, free shipping Easy refills Confirm & enroll Digital Access #### Seamless Digital Experience & Direct-to-Patient Services Engage patients at every touchpoint with a branded, end-to-end medication access experience. From intake to routing to dispensing, PHIL helps pharma brands build a digital front door that drives patient starts, adherence, and satisfaction. 2x+ Patient Starts 3x+ Refill Adherence 4.9/5.0 Patient Satisfaction PA Portal PatientSarah Smith PrescriberDr. Jones, MD DrugAdaptrex 150 MG Insurance information Plan NameBlue Shield Group NumberB456852VCE Submit PA Script quality checks Proactive updates 1-click PA submissions PA & Coverage #### Superior Prior Authorization & Coverage Outcomes Improve affordability with an advanced prior authorization process and built-in coverage workflows to help reduce out-of-pocket costs for patients. We bring copay support, financial assistance, and flexible access pathways together in one seamless experience. 90%+ PA Submission Rate 2x+ Covered Dispenses It's time for your next fill Your prescription is ready to refill. Confirm Manage Your Rx is on the way! Arrives June 30 · Free delivery ShippedIn transitDelivered Dispense Network #### Integrated Dispense Network & Wholesale Deliver medications quickly through our nationwide pharmacy network with commercial and cash dispense capabilities. Our integrated dispense network offers fast fulfillment with free shipping, refill reminders, and a seamless delivery experience. 50-state Dispense Network 99%+ Plan Coverage Program Data Dashboard NRx volume 116k 48% Enrollment 92% 22pt Pull-thru rate 74% 18pt Patient journey+32% Enrollment funnel Eligible100% Enrolled92% Dispensed86% Refilled77% Adherence over time Payer behavior+18pt Plan mix Commercial Medicare Medicaid PA approval rate Program performance+2.1x GTN lift vs. baseline Program optimization Time to fill−42% Abandonment−36% Data & Insights #### End-to-End Technology, Data & Insights Build a lasting commercial advantage with a unified access platform. PHIL's advanced data capabilities, AI-powered workflows, and dedicated Client Insights team work seamlessly to surface opportunities to improve patient outcomes and brand performance. 3x+ GTN Lift 360° Program Insights AI Powered Workflows Explore Our Solution → ### A Trusted Partner to Pharma, Patients, and Providers We're on a mission to simplify medication access for all. We're proud to have industry-leading satisfaction scores that reflect our commitment to delivering a superior experience across the board. What Pharma Says “Phil is very strong in driving starts and adherence across our portfolio. As a partner, we love their willingness to be agile and create new things with us that haven’t been done before.” SVP Market Access, PHIL Client What Patients Say “The staff at PHIL are very customer-oriented, staying connected and providing guidance throughout the whole prescription process. They are knowledgeable and friendly. The experience was pleasant!” Ryan S., Patient What Providers Say “PHILRx is very helpful with getting my patients their medications quickly.” Jeffrey T., Healthcare provider Explore Customer Stories → ### Our Commitment to Your Success We're advancing medication access for patients, providers, and pharma brands through innovative technology and dedicated partnership. Explore our latest news and insights to help move your brand forward. Featured Report #### Patient Perspectives on Direct-to-Patient: Improving Access and Adherence Read report Featured Report #### HCP Perspectives on Direct-to-Patient: Engaging Providers in the Digital Era Read report Featured Report #### 5 Key Success Factors to Drive Brand Excellence Read report Explore Resources → Ready to simplify medication access? ### Accelerate Access, Affordability, and Adherence Discover how PHIL can help your brands maximize patient outcomes and commercial performance. Book Demo --- # Digital Hub | PHIL Source: https://phil.us/solution/hub/ PHIL Digital Hub ## An End-to-End Access Solution that Maximizes Commercial Success PHIL combines a technology-driven hub, integrated dispense network, and end-to-end data capabilities into one powerful platform, helping pharma brands maximize patient outcomes and commercial performance. Book Demo PHILRx ##### My prescriptions Transparent Cost Fast Shipping Easy Management Get started 99%+Plan Coverage NRx 24,815 156%+ PHIL AI InsightsOptimization Opportunity "What's driving the lift in NRx?" ### Where Brands Win with PHIL PHIL offers 10+ years experience building technology-driven access programs for branded retail and specialty-lite therapies. 2x+ Patient Starts vs. Traditional Channels 2x+ Covered Dispenses vs. Traditional Channels 3x+ Refill Adherence vs. Traditional Channels 3x+ Gross-to-Net vs. Traditional Channels 4.9/5.0 Patient Satisfaction Score Trustpilot ### Advance Patient Outcomes and Brand Performance with a Flexible Digital Hub Solution Traditional access solutions address only part of the problem. PHIL Digital Hub delivers an end-to-end access platform designed to maximize patient outcomes and optimize gross-to-net performance in retail and specialty-lite. We build flexible access programs that evolve with your brand, bringing together human-first care and AI-driven outcomes into one powerful solution. #### Direct-to-Patient & Program Flexibility Experience total flexibility to build coverage, cash-pay, or hybrid models. With custom program design and AI-driven workflows, expand your brand’s reach with our integrated Direct-to-Patient platform that seamlessly connects your brand assets into a hub, expanding intake, routing, and dispense options. #### Advanced Digital Hub & PA Process Maximize covered dispenses with PHIL’s digital hub and proprietary PA process. We help verify coverage needs and provide support for easy prior authorization submission, with a simple prescribing process that keeps HCPs in their existing workflows and provides timely updates, education, and support to drive ongoing engagement. #### Pharmacy Network & Fulfillment Leverage our nationwide dispense network with 99%+ plan coverage, streamlined wholesale distribution, and PHIL’s in-house cash pharmacy services. Our fully managed pharmacy network enables greater patient reach, transparent pricing with free shipping, and an optimal dispense experience for patients and brands. #### End-to-End Data & Insights Drive brand performance by connecting data from first touch through intake, fulfillment, and adherence. Leverage our AI-powered dashboards to surface commercial opportunities and reduce access friction, and partner with our dedicated PHIL Client Insights team to translate in-depth performance data into strategic program optimizations. Explore PHIL Direct ### A Frictionless Path From Prescription to Fulfillment PHIL Digital Hub is configured around your brand's unique patient population, payer landscape, and program goals. Work with our team to define the intake channels, pharmacy network, support model, and program economics that fit your strategy, and optimize as your program scales. STEP 1 #### Versatile Intake Seamless HCP workflow within existing EMRs, telemedicine intake, or prescription transfer requests. *Adaptrex is a fictional product used for illustrative purposes only. PHILRxRx at your fingertips ##### Telehealth Direct Dr. Dhanang Prast Telehealth 06:11 Send e-Prescription PHARMACY PhilRx Send eRx PHILRxRx at your fingertips Hi Sarah! Dr. Jones sent your Adaptrex prescription to the PHILRx pharmacy. Tap below to get started. ✓ Enroll in minutes ✓ Fast, free shipping ✓ Easy refills Confirm & Enroll Flexible Routing & Coverage Options Build patient access paths based on patient and brand needs. InsuredCovered, PA/Appeals, Copay Programs Self-PayCash program Other Non-CommercialPAP, Bridge, Quick start Get Started PHILRxRx at your fingertips We found your best price on Adaptrex! Purchase a 30 Day Supply for $25 79% OFF Your total cost$25.00 Next Manage Prescription 50-States&99%+ Plan Coverage PPHIL Distribution Centers PHIL Cash Pharmacies PHIL Pharmacy Partner Network PHILRxRx at your fingertips My prescriptions Adaptrex 3 refills remaining Choose your preferred delivery option Home Delivery Manage Prescription PHILRxRx at your fingertips My prescriptions Adaptrex 2 refills remaining Your next refill is scheduled. Please confirm below. Confirm Next Refill Manage Prescription Scroll to Learn More 1Versatile Intake 2Fast Enrollment 3Flexible Access Paths 4Transparent Cost 5Nationwide Pharmacy Reach 6Fast, Trackable Fulfillment 7Seamless Refill Management *Adaptrex is a fictional product used for illustrative purposes only. Continue to Next Section ### Turn End-to-End Program Visibility into Stronger Patient Outcomes and Brand Performance Gain end-to-end visibility into the entire prescription journey, with AI-powered data capabilities that uncover improvement opportunities across patient engagement, market access, and payer dynamics. PHIL’s Client Insights Team serves as your dedicated strategic partner, delivering targeted recommendations to continually optimize brand performance. Gain AI-Powered Insights Elevate Field & HCP Performance Optimize Script Quality Access End-to-End Visibility Select or Swipe to Explore Data and Insights Territory / Provider Weekly NRx Enrollment PA Approvals Refill Rate PA Submissions Atlanta West, GA 97 87% 90% 84% 90% Dr. Lauren Murray 150 93% 93% 96% 98% Dr. Paul Brenner 62 86% 89% 68% 75% Dr. Kim Marshall 78 83% 88% 88% 97% Above 85% 70–85% Below 70% PHIL AI InsightsOptimization Opportunity Atlanta West, GA is up 134% in NRx this quarter, but 3 high-volume prescribers haven’t enrolled a patient in 30+ days. #### Elevate Field Performance and HCP Engagement PHIL’s integrated portal provides territory-level visibility into script quality, enrollment, and prescriber engagement, helping field teams identify success drivers and accelerate patient access. Territory % Missing Script Info % Missing ICD-10 % Missing Sig Hartford West, CT 2% 1% 1% West Palm, FL 10% 6% 4% Atlanta West, GA 8% 3% 5% Irvine, CA 1% 0% 1% Oklahoma, OK 5% 2% 3% Below 3% 3–5% Above 5% PHIL AI InsightsOptimization Opportunity Missing script information has gone down 13% in the last 30 days. #### Optimize Script Quality PHIL monitors incoming scripts with AI-driven quality checks to identify missing payer-required details and gives field teams insight into coverage gaps, while ensuring complete and accurate information maximizes support for payer-covered access to therapy. Insight Understand intake channel impactView intake conversion Intake Patient Appointment Prescription Generation Insight Analyze provider adoption Prior Authorization Insight Track payer responses Insight Get visibility into program utilization Affordable Pathways Shipping & Dispensing Refills Insight Spot patient drop-off points - Intake Insight Understand intake channel impact - Patient Appointment - Prescription Generation Insight Analyze provider adoption - Insight Track payer responses Prior Authorization - Affordable Pathways Insight Get visibility into program utilization - Insight Spot patient drop-off points Shipping & Dispensing - Refills PHIL AI InsightsOptimization Opportunity Refill adherence is up 32% over the last 60 days. #### Support the Entire Patient Journey with End-to-End Visibility PHIL captures the full script journey in one unified data stream, from intake through delivery, and adherence, giving brands clear visibility to optimize performance at every step. NRx 24,815 156%+ Patient Starts94%88% PA Submissions87%67% Covered Dispenses92%34% Refill Adherence84%19% PHIL AI InsightsOptimization Opportunity "What's driving the lift in NRx?" #### Gain AI-Driven Insights into Brand Performance PHIL's program dashboards give you end-to-end insights into your brand's performance, with a built-in agent that surfaces actionable program insights in real time. ### Your Partner in Patient Support and Provider Engagement We believe the best experience occurs when dedicated human-first engagement and intelligent technology work together to deliver better, faster care. #### Patient Support Team Provides hands-on assistance throughout the entire medication access journey, offering live support via phone and email to help patients navigate coverage options, address questions, and stay informed about their prescriptions, improving patient education, trust, and satisfaction. #### HCP Engagement Team Supports healthcare providers by simplifying the prescription process through proactive outreach, tailored communication, and clear education on program workflows, reducing administrative burden and strengthening office relationships by meeting each provider's unique needs. #### What PHIL Patients & Providers Say Patient Review “I wasn’t able to afford a medication that helped me. My doctor found it through PHILRx, and I could continually purchase 3 months of this prescription at a time to receive a HUGE discount. It changed my life.” Carla R., PHIL Patient Provider Review “PHILRx provides great support for patients, and convenient ways for providers to reach out.” Elizabeth R., Healthcare Provider Patient Review “I felt that my needs were being considered from the very beginning. That was so refreshing to me because it was out of the ordinary for a company to express such consideration, especially for a new customer like myself!” Dawn M., PHIL Patient Trustpilot ### Calculate your GTN Performance Potential with PHIL The calculator was built by PHIL's Commercial Insights architects to translate our sophisticated GTN modeling to provide a clear view into a brand's GTN potential. Calculate Your Potential New Scripts 1,240/ mo Covered Dispenses 2x+ PA Submission 90%+ GTN Lift 3x+ ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. Book Demo --- # Direct-to-Patient | PHIL Source: https://phil.us/solution/direct/ PHIL Direct-to-Patient ## Create a Seamless Access Experience with a Proven Direct-to-Patient Solution PHIL Direct delivers a future-ready, ecommerce-like Direct-to-Patient experience, combining intake, fulfillment, and analytics into one flexible solution that grows with your brand, boosts performance, and expands affordable access to medications with coverage, cash-pay, and hybrid programs. Book Demo Out for delivery Arrives today by 5 PM OrderedShippedDelivered 30-day supply In stock · ships free $25$11979% OFF Free shipping Affordable cost Secure Checkout You saved $94 on this prescription ### Our Proven Approach to DTP Success Thought Leadership Compliance-By-Design: The Critical Layer for Pharma’s Direct-to-Patient Play Read feature Press Release Tenpoint and PHIL have partnered on a DTP program to improve access, reduce costs, and boost long-term adherence. Read announcement Thought Leadership How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences Read feature Case Study Designing a Transformative Direct-to-Patient Program to Drive Brand Growth Read case study Thought Leadership ##### Why Direct-to-Patient Is Becoming Pharma’s New Standard Read feature Press Release PHIL and Sprout Pharmaceuticals Expand Their Affordable Direct-to-Patient Access Program Read announcement Fierce Pharma Patient Perspectives on Direct-to-Patient: Improving Access and Adherence Read feature Press Release PHIL Invests in State-of-the-Art Cash Dispense Capabilities Read announcement Featured Report What HCPs Want from Pharma's Digital Access Channels Read report 1 #### Seamless Digital Access Deliver one seamless experience for prescribing, coverage, payment, and fulfillment that meets patients where they are, without handoffs or friction. 2 #### Transparent Affordability Lead with transparent pricing that makes out-of-pocket costs clear, reducing financial uncertainty so patients can start and stay on therapy. 3 #### Clear Path to Adherence Design the access experience to drive sustained adherence by combining convenient access with cost clarity and flexible refill management. ##### Explore our full library of DTP resources. Explore All Resources ### Enable Every Path to Your Patient with a Fully Customizable Solution PHIL Direct delivers a flexible Direct-to-Patient experience that meets patients where they are, with a seamless and affordable path to therapy. Our custom program design supports branded and white-labeled experiences with hybrid, cash-pay and coverage models. Design Your DTP Program with PHIL Direct Telemed DTP In-Office DTP Patient Request Patient Journey #### Advertisement Click Enable an immediate start to the patient journey the moment they click, transforming interest into action instantly while capturing data from first touch through dispense. Explore PHIL Digital Hub → 1Advertisement Click Instagram Your Story Emmanuelle Rogers.Sm Kevin_John AdaptrexSponsored ###### Take control of your health today Get the treatment you need 100 Likes Expands digital intake while capturing data to track patient journeys from first click through dispense. 2Brand Website Adaptrex ###### Learn if Adaptrex may be right for you Enjoy savings, pay as low as $0 FDA approved treatment Quick online consultation Private & confidential Start your online visit Delivers a consistent, on-brand experience while strengthening engagement and improving conversion. 3Telemedicine Appointment PHILRx Telemedicine Questionnaire Let's see if Adaptrex is right for you Date of Birth MM DD YYYY Weight Enter weight lbs Have you tried any of the following medications? Select all that apply Have you been diagnosed with any of the following? Select all that apply Submit interest form Creates a seamless, integrated care experience from consultation to prescription. 4Into PHIL’s Platform PHILRxRx at your fingertips Hi Sarah! Dr. Jones sent your Adaptrex prescription to the PHILRx pharmacy. Tap below to get started. ✓ Enroll in minutes ✓ Fast, free shipping ✓ Easy refills Confirm & enroll Extends the brand experience with an optional white-labeled program that feels fully integrated, even as patients move from the manufacturer site through PHIL. Example Paths 1Advertisement Click 2Brand Website 3Telemedicine Appointment 4Into PHIL’s Platform *Adaptrex is a fictional product used for illustrative purposes only. Patient Journey #### In-Office Visit Keep patients supported across varied entry points by enabling in-office visits where providers can diagnose, select therapy, and initiate a fully supported treatment journey. Explore PHIL Digital Hub → 1In-Office Visit Starting the patient journey with an in person visit to their local healthcare provider where the doctor determines a specific therapy is required. 2HCP e-prescription EHR Sarah Mitchell AllergiesNone on file New PrescriptionAdaptrex Send e-Prescription PHARMACY Manufacturer RX Send eRx Delivers a consistent, on-brand experience while strengthening engagement and improving conversion. 3Patient Digital Enrollment PHILRxRx at your fingertips Hi Sarah! Dr. Jones sent your Adaptrex prescription to the Manufacturer Rx pharmacy. Tap below to get started. ✓ Enroll in minutes ✓ Fast, free shipping ✓ Easy refills Confirm & enroll Extends the brand experience with an optional white-labeled program that feels fully integrated, even as patients move from the manufacturer site through PHIL. 4And into PHIL’s Platform PHILRxRx at your fingertips We found your best price on Adaptrex! 30 Day Supply with Copay Offer for $25 79% OFF 30 Day Supply with Cash Price for $50 58% OFF Next Manage prescription Creates a seamless, integrated care experience from consultation to prescription. Example Paths 1In-Office Visit 2HCP e-prescription 3Patient Digital Enrollment 4Payment and Dispense *Adaptrex is a fictional product used for illustrative purposes only. Patient Journey #### Branded Direct Intake Empower patients to take action directly from the brand website, whether initiating a prescription request with their doctor or transferring an existing script into PHIL, creating a connected, seamless path to access. Explore PHIL Digital Hub → 1Branded Direct Intake Adaptrex ###### Begin your path to Adaptrex Enjoy savings, pay as low as $0 Private & confidential Interest request shared directly to your doctor Request an Rx Transfer a script Expands digital intake while capturing data to track patient journeys from first click through dispense. 2Patient Digital Enrollment PHILRxRx at your fingertips Hi Sarah! Dr. Jones sent your Adaptrex prescription to the PHILRx pharmacy. Tap below to get started. ✓ Enroll in minutes ✓ Fast, free shipping ✓ Easy refills Confirm & enroll Creates a seamless, integrated care experience from consultation to prescription. 3PA & Affordability Optimization PHILRxRx at your fingertips We found your best price on Adaptrex! 30 Day Supply with Insurance Copay for $125 5% OFF 30 Day Supply with Cash Price for $50 58% OFF Next Manage prescription Extends the brand experience with an optional white-labeled program that feels fully integrated, even as patients move from the manufacturer site through PHIL. Example Paths 1Branded Direct Intake 2Patient Digital Enrollment 3PA & Affordability Optimization *Adaptrex is a fictional product used for illustrative purposes only. ### Transform Full-Funnel Visibility Into Measurable Commercial Impact PHIL gives manufacturers real-time, end-to-end visibility across the prescription journey, from first engagement through fulfillment and adherence. Brands can see which channels drive patients to initiate care, monitor appointment completion, and link new prescriptions back to their originating source. This unified foundation enables proactive identification of friction points, continuous optimization, and tighter alignment between commercial strategy and outcomes. #### Full-Funnel Program Insights Explore End-to-End Journey Data Access Key Metrics Leverage AI Insights PHIL AI Insights Optimization Opportunity Speed to First Fill rate increased 28% after implementing the new bridge program. PHIL's AI-powered program dashboard leverages a built-in agent that helps surface actionable program insights across the patient's journey. ##### Follow the Patient Journey + Access Data to Identify Patient Clicks Doctor Appts Prescriptions Covered Dispenses Refills - Drop-off points - Friction areas - Affordability impact - Adherence trends Access Full End-to-End Data Insights ### What Patients and Providers Want From Pharma's DTP Programs PHIL conducted first-party research with over 1,000 U.S. patients and 200+ healthcare providers to better understand what’s driving medication access, abandonment, and adherence, revealing key insights for designing more effective DTP programs. Patient Research #### What Pharma Needs to Know About Today's Patients PHIL surveyed 1,049 U.S. patients. The findings highlight the most pressing needs, challenges, and preferences of today's patients, and what the next generation of DTP programs must deliver. Read Report Key Findings From Patients 32% of patients want a fully online or hybrid medication access experience 65% would use DTP programs if they offer the lowest medication cost 95% of patients want DTP programs to mirror ecommerce experiences 1 in 3 patients won't pursue a medication they're interested in if they can't go through their preferred access experience Provider Research #### What HCPs Think About Pharma's Direct-to-Patient Programs New research from PHIL uncovers what healthcare providers need from pharma's digital access and direct-to-patient programs, and what pharma can do to improve patient outcomes. Read Report ### Discover the DTP Possibilities with PHIL Direct Maximize patient access, affordability, and adherence while safeguarding commercial performance with PHIL Direct. ### Direct-to-Patient Success, Solved Take a tour of the PHIL Direct platform today and discover how our team of experts can build a tailored DTP program that maximizes access, affordability, and adherence for your patients. Book Demo --- # Our Approach & Outcomes | PHIL Source: https://phil.us/approach/ Our Approach & Outcomes ## Commercial Success Across Your Portfolio Starts with Getting the Script Journey Right Every year, millions of patients abandon their branded prescriptions, not because a therapy doesn't exist, but because the path to getting it is too complex, too expensive, or too easy to give up on. PHIL's platform removes those barriers, driving measurable outcomes across access, affordability, and adherence. #### Access, Solved PHIL meets patients where they are, offering flexible intake through telehealth, in-person, or hybrid pathways, with SMS enrollment that gets patients onto therapy in minutes, not days. 1 in 3 patients won't pursue a medication if they can't access it through their preferred experience PHIL Research Report, 2026 → #### Affordability, Built In PHIL builds a tailored access path for every patient, automatically navigating insurance, copay programs, and cash-pay options to find the most affordable route to their medication. 96% of patients want to see their price before committing, including insurance and coupons PHIL Research Report, 2026 → #### Adherence, By Design PHIL promotes patient adherence with proactive refill reminders, live support, and a frictionless digital experience built around how patients actually want to engage. 70% of HCPs agree that issues in the PA process create an immediate hurdle to staying on therapy PHIL Research Report, 2026 → See Our Solution ### Keeping Patients Adherent from First Fill to Refill Retail and specialty-lite pharmaceutical brands face unique access barriers at every step of the prescription journey. From the moment a prescription is written to every refill that follows, patients face obstacles that can prevent starting and staying on therapy. We put human-first care at the heart of our platform, layering in compliance-first technology to break through these barriers and improve access, affordability, and adherence. Solution Overview 1 Provider Writes the Prescription 2 Digital Patient Enrollment & Onboarding 3 Benefits Verification & Prior Authorization 4 Patient Out-of-pocket Cost 5 Shipping & Distribution 6 Ongoing Refills 7 Program Optimization 01Step #### Provider Writes the Prescription What happens The treatment decision is made and the prescription is sent. Where it breaks Prescribers have no reliable way to know where to send a script, scripts can be routed to pharmacies not contracted within plan, and coverage is left on the table before the journey even starts. How PHIL helps PHIL is a single solution for pharmacy fulfillment, helping to connect each script to the right pharmacy, based on patient coverage and preference, across our 50-state network to help enable brand access to more covered dispenses compared to traditional channels. 02Step #### Digital Patient Enrollment & Onboarding What happens The patient is invited to join the brand's access program. Where it breaks Long enrollment forms, call-center waits, and app downloads create abandonment and many patients never complete this step. How PHIL helps App-free SMS enrollment and an eCommerce-like digital experience make joining frictionless, getting patients enrolled into the program and on their way to therapy in minutes. 03Step #### Benefits Verification & Prior Authorization What happens The prescription enters the insurance and Prior Authorization process. Where it breaks Prior Authorization requests get stuck in manual workflows, patients wait, and providers may not submit a Prior Authorization, resulting in delays to patient therapy access. How PHIL helps PHIL's electronic benefits verification and Prior Authorization process works within existing providers workflows, reducing delays and supporting timely script fulfillment. PHIL delivers 90%+ HCP PA submission rates across our programs. 04Step #### Patient Out-of-pocket Cost What happens The patient receives notification of their out-of-pocket medication cost. Where it breaks Sticker shock at out-of-pocket cost causes patients to abandon, especially when affordability programs are hard to find or apply. How PHIL helps PHIL builds flexible access programs that automatically identify each patient's lowest out-of-pocket cost. Our AI-driven copay workflows evaluate each patient's coverage in real time, applying the appropriate program to compliantly address access barriers, so patients receive an accurate and affordable cost. 05Step #### Shipping & Distribution What happens After the patient pays, they need to get the medication into their hands. Where it breaks Patients are often defaulted to retail pickup with little to no guidance. Missed pickups, long specialty pharmacy wait times, and confusing logistics cause many patients to never start therapy. How PHIL helps PHIL leverages 99%+ plan coverage across our 50-state contracted pharmacy network with free home delivery options combined with proactive shipment notifications, tracking, and flexible scheduling. 06Step #### Ongoing Refills What happens The patient manages their refills to stay on therapy long-term. Where it breaks Refill drop-off isn't just forgetfulness or lack of clinical need. Patients lack guidance, miss the value of staying on therapy, and fall off before the medication even has a chance to work. How PHIL helps Proactive refill reminders, flexible rescheduling, live patient support, and engagement tools to make staying on therapy easier. Delivering 3× higher refill adherence than traditional pharmacy channels. 07Step #### Program Optimization What happens The brand evaluates what's working and where to improve. Where it breaks Fragmented vendors and siloed data make it nearly impossible to see where patients dropped off, why, or whether there are appropriate solutions to support adherence. How PHIL helps Access 120+ real-time data points, with full data visibility across the prescription journey. Our AI-powered data dashboard continuously monitors program performance, automatically flagging where patients are dropping off and surfacing recommendations for your commercial team to take action. Brands that optimize programs with PHIL have seen meaningful improvements in patient access to drug therapies. ### Drive Measurable Brand Performance with PHIL #### One Platform, Every Path to the Patient Traditional access solutions only solve part of the problem. PHIL's purpose-built platform simplifies the script journey for patients and providers, maximizing covered dispenses, improving adherence, and driving commercial success for retail and specialty-lite brands. ##### Direct-to-Patient A fully integrated, eCommerce-like experience that streamlines intake, telemedicine, coverage, routing, and fulfillment, supporting the script journey from start to finish and maximizing program performance. ##### Digital Hub A technology-driven hub that streamlines medication access through proprietary prior authorization and benefits verification, enabling flexible navigation across both payer-covered and cash pathways to therapy. ##### Pharmacy Network A fully integrated dispense model across our PHIL pharmacies and 50-state partner network, with 99%+ plan coverage, enables seamless fulfillment and patient access to medications at the most affordable price. ##### Data & Insights AI-powered program intelligence continuously surfaces end-to-end script visibility and commercial optimization opportunities, with consultative, white-glove support from PHIL's Client Insights team. Flexible By Design Sample patient journey pathways Coverage PathCoverage Cash PathCash Hybrid PathHybrid #### Expanded Intake Paths - In-Person HCP Visits: Seamless integration into existing physician workflows. - Digital & Telemedicine: Expand your brand's reach by meeting patients online with a seamless, digital onboarding experience that integrates telemedicine appointments directly into the hub. - Rx Transfers: Effortless onboarding of existing prescriptions. #### Adjustable Routing & Coverage - Coverage-First Models: Focused on maximizing payer reimbursement. - Cash-Pay Programs: Streamlined, predictable cash pricing for immediate access. - Hybrid Models: Dynamic routing designed to optimize your Gross-to-Net. #### Scalable Dispensing - National Pharmacy Network: Deliver medications directly to patients' homes via a fully integrated, 50-state dispense network. - PHIL In-House Pharmacies: Provide a dedicated, predictable cash-pay program through our own specialized pharmacies. - Wholesale Services: Streamline and optimize product distribution with efficient, integrated wholesale fulfillment. Explore PHIL Digital Hub Explore PHIL Direct ### Trusted by the People Who Matter Most The best measure of whether a patient access program works isn't a metric on a dashboard, it's whether patients receive their medication, have a positive experience along the way, and whether providers feel confident guiding them through the program. Here's what they say about PHIL. #### Hear from Happy PHILRx Patients Trustpilot #### Feedback from Pharma, Patients, and Providers What pharma says “ “Phil is very strong in driving starts and adherence across our portfolio. As a partner, we love their willingness to be agile and create new things with us that hadn't necessarily been done before.” SVP, Market AccessPHIL Client What patients say “I wasn't able to afford a medication that helped me. My doctor found it through PHILRx, and I could continually purchase 3 months of this prescription at a time to receive a HUGE discount. It changed my life.” Carla R.PHIL Patient What providers say “PHILRx provides great support for patients, and convenient ways for providers to reach out.” Elizabeth R.Healthcare provider ### Organizations See Results with PHIL Case Study Continued engagement. Simple refill management. 3× more refills than retail. Neurology brand Learn how Case Study Less abandonment. More coverage. 4× covered dispenses where other channels fell short. Women's health brand Learn how Case Study Two minutes. Easy enrollment. 5× first fills per patient for the ophthalmology brand. Ophthalmology brand Learn how Case Study No PA bottlenecks. No provider frustration. 91% HCP PA submission rate from day one. Women's health DTP Learn how Explore Customer Stories Measure Your Impact ### Measure the Impact of Better Patient Access & Adherence See how covered dispenses, patient starts, and refill rates drive brand performance. Our calculator was built by PHIL's Commercial Insights team for retail and specialty-lite pharma teams. Calculate Your Potential Patient Starts 2×+ vs. baseline Covered Dispenses 2×+ vs. baseline Gross Revenue 3× vs. baseline Net Revenue 4.1× vs. baseline ### Access, Affordability, and Adherence. Delivered. See how PHIL's integrated platform can drive access, affordability, and adherence for your brand. Book Demo --- # Pharma | PHIL Source: https://phil.us/pharma/ For Pharma Manufacturers ## Secure Commercial Success in Retail and Specialty-Lite PHIL is the end-to-end access platform that helps retail and specialty-lite brands overcome access barriers, improve patient outcomes, and optimize commercial performance at every stage of the script journey. Our platform combines human-first care with thoughtful AI integration, turning enrollment into starts, starts into covered dispenses, and dispenses into long-term adherence. ### Unlock the Full Potential of Your Program 2×+ Patient Starts vs Traditional Channels 90%+ PA Submission Rates 2×+ Covered Dispenses vs Traditional Channels 3×+ Refill Adherence vs Traditional Channels 99%+ Plan Coverage · 50-State Network 4.9/5.0 Patient Satisfaction Score Trustpilot ### Enhance Performance Across Your Patient Access Strategy at Any Stage PHIL partners with pharma brands of all sizes, from top global biopharma companies to emerging biotech launches, across every stage of the product lifecycle. Supporting Pharma Brands Across Products and Therapeutic Areas In Outcomes and Impact #### Supporting Pharma Brands in Program Success Not every brand fits neatly into one box, and neither does PHIL. We custom-build every program around the specific needs of each brand, retail or specialty-lite, cash or coverage, single product or full portfolio. From scaling a flagship to navigating mid-cycle growth to managing loss of exclusivity, our platform flexes with your brand at every stage of the lifecycle. We build the right program, for the right patient, for your brand. #### To Improve Access, Affordability, and Adherence Across Different Products and Therapeutic Areas With over 10 years of digital hub experience across specialty and retail channels, we help pharmaceutical manufacturers navigate pharmacy benefit design and access pathways to drive transformative results, improving patient access, affordability, and adherence across a wide range of therapeutic areas. #### Deliver Measurable Commercial Impact PHIL helps pharma brands improve patient access to therapy from the moment a script is written. From delivering an exceptional patient experience to implementing custom business rules design, we bring together best-in-class care and technology-driven outcomes in one seamless platform. Brands on PHIL see improved script to fill rates and stronger patient adherence compared to traditional channels. Book DemoLearn About Our Approach & Outcomes → ### Deliver a Seamless Medication Access Experience for Patients and Providers PHIL's platform pairs an innovative digital hub with a Direct-to-Patient solution, giving brands the flexibility to design the program that fits their commercial strategy while driving economic success at every step. PHIL Digital Hub #### Achieve Commercial Success with a Flexible Digital Hub Solution With PHIL, every step of the prescription journey is supported. Our advanced prior authorization, benefits verification, and pharmacy routing process with AI-driven script checks to proactively resolve barriers, supports patients in a seamless and affordable path to therapy. Explore PHIL Digital Hub → PHIL Direct #### Create a Future-ready, Direct-to-Patient Experience with a Proven DTP Solution PHIL Direct connects intake, telemedicine, coverage routing, and fulfillment in one seamless DTP experience, helping brands drive patient starts, maximize affordability, and promote adherence beyond the first fill. Explore PHIL Direct → ### The Right Partner for Every Commercial Stakeholder Select your role to see the access challenges PHIL solves and how we drive measurable impact for your team. Brand & Commercial Leaders Market Access Leaders Trade & Channel Teams Patient Services & Hub Leaders Innovation & Digital Health For You #### Brand & Commercial Leaders The Problem ##### Traditional retail is eroding net revenue and limiting visibility into script outcomes. PHIL's Solve We optimize program performance by providing end-to-end visibility across the journey, delivering AI-enabled data insights that strengthen access and outcomes. Learn More For You #### Market Access Leaders The Problem ##### Fragmented access experience, payer restrictions and prior auth burdens can block patients from starting therapy. PHIL's Solve We give market access teams visibility across the access journey, reducing barriers to affordable therapy access, supporting patient starts, and connecting program activity to dispense outcomes. Learn More For You #### Trade & Channel Teams The Problem ##### Lack of end-to-end control in traditional retail channels is restricting the ability to optimize distribution and fulfillment. PHIL's Solve We optimize pharmacy routing and channel performance across all 50 states, helping connect every script to the fastest, most cost-effective path to the patient based on patient coverage and preference. Learn More For You #### Patient Services & Hub Leaders The Problem ##### Fragmented patient journey and affordability support create delays, drop-offs and a poor patient experience. PHIL's Solve We provide an integrated platform connecting every touchpoint, from affordability to fulfillment, in one seamless and top rated patient experience. Learn More For You #### Innovation & Digital Health Teams The Problem ##### Legacy access infrastructure can't keep pace with how patients and providers expect to engage with brands today. PHIL's Solve We help brands deliver on what's next through advanced technology and AI-powered workflows that provide the flexibility and scalability in a single, end-to-end channel. Learn More ### Improve Patient Outcomes and Provider Engagement While Driving Brand Performance “ What Patients Say “The staff at PHIL are very customer-oriented, staying connected and providing guidance throughout the whole prescription process. They are knowledgable and friendly. The experience was pleasant!” Ryan S., Patient Customer Stories #### Real brands. Real results. See how leading retail and specialty-lite brands are partnering with PHIL to drive measurable performance across patient access, affordability, and adherence. Read More What Providers Say “PHILRx is very helpful with getting my patients their medications quickly.” Jeffrey T., Healthcare provider Trustpilot Frequently Asked Questions ### Everything Pharma Teams Want to Know Talk to Our Team - Platform & Partnership - Patient & Provider Experience - Pharmacy Network - Impact & Outcomes What does PHIL do? PHIL is a medication access platform designed to improve patient outcomes and brand performance for retail and specialty-lite brands. Through PHIL Digital Hub, and PHIL Direct-to-Patient, our (DTP) solution, we enable seamless medication access via our integrated pharmacy network and our own PHIL cash pharmacies, delivering simple, affordable paths to therapy. What types of medications are best suited for the PHIL platform? Our platform is purpose-built to support branded retail and specialty-lite therapies, including medications that are self-administered, pharmacy benefit, controlled or non-controlled, and often require prior authorization and patient support services. Which therapeutic areas and launch stages do you support? Our platform successfully supports brands across many therapeutic areas and launch stages, working with brands from new launch through LOE. How are you different from traditional access channels (i.e. retail, specialty pharmacy, etc.)? PHIL is redefining medication access for branded retail and specialty-lite therapies. Traditional access channels rely on fragmented, legacy workflows that increase access barriers and leave patients facing high costs and long delays. PHIL replaces this outdated friction with a modern, technology-first platform. Designed with ultimate flexibility, our platform structures can be fully whitelabeled to align with your brand's unique footprint. By streamlining the entire prescription journey, we provide patients cost transparency, unlock real-time visibility for brands, and ensure patients can effortlessly access, afford, and stay on their prescribed therapies. Curious if your brand could benefit from partnering with PHIL? Contact us for a discovery call. What does your patient experience look like? PHIL provides a seamless, e-commerce-like medication access experience for patients. This includes timely updates, free home delivery, easy refill management, and a dedicated patient support team. We're proud to have an industry-leading patient satisfaction score of 4.9/5.0 on TrustPilot from 22,000+ reviews. Get in touch for a full tour of our patient experience and support services. What does your provider experience look like? Our provider experience is easy and intuitive. Prescribers simply send a prescription to PHILRx in the EMR, and our platform has one-click PA submissions and ongoing updates directly built in, ensuring patients receive prescriptions easily and affordably while allowing prescribers to use their existing tools and workflows. There is no new software to download or tools to learn with PHILRx. We also offer a dedicated HCP Engagement Team for ongoing education and support. Get in touch to learn more about our HCP experience and engagement services. How does your pharmacy network work? Our integrated pharmacy network of retail, chain, and specialty pharmacy partners offers 99%+ plan coverage across all 50 states and territories, with free Rx delivery. A dedicated Partner Pharmacy team manages our network, and each partner pharmacy is fully integrated and contracted with PHIL, equipping our pharma clients with full control and visibility at the point of dispense. We also offer wholesale capabilities to support our integrated network. Do you have a cash pharmacy? Yes. PHIL offers a highly flexible, end-to-end patient access platform that empowers brands to custom-build the optimal path to therapy. While we excel at Direct-to-Patient (DTP) models, our capabilities span comprehensive coverage, cash-pay, and hybrid solutions. We offer a flexible, multi-pharmacy ecosystem that combines PHIL's cash pharmacies with a robust, national network of partner pharmacies. Rather than relying on a single channel, brands leverage this comprehensive network to support nationwide fulfillment and maximize patient reach. Reach out and we can help you determine the right-fit access solution for your brand. Do you support non-commercial programs (i.e. PAP, bridge, quick start)? Yes. We support non-commercial programs through our non-commercial dispensing pharmacies, including our cash pharmacy, and through non-commercial pharmacies in our network for additional capacity. How are you able to achieve 90%+ PA submission rates? We offer a proprietary prior authorization (PA) process that integrates seamlessly into prescribers' existing workflows, enabling e-prescribing through EHR integration and one-click PA submissions. AI-driven script checks proactively resolve barriers and help maximize covered dispenses. Our dedicated PA Specialist team actively monitors PA submissions and ensures script quality, while field team tools empower representatives to be proactive and engage prescribers about the status of each script. What data capabilities does PHIL offer? We have a real-time data dashboard with AI-powered insights that provides in-depth program recommendations at the script, provider, territory, and payer level. Additionally, we have a dedicated Client Insights team that partners closely with clients to actively review program data and provide strategic recommendations and optimization plans. Click here to book a full walk-through of PHIL's comprehensive data tools. How does PHIL improve Gross-to-Net (GTN)? We are proud to achieve industry-leading outcomes for our clients: 2x+ patient starts, 90%+ PA submissions, 2x+ covered dispenses, and 3x+ refill adherence (vs traditional channels), which have a multiplicative effect, driving 3x+ gross-to-net performance. We help pharmaceutical brands improve commercial performance through our tech-enabled hub, proprietary PA process, and integrated pharmacy network, seamlessly integrated into a high-touch support model and white-glove partnership approach. Want to forecast your brand's GTN potential with PHIL? Use our self-serve GTN calculator. ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. Book Demo --- # Medication Access Services for Patients — PHIL Source: https://phil.us/patients/ For Patients ## Easy, Affordable Prescriptions with PHILRx We're here to help you get your medications quickly and affordably. Our easy mobile experience helps get your prescriptions covered by insurance for an affordable cost, with free home delivery, real‑time prescription updates, and timely refill reminders. Patient LoginVisit Help Center PHILRx Today at 12pm Hi Sarah! Dr. Jones sent your Adaptrex® prescription to the PHILRx pharmacy. Tap below to get started. ✓ Enroll in minutes ✓ Fast, free shipping ✓ Easy refills ✓Confirm & enroll ### We Believe Patients Deserve Affordable Medications PHILRx helps you get your medications at the right price, with a quick and simple way to receive them. Why patients choose PHILRx 2×+ Patient Starts You're more likely to start the medications you're prescribed 2×+ Covered Dispenses More prescriptions covered by insurance, so you pay less out of pocket 3×+ Refill Adherence You're more likely to stay on track with your medications How we support patients #### Affordable Medications We work hard to get you an affordable price for your medications. We check what your insurance covers and make sure you're getting the right savings with transparent pricing throughout the process. #### Convenient Access Skip the trip to the pharmacy. We deliver your medications straight to your door for free. Refills are easy to manage, and our dedicated team is available if you have questions or need support. #### Seamless Experience We keep you and your doctor informed about your prescriptions at every step of the process. We're proud to have a 4.9/5.0 satisfaction score on TrustPilot from our strong and growing patient community. Hear From PHILRx Patients Trustpilot ### Getting Your Medications with PHILRx is Easy Here's how we work to get you quick, affordable medication access: 1 #### Your Doctor Sends Your Rx to PHILRx Your doctor sends your prescription to PHILRx. Within minutes, we will send you a text to enroll. 2 #### We Work To Get You An Affordable Copay Cost We work hard to ensure you have affordable access to your prescription. 3 #### You Confirm and Receive Your Rx with Fast, Free Shipping Confirm payment and delivery information, and you're set! We offer fast, free home delivery on all prescriptions. You're done! Getting your prescriptions from PHILRx is that simple. Patient Login ### How PHILRx Helps You Save on Your Prescriptions ### Hear from Happy Patients “ “I wasn't able to afford a medication that helped me. My doctor found it through PHILRx, I could continually purchase 3 months of this prescription at a time to receive a HUGE discount. It changed my life.” C Carla R. PHIL Patient “I felt that my needs were being considered from the very beginning. That was so refreshing to me because it was out of the ordinary for a company to express such consideration, especially for a new customer like myself!” D Dawn M. PHIL Patient “The staff at PHILRx are very customer-oriented, staying connected and providing guidance throughout the whole prescription process. They are knowledgeable and friendly. The experience was pleasant!” R Ryan S. PHIL Patient “PHILRx does everything right! They ship quickly, bill my insurance directly, and I do not have to remember to ask for a refill. The entire process is easy and simple, it's really a no brainer. Love the service!” M Margaret Y. PHIL Patient “My experience with PHILRx is always reliable. My medication delivery has always been exactly when they said it would be, the packaging has been very good, and I appreciate the updates about my prescription and refills.” H Henry L. PHIL Patient “PHILRx makes it so easy to get your prescription! From getting the required authorization to delivering it right to your door, they do it all for you.” J Joyce W. PHIL Patient Trustpilot Frequently Asked Questions ### Your Questions About PHILRx, Answered Visit Help Center Is my information secure with PHILRx? Our fully HIPAA-compliant system protects your health data at all times. Your information is only seen by licensed pharmacy personnel and HIPAA-certified Patient Advocates. We take reasonable administrative, physical, and electronic measures designed to protect the information that we collect from or about you (including your personally identifiable information and personal health information) from unauthorized access, use, or disclosure. When you enter sensitive information on our forms, we encrypt this data using SSL or other technologies. Can I cancel my prescription? To cancel your prescription: - Log into your account at my.phil.us - Make sure you are on the Rx Prescriptions section - Click the green arrow next to the prescription you'd like to manage - Select "More Options" - Click "Remove This Prescription" From here, you also have the ability to pause, unpause, and change your refill date. How do I update my payment information? You can log into your My.PHIL account and upload a photo of your payment card: - From the homepage, click on the person icon in the upper right-hand corner - Click the arrow next to the Payment Card section - Select "Add Card" - Enter your card information (card number, expiration date, CVV code) - Check the box if the payment card is an FSA, HSA, or HRA card - Confirm or add your billing address - Click "Save" How much will my prescription cost? While the final cost of your prescription will vary based on your insurance coverage and medication need, we offer lifetime free delivery to all PHIL patients who maintain an active account. We never charge for shipping, making prescription management with PHIL a completely free service. When will I receive my prescription? Your first fill is sent out via first class mail and should arrive within 1–5 business days. Refills are processed ahead of time and shipped standard to ensure you receive your prescription before your previous fill runs out. If you have any concerns or questions, please contact us for assistance. Why did my doctor send my prescription to PHIL? There are several reasons doctors choose to send your prescription to PHIL: Pricing We are able to get special pricing from the manufacturer on numerous commonly used, brand-name medications. In addition to special pricing, we add any applicable manufacturer's coupons to bring pricing down as much as possible for you. Prior Authorizations We work with your doctor to submit prior authorizations should they be required by your insurance for your prescription. Shipping Shipping is always free. Your first fill is expedited at no cost to ensure medication can be started ASAP. Informed Refill Reminders Keeps you updated about when it's time to refill, with easy scheduling. Support Our Patient Advocate team is composed of compassionate and enthusiastic problem-solvers who are here to help. We offer 365 days of support should you have any questions and need assistance. ### Get Affordable Medications with PHILRx Patient LoginVisit Help Center --- # Affordable Patient Medications — PHILRx for Providers Source: https://phil.us/providers/ For Healthcare Providers ## Affordable Medications for Your Patients with PHILRx PHILRx makes it easy for your patients to get their medication at an affordable price with free home delivery and PA support for your office. Read FAQsGet Support #### Deliver Affordable Medication Access For Your Patients ##### Affordable prescriptions with fast, free delivery ##### Prior authorization support for your office ##### Dedicated patient & provider support ### Helping Your Patients Get the Medications You Prescribed at a Price They Can Afford PHILRx helps patients get their medications at the right price, with a simple and easy way to receive them. Why providers choose PHILRx 2×+ Patient starts More patients start the medications you prescribed 2×+ Covered dispenses More prescriptions covered by insurance 3×+ Refill adherence More patients stay on track with their medications How we support patients #### Affordable Medications We work hard to get patients an affordable price for their medications, every time. We check what their insurance covers and make sure they're getting the right savings with transparent pricing throughout the process. #### Convenient Access Patients enroll in minutes, and we keep them informed about their prescription status at every step of the journey. We offer fast, free home delivery on all prescriptions, with easy refill management to support access and adherence. #### Seamless Experience Our friendly support team is available to help patients via phone, chat, and email. We're proud to have a 4.9/5.0 satisfaction score on Trustpilot from our strong and growing patient community. Hear from PHILRx patients Trustpilot ### Why Prescribers Write to PHILRx We take on the work that gets in the way of timely medication access, so your practice can focus on delivering care and your patients can start their prescribed therapies faster, pay less, and stay on track. #### Better Patient Outcomes A great patient experience that improves medication access, affordability, and adherence. #### Prior Authorization Support A seamless prior authorization process with dedicated PA support and timely prescription status updates for your office. #### Dedicated Patient & HCP Support An expert team handles questions and follow-ups, so your patients can start and stay on therapy with confidence. ### How to Prescribe to PHILRx 1 #### Find PHILRx in Your EMR Search for "PHILRx" (or NPI: 1487163598) in the retail pharmacy section of your EMR's Pharmacy Finder. 2 #### Send the eRx to PHILRx Send the eRx to PHILRx, or send via phone (855.977.0975) or fax (888.975.0603). 3 #### Submit the Pre‑Filled Prior Authorization We'll fax you when the pre‑filled prior authorization is ready to be submitted. ### Sending a Script to PHILRx is Easy ### Trusted by Healthcare Providers “ Communication is fantastic! From start to finish, PHILRx does a great job keeping our office in the loop. Susan F. Dermatology PHILRx provides great support for patients, and convenient ways for providers to reach out. Elizabeth R. Neurology PHILRx is very helpful with getting my patients their medications quickly. Jeffrey T. Ophthalmology Communication is fantastic! From start to finish, PHILRx does a great job keeping our office in the loop. Susan F. Dermatology *Real provider quote, stock image used to protect privacy ### Hear from Happy Patients “PHILRx does everything right! They ship quickly, bill my insurance directly, and I do not have to remember to ask for a refill. The entire process is easy and simple, it's really a no brainer. Love the service!” M Margaret Y. PHILRx Patient “My experience with PHILRx is always reliable. My medication delivery has always been exactly when they said it would be, the packaging has been very good, and I appreciate the updates about my prescription and refills.” H Henry L. PHILRx Patient “PHILRx makes it so easy to get your prescription! From getting the required authorization to delivering it right to your door, they do it all for you.” J Joyce W. PHILRx Patient “I wasn't able to afford a medication that helped me. My doctor found it through PHILRx, and I could purchase 3 months at a time to receive a HUGE discount. It changed my life.” C Carla R. PHILRx Patient “I felt that my needs were being considered from the very beginning. That was so refreshing because it was out of the ordinary for a company to express such consideration, especially for a new customer like myself!” D Dawn M. PHILRx Patient “The staff at PHILRx are very customer-oriented, staying connected and providing guidance throughout the whole prescription process. They are knowledgeable and friendly. The experience was pleasant!” R Ryan S. PHILRx Patient Trustpilot Frequently Asked Questions ### Your Questions About PHILRx, Answered - Why PHILRx? - EMR Information - General Patient Information - Language Support - Prescription Status - General Prior Authorization (PA) Information - HCP Communication Information - Pharmacy Why should I send prescriptions to PHILRx? PHILRx simplifies the prescription process by assisting with prior authorization and transparency in prescription and cost tracking, ensuring your patients start and stay on the medication you prescribed. PHILRx helps patients receive an affordable out-of-pocket cost for their medications, with fast, free home delivery and ongoing refill reminders. How do I send prescriptions to PHILRx? You can use one of the following: To eRx in your EMR: - Select the pharmacy type as RETAIL - Search the exact spelling and spacing of the name: PHILRx, LLC - Zip: 43235 - NPI #: 1487163598 To call in a verbal Rx: 855-977-0975 To fax in an Rx: 888-975-0603 We cannot find PHILRx in the EMR. What should we do? To find PHILRx in the EMR, ensure you have selected the pharmacy type as RETAIL. - Search with the exact spelling and spacing of the name "PHILRx, LLC" - Search by NPI #: 1487163598 - If you still cannot find PHILRx, reach out to your EHR's customer service line - You can also prescribe to PHILRx via fax: (888) 975-0603 or phone: (855) 977-0975 What happens if a patient does not enroll with PHILRx after I send their prescription? If a patient has not enrolled, PHILRx will send a series of SMS messages and leave voicemails reminding the patient to enroll. In addition, PHILRx will note on the HCP summary fax/email that arrives every Monday morning that the patient has not enrolled. Is there a place where I can proactively see all of the patients I've sent through PHILRx? We fax or email weekly updates to your office outlining all relevant patient and processing updates from PHILRx. What happens if a patient does not have access to a mobile device or computer? The patient can also enroll via phone or via web browser on a tablet or personal computer. To enroll via phone, the patient can call PHILRx's Patient Support Team using the phone number provided via voicemail, and a PHILRx representative will walk them through the prompts. Please note that the patient will need to have an email address (and the PHIL team can assist them if they do not have one already). Can PHILRx support patients where English is not their first or preferred language? Yes. We support patients in over 120 languages. Simply indicate the language needed for the patient, and PHILRx provides foreign-language support. We text patients in Spanish, Korean, Vietnamese, and Chinese, and have Spanish-speaking patient support reps and translation services for all other languages. Dedicated foreign-language support lines: - Spanish855-970-5222 - Chinese (Mandarin)855-970-6659 - Korean855-970-4420 - Vietnamese855-970-8551 - All other languages855-970-9899 Is there one place where prescribers can see all of the Rx they've written versus only the updates where action needs to be taken? We send a weekly HCP summary fax/email consisting of the patient cases with a pending action (either from the patient or HCP), along with the scripts that have been successfully processed/shipped (typically at the bottom of the fax, and may be on the 2nd or 3rd page). How long does it take for PHILRx to initiate the PA after receiving the script? After a patient confirms their information, PHILRx verifies your patient's insurance and pre-fills the prior authorization. Your office will receive a notification within 3.5 days that the PA is ready to review and submit. Can the PA process be started even before the patient completes their PHILRx registration? Before PHILRx may begin processing a patient's prescription, the patient must enroll with PHIL by creating their account. Most patients are able to complete their enrollment easily via the PHILRx Digital Hub, but this can also be done over the phone with our Patient Support team. During enrollment, the patient must validate their demographic information and ensure the insurance information we've found is correct. Once the patient completes the crucial steps of validating/adding their information, we are able to begin the prior authorization process. How can I (doctor) change my communication preferences? You can update your preferences by emailing the PHIL HCP Support team at mdsupport@phil.us, or by calling PHIL's HCP Support team at 855-588-0387, Option 1. How many follow-up status emails will I get? Is there a more convenient way to get these updates? As a prescriber, you will receive a weekly summary fax/email on Monday mornings. You can update the preference for fax/email by emailing mdsupport@phil.us or by calling PHIL's HCP Support team (855-977-0975, Option 1). Updates will continue as long as you have patients enrolled at PHIL. They may at any time contact PHIL to stop the updates. How can offices change their default preference and frequency of receiving summary updates? Offices can update this preference by emailing mdsupport@phil.us, or by calling PHIL's HCP Support team at 855-977-0975, Option 1. The frequency of the faxes cannot be changed at this time, but HCPs can contact PHIL's HCP Support team any time if they need info on a script. Is there a difference between the AZ and OH pharmacies? We have two locations, one in Columbus, OH and one in Scottsdale, AZ. Each location has a dedicated team to support different medications. Regardless of which location you send the script to, it will be directed appropriately, without impact to the patient experience. ### Get MD Support from the PHILRx Team Contact Support --- # Customer Success Stories — PHIL Source: https://phil.us/customer-success/ Customer Success ## Flexible Programs and Expert Partnerships that Elevate Brand Performance From launch to long-term adherence, discover how pharma brands partner with PHIL to build tailored programs that maximize patient access, brand performance, and commercial growth. Read ProofBook Demo PHIL’s Impact 90%+PA submission rate 2x+Patient starts vs. traditional channels 2x+Covered dispenses vs. traditional channels 3x+Refill adherence vs. traditional channels Read ProofBook Demo ### Driving Measurable Results Across Key Brand Access and Affordability Challenges Turn access challenges into measurable brand growth across every stage of the lifecycle. Our flexible program structures and data-driven approach maximize program performance while delivering the seamless experience patients and providers expect. Access Affordability Adherence Adoption #### Overcoming Low Enrollment and High Abandonment Rates Challenge Low patient enrollment, poor coverage conversion, and high drop-off threatened financial viability. Solution Partnered with PHIL to implement a modern, digital-first access program with seamless enrollment, optimized workflows, and ongoing digital and live patient support. 2x First Fills 4x Covered Dispenses Read the full storyWomen's Health Brand View All Case Studies ### Recent Client News Press Release #### Evolved Health and PHIL Announce Novel Dermatology Program for New Day™ Direct-to-Patient Read announcement Press Release #### PHIL Invests in State-of-the-Art Cash Dispense Capabilities, Expanding Direct-to-Patient Fulfillment for Pharma Read announcement Press Release #### Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program Read announcement View All Coverage ### A Dedicated Partner to Pharma, Patients, and Providers What Pharma Says “PHIL is very strong in driving starts and adherence across our portfolio. As a partner, we love their willingness to be agile and create new things with us that hadn’t necessarily been done before.” SVP Market Access, PHIL Client What Patients Say “I wasn’t able to afford a medication that helped me. My doctor found it through PHIL, I could continually purchase 3 months of this prescription at a time to receive a HUGE discount. It changed my life.” Carla R., Patient What Providers Say “Communication is fantastic! From start to finish, PHILRx does a great job keeping [our office] in the loop.” Susan F., Healthcare provider ### Setting the Standard for Reliability in Access Platforms #### Trustpilot Category Rankings PHIL4.9/5 Industry Average2.6/5 Based on verified Trustpilot reviews. Industry average compiled from leading specialty pharmacy and access platforms. Trustpilot Measure Your Impact ### Measure the Impact of Better Patient Access & Adherence See how covered dispenses, patient starts, and refill rates drive brand performance. Our calculator was built by PHIL’s Commercial Insights team for retail and specialty-lite pharma teams. Calculate Your Potential Patient Starts 2×+ vs. baseline Covered Dispenses 2×+ vs. baseline Gross Revenue 3× vs. baseline Net Revenue 4.1× vs. baseline Calculate Your Potential Ready to simplify medication access? ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. Book Demo --- # /gtn/ Source: https://phil.us/gtn/ GTN Performance Calculator ## See How Your Brand’s Gross‑To‑Net Could Grow Your brand team is focused on improving starts, coverage, and adherence. See what’s possible when all three components kick into hyperdrive to multiply gross‑to‑net impact, with an alternative channel built to maximize commercial control and patient outcomes. Uncover your brand’s untapped potential. Capture your commercial potential 2.2×Patient startsvs. baseline 2.8×Covered dispensesvs. baseline 2.6×Gross Revenue Potentialvs. baseline Run Your Numbers #### Your brand's commercial potential, modeled in a minute. Gain a clear view of what's possible for your portfolio. By submitting, you agree to PHIL's privacy policy. Uncover Your Commercial Potential ### Benchmarks grounded in real brand performance The outputs from this calculator aren’t generic industry averages. They are based on real program data from pharma brands working with PHIL. - Baselines from real pharma brands Every calculation is based on real performance data from brands, giving you a realistic estimate of what's achievable for your portfolio. - Customized to your access strategy The calculator is built to deliver a strong GTN estimate based on your brand's actual channel strategy inputs, layered on top of PHIL program data, not a generic industry average. - Built by Commercial Insights experts The model behind this calculator was built by PHIL's Commercial Insights team, translating the framework we use with our pharma clients into a self‑serve tool that commercial leaders can leverage. The Opportunity ### Your GTN goals are within reach. Here’s what getting there looks like. PHIL has 10+ years experience helping pharma teams improve their commercial performance through technology. Our all‑in‑one solution is built to optimize starts, coverage, and adherence to maximize gross‑to‑net impact. Stronger Starts #### Maximize patient access and therapy starts. Achieve an industry-leading 2x+ first fill rate vs. traditional channels, ensuring your therapy reaches as many patients as possible. Higher Coverage #### Convert covered scripts into covered dispenses. Drive 90%+ PA submission rates and 2x+ covered dispenses vs. traditional channels. Better Adherence #### Support long-term patient adherence. Build a sustainable refill process that ensures patients can easily stay on therapy, with 3x+ refill adherence rates vs. traditional channels. 3× Multiplied Impact #### GTN impact vs. other channels. Experience the compounding effect on commercial performance with PHIL. “ We've seen outstanding commercial results with PHIL, stronger than any of our best case scenario forecasts. Vice President of Market AccessPHIL Client #### Ready to unpack your results? Book a call with our team for a deep dive into your brand's commercial potential with PHIL. Book A Call Run Your Numbers #### Your brand's commercial potential, modeled in a minute. Gain a clear view of what's possible for your portfolio. By submitting, you agree to PHIL's privacy policy. --- # Resources | PHIL Source: https://phil.us/resources/ Resource Hub ## Insights to Move Your Access Strategy Forward A curated library of research, thought leadership, and expert perspectives for pharma manufacturers that want to drive best-in-class results. P Featured Resources Featured Report #### Patient Perspectives on Direct-to-Patient: Improving Access and Adherence Read report Featured Report #### HCP Perspectives on Direct-to-Patient: Engaging Providers in the Digital Era Read report Featured Report #### 5 Key Success Factors to Drive Brand Excellence Read report Explore topics Direct-to-Patient Access Strategy & Channel Design Patient Experience, Support & Assistance Utilization Management Field Enablement & HCP Engagement Data, Technology & Optimization Commercial Performance Customer Success Stories Topic I'm interested in… Type All formats Search press #### Evolved Health and PHIL Announce Novel Dermatology Program for New Day™ Direct-to-Patient Read press #### Compliance-By-Design: The Critical Layer for Pharma's Direct-to-Patient Play Read press #### Protecting Gross-to-Net Performance Through Single-Channel Ecosystems Read report #### Building Direct-to-Patient Programs that Exceed Today's Patient Expectations Download press #### Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program Read press #### DTP Survey Findings: Patients Want Price Transparency and e-Commerce Experience Read press #### Beyond DTP 2.0: How Flexible Programs Power Best-in-Class Patient Experiences Read report #### Bridging the Gap to Better Patient Outcomes: What HCPs Want from Pharma's Digital Access Channels Download webinar #### Capturing Actionable Metrics to Improve Patient & Brand Outcomes Watch Showing 1–9 of 106 resources In the News ### PHIL in the Press Press Release ##### Evolved Health and PHIL Announce Novel Dermatology Program for New Day™ Direct-to-Patient Read feature Pharmaceutical Commerce ##### Compliance-By-Design: The Critical Layer for Pharma's Direct-to-Patient Play Read feature Drug Channels ##### Protecting Gross-to-Net Performance Through Single-Channel Ecosystems Read feature Digital Medicine Society ##### PHIL is Rewriting the Rules of Direct-to-Patient Read feature Press Release ##### PHIL Invests in State-of-the-Art Cash Dispense Capabilities, Expanding Direct-to-Patient Fulfillment for Pharma Read feature Press Release ##### Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program Read feature Fierce Pharma ##### DTP Survey Findings: Patients Want Price Transparency and e-Commerce Experience Read feature Drug Channels ##### Beyond DTP 2.0: How Flexible Programs Power Best-in-Class Patient Experiences Read feature Press Release ##### Sprout Pharmaceuticals and PHIL Expand Their Affordable Direct-to-Patient Access Program for Addyi Read feature Life Science Leader ##### Pharma Direct-To-Patient 2.0: From Experiment To Imperative Read feature Press Release ##### PHIL Launches Direct-to-Patient 2.0 Platform to Transform Access, Affordability, and Adherence in Pharma Read feature Biopharma Dive ##### Redefining Commercial Success in Specialty-Lite Read feature Fierce Pharma ##### The Hidden GTN Drain: Why Specialty-Lite Brands Need To Streamline The PA Process Read feature Press Release ##### Phil Secures $60 Million Growth Capital Facility from K2 HealthVentures to Accelerate AI Integration Read feature Biopharma Dive ##### Bridging Data Gaps that Impact Retail and Specialty-Lite Success Read feature Drug Channels ##### Harnessing the Power of Comprehensive Data to Drive GTN Read feature Press Release ##### Phil Inc. Adds Duchesnay USA’s Women’s Healthcare Product to Its Patient Access Platform Read feature View Coverage Ready to simplify medication access? ### See how PHIL moves more patients to therapy, quickly and affordably Take a tour of the PHIL platform and discover how we can help amplify starts, adherence, coverage, and commercial success. Book A Demo --- # Press | PHIL Source: https://phil.us/press/ Pressroom ## PHIL in the Press Read our latest news, announcements, and thought leadership. P Latest Announcements #### Evolved Health and PHIL Announce Novel Dermatology Program for New Day™ Direct-to-Patient Read announcement #### PHIL Invests in State-of-the-Art Cash Dispense Capabilities, Expanding Direct-to-Patient Fulfillment for Pharma Read announcement #### Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program Read announcement Featured Thought Leadership Pharmaceutical Commerce #### Compliance-By-Design: The Critical Layer for Pharma's Direct-to-Patient Play Read feature Drug Channels #### Protecting Gross-to-Net Performance Through Single-Channel Ecosystems Read feature Digital Medicine Society #### PHIL is Rewriting the Rules of Direct-to-Patient Read feature All Coverage Press Release ##### Evolved Health and PHIL Announce Novel Dermatology Program for New Day™ Direct-to-Patient Pharmaceutical Commerce ##### Compliance-By-Design: The Critical Layer for Pharma's Direct-to-Patient Play Drug Channels ##### Protecting Gross-to-Net Performance Through Single-Channel Ecosystems Digital Medicine Society ##### PHIL is Rewriting the Rules of Direct-to-Patient Press Release ##### PHIL Invests in State-of-the-Art Cash Dispense Capabilities, Expanding Direct-to-Patient Fulfillment for Pharma Press Release ##### Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program Ready to simplify medication access? ### See how PHIL moves more patients to therapy, quickly and affordably Take a tour of the PHIL platform and discover how we can help amplify starts, adherence, coverage, and commercial success. Book A Demo --- # Research Report · March 2026 Source: https://phil.us/dtp-research/ Research Report · MARCH 2026 ## The DTP Imperative: Building Direct-to-Patient Programs That Exceed Expectations New research from PHIL uncovers patient's most pressing expectations for today's direct-to-patient programs, and why this matters for pharma. 1,049 U.S. Respondents March 2026 Free Download 6 in 10 patients never fill a prescription after seeing an ad 96% want price transparency before committing to a medication 95% want DTP programs to mirror e-commerce experiences WHAT'S INSIDE ### What Pharma Needs to Know About Today's Patients PHIL surveyed 1,049 U.S. patients who have received a prescription medication in the past five years. The findings highlight the most pressing needs, challenges, and preferences of today's patients — and what the next generation of DTP programs must deliver. ##### Finding 1 · The Awareness-to-Access Gap How access and affordability barriers are creating drop-off between patient interest and first fills – and where DTP programs can meaningfully bridge the gap. ##### Finding 2 · The Pricing Imperative Affordable, transparent pricing is pharma's single biggest lever for driving DTP adoption, starts, and long-term adherence. ##### High Standards for Experience Patients expect DTP programs to mirror the seamless digital experience they get everywhere else – and brand-led experiences are key for driving trust. Get the full report Fill out the form below to download the PDF. EXPERT PERSPECTIVES ### What the Research Shows Today, consumer-grade direct-to-patient programs that are custom-built to exceed patient expectations are the industry's most powerful strategic lever for improving patient outcomes while driving commercial performance at scale. D Deepak Thomas CEO & Founder, PHIL Inc. Affordable, transparent pricing is pharma's single biggest opportunity for maximizing patient starts and adherence. Manufacturers who surface multiple payment pathways with the most affordable price, customized to the individual patient, in their DTP programs will see the greatest improvements in overall patient outcomes and commercial impact. S Sahil Naik Chief Growth Officer, PHIL Inc. A brand-led DTP channel is one of the most underleveraged opportunities in pharma today – it's how manufacturers win patient trust, drive adherence, and build lasting brand loyalty. A Allison Bridges SVP Client Success, PHIL Inc. Today, consumer-grade direct-to-patient programs that are custom-built to exceed patient expectations are the industry's most powerful strategic lever for improving patient outcomes while driving commercial performance at scale. D Deepak Thomas CEO & Founder, PHIL Inc. Affordable, transparent pricing is pharma's single biggest opportunity for maximizing patient starts and adherence. Manufacturers who surface multiple payment pathways with the most affordable price, customized to the individual patient, in their DTP programs will see the greatest improvements in overall patient outcomes and commercial impact. S Sahil Naik Chief Growth Officer, PHIL Inc. A brand-led DTP channel is one of the most underleveraged opportunities in pharma today – it's how manufacturers win patient trust, drive adherence, and build lasting brand loyalty. A Allison Bridges SVP Client Success, PHIL Inc. SEE WHAT'S POSSIBLE ### Ready to Build a Best-in-Class ### DTP Program? PHIL helps leading pharma brands launch custom direct-to-patient programs that exceed patient expectations and drive commercial impact at scale. --- # Research Report · April 2026 Source: https://phil.us/hcp-research/ Research Report · April 2026 ## Bridging the Gap to Better Patient Outcomes: What HCPs Want from Pharma's Digital Access Channels New research from PHIL uncovers what healthcare providers need from pharma's digital access and direct-to-patient programs, and what pharma can do to improve patient outcomes. 207 U.S. Healthcare Providers April 2026 Free Download 1 in 2 HCPs are not confident patients can navigate out-of-pocket medication costs on their own 70% say prior authorization process prevents timely, affordable access #1 factor HCPs consider when prescribing to a digital channel: patient receives lowest price WHAT'S INSIDE ### What HCPs Think About Pharma's Direct-to-Patient Programs The findings highlight what moves the needle on improving patient outcomes and provider adoption. ##### Finding 1 · Patient Affordability is the #1 Priority 1 in 2 HCPs lack confidence that patients can navigate out-of-pocket costs on their own, and top abandonment reasons include non-insurance coverage and high OOP costs. When prescribing to a digital channel, HCPs say lowest available price is the #1 most important factor they consider. ##### Finding 2 · Utilization Management Support Drives Adoption 70% of HCPs cite prior authorization as the top barrier to timely, affordable access. Beyond pricing, HCPs want administrative support for utilization management tasks and dedicated patient and provider support as key program features. Get the full report Fill out the form below to download the PDF. WHAT THE RESEARCH SHOWS ### Why This Matters for Pharma Healthcare providers are focused on delivering the best possible care for their patients. The pharma brands that win long-term are those building digital access programs that remove affordability barriers and prior authorization hurdles, while easing the operational burden on the office staff who manage these processes every day. L Lirys Crawford VP HCP Engagement, PHIL Inc. SEE WHAT'S POSSIBLE ### Ready to Build a Best-in-Class ### Access Program? PHIL helps leading pharma brands launch direct-to-patient programs that exceed HCP and patient expectations and drive commercial impact at scale. --- # Frequently Asked Questions Source: https://phil.us/faqs/ Need Help? ## Frequently Asked Questions about PHILRx ### Pharma - Platform & Partnership What does PHIL do? PHIL is a medication access platform designed to improve patient outcomes and brand performance for retail and specialty-lite brands. Through PHIL Digital Hub, and PHIL Direct-to-Patient, our (DTP) solution, we enable seamless medication access via our integrated pharmacy network and our own PHIL cash pharmacies, delivering simple, affordable paths to therapy. What types of medications are best suited for the PHIL platform? Our platform is purpose-built to support branded retail and specialty-lite therapies, including medications that are self-administered, pharmacy benefit, controlled or non-controlled, and often require prior authorization and patient support services. Which therapeutic areas and launch stages do you support? Our platform successfully supports brands across many therapeutic areas and launch stages, working with brands from new launch through LOE. How are you different from traditional access channels (i.e. retail, specialty pharmacy, etc.)? PHIL is redefining medication access for branded retail and specialty-lite therapies. Traditional access channels rely on fragmented, legacy workflows that increase access barriers and leave patients facing high costs and long delays. PHIL replaces this outdated friction with a modern, technology-first platform. Designed with ultimate flexibility, our platform structures can be fully whitelabeled to align with your brand's unique footprint. By streamlining the entire prescription journey, we provide patients cost transparency, unlock real-time visibility for brands, and ensure patients can effortlessly access, afford, and stay on their prescribed therapies. Curious if your brand could benefit from partnering with PHIL? Contact us for a discovery call. - Patient & Provider Experience What does your patient experience look like? PHIL provides a seamless, e-commerce-like medication access experience for patients. This includes timely updates, free home delivery, easy refill management, and a dedicated patient support team. We're proud to have an industry-leading patient satisfaction score of 4.9/5.0 on TrustPilot from 22,000+ reviews. Get in touch for a full tour of our patient experience and support services. What does your provider experience look like? Our provider experience is easy and intuitive. Prescribers simply send a prescription to PHILRx in the EMR, and our platform has one-click PA submissions and ongoing updates directly built in, ensuring patients receive prescriptions easily and affordably while allowing prescribers to use their existing tools and workflows. There is no new software to download or tools to learn with PHILRx. We also offer a dedicated HCP Engagement Team for ongoing education and support. Get in touch to learn more about our HCP experience and engagement services. - Pharmacy Network How does your pharmacy network work? Our integrated pharmacy network of retail, chain, and specialty pharmacy partners offers 99%+ plan coverage across all 50 states and territories, with free Rx delivery. A dedicated Partner Pharmacy team manages our network, and each partner pharmacy is fully integrated and contracted with PHIL, equipping our pharma clients with full control and visibility at the point of dispense. We also offer wholesale capabilities to support our integrated network. Do you have a cash pharmacy? Yes. PHIL offers a highly flexible, end-to-end patient access platform that empowers brands to custom-build the optimal path to therapy. While we excel at Direct-to-Patient (DTP) models, our capabilities span comprehensive coverage, cash-pay, and hybrid solutions. We offer a flexible, multi-pharmacy ecosystem that combines PHIL's cash pharmacies with a robust, national network of partner pharmacies. Rather than relying on a single channel, brands leverage this comprehensive network to support nationwide fulfillment and maximize patient reach. Reach out and we can help you determine the right-fit access solution for your brand. Do you support non-commercial programs (i.e. PAP, bridge, quick start)? Yes. We support non-commercial programs through our non-commercial dispensing pharmacies, including our cash pharmacy, and through non-commercial pharmacies in our network for additional capacity. - Impact & Outcomes How are you able to achieve 90%+ PA submission rates? We offer a proprietary prior authorization (PA) process that integrates seamlessly into prescribers' existing workflows, enabling e-prescribing through EHR integration and one-click PA submissions. AI-driven script checks proactively resolve barriers and help maximize covered dispenses. Our dedicated PA Specialist team actively monitors PA submissions and ensures script quality, while field team tools empower representatives to be proactive and engage prescribers about the status of each script. What data capabilities does PHIL offer? We have a real-time data dashboard with AI-powered insights that provides in-depth program recommendations at the script, provider, territory, and payer level. Additionally, we have a dedicated Client Insights team that partners closely with clients to actively review program data and provide strategic recommendations and optimization plans. Click here to book a full walk-through of PHIL's comprehensive data tools. How does PHIL improve Gross-to-Net (GTN)? We are proud to achieve industry-leading outcomes for our clients: 2x+ patient starts, 90%+ PA submissions, 2x+ covered dispenses, and 3x+ refill adherence (vs traditional channels), which have a multiplicative effect, driving 3x+ gross-to-net performance. We help pharmaceutical brands improve commercial performance through our tech-enabled hub, proprietary PA process, and integrated pharmacy network, seamlessly integrated into a high-touch support model and white-glove partnership approach. Want to forecast your brand's GTN potential with PHIL? Use our self-serve GTN calculator. ### Patients Get Support - Is my information secure with PHILRx? Our fully HIPAA-compliant system protects your health data at all times. Your information is only seen by licensed pharmacy personnel and HIPAA-certified Patient Advocates. We take reasonable administrative, physical, and electronic measures designed to protect the information that we collect from or about you (including your personally identifiable information and personal health information) from unauthorized access, use, or disclosure. When you enter sensitive information on our forms, we encrypt this data using SSL or other technologies. - Can I cancel my prescription? To cancel your prescription: Log into your account at my.phil.us Make sure you are on the Rx Prescriptions section Click the green arrow next to the prescription you'd like to manage Select "More Options" Click "Remove This Prescription" From here, you also have the ability to pause, unpause, and change your refill date. - How do I update my payment information? You can log into your My.PHIL account and upload a photo of your payment card: From the homepage, click on the person icon in the upper right-hand corner Click the arrow next to the Payment Card section Select "Add Card" Enter your card information (card number, expiration date, CVV code) Check the box if the payment card is an FSA, HSA, or HRA card Confirm or add your billing address Click "Save" - How much will my prescription cost? While the final cost of your prescription will vary based on your insurance coverage and medication need, we offer lifetime free delivery to all PHIL patients who maintain an active account. We never charge for shipping, making prescription management with PHIL a completely free service. - When will I receive my prescription? Your first fill is sent out via first class mail and should arrive within 1–5 business days. Refills are processed ahead of time and shipped standard to ensure you receive your prescription before your previous fill runs out. If you have any concerns or questions, please contact us for assistance. - Why did my doctor send my prescription to PHIL? There are several reasons doctors choose to send your prescription to PHIL: Pricing We are able to get special pricing from the manufacturer on numerous commonly used, brand-name medications. In addition to special pricing, we add any applicable manufacturer's coupons to bring pricing down as much as possible for you. Prior Authorizations We work with your doctor to submit prior authorizations should they be required by your insurance for your prescription. Shipping Shipping is always free. Your first fill is expedited at no cost to ensure medication can be started ASAP. Informed Refill Reminders Keeps you updated about when it's time to refill, with easy scheduling. Support Our Patient Advocate team is composed of compassionate and enthusiastic problem-solvers who are here to help. We offer 365 days of support should you have any questions and need assistance. ### Providers - Why PHILRx? Why should I send prescriptions to PHILRx? PHILRx simplifies the prescription process by assisting with prior authorization and transparency in prescription and cost tracking, ensuring your patients start and stay on the medication you prescribed. PHILRx helps patients receive an affordable out-of-pocket cost for their medications, with fast, free home delivery and ongoing refill reminders. - EMR Information How do I send prescriptions to PHILRx? You can use one of the following: To eRx in your EMR: Select the pharmacy type as RETAIL Search the exact spelling and spacing of the name: PHILRx, LLC Zip: 43235 NPI #: 1487163598 To call in a verbal Rx: 855-977-0975 To fax in an Rx: 888-975-0603 We cannot find PHILRx in the EMR. What should we do? To find PHILRx in the EMR, ensure you have selected the pharmacy type as RETAIL. Search with the exact spelling and spacing of the name "PHILRx, LLC" Search by NPI #: 1487163598 If you still cannot find PHILRx, reach out to your EHR's customer service line You can also prescribe to PHILRx via fax: (888) 975-0603 or phone: (855) 977-0975 - General Patient Information What happens if a patient does not enroll with PHILRx after I send their prescription? If a patient has not enrolled, PHILRx will send a series of SMS messages and leave voicemails reminding the patient to enroll. In addition, PHILRx will note on the HCP summary fax/email that arrives every Monday morning that the patient has not enrolled. Is there a place where I can proactively see all of the patients I've sent through PHILRx? We fax or email weekly updates to your office outlining all relevant patient and processing updates from PHILRx. What happens if a patient does not have access to a mobile device or computer? The patient can also enroll via phone or via web browser on a tablet or personal computer. To enroll via phone, the patient can call PHILRx's Patient Support Team using the phone number provided via voicemail, and a PHILRx representative will walk them through the prompts. Please note that the patient will need to have an email address (and the PHIL team can assist them if they do not have one already). - Language Support Can PHILRx support patients where English is not their first or preferred language? Yes. We support patients in over 120 languages. Simply indicate the language needed for the patient, and PHILRx provides foreign-language support. We text patients in Spanish, Korean, Vietnamese, and Chinese, and have Spanish-speaking patient support reps and translation services for all other languages. Dedicated foreign-language support lines: Spanish855-970-5222 Chinese (Mandarin)855-970-6659 Korean855-970-4420 Vietnamese855-970-8551 All other languages855-970-9899 - Prescription Status Is there one place where prescribers can see all of the Rx they've written versus only the updates where action needs to be taken? We send a weekly HCP summary fax/email consisting of the patient cases with a pending action (either from the patient or HCP), along with the scripts that have been successfully processed/shipped (typically at the bottom of the fax, and may be on the 2nd or 3rd page). - General Prior Authorization (PA) Information How long does it take for PHILRx to initiate the PA after receiving the script? After a patient confirms their information, PHILRx verifies your patient's insurance and pre-fills the prior authorization. Your office will receive a notification within 3.5 days that the PA is ready to review and submit. Can the PA process be started even before the patient completes their PHILRx registration? Before PHILRx may begin processing a patient's prescription, the patient must enroll with PHIL by creating their account. Most patients are able to complete their enrollment easily via the PHILRx Digital Hub, but this can also be done over the phone with our Patient Support team. During enrollment, the patient must validate their demographic information and ensure the insurance information we've found is correct. Once the patient completes the crucial steps of validating/adding their information, we are able to begin the prior authorization process. - HCP Communication Information How can I (doctor) change my communication preferences? You can update your preferences by emailing the PHIL HCP Support team at mdsupport@phil.us, or by calling PHIL's HCP Support team at 855-588-0387, Option 1. How many follow-up status emails will I get? Is there a more convenient way to get these updates? As a prescriber, you will receive a weekly summary fax/email on Monday mornings. You can update the preference for fax/email by emailing mdsupport@phil.us or by calling PHIL's HCP Support team (855-977-0975, Option 1). Updates will continue as long as you have patients enrolled at PHIL. They may at any time contact PHIL to stop the updates. How can offices change their default preference and frequency of receiving summary updates? Offices can update this preference by emailing mdsupport@phil.us, or by calling PHIL's HCP Support team at 855-977-0975, Option 1. The frequency of the faxes cannot be changed at this time, but HCPs can contact PHIL's HCP Support team any time if they need info on a script. - Pharmacy Is there a difference between the AZ and OH pharmacies? We have two locations, one in Columbus, OH and one in Scottsdale, AZ. Each location has a dedicated team to support different medications. Regardless of which location you send the script to, it will be directed appropriately, without impact to the patient experience. More Questions? ### We’re here to help Whether you’re a patient, caregiver, or provider looking for support, or a pharma manufacturer interested in a partnership with PHIL, our friendly team can help. Contact Us --- # About Phil: Learn about our patient access programs, careers, pharmacy and more Source: https://phil.us/company/ ### Who We Are We believe that helping patients get prescriptions with seamless convenience can improve health and save lives. - We put the patient first - We value our people - We value our partners - We have a startup mentality ### What we do We revolutionize life sciences access and commercialization through advanced technology. Our solution maximizes brand value and offers an unparalleled experience for providers, patients, and manufacturers. See the PhilRx digital hub platform in action. Loading... ### Meet Our Leadership Team ###### MEET THE LEADER #### Deepak Thomas ###### Founder & ###### Chief Executive Officer ###### MEET THE LEADER #### Puran Singh ###### Co-Founder, ###### Vice President Engineering ###### MEET THE LEADER #### Chander Viswanathan ###### Chief Technology & ###### Operations Officer ###### MEET THE LEADER #### Sean Burkardt ###### Chief Financial Officer ###### MEET THE LEADER #### Sahil Naik ###### Chief Growth Officer ###### MEET THE LEADER #### Allison Bridges ###### SVP Client Success ###### MEET THE LEADER #### Josh Zeidman ###### Senior Vice President, Business Development ###### MEET THE LEADER #### Lirys Crawford ###### Vice President, HCP Engagement ###### MEET THE LEADER #### Dhananjay Ramaswamy ###### Vice President of Product Management ###### MEET THE LEADER #### Maria Klagos ###### Senior Vice President, People Operations ###### MEET THE LEADER #### Robert Schumaker ###### Vice President, ###### Pharmacy Network & Wholesale Operations ###### MEET THE LEADER #### Peggy Wang ###### Vice President of Finance ###### MEET THE LEADER #### Ryan Sutton ###### Vice President of Operational Excellence ###### MEET THE LEADER #### Justin Mills ###### Vice President, Controller ###### MEET THE LEADER #### Zaccheus Lim ###### Vice President of Pharmacy Operations ###### MEET THE LEADER #### Peter Darch ###### Vice President of Business Operations Meet our Leaders ### The People Behind PHIL MEET #### Neil Dean, ##### Director of Product Management “Everything we do is in service of the patient. Even when we're figuring out ways to improve our clients’ experience, our ultimate goal is to make a difference in patients' lives and health outcomes.” Read Spotlight MEET #### Molly Fields ##### Director of Patient Support “Our biggest triumph is when a patient doesn't understand what's happening with their order, and our team is able to offer a really helpful explanation of what's happened and what will happen next.” Read Spotlight MEET #### Abhyuday Polineni ##### Director of Engineering “The engineering team is like the connective tissue of our stakeholders. Everyone plugs into the same platform, which needs to be orchestrated perfectly so that prescriptions seamlessly flow through the system." Read Spotlight ### Life at Phil We’re a team of mission-driven, analytical, and passionate people—brought together by a shared purpose: improving human wellbeing through technology. At PHIL, we operate with high trust and autonomy, empowering each team member to take ownership and drive meaningful impact through focused execution. Come join us! Explore Open Roles ### Our Investors --- # /leadership/ Source: https://phil.us/leadership/ ## Meet the PHIL Leadership Team #### Deepak Thomas ###### Founder & ###### Chief Executive Officer View LinkedIn Profile #### Puran Singh ###### Co-Founder, ###### Vice President Engineering View LinkedIn Profile #### Chander Viswanathan ###### Chief Technology & ###### Operations Officer View LinkedIn Profile #### Sean Burkardt ###### Chief Financial Officer View LinkedIn Profile #### Sahil Naik ###### Chief Growth Officer View LinkedIn Profile #### Allison Bridges ###### SVP Client Success View LinkedIn Profile #### Josh Zeidman ###### Senior Vice President, Business Development View LinkedIn Profile #### Lirys Crawford ###### Vice President, HCP Engagement View LinkedIn Profile #### Dhananjay Ramaswamy ###### Vice President of Product Management View LinkedIn Profile #### Maria Klagos ###### Senior Vice President, People Operations View LinkedIn Profile #### Robert Schumaker ###### Vice President, ###### Pharmacy Network & Wholesale Operations View LinkedIn Profile #### Peggy Wang ###### Vice President of Finance View LinkedIn Profile #### Ryan Sutton ###### Vice President of Operational Excellence View LinkedIn Profile #### Justin Mills ###### Vice President, Controller View LinkedIn Profile #### Zaccheus Lim ###### Vice President of Pharmacy Operations View LinkedIn Profile #### Peter Darch ###### Vice President of Business Operations View LinkedIn Profile --- # Careers - Join the Phil Team Source: https://phil.us/careers/ ## Careers at Phil --- # Contact Us — PHIL Source: https://phil.us/contact/ Contact Us ## Get In Touch Our team is happy to help! Tell us who you are, and we'll connect you to the right people for support. ### Pharma Interested in partnering with PHIL? Book a discovery call with our sales team. Book Demo ### Patients & Caregivers Questions about your PHILRx prescription? Visit our patient help center for support. Contact Patient Support ### Healthcare Providers Questions about prescribing to PHILRx? Our HCP support team can help. Contact HCP Support Still have a question? Reach out to the PHIL team here Get in touch --- # Book a Demo | PHIL — Patient Access Platform for Pharma Brands Source: https://phil.us/demo/ ## One Powerful Platform, Every Path to Your Patient Discover how PHIL can help your brand maximize patient outcomes and commercial performance. Maximize patient starts, adherence, and satisfaction.Top-rated experience to start and stay through refill. Improve affordability with flexible access pathways.Custom program design with hybrid, coverage, and cash models. Transform end-to-end data into commercial growth.360° visibility with AI-powered insights for continual improvement. ### Request a Demo Schedule a 30-minute discovery call with our Sales team. Helping Pharma Brands Grow 2x+ Patient Starts vs. Traditional Channels 3x+ Adherence vs. Traditional Channels 2x+ Covered Dispenses vs. Traditional Channels 3x+ GTN Lift vs. Traditional Channels 4.9/5.0 Patient Satisfaction Score Excellent --- # Contact our HCP Support team — PHIL Source: https://phil.us/contact/hcp-support/ ## Contact our HCP Support team You're in the right place for support. Reach out below and our HCP support team will be in touch. --- # 3 Patient Engagement Technology Myths Source: https://phil.us/3-patient-engagement-technology-myths/ ## 3 Patient Engagement Technology Myths A recent survey by Boston Consulting Group, exploring what patients want from pharma companies and how well companies are meeting those needs, revealed a deficiency in patient engagement. The growing demand for improved and more efficient communication between patients and healthcare entities has created an opportunity for pharmaceutical manufacturers to promote patient engagement through digital tools. However, three common myths may be holding them back. - Older adults do not prefer technology Even though older adults stand to benefit the most from technology-driven patient engagement, pharma manufacturers are often reluctant to gear patient support platforms to older populations. Older adults are not digital natives – people who are viewed as tech-savvy because they grew up in the digital age, so there is a general assumption that this demographic does not use health technology. The reality contradicts this stereotype As of 2021, 3 out of 4 people aged 65 and older are using the internet. Data from 2016 showed that patients in their 60s were just as likely to register for online patient portals as younger people, and a 2020 study found that people over the age of 85 had high portal use, particularly around therapy questions, medication refills, scheduling, and billing. The AARP 2021 Tech Trends Report revealed that the pandemic has driven even greater digital technology adoption among seniors. Technology-driven patient engagement can enhance medication adherence. For example, as part of a patient engagement strategy, manufacturers can provide pharmacies with appointment-based medication synchronization (ABMS) support that decreases medication non-adherence by more actively engaging patients in their treatment plans and simplifying pharmacy workflow. - Technology will replace the human touch Empathy is the foundation of patient-centered care. Many stakeholders share the concern that digital health technologies take the human connection out of the patient journey, depriving patients of empathy. So how can an algorithm possibly deliver empathy? It’s essential to keep in mind that empathy in healthcare is inextricably linked to patient-centricity and patient experience. A well-designed patient engagement platform elevates engagement, personalizes the experience, and enables high-quality patient-centered care. In fact, The Future Health Index 2019 found that 82% of people with access to their digital health records described their personal experience of care as good, very good, or excellent, compared to 66% of those without access. The aim of automation shouldn’t be to replace personal engagement. It should be to bring more value to healthcare by making each patient encounter more meaningful. In pharma, a patient engagement platform can provide opportunities for improving medication access, driving medication adherence, and delivering data insights to optimize patient care and demonstrate value. - Patient engagement technology is expensive It is true that developing a technology solution from scratch is indeed an expensive undertaking. Life science companies already heavily invested in drug development may not have the resources to build and maintain digital technology, such as a patient engagement platform. There are many direct and indirect costs related to in-house software development, including: - Project planning, development, and management - Infrastructure - User interface (U/I) and user experience (U/X) design - Size and complexity - Cybersecurity - Training - Troubleshooting and support - Maintenance However, implementing a successful patient engagement platform can be affordable. By outsourcing, pharma manufacturers can pay a fraction of the cost it takes to configure one in-house. Return on investment (ROI) should always be considered, so evaluating prospective platforms and determining the anticipated ROI is crucial. ### The bottom line The evolving healthcare landscape is altering expectations across the continuum of care. Pharma companies are struggling with how to engage patients in this complex environment, and misconceptions may be preventing them from embracing digital tools. However, it’s time to appreciate the power of technology-driven patient engagement to build trust, a competitive advantage, and value. Adopting new technologies is not something to be taken lightly. Discover how Phil’s commercialization platform improves patient experience while driving better business outcomes here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 3 Reasons to Work with a Commercialization Partner that has an Integrated Distribution Network Source: https://phil.us/3-reasons-to-work-with-a-commercialization-partner-that-has-an-integrated/ ## 3 Reasons to Work with a Commercialization Partner that has an Integrated Distribution Network The stakes are high for life science companies when establishing the “best fit” drug distribution and channel strategy for a brand across the lifecycle, particularly since strong market access is no longer a guarantee to ensure a high percentage of covered dispenses at the pharmacy. Many manufacturers know that a critical input into maximizing gross-to-net is the pharmacy network. A robust, and varied national network of pharmacies that combine retail, chain and specialty pharmacies is the best way to maximize plan contract coverage and reimbursement rates. Unfortunately, they conclude that the solution is to string together their own network of pharmacies or specialty pharmacy partners.. However, committing to managing a disparate and convoluted dispensing network is risky, operationally challenging, and often proves to be a costly mistake. A complicated network design can create confusion for prescribers, dilute the patient experience, and reduce the percentage of covered dispenses realized by your brand which will ultimately negatively impact over gross to net and contribute to commercial stagnation. The good news is that this scenario can be avoided. Here are three advantages of developing a strategic commercialization partnership that connects your brand with a broad dispense network offering a high health plan coverage. #### 1. More influence over the prescription access journey Even after a successful launch, life sciences companies cannot rest easy that their products are making their way through the various distribution and dispensing entities into the patients’ hands – unless they are confident these partners are executing against properly established business rules. Without some control and insight into the process, it’s too easy to be blindsided by a pharmacy network running awry and then scrambling to do damage control. Once problems arise, it can require significant resources, time, and money to fix the issues and repair any negative perceptions in the marketplace. A business rules engine embedded within supply chain software automates decision-making and can provide guidelines on how a pharmaceutical manufacturer’s products are distributed and dispensed. With the ability to set and update business rules as necessary, commercialization teams can leverage distribution operations across a brand’s lifecycle to better connect patients to therapy. Life sciences companies are best served by a patient support hub that functions as a liaison between the distribution channel and the patient. This partnership will give them more control over business rules so that each prescription is triaged to the pharmacy with the best coverage and reimbursement, improving the experience of healthcare providers and patients. Providers know upfront to which pharmacy they should send the script so that it gets covered and patients can pay the lowest possible out-of-pocket costs. #### 2. Comprehensive data reporting that translates into meaningful insights Technology powered by data and analytics can empower lean organizations to do more with less. However, data is useless if locked away in databases and unwieldy platforms or siloed across a disjointed supply chain. Users should not have to waste time sifting through complicated and disparate reports only to find outdated, inaccurate data. Inevitably, this is often the case when managing a home built pharmacy network comprising a range of network partners. Poor data quality is a barrier to digital transformation that often leads to inadequate decision-making. Real-time data capture and management across the supply chain provide visibility into all stages of product movement and offer insight into market activities around product usage. This visibility helps life sciences companies stay competitive and leverage data in their favor throughout every step of their supply chain. An effective commercialization partner will provide the metrics that matter to the success of your brand and allow your teams to unlock insights easily through intuitive, interactive dashboards. #### 3. Lowering DSA and administrative costs According to an IQVIA report, the share of drug launches by emerging life sciences companies has grown four-fold over the last decade. In 2021, small biopharma companies originated and launched 42% of all novel drugs, up from 11% in 2012. The report also notes that products originating from these biopharma companies “have generally achieved lower sales when they launch themselves compared to when larger companies launch the products.” Not surprising given that smaller manufacturers are typically very lean organizations – which on the upside, enables them to be very agile and innovative – but when it comes to investing in and developing the internal capabilities to manage their supply chain, they are at a disadvantage. Managing product distribution is a significant expense for pharmaceutical manufacturers due to the complex nature of the infrastructure, which may include distributors, third-party logistics providers (3PL), and specialty pharmacies. The administrative burden associated with inventory management, logistics, regulatory compliance, IT systems, and working with multiple vendors can quickly become overwhelming for smaller companies. Minimizing supply chain costs and maximizing efficiencies need to be a top priority. Finding a commercialization partner that offers end-to-end integration of a patient access hub and a distribution network structure that already has dispensing and wholesale contracts with retail pharmacies can empower smaller drug companies to achieve commercial success on their own. ### Elevate your brand’s potential with the PhilRx Patient Access Platform A fragmented dispensing network diminishes a manufacturer’s ability to deliver to patients and negatively impacts the bottom line. Teaming up with a commercialization partner that has invested in the distribution entities, technologies, and processes to support the needs of emerging life sciences companies bringing novel therapies to market, is the key to brand success. With Phil, you can access a nationwide pharmacy composed of retail, chain, and specialty pharmacies with 98% plan coverage. Real-time insights and the ability to set business rules ensure a consistent, predictable experience across the supply chain. Read this case study to discover how Phil unlocked coverage and maximized reimbursement for a leading women’s health product. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 3 Reasons Why Your Patient Services Program May be Falling Short on Medication Adherence Source: https://phil.us/3-reasons-why-your-patient-services-program-may-be-falling-short-on/ ## 3 Reasons Why Your Patient Services Program May be Falling Short on Medication Adherence Medication nonadherence is a long-standing problem linked to poor health outcomes, increased hospitalizations, and significantly higher healthcare costs. According to the CDC, out of the 3.8 billion prescriptions written in the U.S., one out of five are never filled. Even with good insurance and drug coverage, medication adherence rates for chronic conditions fall between 50-60%– a far cry from the 80% adherence rates medical experts say are necessary for optimal therapeutic efficacy. ### The financial impact of medication adherence on life science companies Disease-related complications arising from drug nonadherence take a toll on all healthcare stakeholders. For pharmaceutical companies, it becomes more difficult to prove a treatment’s value, and both short-term and long-term revenue suffer which can prevent their ability to continue to serve patients. A 2016 study estimated that the pharmaceutical industry loses $250 billion in actual and potential revenue due to nonadherence in the U.S. alone. Clearly, investing in medication adherence strategies promises the dual benefits of driving more revenue while positively impacting healthcare outcomes and costs. Life science companies that market specialty and specialty-lite therapies are tasked with developing support programs to help patients access and stay on their medicines. A lack of awareness leads to suboptimal tractionwith many of these programs. However, enhancing awareness is not enough to achieve optimal medication adherence. ### Is your patient services program optimizing adherence? Here are three major reasons your patient services program may fail to boost adherence to your branded therapy: #### 1. It’s not effectively addressing out-of-pocket costs Cost has long been considered one of the biggest barriers to medication adherence. The proliferation of high deductible health plans, more expensive medications, and larger copays have made it even more difficult for patients to afford the medications they need to treat their health conditions effectively. In a recent survey published in JAMA Open Network, one out of five patients reported cost-related nonadherence. Increases in out-of-pocket medication costs are directly correlated with higher prescription abandonment rates and nonadherence. For example, a 2022 IQVIA study found that 61% of prescriptions with an out-of-pocket over $250 are not filled by patients compared to just 7% when the cost is less than $10. Another study identified an out-of-pocket threshold of $51-$75, where adherence dropped significantly. Understanding (and addressing) the price sensitivity of the therapy’s patient population is crucial to your brand’s commercial success. You can drive better adherence through a patient services program that leverages data to offer the optimal patient out of pocket costs and ensures in-network pharmacy utilization to maximize prescription coverage. The keys to success are twofold: - Using an automated process that efficiently funnels patients to the best financial outcome for their prescribed medication. - Implementing a data-driven approach that optimizes any manufacturer-sponsored financial assistance programs by ensuring they support patients as intended while protecting your margins. #### 2. It lacks a truly digital-first patient experience Offering patient support services is the most tangible way for life sciences companies to connect and engage with patients across their prescription journey. When it comes to driving medication adherence in 2023, a digital-first approach is essential. Simply switching to electronic prescribing has been found to increase first-fill medication adherence by 10% compared to traditional paper prescriptions. Today’s healthcare consumers expect a frictionless healthcare experience driven by digitally enabled tools that provide: - Personalized information - Active participation in care and treatment - Real-time feedback - Convenience and on-demand services inclusive of refills - Options for how care is delivered and paid for A consumer-centric digital experience should make staying on therapy as easy as possible. Tailored outreach, such as refill reminders or giving patients the option to receive their medication by mail – several studies have shown that using mail-order pharmacies improves adherence rates – will help patients get started on their prescribed therapy faster and stay on it. With the understanding that patients often face logistical barriers to medication adherence, the PhilRx platform offers simple refill management, where patients can easily manage and be informed during the refill process. At checkout patients are notified of this and receive refill reminders 7 days prior to a refill via text informing them of the upcoming refill and allowing them to make any changes to their refill cadence if the timing doesn’t suit them. This process, coupled with the fact that we are able to drive higher coverage than other channels results in significantly higher refill adherence than other pharmacy channels. #### 3. It’s not leveraging data insights Without data insights, there’s no way your team can be adequately equipped to make informed decisions that drive therapy adherence. Every touchpoint along the patient's journey can influence the likelihood of prescription abandonment, time to therapy initiation, and adherence to therapy. Data insights offer greater visibility into the prescription process and how it impacts patients, so you can evolve your program as needed throughout the brand’s lifecycle and reduce the risk of a mid-life cycle crisis. You can develop more effective adherence strategies by tracking specific key performance indicators (KPIs) for your patient services program, such as patient engagement, time to fill, and covered dispenses. Data analytics also provide insight into what is typically an opaque process for all stakeholders, the prior authorization process. By tracking and analyzing this data, you gain insights into the utilization of your brand, payer reasons for denials or delays, how patients and prescribers respond to delays (i.e., prescription abandonment or writing a script for a different medication), and the impact of out-of-pocket costs and reimbursements. Pairing a data-driven approach with feedback loops helps commercialization teams develop a comprehensive understanding of the PA process, enabling them to enhance the overall process for key stakeholders – ultimately increasing medication adherence. ### Unlock medication adherence for your brand A patient services program in today's healthcare environment must address affordability issues, offer a modern digital experience, and leverage data insights across the prescription journey to drive medication adherence. Phil does just that – and more. Get in touch today to discover how partnering with Phil can help you transform patient access and reach brand goals. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 3 Ways a Patient Access Platform Breaks Through Barriers to Medication Source: https://phil.us/3-ways-to-breakthrough-barriers-to-medication/ ## 3 Ways a Patient Access Platform Breaks Through Barriers to Medication There was a time when the path from a physician prescribing to the patient starting drug therapy was straightforward. With the rise of value-based healthcare and novel specialty treatments, that’s no longer the case. Today, rigorous payer requirements and increasing out-of-pocket obligations frequently hinder patient access. Up to one-third of patients report they experience difficulties getting their prescription drugs due to delays, denials, and costs. At the same time, one in ten fail to take medications as prescribed solely because of financial constraints. For specialty drug manufacturers, patient access services have become as vital to a brand’s success as efficacy and price. Here are three ways manufactures can maximize the support they provide patients with a patient access platform: #### 1. Streamline benefits and reimbursement workflows Specialty and specialty-lite medication reimbursements are complicated by strict patient authorization (PA) and step-therapy criteria. There are a multitude of financial assistance programs from manufacturers and foundations that patients qualify for if they meet certain conditions. Managing insurance coverage, prior authorizations, reimbursements, and patient assistance program enrollments are labor- and time-intensive and can extend the time to therapy by days or weeks when done manually. It is well-established that impeding speed to therapy dramatically increases the risk of therapy abandonment and is detrimental to patient outcomes. Manual patient support workflows translate to missed opportunities; however, a patient access platform alleviates pressure on patients, providers, and pharmacies. Electronic benefits verification (eBV) and prior authorizations (ePAs) can be initiated at the point of care, decreasing delays, accelerating time to therapy, and minimizing patient out-of-pocket costs. By streamlining the entire patient access process, all stakeholders achieve better outcomes. #### 2. Enable data-driven decision-making Unlocking and leveraging data have been at the forefront of pharmaceutical manufacturers’ efforts to align business goals and outcomes for decades. With an over-abundance of data and a complex healthcare ecosystem, getting a holistic – and timely – view of stakeholders is more important than ever. Visibility into performance, real-time connectivity, and flexibility will enable the most accurate insights and best decisions to improve patient access. To drive better insights, manufacturers should be looking for the following elements in a patient access services platform: - Real-time data reporting that provides an accurate view of what’s happening across the patient access journey - The flexibility to support rapid onboarding, response to changes in reimbursement criteria or other data requirements, and scaling of support services up or down - Data integration and aggregation capabilities that offer a more comprehensive look at the effectiveness of and gaps within programs - Ease of use with customizable dashboards and reports - Interoperability with other systems along the supply chain - Security features that include encryption of health data and compliance with HIPAA guidelines #### 3. Deliver a patient-centered experience A large survey of U.S. healthcare consumers revealed that 59 percent expect a digital experience similar to online retailers like Amazon and Apple. Seventy-four percent felt improvement was needed when it comes to filling prescriptions. And this was before the Covid-19 pandemic. Undoubtedly, the consumerization of healthcare has accelerated over the last several years. Patients today expect simple and reliable digital interactions to help them get the care they want when they need it. A well-designed eHub platform delivers the patient-centered experience that healthcare consumers prefer and should include supplementing digital interactions with call-based support for those who prefer that route. While many patients may not want to talk on the phone and will rarely answer a call from an unknown number, a patient access platform has tech-enabled tools that connect with patients through their preferred communication channels. They can also support patients with automated reminders to take their medication or refill a prescription. A digitally enabled platform not only enhances dialogue with patients, but also personalizes their experience and increases engagement, all of which will help sustain medication adherence. ### Elevating your brand’s success Pharmaceutical manufacturers face substantial hurdles to enabling access to their brands – and they cannot afford to miss a piece of the puzzle when it comes to patient support services. A patient access platform can be an effective and efficient way to manage the complexities of patient access. It’s crucial to implement a strong patient support services program that aligns with your business goals and delivers on your brand objectives while helping patients access their therapy as conveniently and reliably as possible. Phil partners with life sciences and pharmaceutical companies to support the commercialization of their brands in a complex and ever-changing marketplace. Our next-generation patient access platform improves outcomes and experience by enabling speed to therapy with the lowest possible out-of-pocket burden. Learn more here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 4 Commercial Practices Shaping the Future of Life Sciences Source: https://phil.us/4-commercial-practices-shaping-the-future-of-life-sciences/ ## 4 Commercial Practices Shaping the Future of Life Sciences Developing a new drug is an incredibly costly, time-consuming, and high-risk venture. In the 12-15 years it takes to move a prescription therapy from discovery into the marketplace, pharmaceutical manufacturers invest an average of $2.3 billion. Given the considerable investment to make the drug available to patients, it's critical for commercial teams to develop a go-to-market model that delivers an appropriate return on investment (ROI). However it’s evident that conventional strategies are waining in their effectiveness – according to Deloitte, biopharma companies realized a mere 1.2% ROI in 2022, am 82% drop from 2021. With the BioPharma industry in the midst of a period of significant market pressures, including pricing and access challenges and growing consumer demands, manufacturers must consider new, innovative commercial models to ensure financial sustainability. This is supported by recent research that top biopharma companies have generated $1 billion in incremental revenue by modernizing their commercial practices. Here are four commercialization strategies that offer sustainable value in today's complex drug channel. ### 1. Utilizing digital channels to engage stakeholders Digital channels modernize the patient experience, amplify sales and marketing efforts, and present opportunities for operational efficiencies. From the point of prescription to enabling therapy adherence, digital processes reduce friction in the medication access journey while offering savings. For example, embedding Hub enrollment within the clinical workflow of HCPs improves the likelihood that they will prescribe your therapy, and patients will utilize support services that help them be successful. Simplifying this typically cumbersome process improves patient outcomes by ensuring that they use programs that can reduce out-of-pocket costs and accelerate therapy initiation. Other advantages that come with adopting digital channels include: - Earning a better return on investment from patient service programs - Increasing transparency across the patient access journey - Addressing prior authorization challenges effectively and efficiently - Making the most of manufacturer-sponsored financial assistance ### 2. Leveraging data to make informed decisions The quality of insights that can be derived from data along the prescription access journey present a tremendous opportunity to enhance commercial strategies that can deliver brand value. A McKinsey analysis found that advanced analytics can improve the EBITDA of pharmaceutical companies by anywhere from 45 to 75 percent enabling greater investment in programs that can improve patient outcomes. Real-time insights into the patient journey – from the provider visit to prescription processing to the patient receiving their medication from the pharmacy – help manufacturers uncover and respond to friction points to help them reach their commercial objectives. By implementing feedback loops, manufacturers dynamically glean data & insights to positively impact patient access to their brands. ### 3. Taking a gross-to-net lens to patient Hub services Market and economic realities increasingly challenge life science companies' efforts to meet forecasts and drive sustainable growth of their novel therapies – with patient access and gross-to-net (GTN) margins taking a hit. Consequently, GTN should be guiding prospective commercial strategies and fund allocations. With as many as 7 out of 10 patients on newly launched specialty drugs using a patient assistance program subsidized by the manufacturer, companies must analyze the financial implications and evaluate the balance between supporting patients and managing their GTN performance to sustain the long-term viability of their brands. Check out our whitepaper, “Optimizing Patient Access for Sustainable Growth: A playbook for life sciences manufacturers,” to learn more about this approach. ### 4. Implementing integrated commercialization strategies A fragmented commercialization approach diminishes a manufacturer’s ability to streamline access and deliver a positive patient experience. Conversely, deeper integration with providers, wholesalers, payers, pharmacies, patient services programs, and fulfillment minimizes interruptions to medication access. For example, integrated telemedicine models offer consumers the modern experience they want while providing manufacturers greater control over the entire medication access journey. And working with a hub partner with an integrated dispensing network can deliver significantly higher health plan coverage, enabling faster, more affordable patient access to branded therapies. The deeper the integration with the value chain, the greater the opportunity manufacturers have to positively influence outcomes and prove value to payers. ### Building sustainable value begins here In an era where developing a new drug is an arduous journey, the imperative for pharmaceutical manufacturers to rethink their commercialization strategies has never been more evident. The good news is that forward-thinking companies can build sustainable value by embracing modernized commercial practices. By partnering with Phil, your company can navigate the complex drug channel with confidence. As an end-to-end commercialization platform, PhilRx helps specialty-lite brands protect their GTN margins while unlocking patient access to maximize reimbursement. Life sciences companies access a nationwide partner pharmacy network designed to help patients receive prescribed therapy quickly, conveniently, and affordably. Phil automates prior authorizations and ensures manufacture-driven copay coupon utilization. Real-time insights give our manufacturer partners strategic visibility across the prescription journey. Check out this resource to discover how Phil can help unlock the unique value of your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 4 Strategies to Maximize Enrollment in your Patient Services Program Source: https://phil.us/4-strategies-to-maximize-enrollment-in-your-patient-services-program/ ## 4 Strategies to Maximize Enrollment in your Patient Services Program Low enrollment in manufacturer-sponsored patient services programs is rampant, so much so that many industry stakeholders have come to accept this as inevitable. This disappointing trend nearly always holds true if brands employ traditional “call center-based” hubs or specialty pharmacies that lack consumer-friendliness, creating unnecessary friction for patients and HCPs. These “clunky” programs typically result in enrollment rates between 20-30%. Whereas, digital hubs that deliver more responsive user experiences, in line with what patients engage with in other industries can witness up to 90% enrollment rates. However, numerous factors can diminish those rates, resulting in suboptimal results for brands looking to improve adoption, patient outcomes, and gross-to-net. At Phil, we’ve learned that there are a number of proven strategies that companies should deploy to maximize enrollment in patient services programs. ### 1. Elevate the hub to make it a core element of your go-to-market strategy A crucial objective for pharmaceutical manufacturers – second only to developing an efficacious drug – is getting that therapy into the patient’s hands. A brand’s go-to-market strategy must be built around the most productive channels and channel partners to make this happen. Additionally, brands going to market must have a realistic timeline of when they can expect to receive payer coverage. The right hub partner can be the most effective tool to maximize patient access and covered dispenses, yet this approach often takes a back seat to other priorities like building a large sales team or investing in marketing campaigns which are necessary but not sufficient to ensure strong brand growth. When the hub is viewed simply as a service provider at the end of the line, it’s unlikely to help the manufacturer meet its access and growth goals. Designing your hub as a core part of your brand’s go-to-market strategy that evolves with your patient access strategy requires integrating it within the prescription journey to maximize field team promotion, patient enrollment, prescription pull-through, and coverage. The bottom line? If you fail to treat your hub as a primary go-to-market partner, you are leaving patients and net revenue that can drive growth on the table. ### 2. Educate key stakeholders in the prescription journey Not taking the time or investing in the resources to effectively educate key stakeholders in the prescription journey on the value of your hub partner is a critical mistake. A lack of knowledge about the existence of the patient support program and how it works will significantly chip away at not only adoption but also its overall potential to transform your gross to net. Your field teams must ensure that healthcare providers and their office staff know what to do when a script is generated and that they are educated on the correct information to send to the hub. Patients will not enroll or engage in a hub if they don’t realize what it is, its benefits, and what they need to do to enroll, and their most trusted source is their provider. So, field representatives must be armed with the knowledge, messaging, and resources to educate healthcare provider offices properly. Manufacturers should monitor key success factors such as hub adoption, script quality, and patient enrollment at the territory level to gauge field performance to optimize outcomes nationally. With PhilRx, manufacturers have access to territory and HCP level insights to help them create hub performance benchmarks, so that they can identify and address any territories that are not effectively delivering strong outcomes. ### 3. Ensure your hub partner delivers a modern patient experience With the vast majority of brands coming to market today falling into the specialty and specialty-light categories, the hurdles to obtaining coverage are growing exponentially. The reality is that if a manufacturer thinks that utilization management is going to be a barrier (which it almost always is), the decision not to have a hub is very shortsighted because retail pharmacies are not going to provide the necessary diligence to fill out prior authorizations, step therapies, or whatever other coverage hurdles exist. Many specialty-light manufacturers have shied away from hubs because they perceive that a hub is 1,000 people in a call center with many fax machines. While these burdensome and expensive “traditional” hubs still exist, they’re no longer the only option. A digital hub can onboard and integrate into a brand’s patient access program quickly and essentially be up and running in just weeks at a fraction of the cost. Ideally, a digital hub partner enables manufacturers to only pay for outcomes like enrollments, coverage, and dispenses, eliminating the considerable overhead fixed costs incurred by legacy hub solutions that rely on human capital to generate activity. Additionally, digital hubs are much better equipped to partner with specialty-lite manufacturers using telehealth channels. For example, they can directly enroll patients in the support programs and automatically route the scripts to the hub pharmacy. ### 4. Aligning brand incentives with HCPs and Field Teams Incentivizing sales reps, patients, and HCPs to use your hub is crucial to maximizing patient enrollment and access. From a patient and HCP standpoint, you want to incentivize the program not with actual dollars but by employing a differentiated copay strategy. For example, suppose a manufacturer has a $1,000 WAC drug with a $30 copay with insurance coverage. The data clearly shows that they lose about 15% of their covered patients at that copay level. Their goal should be to incentivize the patient support program to reduce that out-of-pocket hurdle by an amount that incrementally increases the volume of filled scripts while maintaining positive gross-to-net and enables reps to assure potential prescribers by saying, "Your patient can get their prescription filled at the lowest cost by enrolling in our hub." It's also imperative to financially incentivize field reps to drive patient enrollment. While field reps must understand how the hub works and trust that it will work as promised,the best way to get buy-in and drive the desired actions is to develop a rep compensation scheme that heavily favors enrollment in your most productive channel. This can be accomplished either by incentivizing based on the number of new prescriptions sent to the hub, or offering incremental incentives for scripts that get covered - the logic on the latter is that the hub will deliver the highest percentage of covered dispenses. ### Unlocking patient access to reach your brand’s goals Sending a product into the retail “wild”without a preferred channel that is likely to get coverage is a recipe for stagnation in the modern drug channel. Phil’s manufacturer partners are achieving 90%-plus enrollment rates and improving their visibility beyond lagging retail claims data, so they can map out friction points along the patient journey to make program adjustments accordingly. One example is a women’s health brand that was working with a large specialty pharmacy witnessing enrollment rates in the single digits. Once they adopted the PhilRx platform, they quickly reached a 91% program enrollment rate. As their trusted partner, we co-developed their hub program and have helped them mold it as their brand goals and market conditions have changed. Visit https://phil.us/life-sciences to learn more. Andrew Duncan is Vice President of Business Operations and Analytics at Phil, Inc. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Strategies to Ensure the Long-term Success of Your Patient Services Programs Source: https://phil.us/5-strategies-to-ensure-the-long-term-success-of-your-patient-services/ Infographic ## Strategies to Ensure the Long-term Success of Your Patient Services Programs Discover the key tenants of a successful patient services program that drives transformative brand outcomes Download PDF Life sciences manufacturers face growing challenges with building patient support programs that are also financially sustainable. Discover key research findings and industry insights that offer a strategic approach to ensuring patient service programs drive long-term brand value. #### In this infographic, you’ll learn: - The state of drug utilization management and how manufacturers are responding - Key trends in optimizing patient support with a gross-to-net lens - Strategies for building a sustainable patient services program #### Harness your patient access potential Ready to accelerate your access program? We partner with speciality lite brands to create sustainable access approaches that drive transformative outcomes. Book a demo to learn more about the PhilRx patient access platform. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 5 Trends Set to Impact Patient Access to Prescription Therapy in 2024 Source: https://phil.us/5-trends-set-to-impact-patient-access-to-prescription-therapy-in-2024/ ## 5 Trends Set to Impact Patient Access to Prescription Therapy in 2024 The pharmaceutical industry finds itself at the crossroads of innovative treatments and technological advancements redefining how patients access prescribed therapy. However, this tremendous innovation has also presented unique challenges in securing patient affordability and access to therapy. These five key trends should be considered and will influence how manufacturers should think about shaping their services programs heading into 2024. ### 1) Patients are struggling with affordability challenges Patients continue to worry about affording their healthcare. A recent KFF consumer survey found that in the past year, 4 out of 10 insured adults skipped or delayed some care due to cost, and 1 out of 6 had trouble paying medical bills. In 2022 alone, out-of-pocket costs led to the abandonment of 94 million prescriptions. Unsurprisingly, as we move into the 2024 election year, 80% of voters expect the presidential candidates to address the affordability of healthcare, and 64% want to hear about prescription drug costs. According to a Deloitte survey, life sciences companies are acutely aware of these affordability concerns and expect the economy and inflation to influence their strategies in 2024. Biopharmaceutical companies have stepped up their efforts to support patients, spending over $80B during the last five years to help offset OOP costs for commercially insured patients. In 2024, manufacturers should continue to analyze patient access program design and consider the subsequent financial implications to ensure that they sustainably support affordability while effectively managing their gross-to-net (GTN) performance to sustain the long-term viability of their branded therapies. ### 2) A fragmented healthcare experience persists Fragmented healthcare is a persistent problem that negatively affects patient outcomes and experience, particularly for patients with chronic conditions. Consumers want to be able to navigate the prescription journey quickly and conveniently, but what they typically get is a disjointed, cumbersome, and frustrating experience. This problem is compounded by the fact that healthcare providers, pharmacies, and payers mainly operate in silos resulting in limited transparency for patients. Pharmaceutical manufacturers can be part of the solution. By partnering with a technology-enabled hub providers that offer the integrated, streamlined experience across the prescription journey that consumers expect, brand teams can set the stage for successful, modern patient access services in 2024. ### 3) Digital innovations in healthcare continue to evolve Digital technologies powered by generative AI are exploding across industries. The global generative AI market in healthcare is expected to reach $21.74 billion by 2032. However, according to a McKinsey analysis, pharmaceutical companies are substantially lagging when it comes to adopting digital technologies to transform their business models. In 2024, life science manufacturers should undertake commercialization practices that increase patient access to their branded therapies and offer sustainable value in a complex drug channel. With advanced digital technologies, brand teams can: - Utilize digital channels to engage stakeholders - Leverage real-time data to make informed decisions - Monitor gross-to-net impact - Implement integrated commercialization strategies ### 4) Payer cost controls are growing MGMA’s recent Annual Regulatory Burden Survey finds that medical practices face ongoing – and growing – burdens associated with payer cost controls. Respondents overwhelmingly noted increasing prior authorization (PA) requirements, patient access delays, and high administrative burdens: - 89% of respondents rated PA as very or extremely burdensome - 97% said their patients had experienced care delays or denials due to PA requirements - 92% have hired or redistributed staff to keep up with increasing PA requests Considering that PBM organizations anticipate using price negotiations and UM tools to reduce spending by consumers and plan sponsors by more than $1 trillion through 2029, it’s safe to say these price control tactics will continue to challenge patient access to branded retail therapies. Many pharma companies already invest considerably in rebate programs, value-based contracting, and patient hubs for their specialty therapies. Moving forward, it’s critical for brand teams not to overlook the high-impact – and cost-effective – strategy of investing in digital technology to reduce the administrative burden of PAs. ### 5) Employers want transparency Survey data from Business Group on Health shows that the rising cost of prescription drugs is a prevalent concern for employers. In 2022, prescriptions accounted for almost a quarter of employers’ healthcare costs, with specialty medications accounting for over 50%. Going into 2024, employers are particularly concerned about high-cost drugs in the pipeline and identify transparency as a tool to help contain costs and improve quality. They strongly support engagement platforms, enabling employees to make more educated healthcare decisions and better navigate their care. This trend presents a tremendous opportunity for pharmaceutical manufacturers to enhance transparency with patient access platforms that: - Help employees navigate the complicated prescription journey - Make it easier for employees to access and afford prescribed treatment - Give employees options for how to engage and receive communications - Provide more visibility into prescription status ### Stay ahead of the curve In this ever-evolving landscape, staying ahead of the curve is not just a strategic choice – it’s essential to thrive in a highly competitive marketplace. The manufacturers that can navigate these trends strategically and proactively will be well-positioned to optimize patient access and drive the success of their branded therapies. Request a demo today to discover how Phil can future-proof your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 5 Ways PhilRx Meets Patients’ Expectations for Digital Healthcare Source: https://phil.us/5-ways-philrx-meets-patients-expectations-for-digital-healthcare/ ## 5 Ways PhilRx Meets Patients’ Expectations for Digital Healthcare From travel and entertainment to shopping and banking, digital experiences surround consumers daily. So, it should come as no surprise that they have high expectations for seamless and connected digital experiences in healthcare. And these expectations are driving demand. The estimated size of the global digital health market in 2023 was $240.9 billion and is expected to grow at a CAGR of almost 22% through 2030. A strong U.S. market for e-prescription services is a driver of this growth. According to a 2023 consumer survey, 69% of respondents preferred to refill their prescriptions virtually rather than in person – an eight percentage point increase from the previous year. A digital hub can be instrumental in breaking down patient access barriers to retail and specialty-lite therapies. And, ensuring that it has a user-first design that effectively meets consumer expectations is critical. Here are five ways the PhilRx Digital Hub supports brand teams’ efforts to meet those expectations: #### 1) Streamlined access to medications Consumers want digital solutions that provide easy and quick access to healthcare services and information, including their prescribed medications. PhilRx Digital Hub streamlines the patient access experience from start to finish by integrating various services, such as prescription management, program enrollment, benefits investigation, prior authorization (PA) assistance, and prescription delivery. With digital tools that deliver a frictionless experience on par with what consumers experience in other industries, this integration ensures that patients can receive their medications without unnecessary delays, addressing the expectation for convenient, hassle-free access. #### 2) Communication and engagement Many pharmaceutical companies struggle to engage effectively with patients. A patient services program that is too complex or not delivered in a consumer-friendly way is bound to underperform. Today’s consumers expect an anytime-anywhere mobile experience. With 8 out of 10 preferring digital channels to communicate with healthcare providers and brands, it is essential to consider how a hub partner engages with patients. PhilRx provides digital communication tools that enable brand teams to engage with patients on their terms, including a patient portal, digital enrollment, and text reminders to keep patients informed about their prescription at every step. #### 3) Affordability and transparency With the rise in out-of-pocket healthcare costs, consumers are more concerned than ever about the affordability of their medications. Drug utilization management requirements, such as PAs and step therapy, often lack the transparency required for patients and their providers to make informed treatment decisions that support adherence. Pharmaceutical manufacturers have an opportunity to build trusted relationships with patients by enabling greater visibility into the prescription journey. While keeping patients in the loop, PhilRx provides real-time information on out-of-pocket costs, insurance coverage, and available copay assistance programs. This transparency helps patients navigate the complexities of medication access more efficiently while pharmacy network integration drives affordability. #### 4) High quality care Consumers expect digital solutions to improve their quality of care. PhilRx utilizes data analytics and automation to enhance the quality of care for patients by: - Offering education and support to maximize enrollment and ensure a positive experience with the brand’s patient services program - Boosting adherence by simplifying the prescription refill and streamlining the delivery process #### 5) Data security and privacy In a 2022 survey, 9 out of 10 patients believed their provider or hospital should be able to review and verify the security of health apps before those apps gain access to their health data. With the unprecedented number of healthcare security breaches in 2023, data security and privacy concerns continue to grow for consumers using digital health services. At the same time, patient access has become more complex, increasing manufacturers' compliance challenges. PhilRx is a fully HIPAA-compliant system that handles all patient data securely. Only licensed pharmacy personnel and HIPAA-certified patient advocates can view relevant patient information. Any sensitive information entered on hub forms is encrypted using SSL or other technologies. #### Meet patients where they are with PhilRx PhilRx Digital Hub meets patients' expectations with a user-first design that seamlessly connects them with their prescribed therapy. We offer an alternative channel solution to help retail and specialty-lite brands drive patient access, unlock coverage, and maximize reimbursement without compromising gross-to-net. Our consultative approach uses real-time insights to provide strategic recommendations and visibility across the prescription journey - book a demo for a personalized tour of the PhilRx Digital Hub. Check out our eBook on how your commercial team can create an exceptional patient access experience that will transform your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 6 Healthcare Trends Impacting Pharma Commercialization Source: https://phil.us/6-trends-impacting-pharma-commercialization/ ## 6 Healthcare Trends Impacting Pharma Commercialization What commercialization strategies should life sciences companies focus on as they look ahead? It’s crucial to monitor trends closely to navigate the evolving healthcare landscape better and build winning strategies. Here are the top six healthcare trends affecting pharma commercialization today: #### 1. Patient financial responsibility Healthcare costs are increasingly burdensome for many patients. In 2021, total out-of-pocket patient obligations amounted to about $91.6 billion, up 10% from the previous year. What’s more, patient financial responsibility is expected to increase annually by 9.9%, hitting $800 billion by 2026. Already, 3 out of 10 Americans cite high out-of-pocket costs as a barrier to obtaining care. An estimated 13 million U.S. adults fail to fill their prescriptions due to affordability issues. Pharmaceutical manufacturers will need to adopt pricing strategies and meaningful interventions to address patient financial obligations and drive medication adherence. #### 2. Value-based payment The U.S. healthcare industry is under extreme pressure to contain soaring costs, particularly as the population ages. In the fight to manage unsustainable healthcare costs, policymakers and payers are focusing on value-based payment models. Value-based payment is “a concept by which purchasers of health care (government, employers, and consumers) and payers hold the health care delivery system at large accountable for both quality and cost of care.” The shift from fee-for-service has led to payers establishing treatment protocols, such as tiered drug formularies. The Department of Health and Human Services (HHS) recently announced a plan to curb drug prices through value-based payments. As pay-for-performance escalates, pharma companies need to be prepared to demonstrate value to payers. #### 3. Consumerization The rise of digital technologies over the last decade fueled the growth of consumerization within healthcare. The COVID-19 pandemic has only accelerated this trend. Patients-turned-consumers are demanding the same access, convenience, and transparency they experience in other industries. Today’s patient is in the driver’s seat – they are more informed and more proactive about their care. Pharma manufacturers can take advantage of this trend by finding innovative ways to engage and empower patients. #### 4. Big data and analytics Big data refers to the vast amounts of data that inundate businesses and organizations every day. According to the Healthcare Information and Management Systems Society (HIMSS), big data and analytics are top trends in healthcare. Currently, big data is categorized by what is known as the five V’s: - Volume : There is more data than ever collected from various sources, such as smart devices, transactions, social media, medical equipment, and more. - Velocity : Data streams are coming in at an unprecedented speed – often in real-time – from Apps, patient portals, and electronic health records. - Variety : Data comes in all types of structured and unstructured formats. - Veracity : Verifying the quality of data is essential to ensuring its credibility. - Value : What data brings to an organization, such as improving health outcomes, defines its value. According to McKinsey & Company, the application of big data analytics in the pharma industry can lead to better decision-making and a value generation of $100 billion across the U.S. healthcare system. Manufacturers have the opportunity to leverage data analytics to drive market access. #### 5. Artificial intelligence Big data is the foundation of artificial intelligence (AI), which according to IBM, “leverages computers and machines to mimic the problem-solving and decision-making capabilities of the human mind.” AI offers health science companies opportunities to address many challenges, including finding new ways to lower costs, improve outcomes, and design effective commercialization, marketing, and post-launch strategies. Recent research finds that about 50 percent of global healthcare companies plan to implement AI strategies and broadly adopt this advanced technology by 2025. In fact, the size of the global AI healthcare market is expected to reach $67.4 billion by 2027. #### 6. Specialty drugs Specialty drug development is a rapidly expanding area in pharma, and the utilization of these medications is expected to grow exponentially in the coming years. In fact, nearly two-thirds of all new FDA drug approvals have been for specialty drugs over the past several years, with many more in the pipeline. Advanced medical technologies are driving the demand for curative therapies, such as cell and gene therapies. Specialty drugs – while expensive – often offer the most effective and possibly only treatment for diseases that historically had few treatment options. Payers are closely scrutinizing these medications because of their high cost. Specialty drug manufacturers will need to work closely with payers and formulary decision-makers to prove the value their brands bring to patients and healthcare. As pharmaceutical markets, pipelines, and policies continue to evolve, life science companies of all sizes need an agile and flexible approach to optimize commercialization. Commercialization strategies are highly complex, costly, and cumbersome to execute – learn how Phil can help your company here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 8 Metrics that Matter When it Comes to Measuring Your Patient Access Program Source: https://phil.us/8-metrics-that-matter-when-it-comes-to-measuring-your-patient-access-program/ ## 8 Metrics that Matter When it Comes to Measuring Your Patient Access Program For life science companies, patient support services have become as vital to a brand’s success as efficacy and price. A patient support services program has the potential to help break through barriers to medication access. That’s why it’s crucial to make sure it aligns with your business goals and delivers on your brand objectives while helping patients access their therapy as easily as possible. The only way to evaluate this is by examining the right metrics. Each touchpoint along the patient's journey can influence the likelihood of prescription abandonment, time to therapy initiation, and adherence to therapy. With more than $300B in estimated treatment value lost due to medication non-adherence, investing in services to help patients comply with their prescribed treatment is well worth the investment. Tracking specific key performance indicators (KPIs) for patient access and support programs can help drug manufacturers evaluate their return on investment and develop more effective adherence strategies. ### How well is your patient access and support program performing? If your commercialization team doesn’t know the answer to that question, it’s time to identify KPIs that will help you determine where your program stands. Metrics bring visibility into the patient journey and help pharmaceutical manufacturers measure the impact of their patient support program and advance medication adherence with data-driven interventions. Here are eight KPIs that hold valuable patient access insights for pharmaceutical manufacturers: #### 1. New scripts Getting a prescription is the first step in the patient access journey. At the very least, providers need to know your brand exists, its clinical profile, and which patients are the right fit for your therapy. Tracking new scripts gives manufacturers an idea of the effectiveness of their sales and marketing efforts; additionally, it is a key measure that can be utilized to determine if your team is getting the message across about specific access channels that you are looking to support. #### 2. Enrollments A common struggle pharmaceutical manufacturers face with their access programs is getting patients to join them. Once a program is launched, tracking the number of enrollments is a crucial indicator for evaluating its potential impact on new patient starts, access, and medication adherence. In addition to evaluating the number of patients that enroll, it’s important to look at how quickly they sign up after their provider prescribes the treatment, which channels they opt into, and which enrollment channels perform best for recruitment. #### 3. Engagement After enrollment, it’s important to assess members’ levels of engagement with the program. A successful program translates to long-term medication adherence and sales growth, so metrics that show how long patients stay engaged with the program and the patient drop-off rate will give the medication access team a better picture of engagement over time and if that corresponds to improved time on therapy. Discover how to improve patient engagement by downloading our guide, “Modernize the Patient Access Experience. Transform Your Pharmaceutical Brand.” #### 4. Time to fill Drug utilization measures, such as prior authorizations (PAs), increase the risk of prescription abandonment, treatment delays, and therapy disruption. The amount of time it takes from writing a prescription to fulfillment at the pharmacy – also known as speed-to-therapy – is an indicator of how efficient the PA process is for a specialty therapy. To effectively optimize market access of their brands across the lifecycle, pharma manufacturers need to be able to track the time to fill metric and take steps to reduce the negative impacts of PAs. Read our guide, “Successfully Navigating Prior Authorization” to learn more. #### 5. Refills Analyzing medication refill patterns can provide insight into how well a patient access program is working to keep patients adherent. Not only does nonadherence negatively impact health outcomes, but it also hurts the bottom line. One study found that medication nonadherence costs the pharma industry an estimated $250 billion in potential annual revenue, a 33% increase from 2012. Measuring refill rates and the gap days between refills are both KPIs that gauge medication adherence. With these metrics on hand, manufacturers can make data-informed decisions to improve adherence, creating more opportunities to demonstrate their therapy’s value to payers. #### 6. Covered dispenses Low levels of insured patients receiving prescription coverage is detrimental to brand success. That’s why it’s crucial to track the percentage of branded dispenses that are covered by an insurance plan. An effective patient access program should operate in a way that results in the highest possible coverage. Check out this case study to see how a pharmaceutical brand unlocked coverage for 90% of their dispenses. #### 7. Reimbursement rates Reimbursement rates are indicative of the “quality” of the pharmacy network in terms of coverage. High reimbursement rates indicate financial alignment with dispensing pharmacies and minimize uncovered card usage. Low reimbursement is more likely to lead to prescription abandonment and overutilization of manufacturer coupons. #### 8. Coupon utilization Knowing the rate of sponsored coupon redemptions can help manufacturers evaluate whether their financial support is performing as planned or being overutilized and abused. Depending on the life-cycle of the product, it may also reveal issues with the pharmacy network and higher out-of-pocket costs than are necessary. ### What’s your brand’s untapped potential? At every stage of your brand’s lifecycle, there is untapped potential to accelerate growth and capitalize on opportunities in the marketplace. A Forrester report revealed that data driven companies experience an annual average growth rate of over 30%. Pharma companies that invest in capabilities to capture and analyze the best data to make informed commercialization decisions will realize better business outcomes and a competitive advantage. Finding a commercialization partner to capture impactful data and then help leverage the analytics to inform efficient and effective decision-making will drive your brand's success. Phil provides an integrated approach to data analytics across the patient journey giving manufacturers real-time visibility into the patient prescription journey and control over their distribution channels. Discover how you can leverage Phil’s technology to improve patient access to your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 8 Patient Access Trends Pharma Leaders Should Consider in 2025 Source: https://phil.us/8-patient-access-trends-pharma-leaders-should-consider-in-2025/ ## 8 Patient Access Trends Pharma Leaders Should Consider in 2025 With a new year brings new brand goals. Retail and specialty-lite brand teams continue to face an evolving patient access landscape that's significantly impacting their commercialization strategies. From the expansion of direct-to-consumer (DTC) models to the growing importance of real-world evidence, these emerging trends are reshaping how patients interact with healthcare systems and access prescribed therapies. To stay competitive and meet evolving patient needs, pharma leaders should adapt their approaches to patient support, leverage new technologies, and embrace innovative channel solutions. Here’s a look at eight key patient access trends that pharmaceutical manufacturers need to watch to prepare for in the upcoming year and beyond. #### 1) Expansion of Direct-to-Consumer (DTC) Models Pharmaceutical companies are increasingly implementing DTC programs to transform the patient experience, creating new opportunities to better serve patients and healthcare providers (HCPs). A few examples of this include telemedicine channels, digital pharmacy services, and automated prior authorization (PA) processing. For an in-depth overview and strategic roadmap for building an effective digital care initiative, read our guide to DTC success. #### 2) Growth in AI-Driven Patient Support AI investment in healthcare is projected to grow significantly, from about $20 billion in 2024 to $150 billion over the next five years. Pharmaceutical companies are using more AI-powered tools, such as chatbots, to provide medication reminders through text or voice interactions. #### 3) Surge of Digital Health Tools The market value of digital patient engagement was over $200B in 2022 and is forecasted to grow over 18% annually through 2032. As more patients value online, self-serve models to improve their healthcare experience, pharmaceutical manufacturers will need to offer digital services that meet patients' expectations and seamlessly connect them with their prescribed therapies. #### 4) Shifts in Patient Engagement Channels Patients and providers are increasingly seeking health information through non-traditional channels like social media. According to recent surveys: - 71% of healthcare-related searches on YouTube are focused on finding information about specific medical conditions and treatments - 73% of consumers trust the health information shared by HCPs on Instagram - 91% of HCPs use social media for professional purposes, with 65% using it for patient education. Pharmaceutical companies are adapting their patient support communication strategies to better align with evolving needs. #### 5) Greater Focus on Personalized Medicine The trend towards personalized medicine will impact patient access strategies for pharmaceutical manufacturers. Companies can capitalize on this shift by developing tailored patient support programs that facilitate access to specialty-lite therapies. By leveraging real-time data tools, manufacturers can create personalized access pathways for each brand, streamlining access to care and improving medication adherence. Additionally, flexible financial assistance programs will continue to be crucial to ensure equitable access to prescribed therapies across diverse patient populations. #### 6) Increased Importance of Real-World Evidence The mounting recognition of the value of real-world evidence (RWE) to shape informed decision-making within the healthcare regulatory landscape is leading the vast majority of pharmaceutical companies to invest in dedicated RWE teams. RWE can significantly impact medication access by providing valuable insights into drug safety, effectiveness, and value in real-world settings. Pharmaceutical manufacturers can use this data to support regulatory decisions, optimize clinical trials, and demonstrate product value to payers, ultimately improving patient access to innovative therapies. #### 7) Rise of Value-Based Care Models The value-based care (VBC) market, valued at $12.2B in 2023, is projected to reach $43.4B by 2031. From 2023 to 2024, HCP participation in VBC models increased by 25%. These payment models impact patient access to prescribed therapies by emphasizing cost-effectiveness and outcomes. Pharmaceutical manufacturers should adapt by demonstrating the long-term value of their products through RWE, developing innovative risk-sharing agreements with payers, and creating patient support programs that align with VBC goals of improving adherence and reducing overall healthcare costs. #### 8) Growing Expectations for Transparency Patients’ expectations for greater transparency in healthcare needs to be addressed by manufacturers. According to one study, only 16% of consumers believe pharmaceutical companies market their products in a trustworthy manner. To address this, manufacturers must prioritize transparency in their patient access strategies. Implementing digital tools that provide proactive updates on prescription status and costs, benefits verification, and PA processes can help earn patient trust. #### Navigating a Complex Access Landscape In 2025, staying ahead of the curve is not just a strategic choice – it’s essential to surviving in a highly complex and competitive market. The brand teams that can effectively navigate these shifts will be well-positioned to create a seamless the medication access experience for patients and providers while driving brand outcomes. PhilRx is an innovative digital hub that uses a modern approach to help retail and specialty-lite brands facilitate patient access and adherence, maximize covered dispenses, and drive reimbursement without compromising gross-to-net. Discover how your brand team can set the stage for commercial success in 2025 – read our eBook for industry-trusted strategies and best practices. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 8 Strategies to Decrease Prescription Abandonment and Improve Medication Adherence Source: https://phil.us/8-strategies-to-decrease-prescription-abandonment-and-improve-medication/ ## 8 Strategies to Decrease Prescription Abandonment and Improve Medication Adherence An estimated 1 in 5 prescriptions are left at the pharmacy counter. This vexing healthcare challenge, known as prescription abandonment, is part of the broader concern of medication non-adherence, which also includes not taking medications as prescribed or failing to refill prescriptions. The issue is so prevalent that the American Medical Association (AMA) advises healthcare providers to "consider medication non-adherence first as a reason a patient's condition is not under control." #### Consequences of Prescription Abandonment Failure to stick with prescribed therapy is a substantial obstacle to a providers’ ability to deliver good patient outcomes and realize the value of pharmaceutical innovation. Prescription abandonment can have severe consequences for patients, particularly those with chronic conditions. When patients do not take their medications as prescribed, they risk worsening their health conditions, which can lead to increased hospitalizations and even death. Studies show that poor medication adherence is responsible for approximately 125,000 preventable deaths and as much as $300 billion in avoidable healthcare costs each year. Conversely, good medication adherence is linked to a 21% reduction in long-term mortality. For pharmaceutical companies, medication non-adherence and prescription abandonment often translate to lost revenue and diminished brand reputation. High abandonment rates can signal to healthcare providers that a medication is not accessible or affordable, potentially leading to decreased prescribing. #### 8 Strategies to Improve Medication Adherence Each touchpoint along the prescription journey can influence the likelihood of a patient accessing their medication and taking it as prescribed. With that in mind, there are several strategies that pharmaceutical brands can leverage to mitigate the risks of prescription abandonment and medication non-adherence. - Enhance patient education. Educating patients about the importance of their medication, how it works, and the consequences of non-adherence can significantly improve adherence rates. For optimal accessibility, create a modern patient experience that utilizes various channels catered to diverse populations. - Implement copay assistance programs. Higher out-of-pocket costs are associated with increased rates of cost-related medication non-adherence and prescription abandonment. Manufacturer-sponsored copay assistance programs can reduce or eliminate out-of-pocket costs, making medications more affordable and accessible – and less likely to be left behind at the pharmacy counter. - Leverage digital tools. Digital tools, such as text reminders and simple refill management, can help patients start and stay on therapy with less effort. Find a digital solution that offers a comprehensive approach to improving medication management that includes educational content and adherence tracking. This playbook covers our recommended hub approach. - Increase transparency. Enabling greater visibility across the prescription journey can improve treatment adherence, patient satisfaction, and health outcomes. For example, learning about the cost of medications at the point of care can help patients make informed decisions and avoid sticker shock at the pharmacy, mitigating the risk of prescription abandonment. - Offer mail-order delivery and easy refills. Providing options to have a prescription delivered and easily refilled makes it more convenient and easier for patients to adhere to their medication regimen, particularly for those with mobility issues or who live in pharmacy deserts. - Simplify the prior authorization process. In a 2023 AMA survey, 78% of HCPs reported that PAs at least sometimes lead to treatment abandonment, and 83% reported that the number of PAs required for prescription medications have increased over the last five years. Taking steps to simplify the PA process can significantly improve the likelihood that patients will follow through with their prescribed medication. - Partner with a robust dispensing network. Working with a commercialization partner that integrates a solid national network of pharmacies, particularly a non-dispensing model, into its solution will help lay the foundation for covered dispenses, ensuring patients have consistent and affordable access to their prescribed medication. - Introduce a digital channel strategy. This approach allows manufacturers to leverage advanced analytics so brand teams can have a complete picture of the patient access journey—from prescribing to dispensing—and even down to the territory level. With this information in hand, they can monitor prescription abandonment and make program adjustments that will have the best impact. #### Ready to combat prescription abandonment? At Phil, we are driven to help retail and specialty-lite manufacturers unlock patient access. PhilRx is an innovative, end-to-end digital hub platform with an integrated pharmacy network that streamlines the PA process, provides full visibility across the prescription journey, and delivers a modern access experience that improves prescription adherence. Get started by booking a tour of the PhilRx Digital Hub. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Addyi Prescription Source: https://phil.us/addyi/ Powered by PHIL, Inc. HAVE AN ADDYI® PRESCRIPTION NEED AN ADDYI® PRESCRIPTION FOR PATIENTS: ## WHY I CHOOSE PHILRX PHARMACY FOR MY ADDYI® PRESCRIPTION "I transferred my Addyi® prescription to PhilRx and not only did they save me over $250, they shipped my Addyi® directly to my house, and their refill process has been simple and straightforward. No more waiting in the line at the pharmacy down the road. This has been a great experience!" Jennifer 37, actual Addyi® patient Free home delivery (Most convenient way to get Addyi®) Refills made simple (For the best pharmacy experience) ### ABOUT ADDYI® HAVE AN ADDYI® PRESCRIPTION? NEED AN ADDYI® PRESCRIPTION? Take Addyi® once daily, at bedtime, for two months to realize the full ongoing benefits.* *Some patients notice changes in a couple of weeks but continue daily use for up to 8 weeks to realize Addyi®'s effects. Prescribing Information.pdfMedication Guide.pdf Getting Addyi® was not only simple with PhilRx, I could not believe the savings! And I love that my prescription is shipped right to my door. Thank you PhilRx for an excellent experience! Christine, 41 Actual Addyi® patient I had no desire. I thought it was just me… Something that happened as I got older. But then one of my girlfriends told me about Addyi® All I have to say is OMG… I wish I had learned about this sooner! Shannon, 44 Actual Addyi® patient FOR PROVIDERS: How toPrescribeADDYI® "Getting Addyi® should not be difficult. And unfortunately that's what my patients were experiencing with the big box pharmacies. I only prescribe Addyi® through PhilRx and the process is great - more of my patients are getting their Addyi® covered and less hassle for my staff and me. It's a win win!" Dr. Miller, Addyi® #### SEARCH "PHILRX" IN THE EMR'S RETAIL PHARMACY FINDER OR SEARCH BY: Phone: (855) 977-0975 NPI: 1487163598 Address: 150 E. Campus View Blvd, Suite 210, Columbus OH 43235 #### SEND AN RX VIA PHONE OR FAX: Phone: (855) 977-0975, Option 1 Fax: (888) 975-0603 #### Important Safety Information ##### What is ADDYI® (add-ee) (flibanserin) Tablets? ADDYI® is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: - a medical or mental health problem - problems in the relationship - medicine or other drug use. ADDYI® is not indicated in men. ADDYI® is not for use to improve sexual performance. ##### IMPORTANT SAFETY INFORMATION What is the most important information I should know about ADDYI®? Your risk of severe low blood pressure and fainting (loss of consciousness) is increased: - if you drink alcohol close to the time you take your ADDYI® dose, - if you take ADDYI® with certain medicines, or - if you have liver problems and you take ADDYI®. To lower your risk of low blood pressure and fainting (loss of consciousness): - Do not drink alcohol close to the time you take your ADDYI® dose Wait at least 2 hours after drinking 1 or 2 standard alcoholic drinks before taking ADDYI® at bedtime. Skip your ADDYI® dose if you drink 3 or more standard alcoholic drinks that evening. - After taking ADDYI® at bedtime do not drink alcohol until the following day. Examples of 1 standard alcoholic drink include: - one 12-ounce regular beer - 5 ounces of wine - 1.5 ounces of distilled spirits or shot Tell your doctor about other medicines you take. Do not take or start taking any prescription or over-the-counter medicines, or herbal supplements without first talking to your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI®. Do not take ADDYI® if you have liver problems. If you take ADDYI® and you feel lightheaded or dizzy, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you feel like you could faint (lose consciousness). If you faint, tell your doctor as soon as you can. Who should not take ADDYI®? Do not take ADDYI® if you: - take certain medicines. Taking ADDYI® with certain other medicines can increase the amount of ADDYI® in your blood and cause severe low blood pressure, fainting (loss of consciousness), and sleepiness. - Do not take ADDYI® if you are taking any of the following medicines: Certain medicines used to treat HIV-1 infection Certain medicines that you take by mouth used to treat fungal infections Certain antibiotics Certain medicines used to treat Hepatitis C infection Certain medicines used to treat high blood pressure, chest pain (angina), or other heart problems Nefazodone: a medicine used to treat depression - Ask your doctor or pharmacist if you are not sure if you take any of the medicines listed above. These are examples of the medicines that you should not take if you are taking ADDYI®. Tell your doctor about all the medicines you take before you start taking ADDYI® - have liver problems - are allergic to flibanserin or any of the ingredients in ADDYI®. See Medication Guide for the full list of ingredients. What should I tell my doctor before taking ADDYI®? Before you take ADDYI®, tell your doctor about all of your medical conditions, including if you: - drink alcohol, use drugs, or have a history of alcohol or drug abuse - have ever had depression or other mental health problems - have low blood pressure or a medical condition that can cause low blood pressure - are pregnant or plan to become pregnant. It is not known if ADDYI® will harm your unborn baby. - are breastfeeding or plan to breastfeed. It is not known if ADDYI® passes into your breast milk. You and your doctor should decide if you will take ADDYI® or breastfeed. You should not do both. Tell your doctor if you have had an allergic reaction such as hives, itching, or trouble breathing during or after receiving a dose of ADDYI®. Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADDYI® can affect the way other medicines work, and other medicines can affect the way ADDYI® works, and can cause serious side effects. What should I avoid while taking ADDYI®? - Do not drink alcohol close to the time you take your ADDYI® dose because this increases your risk of severe low blood pressure and fainting (loss of consciousness). - Do not drive, operate machinery, or do things that require clear thinking until at least 6 hours after you take ADDYI® and until you know how ADDYI® affects you. - Do not drink grapefruit juice if you take ADDYI®. Drinking grapefruit juice during your treatment with ADDYI® increases your risk of severe low blood pressure and fainting (loss of consciousness). - You should not take the herbal supplements St. John's Wort, ginkgo, or resveratrol or certain over-the-counter medicines such as cimetidine until you talk to your doctor. Taking ADDYI® with these herbal supplements and over-the-counter medicines may increase your risk of low blood pressure, fainting (loss of consciousness), and sleepiness. What are the possible side effects of ADDYI®? ADDYI® can cause serious side effects, including: - Sleepiness is a common side effect of ADDYI® and can be serious. Taking ADDYI® can increase your risk of sleepiness if taken during waking hours, if you drink alcohol, or take certain medicines or herbal supplements. - Low blood pressure and fainting (loss of consciousness) can happen when you take ADDYI® even if you do not drink alcohol or take other medicines or herbal supplements. Your risk of low blood pressure and fainting (loss of consciousness) is increased if ADDYI® is taken during waking hours, if you drink alcohol within 2 hours of taking ADDYI®, or if you take certain medicines or herbal supplements. The most common side effects of ADDYI® include: - Dizziness - Difficulty falling asleep or staying asleep - Nausea - Dry mouth - Tiredness These are not all of the possible side effects of ADDYI®. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. See full Prescribing Information, including Boxed Warning regarding severe low blood pressure and fainting in certain settings, and Medication Guide at addyi.com/pi. This information does not take the place of talking with your doctor. --- # Advancing Medication Adherence with Data-Driven Interventions Source: https://phil.us/advancing-medication-adherence-with-data-driven-interventions/ ## Advancing Medication Adherence with Data-Driven Interventions Medication adherence refers to how closely patients take their medications as prescribed. Nonadherence – which may involve failing to initiate treatment, taking incorrect doses, or discontinuing treatment – is associated with poor outcomes and higher healthcare costs. Beyond the primary goal of enabling healthier and longer lives for patients, medication adherence directly impacts pharmaceutical manufacturers’ bottom lines. Understanding the factors contributing to adherence and using meaningful interventions based on data analytics will enable a brand's full potential to be realized. ##### The dilemma of medication nonadherence Medication nonadherence is a long-standing problem that has been linked to poor health outcomes, increased hospitalizations, and higher costs of care. Consider the following findings: - Failure to adhere to prescribed therapy is an issue across almost all chronic conditions, including serious illnesses such as oncology, HIV, organ transplants, and glaucoma. - Even with good insurance and drug coverage, medication adherence rates for chronic conditions are between 50-60%. - For every 100 prescriptions written: 50-70 are filled by the pharmacy 48-66 are picked up from the pharmacy 25-30 are taken properly 15-20 are refilled as prescribed - Good medication adherence is linked to a 21% reduction in long-term mortality and poor adherence with a 17% higher risk of hospitalization. Nonadherence to prescribed treatment causes an estimated 125,000 avoidable deaths and $100 billion in preventable healthcare costs each year. The issue is so prevalent that the American Medical Association (AMA) advises physicians to “consider medication nonadherence first as a reason a patient's condition is not under control.” ##### The value of investing in medication adherence strategies Disease-related complications that arise due to drug nonadherence come at a high cost to all stakeholders in the healthcare ecosystem. Pharmaceutical companies have long known that revenue suffers when prescriptions are never filled, or medications are not taken often enough. A 2012 study estimated that the pharmaceutical industry loses $188 billion in actual and potential revenue each year due to nonadherence in the U.S. alone. That same study concluded that addressing medication adherence should be a top priority for pharmaceutical companies, particularly with the growing emphasis on value-based healthcare. Increasing adherence rates by just ten percentage points translates to $41 billion in revenue opportunity for manufacturers in the U.S. Clearly, investing in medication adherence strategies promises the dual benefits of driving more revenue while positively impacting health outcomes and costs. ##### Barriers to medication adherence A review of 79 studies on prescription nonfulfillment concluded that the primary reasons given by patients were concerns about medications – such as side effects or taking too many different drugs, lack of perceived need for the medication, and affordability issues. However, the root causes of medication nonadherence are quite complex, multifactorial, and challenging to pinpoint. An in-depth analysis by McKinsey & Company determined there are four dimensions of variables that drive adherence: - Social, economic, and patient-related, including nonbehavioral factors, such as social determinants of health, and behavioral patient factors, such as social activity levels - Condition related, such as disease experience and comorbidities - Drug-related, such as experience with a drug and co-prescriptions - Health system-related, including provider’s disease experience, payer type, copay amount, and pharmacy type Failure to stick with prescribed therapy is a substantial obstacle to realizing the inherent value of pharmaceutical innovation. Consequently, manufacturers must recognize the factors that impede medication adherence. ##### Employing data-driven, technology-based interventions to improve adherence When pursuing medication adherence initiatives, pharma companies should be tracking real-world data on adherence rates, clinical outcomes, revenue, cost savings, and patient experience. They can then leverage data analytics to identify patients at high risk of nonadherence and employ proactive interventions that drive medication adherence. Examples include: - Sending out personalized refill reminders via text messaging - Disseminating educational materials on proper drug administration, dosing, storage, clinical safety, and efficacy and facilitating communication with an easy-to-use patient portal - Monitoring and promoting medication adherence and facilitating communications through a patient-friendly mobile application - Alerting nurse navigators to reach out to patients who are at risk of non-compliance through digital notifications - Facilitating and tracking benefits verifications, prior authorizations, enrollments in financial assistance programs, and copays with workflow tools ##### What does this mean for life sciences companies? Beyond its commercial value, medication adherence is linked to better disease control and improved patient outcomes. A 2003 report by the World Health Organization (WHO) noted that “increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.” Ultimately, drug manufacturers’ efforts to improve adherence will positively impact patient health outcomes and generate substantial clinical and financial rewards. Phil provides an integrated approach to data analytics across the patient journey that provides manufacturers with real-time visibility into their distribution channels and supports efforts to drive medication adherence. Learn more about how Phil partners with manufacturers to facilitate patient access. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Antivirals - Post-Approval Insights Source: https://phil.us/antivirals-post-approval/ ## Antivirals - Post-Approval Insights Antiviral drug approvals over the last decade have been dominated by drugs aimed at treating Hepatitis C (HCV) and human immunodeficiency virus (HIV). An estimated 2.4 million to 4.7 million people are living with HCV in the US, while about 1.2 million people in the US live with HIV. While these are both huge markets that continue to attract big pharma development efforts, the competitive landscape has become multi-layered and complex with long-standing therapies being evaluated alongside newly approved combinations. While better options become available to patients – even a possible cure for HCV patients – research shows that the prior authorization process is the biggest factor contributing to delayed treatment for patients suffering from both HIV and HCV. This becomes a material factor for overall patient outcomes as delayed treatments – while an obvious inconvenience and frustration for patients – can also contribute to viral resistance and disease worsening. For manufacturers, eventual sales aren’t always a reflection of therapeutic merit as a more laborious authorization process can often translate to lower sales. As the treatment paradigm grows, there is a high unmet need to improve processes within healthcare systems to match eligible patients to the most appropriate treatments in a seamless and timely manner. Here’s a snapshot of some of the blockbuster HIV and HCV drugs with annual sales over $1 billion, that were approved between 2015 - 2018 and how they’ve fared on the market over recent years. ### Drug: Genvoya Company: Gilead Generic: fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide Indication: Complete regimen for HIV treatment for adults and pediatrics over 12 Approval date: 5 November 2015 Analyst peak sales forecasts: $4 billion by 2021 Actual peak sales: $3.6 billion (US); $4.7 billion (global) in 2018 Full year 2021 sales: $2.9 billion Market reception: Genvoya had a strong launch which continued in its first few years on the market, but the entry of Gilead’s other HIV drug Biktarvy, approved in 2018, chipped away at Genvoya’s market share. While sales in 2021 were still impressive, the two-drug regimen has greater contraindications to competition and may have a lower barrier to viral resistance. ### Drug: Zepatier Company: Merck Generic: elbasvir and grazoprevir Indication: chronic HCV genotypes 1 and 4 in adults Approval date: 28 January 2016 Analyst peak sales forecast: $2 billion by 2020 Actual peak sales: $772 million (US); $1.6 billion (global) in 2017 Full year 2021 sales: not material Market reception: Initially expected to be a bigger blockbuster drug, Zepatier suffered stiff competition from a couple of game-changing drug approvals (see below) in its first two years after launch. Its market was also limited in that it was only indicated for two HCV genotypes. In 2018, Merck cut the price of Zepatier by 60%. ### Drug: Epclusa Company: Gilead Generic: sofosbuvir and velpatasvir Indication: HCV Approval date: 28 June 2016 Actual peak sales: $2.4 billion (US); $3.5bn in 2017 (global) Full year 2021 sales: $815 million (US); $1.46 billion (global) Market reception: Epclusa was a major advance in the HCV space, indicated for all six HCV genotypes. The drug reached an impressive blockbuster status a year after its launch, however sales began to decline faster than expected, again due to yet another market improvement. ### Drug: Mavyret Company: Abbvie Generic: glecaprevir and pibrentasvir Indication: chronic HCV for all adults Approval date: 3 August 2017 Actual peak sales: $1.6 million (US); $3.44 billion (global) in 2018 Full year 2021 sales: $754 million (US); $1.7 billion (global) Market reception: Mavyret represented yet another incremental improvement for patients with HCV, with a reduced 8-week regimen compared to Epclusa’s 12-week regimen, whilst it was also offered at a discount to existing options. With recent HCV therapies offering patients a cure, the decline in sales after its first year was a reflection of the overall HCV market peaking in 2015. Generic options of earlier approved drugs have also put pressure on Mavyret’s market penetration. ### Drug: Biktarvy Company: Gilead Generic: bictegravir, embitcitabine, tenofovir alafenamide Indication: HIV Approval date: 7 February 2018 Analyst peak sales forecast: $11 billion by 2024 Full year 2021 sales: $7 billion (US) $8.6 billion (Global) Market reception: With a competitive safety profile and a high barrier to viral resistance, Biktarvy, the three-drug combo, has reared itself as the poster child of HIV drugs. It superseded records made by Gilead’s predecessor (Genvoya) and is also beating out GSK’s triple and doublet therapies. Biktarvy’s sales grew 19% from 2020 and shows no signs of stopping. The drug remains the leading prescribed treatment for naive and switch patients in the US. Innovative and new therapies will inevitably face reimbursement and access challenges as they launch. The process of getting medications in the hands of the patient can be cumbersome due to difficulties with prior authorization, reimbursement, and delivery. Phil dramatically improves patient outcomes by enabling access to life saving medications. For more information on how Phil works with manufacturers to streamline the patient access channel, visit us at phil.us. Sales data taken from biomedtracker.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Are Traditional Hub Providers Keeping Pace with Today’s Consumers and Providers? Source: https://phil.us/are-traditional-hub-providers-keeping-pace-with-todays-consumers-and/ ## Are Traditional Hub Providers Keeping Pace with Today’s Consumers and Providers? The seismic changes in consumer behavior and expectations brought on by mobile devices and cloud computing seem to have happened overnight, but they’ve been years in the making. The popularity of user-friendly services offered by the likes of Amazon, Uber, and Apple Pay has driven innovation and disruption across industries. The COVID-19 pandemic further accelerated the shift to digital tools, especially in healthcare. Most healthcare organizations have implemented secure Software-as-a-Service (SaaS) applications to deploy cloud-based EHRs, telehealth, and revenue cycle management. So providers are now accustomed to using these solutions to reduce administrative burden and offer more convenience to their patients. For many pharmaceutical specialty brands, hub services represent a major touchpoint with patients and healthcare providers (HCPs). With consumer demands for choice, convenience, and transparency at an all-time high, life science companies must ensure their hub providers aren’t stuck in the past. ### What is a “traditional” hub? Over the last two decades, hub services arose from the need to effectively commercialize brands in the high-growth specialty medication categories, which treat smaller patient populations and require “high-touch” patient support services. The National Council for Prescription Drug Programs (NCPDP) defines hub services – also called Patient Services or Patient Services Support – as “manufacturer-sponsored programs that assist patients and prescribers in the areas of access, affordability and adherence services providing efficient distribution of medication improving patient compliance.” A “traditional” hub is a comprehensive, full-service patient services model. The core of this model is the call center. A team of care coordinators, reimbursements specialists, nurses, and others works via telephone to enroll patients, perform benefit investigations, obtain prior authorizations, and support patients with therapy administration and adherence. Even though the traditional hub model is expensive, cumbersome, difficult to customize, and may be overkill for some therapies, a 2021 survey of life sciences companies found that most still rely on traditional hubs: - 89% utilize a call center as part of their patient services team - 91% outsource their nurse/clinical educator team to a hub - 71% use a hub for reimbursement support ### Most hub services are misaligned with consumer and provider needs While a hub can be a great tool to positively impact the patient journey, it can also be a costly endeavor that results in a poor return on investment – particularly if it’s not aligned with consumer and HCP preferences. Hub service providers can play an integral role in the commercialization of specialty drugs; however, those that fall under the “traditional” model may not be keeping pace with consumer and HCP demands. Responses from a recent survey found that patients had similar “pharma” experience expectations across various disease areas, characterized as personal, trustworthy, accurate, and simple. The results also revealed that: - Services that patients need the most – patient support enrollment, patient support services, medication reminders, checking the status of treatment, and resources to manage health – all rated poorly - Patients who have a poor experience are twice as likely to search for a new treatment option - Patients who have great experiences are three times as likely to enroll in a program or service ### The 3 questions you should be asking Offering patient access and support services is the most tangible way for life sciences companies to connect and engage with patients. Accordingly, consumer experience can be a significant differentiator for specialty brands today. Before product launch and throughout the product life cycle, commercial teams should be asking the following three questions to determine if potential hub providers are delivering a modern, consumer-centered experience that can help them meet their objectives: - How well does the prescribing process integrate into HCP workflows? Prescribing your brand should be as easy for the provider as writing for a generic. However, specialty therapies present challenges. A 2020 survey found that 80% of providers have trouble starting patients on specialty therapies and 75% spend at least one hour per patient per week completing the work required to initiate treatment. It’s crucial to ensure that providers can stay within their EHR using an easy-to-use technology interface that streamlines the prior authorization (PA) process, minimizes administrative burden, and helps them better serve their patients. A better prescriber experience will translate to a higher adoption rate and a better consumer experience. - Do they deliver a seamless and personalized experience for patients? The delivery experience of patient support should be a frictionless, consumer-centric digital experience like other industries. That’s often not the case – 57% of healthcare consumers think retailers or financial services are better at providing personalized omnichannel experiences. Look for easy-to-use digital tools, tailored content delivery, and two-way communications based on each patient’s healthcare needs and preferences. A frictionless patient experience leads to better enrollment rates and medication adherence. - Are patients (and HCPs) kept informed? Healthcare Information and Management Systems Society (HIMMS) recommends that digital patient engagement platforms feature capabilities that deploy regular communications to bridge knowledge gaps. Providing greater transparency – in real time – around out-of-pocket costs, financial assistance, PA status, and prescription and refill status results in better decision-making, higher satisfaction, less prescription abandonment, improved adherence, and better outcomes. Patient services can reduce the patient’s disease burden and improve their experience. For companies that market a specialty therapy, the dilemma should not be whether to offer these services but determining if their commercialization partner delivers a solution that meets today’s consumer and provider expectations. Download our whitepaper to learn more about transforming your brand’s performance with a modern patient access experience. Share this article on: ##### Author Rick Salazar VP Of Business Development, Phil Rick is a senior patient services and distribution leader with expertise helping patients, providers and manufacturers overcome barriers to access and and use via a technology driven platform supporting both buy and bill and pharmacy benefit drugs. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Assessment: Evaluate The Efficacy of Your Channel Strategy Source: https://phil.us/assess-the-efficacy-of-your-channel-strategy/ ## Assessment: Evaluate The Efficacy of Your Channel Strategy Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Branded Retail & Specialty Lite Source: https://phil.us/branded-retail-and-specialty-lite/ ## Branded Retail & Specialty Lite Learn how the PhilRx platform offers a seamless, digital stakeholder experience and maximizes covered dispenses to deliver improved brand outcomes Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # BioPharma Dive: Bridging Data Gaps that Impact Retail and Specialty-Lite Success Source: https://phil.us/bringing-data-gaps-that-impact-retail-and-specialty-lite-success/ ## BioPharma Dive: Bridging Data Gaps that Impact Retail and Specialty-Lite Success Retail and specialty-lite brand teams are facing a paradox – they’re drowning in data yet struggling to gain actionable insight. While manufacturers collect vast amounts of information, most are still making critical business decisions based on incomplete data sets that fail to capture the full prescription journey. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Building a Direct-to-Consumer Program that Wins Source: https://phil.us/building-a-direct-to-consumer-program-that-works/ Playbook ## Building a Direct-to-Consumer Program that Wins A guide for pharma teams to meet evolving patient needs through direct-to-consumer programs Download PDF Pharma manufacturers are embracing direct-to-consumer models as they recognize its potential to improve patient outcomes, provider engagement, and brand performance. However, this transformation comes with challenges and considerations, as it represents a significant shift in how medications are marketed and accessed. If your team is looking to initiate or improve a DTC program as a key component of your channel strategy, this playbook will give you an in-depth overview and strategic roadmap for building an effective digital care initiative. #### In this playbook, you’ll learn: - Growing trends and behavioral shifts that are driving the DTC movement in pharmaceutical industry at the patient, provider, and market level - Key elements of a strong DTC initiative, including important questions and evaluation criteria to align on with your internal teams and Leadership - Tactical strategies, expert commentary, and real-world successes to inform your program strategy and operations #### Drive growth with a strong direct-to-consumer program With the right strategy and tools, a DTC program can be a growth driver that improves outcomes for patients and providers while differentiating your brand from the rest. Book a demo to discover how we can help you stand up a successful access program. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Building Direct-to-Patient Programs that Exceed Today's Patient Expectations Source: https://phil.us/building-direct-to-patient-programs-that-exceed-todays-patient-expectations/ Report ## Building Direct-to-Patient Programs that Exceed Today's Patient Expectations New research from PHIL uncovers patient's most pressing expectations for today's direct-to-patient programs, and why this matters for pharma. Download PDF New research from PHIL uncovers patient's most pressing expectations for today's direct-to-patient programs, and why this matters for pharma. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Calculate your GTN with PHIL Source: https://phil.us/calculate-your-gtn-with-phil-resource/ ## Calculate your GTN with PHIL ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Can I cancel my prescription? Source: https://phil.us/can-i-cancel-my-prescription/ ## Can I cancel my prescription? To Cancel Your Prescription: - Log into your account at my.phil.us - Make sure you are on the "RX Prescriptions" section - Click on the green arrow next to the prescription you'd like to manage - Select "More Options" - Click on "Remove This Prescription". From here, you also have the ability to pause, unpause, and change your refill date. Share this article on: --- # Can PhilRx support patients where English is not their first or preferred language? Source: https://phil.us/can-philrx-support-patients-where-english-is-not-their-first-or-preferred-language/ ## Can PhilRx support patients where English is not their first or preferred language? Yes, we support patients in over 120 languages. You can simply indicate the language needed for the patient, and PhilRx provides foreign language support. We text patients in Spanish, Korean, Vietnamese, and Chinese, and have Spanish-speaking patient support reps and translation services for all other languages. Here are our dedicated foreign language support lines: - Spanish: 855-970-5222 - Chinese (Mandarin): 855-970-6659 - Korean: 855-970-4420 - Vietnamese: 855-970-8551 - All other languages: 855-970-9899 Share this article on: --- # Can the PA process be started even before the patient completes their PhilRx registration? Source: https://phil.us/can-the-pa-process-be-started-even-before-the-patient-completes-their-philrx-registration/ ## Can the PA process be started even before the patient completes their PhilRx registration? Before PhilRx may begin processing a patient’s prescription, the patient must enroll with PHIL by creating their account. Most patients are able to complete their enrollment easily via the PhilRx Digital Hub, but this can also be done over the phone with our Patient Support team. During the enrollment process, the patient must validate their demographics information and ensure the insurance information we've found is correct. Once the patient completes the crucial steps of validating/adding their information, we are able to begin the prior authorization process. Share this article on: --- # Capturing Actionable Metrics to Improve Patient & Brand Outcomes Source: https://phil.us/capturing-actionable-insights-to-elevate-channel-performance/ Upcoming Webinar ## Capturing Actionable Metrics to Improve Patient & Brand Outcomes Oct 29, 2024 at 9am PDT Market-leading manufacturers are embracing new models to improve visibility and insight into patient outcomes, provider, and brand performance. Is your team equipped with the right metrics to maximize your access experience for patients and providers? Join us for an insightful webinar as industry experts explore gaps in today’s channel analytics environment, and offer strategic recommendations to help your team effectively leverage data to improve patient outcomes and brand performance. #### What you’ll learn on the webinar: - Unpacking trends, challenges and opportunities for capturing the right channel metrics - Building a strong data model, including which KPIs to track at the patient, provider, and program level - Training your brand and field teams to optimize your patient and provider experience Uncover a data-driven approach to optimizing patient & brand outcomes. Register now. Registration window is now closed. Sign up below to be informed about future events. ### Meet your Speakers ###### Sahil Naik General Manager, Phil Inc. Sahil Naik is an experienced business leader with an extensive background in strategic consulting and client success. He's passionate about leveraging technology and data to help life sciences companies improve patient outcomes. ###### Tim Jones VP Commercial Excellence, Syneos Health With 18+ years in corporate strategy, analytics, and market research, Tim drives Syneos Health’s data strategy, helping clients exceed goals with innovative solutions. He's skilled in applying marketing and analytics to enhance operations and reduce costs. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Case Study: Defying the Mid-Cycle Curse for Specialty Pharma Source: https://phil.us/case-study-defying-the-mid-cycle-curse-for-specialty-pharma/ ## Case Study: Defying the Mid-Cycle Curse for Specialty Pharma Mid-cycle specialty products often face challenges when it comes to reaching patients several years after launch. ### Case Study: Women’s Health Product Phil was able to assist our client with turning around a tumultuous post-approval journey. Reimbursement challenges led to poor uptake and the pharma manufacturer brought on a telemedicine company to help with the prescribing and authorization process. However, additional changes to patient eligibility criteria led to prescriber confusion, low coverage rates and limited patient access. ### Before Phil Initially, patients were offered a limited two-month free supply, but once that ended, many patients stopped therapy because they couldn’t get their medications authorized for further coverage. There were multiple reasons for this, but the main reason was that prior authorization (PA) forms were not submitted correctly or in a timely manner. There was a lack of education and training among healthcare providers on patient eligibility criteria and how to correctly submit the PAs, while the telemedicine company handling the majority of the prescriptions was taking several days to submit PAs with very little follow up. A contract with a specialty pharmacy hindered patient enrollment as patients failed to engage with automated calls to enroll. The pharmacy also had limited contracts with payers – around 60% of commercial plans, very few regional plans and no contracts with state medicaid plans. As a result, only 12% of TRx were covered by payers despite good formulary. For a therapeutic that required long-term adherence, the average refill rate per patient was no better than 2.5 fills and the company was losing money with every script. The company sought help from Phil to improve its patient access and saw immediate results after adopting the platform. ### The HCPs The Phil portal was more user-friendly for physicians and healthcare providers, eliminating the need for physicians to fill in spreadsheets and reply to emails. HCPs were better educated on the process, which held them accountable to complete authorizations. After Phil’s platform was adopted, 98% of PAs were submitted on the same day. ### The Patients Patient engagement was notably improved with the help of text messages to guide the patient through every step of the process. From the seamless 1 minute onboarding to the post-dispense texts tailored to the patient’s clinical journey, Phil was able to remove most of the administrative burdens and allow for a greater focus on the promotion of therapy adherence. Scripts covered by payers quadrupled in just 18 months – from 12% to 55% – with the refill rate adherence increasing by 45%. ### The Coverage Phil was able to enroll 90% of patients through its intuitive platform and scripts were dispensed across a large network of pharmacies that have contracts in place with 98% of all US plans, commercial, medicare and medicaid. ### The Company Month over month sales growth driven by Phil has meant that the company is now profitable. The sharp increase in volume and revenues has attracted additional venture funding for growth, while profits have enabled the company to invest more in a digital marketing campaign to drive profits up further. The program continues to grow at 66% CAGR more than a year after launching with Phil. For more information visit phil.us. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Channel Comparision Source: https://phil.us/channel-comparision/ ## Learn how you can optimize your patient access strategy to improve adherence and gross-to-net How does your brand’s channel stack up? Complete the following for a customized channel comparison report --- # Conventional Biopharma Commercial Strategies are No Longer Enough Source: https://phil.us/conventional-biopharma-commercial-strategies-are-no-longer-enough/ ## Conventional Biopharma Commercial Strategies are No Longer Enough In an era where life sciences companies face unprecedented costs to bring novel therapies to market and declining expected returns upon launch, conventional commercialization strategies are insufficient to deliver brand success. The traditional approach of driving demand to the top of the funnel through clinical differentiation, expensive media campaigns, and large field sales forces no longer guarantees adequate product adoption and long-term financial viability under the constraints of intricate utilization management requirements. Thus, a paradigm shift is in order – one that centers around an integrated commercial strategy that is laser-focused on patient access and underpinned by gross-to-net optimization. ### Why patient access should be a top priority in the era of utilization management Increasingly, insurers are implementing restrictions for costly treatments to contain pharmacy spend, creating challenges for pharmaceutical manufacturers attempting to ensure patients can access their specialty and specialty-lite brands. Drug utilization management requirements such as formulary exclusions, prior authorizations (PAs), and step edits have risen dramatically and are poised for continued growth. Rigorous payer requirements and increasing out-of-pocket obligations are problematic for both patients and healthcare providers. Up to one-third of patients report they experience difficulties getting their prescription drugs due to delays, denials, and costs. According to a 2022 national survey of physicians, about 20% of prescriptions are impacted by PAs and formulary restrictions, which create an administrative burden. As a result, 80% of providers report that they refrain from prescribing certain medications over half the time due to utilization management requirements. Low levels of prescribing and adherence make it difficult – if not impossible – to demonstrate value to payers to ensure strong reimbursement. A media campaign may drive demand but does little to ensure access and positive health outcomes with manufacturers often forced to over subsidize access to their therapies. And a traditional sales approach solely focused on selling the science is not positioned to help prescribers navigate the complexity of patient access meaningfully. For life science companies, an integrated commercial approach that also ensures patients have timely and affordable access to their branded therapies should be a top priority. ### What is Gross-to-Net, and why does it matter for sustained brand growth? Gross-to-Net (GTN) refers to the difference between the total revenue generated by a drug (gross sales) and the actual revenue received by the manufacturer after accounting for various discounts, rebates, financial subsidies, and other adjustments (net sales). In other words, it represents the shift from the initial list price to the actual realized revenue. A proactively managed GTN margin is essential for ensuring that innovative treatments remain accessible to patients who need them, and ultimately, for sustainable brand growth. In today’s pharmaceutical marketplace, the average cost of developing a new drug now exceeds $2 billion, the return on investment is at its lowest in over a decade at 1.2%, and the average peak sales forecast for a pipeline drug fell 22% between 2021 and 2022. Amid these financial outlooks, optimizing Gross-to-Net should be a top commercial priority. ### 3 key components to unlock patient access and drive sustained GTN An integrated commercial model that goes beyond outdated, top of funnel strategies and focuses on optimizing patient access and GTN involves three important components: - A modernized patient services program For many pharmaceutical specialty-lite and specialty brands, the patient services program represents a primary touchpoint with patients and healthcare providers (HCPs). Hence, the hub and other offerings must keep pace with consumer and prescriber expectations and demands by ensuring that the hub prescribing process integrates into provider workflows, delivers a digital-first patient experience that is seamless and personalized, and provides transparency across the patient access journey. - A responsive prior authorization strategy The prior authorization process can adversely impact all stakeholders involved in the prescription access journey. Thus, manufacturers should prioritize partnerships that support the process to facilitate high submission rates and provide real-time visibility into prior authorizations. Access to real-time data can provide field teams with the insight they need to close gaps with HCPs and inform dispense workflows at the payer level, ultimately leading to higher adoption rates. - A robust pharmacy network Pharmacy networks play a pivotal role in the distribution, fulfillment, and reimbursement of medications, which means the brand's short- and long-term commercial success ultimately hinges on pharmacy performance. Pharmaceutical manufacturers must cultivate a pharmacy network that will secure a high level of prescription coverage while minimizing uncovered copay utilization. This can be accomplished by ensuring the dispensing network has contracts with the right health plans, aligns incentives with manufacturers, and can effectively support adoption. ### Discover an integrated commercialization approach with PhilRx By partnering with Phil, life science brands gain access to a nationwide pharmacy network with 98% plan coverage that allows patients to receive prescribed therapy quickly, conveniently, and affordably. The PhilRx Patient Access Platform is designed to ensure manufacturers can drive the adoption of their branded treatments via a digital-first user experience while managing brand growth with unique gross-to-net maximizing capabilities. Read this case study to learn how we unlocked adoption and sustainable growth for a biotech company launching their flagship ophthalmology product. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Defining PSS Success in 2023 & Beyond Source: https://phil.us/defining-pss-success-in-2023-and-beyond/ ## Defining PSS Success in 2023 & Beyond Effective patient support services are essential in the age of utilization management - read this white paper to learn how to optimize your program. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Defining PSS Success in 2023 and Beyond Source: https://phil.us/defining-pss-success-in-2023-beyond/ ## Defining PSS Success in 2023 and Beyond Effective patient support services are essential in the age of utilization management - read this white paper to learn how to optimize your program Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Defining Success for Patient Support Services Source: https://phil.us/defining-success-for-patient-support-services/ Playbook ## Defining Success for Patient Support Services A tactical playbook for designing a patient support services program that accelerates access, adoption, and loyalty Download PDF Life sciences brands aim to develop innovative therapies that improve patient health and wellbeing. Unfortunately, some brands struggle to reach this important milestone - this often occurs when they don’t have the right patient support services in place. This white paper offers key strategic questions you can ask to ensure your patient services programs are built to maximize brand access and growth. #### In this playbook, you’ll learn about: - Strategic questions you can proactively ask to improve brand outcomes, including: - Driving patient adoption, adherence, and refills - Offering a seamless provider experience - Maximizing prescription coverage #### Set the stage for patient-centric growth Shape the future of patient access. Discover how the PhilRx patient access platform can be a strategic partner in your brand’s success. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Developing a Distribution Strategy that Optimizes Gross to Net Source: https://phil.us/developing-a-distribution-strategy-that-optimizes-gross-to-net/ ## Developing a Distribution Strategy that Optimizes Gross to Net Downward pressure on net sales is an ongoing problem for pharmaceutical and life sciences companies. It’s crucial to understand the gross-to-net (GNT) challenges that manufacturers are facing and how they can leverage their distribution strategies to optimize GTN. ### Understanding the challenges surrounding GTN Numerous factors impact a life science company’s GTN, which is the difference between the wholesaler acquisition cost (WAC) – also known as the drug’s list price – and the manufacturer’s net sales. Distributor chargebacks and rebates, 340B Drug Pricing Program rebates, negotiated price reductions, and copay assistance can significantly reduce the net revenue manufacturers realize for their brand-name drugs. The fact is, many companies today are experiencing declining net drug revenue as they offer larger rebates to offset increases in list prices, as depicted in this chart from Drug Channels: There are two major changes in the pharmaceutical environment that underly the GTN challenges companies are facing: #### 1. Consumer expectations Innovations, fueled by mobile technologies, over the last decade or so have removed a lot of friction from buying experiences and have enabled more informed decision-making, which has become part of the standard purchasing experience today. Consumers expect to know upfront how much a product or service costs, how conveniently they can obtain it, and when they can expect to receive it. For most things consumers buy today, they are getting that clarity, except when it comes to their prescription drugs. The pharmaceutical industry is decades behind when it comes to meeting consumer expectations. Failing to deliver that frictionless, consumer-centric experience creates barriers that keep patients from starting on or properly adhering to their prescribed therapies, which for any manufacturer, is going to add up to poor gross to net. #### 2. Prescription coverage As drug and patient out-of-pocket costs have continued to rise, payers have instituted stricter formulary requirements – particularly for more expensive specialty drugs – that must be met before they approve and cover a therapy. In these cases, the prescriber must follow a prior authorization process to get the patient started on their therapy. While the technology to create “back office” efficiencies around administrative workflows is prevalent across many industries, this is not necessarily the case in healthcare. The lack of process optimization and streamlining means that a smaller percentage of prescription drugs get covered by payers because of the friction involved in the approval process. This means that the manufacturer often ends up subsidizing a greater percentage of scripts than would have otherwise been covered in a streamlined process. Now that the financial burden is borne by the manufacturer, nowhere does it show up more clearly than in GTN. The impact of both these challenges combined is multiplicative. If a company loses a few scripts due to a friction-prone path to coverage, it is also losing the subsequent refills. And if a percentage of those scripts or scripts overall are not covered and the manufacturer steps in to subsidize at a much higher percentage than planned, together, these factors represent a greater magnitude of diminished net revenue to pharma brands. ### Why manufacturers need a value-aligned distribution channel Multiple entities are involved in getting a patient on therapy between the manufacturer and the payer. The better manufacturers understand that distribution channel, the more effectively they can employ various mechanisms and measures to help patients get started on therapy faster, stay on their treatment, and access it more affordably. Surprisingly, many prescription models are antiquated and misaligned with the needs of today's patients and prescribers. As a result, some of the manufacturer's distribution costs may not be commensurate with the value added. In other words, some entities capture disproportionately more value than they contribute. This means that fewer dollars are available for manufacturers to improve patient access. Manufacturers have very little pricing power in the highly competitive, highly regulated world of pharma. Cost inflation is typically due to how the distribution channel operates. Due to a lack of visibility, manufacturers may not realize that one-sixth or one-seventh of their brand's value is captured by an entity adding zero value. Pharmaceutical manufacturers budget a certain amount of capital to help patients access their prescribed therapy. When they can track what is happening within the distribution channel in real-time, they can design programs so that most of that capital goes to its intended purpose. It's essential that the distribution channel aligns with the value each stakeholder contributes to achieving the end goal of ensuring patients receive the right therapy at the right time and at the right price. ### Achieving a GTN-optimized distribution strategy There are three key considerations when designing a distribution strategy to optimize GTN: #### 1. Always put the patient-turned-consumer at the center Beyond a traditional patient-centered approach, manufacturers must recognize that the patient is also a consumer who wants a more modern way to access their medications and be informed as to what’s happening behind the scenes. Equip them with the digital-based tools and user experiences that are familiar to them, and that assist them with accessing and staying on therapy. #### 2. Address the healthcare provider experience Make sure providers have modern tools to streamline and facilitate their efforts to meet payer requirements so they can help their patients get started and adhere to prescribed medications. #### 3. Create an incentive-aligned distribution channel All entities and stakeholders along your distribution channels should be working toward the common goals of getting scripts covered and making sure that most patient access dollars go to the patient to underwrite the cost of their care. ### It’s time to embrace innovation Many pharma companies today are not taking full advantage of digital technology. The good news is that while technology has failed the industry for several decades, in the last five to six years, there have been clear strides, especially with consumer- and prescriber-facing innovations. The new technology hype cycle is behind us, and solutions are now production-worthy in a way and at a scale that they’re able to impact lives. It may take a new mindset, but by embracing innovation and implementing the right tools, pharmaceutical manufacturers can improve clinical, financial, and operational outcomes. Phil can be a game-changer for life science companies looking to meet patient expectations and positively impact outcomes while optimizing GTN. With a digital, frictionless experience, providers can more easily meet payer criteria and get their patients on therapy quicker. Patients can better access, adhere to, and afford their medications while staying informed along the way. The platform also provides a holistic end-to-end view of what is happening along the entire patient-prescription journey. Most importantly, data and insights are delivered in real-time, so manufacturers can course correct as necessary. Without a very high commitment hurdle, smaller companies can try it out at a level that best fits their requirements and then scale as needed. Learn more about Phil. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Diabetes - Post Approval Insights Source: https://phil.us/diabetes-post-approval-insights/ ## Diabetes - Post Approval Insights According to the National Diabetes Statistics Report from the CDC, around 37.3 million people have diabetes in the US, while 96 million have prediabetes. Type 2 diabetes remains the most prevalent in the US (90-95% of diagnosis), while both subtypes represent chronic illnesses that require rigorous self management of therapies for effective disease control. The increased prevalence of diabetes over the last 20 years unleashed a multibillion dollar pharmaceutical market that has pushed drug developers to aggressively pursue life-saving treatments for both type 1 and type 2 diabetes. While pharma has made great strides with the approval of many blockbuster drugs over the last two decades, incremental improvements to therapy have been clinically significant given the high disease prevalence across the globe. However, more options don’t equate to easy access for patients requiring medications. As new competitive therapies emerge, the diabetes treatment landscape has become more complex. A therapy’s commercial success in diabetes isn’t always reflective of the therapy’s benefits but rather how easy it is for patients to access it. Factors affecting patient’s ability to access prescribed diabetes medications include: - Pricing Dynamics New and more expensive drugs offering incremental improvements to available treatments are competing with lower cost generics and cost benefits are often difficult to justify. - Administrative Burdens In the US, prior authorizations (PAs) have been put in place to ensure many approved diabetes drugs and devices are being prescribed and used correctly. While a well intended process, PAs have historically delayed access to prescription drugs, to the point where some patients aren’t receiving them in time to keep up with therapy schedules. - Access Hurdles Existing specialty drug distribution channels experience different administrative and commercial roadblocks when processing prescriptions – resulting in the switching of medications and many patients not receiving the drug they were originally prescribed. These challenges lead to long term script abandonment and so manufacturers stand to benefit from higher refill rates and greater revenue predictability if they can work with payers and distributors to improve patient access to their therapies as they come to market. Here’s a snapshot of some high profile diabetes drug approvals and how they’ve fared in the US market in recent years. ### Drug: Toujeo Company: Sanofi Generic: insulin glargine injection Indication: To improve glycemic control in adults with type 1 and type 2 diabetes. Approval date: 25 February 2015 Analyst peak sales forecasts: $1.3 billion by 2022 Full year 2021 sales: $284 million (US); $1.1 billion (global) Market reception: Toujeo was a long-acting follow-up to Sanofi’s mega blockbuster Lantus, which was approaching its patent cliff in 2015. However, Toujeo didn’t quite live up to Sanofi’s expectations as it struggled to position the drug as therapeutically superior to Lantus (which made over $7 billion in 2014). It also faced competitive pressure from Novo Nordisk’s diabetes franchise. While Toujeo missed original peak sales expectations of $1.5 billion by 2018 (only hitting $923 million globally in that year), its sales have steadily increased, with expectations for the drug to hit $1.3 billion in 2022. Additionally, Toujeo is expected to keep above the $1 billion annual sales threshold until 2026. ### Drug: Tresiba Company: Novo Nordisk Generic: insulin degludec injection Indication: To improve blood sugar (glucose) control in adults with diabetes mellitus Approval date: 25 September 2015 Analyst peak sales forecasts: $2 billion by 2025 Full year 2021 sales: $560 million (US); $1.4 billion (global) Market reception: Novo Nordisk’s goal with Tresiba was to usurp Sanofi’s mega blockbuster Lantus and it hoped that nuanced head-to-head hypoglycemia data in 2016 would give it a bonafide edge over Lantus. Data on lower blood sugar episodes in 2017 and a cardiovascular safety study the same year gave it additional competitive armory to challenge Lantus. Sales were quite strong since its launch, hitting over $1 billion in sales from 2017 until this 2021, but never coming close to Lantus’ status given Toujeo was also taking some of the market share. In the end, Tresiba missed its primary endpoint in a head-to-head study with Toujeo in 2019, failing to cut down the number of hypoglycemic events when compared with Toujeo over a 36-week maintenance period. However, Tresiba sales are still expected to steadily increase until 2025. ### Drug: Soliqua Company: Sanofi Generic: insulin glargine and lixisenatide injection Indication: To improve glycemic control in adults with type 2 diabetes Approval date: 21 November 2016 Analyst peak sales forecasts: $288 million by 2026 Full year 2021 sales: $126 million (US); $214 million (global) Market reception: Soliqua entered the diabetes market with big promises as a fixed-dose combination therapy of insulin (Lantus) and a GLP-1 medicine (Adlyxin) in a once-daily regimen. Sanofi was racing with Novo Nordisk’s Xultophy to an approval and launch of a similar combination and despite launching first, Soliqua generated underwhelming sales since its launch. However, recent data vs premixed insulin released in 2021 moved Sanofi executives to vocalize expectations for “a lot of interest” among doctors. ### Drug: Xultophy Company: Novo Nordisk Generic: insulin degludec and liraglutide injection Indication: To improve glycemic control in adults with type 2 diabetes Approval date: 21 November 2016 Analyst peak sales forecasts: $715 million by 2025 Full year 2021 sales: $76 million (US); $392 million (global) Market reception: While Xultophy received approval on the same day as Soliqua, Novo Nordisk was behind Sanofi with its launch of its combination therapy, setting it back on 2017 sales. However, some additional data in 2017 on hypoglycemia and weight reduction gave it a slight competitive edge. From 2018 onward, Xultophy has performed marginally better on the global scale vs Soliqua, though Soliqua has had a slight edge over Xultophy with sales in the US. ### Drug: Ozempic Company: Novo Nordisk Generic: semaglutide injection Indication: To improve glycemic control in adults with type 2 diabetes mellitus Approval date: 05 December 2017 Analyst peak sales forecasts: $12.1 billion by 2027 Full year 2021 sales: $3.4 billion (US); $5 billion (global) Market reception: Novo’s Ozempic, a once-weekly injection of semaglutide, had some great expectations leading up to its approval and has proven to be the star performer Novo Nordisk had hoped for and more. The drug was seen as a standout success at the time of its FDA review, receiving a 16-0 vote in favor of its approval with convincing clinical data on HbA1c reductions vs a number of established competitors. It also notably helped patients to lose weight. Original reported forecasts for 2022 were $2.2 billion, but the drug surpassed that figure in 2020, generating $3.1 billion globally that year. With expectations to exceed $12 billion in 2027, Ozempic is truly Novo Nordisk’s unicorn. The active ingredient semaglutide was also approved for obesity as Wegovy in June 2021, with analysts expecting the obesity drug to hit an additional $5 billion in global sales by 2027. Innovative and new therapies will inevitably face reimbursement and access challenges as they launch. The process of getting medications in the hands of the patient can be cumbersome due to difficulties with prior authorization, reimbursement, and delivery. Phil dramatically improves patient outcomes by tackling these access hurdles to enable patients to get on life saving medications faster. For more information on how Phil works with manufacturers to streamline the patient access channel, visit us at phil.us. Sales data taken from biomedtracker.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Digital Health’s Role in Transforming How Healthcare is Delivered Source: https://phil.us/digital-healths-role-in-transforming-how-healthcare-is-delivered/ ## Digital Health’s Role in Transforming How Healthcare is Delivered Editor’s Note: As the healthcare ecosystem continues to undergo significant digital transformations, life sciences companies would be wise to consider the impact of this evolution on one of their most important stakeholders - health care providers (HCPs). The fusion of the increased prevalence of blended care models, staff shortages, and higher utilization management requirements have resulted in an environment where HCPs find themselves more constrained than ever. This has made it more challenging for life sciences companies to effectively engage providers to ensure that patients can access their therapies. As life sciences companies develop partnerships to ensure that their patients can get their prescriptions covered by insurance and adhere to their care plans, they should seek to understand current HCP dynamics to develop strategies that are responsive to their current needs. The PhilRx platform offers a responsive, modern solution that integrates directly into existing HCP workflows to make it easy for HCPs to prescribe and engage with our digital hub. Our prior authorization process meets HCPs where they are by automating key steps in the process and resulting in 85% or more of PAs. Check out this recent blog post to Learn more about what makes our prior authorization process unique. The digital transformation is changing how providers deliver care, bringing with it a novel set of challenges from this new way of working. To ensure long-term success in providing users with high-quality care, digital health companies must design solutions that take not just the consumer experience, but also the provider perspective, into account. We are witnessing a sea change in healthcare delivery, driven by digital health innovation across offerings such as telemedicine, remote monitoring solutions, and app-based healthcare tools. Care has transitioned beyond the four-walls of a hospital, enabling providers to cater to more consumers innovatively and effectively. Consumers are benefiting from more affordable, easily accessible, and timely care, causing demand for digital health solutions to escalate, with adoption rates of telemedicine reaching as high as 80% in 2022. The surge in demand has attracted unconventional players like tech giants and retailers to the healthcare main stage. For instance, CVS’s acquisition of Signify Health and Amazon’s purchase of One Medical underscore the momentum for alternative care delivery models and the pivotal role non-traditional companies will play in healthcare moving forward. With the entrance and growth of digital health companies, we have started to see a dramatic shift in the provider landscape over the last 5 years, not just in diversity of offerings, but of the players themselves. This transformation, however, brings with it key questions about how providers can continue to deliver high-quality care in a virtual setting, and how companies can effectively recruit and retain top talent for this new modality of care delivery. For digital health, the race to successfully acquire, retain, and support provider supply is more heated than ever. ### Challenges arising from the digital health transformation #### Recruitment in the face of staff shortages The challenges of the provider supply shortage are nothing new. With 1 in 5 Americans expected to be over the age of 65 by 2030, the pressure on our healthcare providers will only continue to grow. By 2034, there could be a shortage of up to 124,000 physicians. There is a dire need to expand supply and digital health companies provide an opportunistic way to deliver more care. However, convincing healthcare professionals to transition from traditional brick and mortar practices to digital modalities comes with its own set of challenges. My colleague, David Schonthal, refers to the headwinds oppose change as “Frictions”. As David highlights in his book, The Human Element, Frictions are our natural human instincts and behaviors that cause us to resist change – no matter how beneficial making the change might be. Unless these Frictions are removed, the changes healthcare innovators are looking to introduce to the market will likely be rejected by the very people they are designed to help. For example, many clinicians harbor concerns about digital solution efficacy, potential legal issues, privacy, security, and reimbursement. Unless these concerns are addressed as part of the introduction of new technologies , adoption will fail. To overcome these Frictions, some virtual-first companies are offering unique solutions. For instance, NOCD, a telehealth platform designed to treat obsessive-compulsive disorder (OCD) and other comorbid severe mental illnesses, simplifies the transition for providers by managing compliance, billing, and scheduling and providing mentorship for challenging cases. #### Augmenting workload Driven by the absence of work-life boundaries in a remote environment, work-related burnout escalated during the pandemic, with 53% of remote workers clocking more hours than before and 61% struggling to disconnect after hours. While most of our nation’s healthcare workers never left the frontlines, the pandemic’s transformation of the workplace had its impact on the sector. Amid the digital health transformation, and with the surge of telemedicine utilization, the excessive, and often unsustainable, workload healthcare professionals face has quickly become a major challenge. While virtual care has led to an increase in engagement for patients, there has not been a similar increase in the support team necessary to handle the increased workflow. Virtual clinicians grapple with video fatigue, mounting asynchronous chat, and elongated workdays, risking burnout and a decline in care quality. Overburdened physicians might even hasten retirement, further contributing to the provider shortage. To counter this, digital health companies are that help clinician’s triage important messages using technology can enable providers to get to the right patient, at the right time. Arcadia Health developed AI-powered analytics tools to stratify high-risk patients and generate actionable insights so providers can prioritize urgent cases and operate at the top of their license. In addition, companies like Brightline, focused on addressing the country’s growing pediatric mental health crisis, lets therapists set availability windows for users to choose, respecting work-life balance. #### Reducing administrative burdens In a similar vein of needing to manage the burdens placed on staff, the time spent on administrative tasks, especially documentation, is a notable concern. Following national care guidelines, a primary care physician would need 26.7 hours a day to see a standard patient count, including 3 hours for documentation alone. A recent survey conducted by athenahealth found that excessive documentation causes burnout for 57% of clinicians. Each year, these administrative burdens accumulate into a $1 trillion cost in the US alone. Although designed to simplify clerical processes, electronic health records (EHRs) have become time-consuming, with physicians spending over 16 minutes per patient. As telemedicine grows, so does time spent on EHRs and out-of-hours work, creating an issue digital health providers must address. The link between increased administrative tasks, burnout, and decreased care quality warrants the need for more efficient platforms. To combat these challenges, the adoption of intelligent automation and consistent feedback about clinicians’ workflows is vital. There’s a growing trend towards asynchronous chat solutions, as seen with companies like Summer Health, which allow for more flexible and efficient care. Additionally, to better support EHR processes, companies such as Jasper Health, a digital oncology platform that delivers psychosocial support and coaching, not only integrates with these platforms but also proactively leverage user data to provide health insights and connect users to non-clinical services. #### Building community Another key challenge as digital health solutions proliferate is the ability to retain employees. A core driver of this is ensuring that providers feel they have a sense of community amongst one another and the consumers they support. Healthcare professionals gain immense satisfaction personally connecting with patients so the willingness of a company to invest in these relationships is crucial. Beyond patient relationships, if uninvested, physicians may feel isolated from the larger healthcare community and miss out on professional growth opportunities, dampening their motivation. According to an American Psychological Association (APA) survey, employees who feel valued at work show better performance and well-being. A staggering 93% of those who felt valued reported being motivated to perform at their best, compared to 33% for those who didn’t feel valued. Hence, fostering a sense of community and recognizing providers’ contributions are pivotal. Companies like Caraway, a digital healthcare company providing mental, physical, and reproductive care to women aged 18-27, describes how its “Caraway Crew” is its secret sauce to making on-campus engagement work, succeeding as student crew members are empowered to co-create and lead events while building a community. #### Training a digitally ready workforce Poor training and workflow optimization is another common culprit of physician disengagement with digital health solutions in most states. Educating providers is critical while transitioning into digital modalities to ensure care quality is not compromised. Such training needs to consider security concerns and how physicians should safeguard patient data, rapidly evolving regulatory compliance, and technical training for different software and interfaces providers may be required to use. Incomplete and irregular training will only increase physician frustration and skepticism of digital health solutions. After all, embracing digitalization isn’t just about upgrading systems; it’s about preserving the core of health and care. But here’s the silver lining: some trailblazers are lighting the path forward. Parsley Health, providing root-cause resolution care, meaningfully invests in training its clinicians — every Parsley doctor completes their Parsley Fellowship in functional medicine and nutrition. The fellowship looks at holistic approaches to medicine with a focus on digestive diseases, autoimmune diseases, cardiometabolic diseases, and endocrine disorders and aligns providers on the same standards of care while equipping them with a new care toolkit. Providers are taught how to support consumers through their longitudinal health journey and meet patients where they are. As we stand at the crossroads of healthcare’s future, it’s crystal clear: the companies that thrive will be those that treasure both the patient experience and the invaluable perspectives of their providers. Investing in Friction-reducing tactics such as community building and providing benefits, training, and personalized support to employees will yield compounding long-term benefits while reducing churn rate. As we transition from the comforting embrace of traditional care settings into the dynamic digital horizon, let’s remember to bring along each caregiver and provider making their debut in this new age of healing. This article was written by Alyssa Jaffee from MedCity News and was legally licensed through the DiveMarketplace by Industry Dive. Please direct all licensing questions to legal@industrydive.co. Note: NOCD, Brightline, Jasper, Caraway are portfolio companies of 7Wire Ventures, the author’s employer. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Does PhilRx have other ways for patients who do not have a smartphone to easily sign-up without using a SMS link? or What happens if a patient does not have access to a mobile device or a computer? Source: https://phil.us/does-philrx-have-other-ways-for-patients-who-do-not-have-a-smartphone-to-easily-sign-up-without-using-a-sms-link-or-what-happens-if-a-patient-does-not-have-access-to-a-mobile-device-or-a-computer/ ## Does PhilRx have other ways for patients who do not have a smartphone to easily sign-up without using a SMS link? or What happens if a patient does not have access to a mobile device or a computer? Yes, the patient can also enroll via phone or via web browser on a tablet or personal computer. To enroll via phone, the patient can call PhilRx’s Patient Support Team using the phone number provided via voicemail and a PhilRx representative will walk them through the prompts. Please note that the patient will need to have an email address (and Phil team can assist them if they do not have one already). Share this article on: --- # Does Your Pharmaceutical Brand’s Data Demonstrate Value to Payers? Source: https://phil.us/does-your-pharmaceutical-brands-data-demonstrate-value-to-payers/ ## Does Your Pharmaceutical Brand’s Data Demonstrate Value to Payers? The traditional route to pharmaceutical market access focuses on successful clinical trials and meeting regulators' safety and efficacy data requirements. In the past, this same data was sufficient for payers to determine that the drug was worth covering at the price point set by the manufacturer. But times have changed. With payers playing a more influential role in market access and the availability of data to provide a more accurate picture of how medications perform after approval, pharmaceutical manufacturers need to prove the real-world value of their brands. ### Payers: gatekeepers to market access An increasingly competitive market, the advent of specialty therapies, and the rise of value-based care have altered the dynamics of market access in the United States. The influence of insurers has escalated to the point that they are considered gatekeepers, acting as the middleman between patients and medication access. In fact, in a survey of pharmaceutical industry experts published in the Journal of Market Access and Health Policy, payers were named as the second most important stakeholder in market access following patients. The market access role of payers - spanning from formulary tiering and drug utilization reviews to implementation of specific access barriers – translates to substantial impacts on treatment decisions, quality of care, and cost savings. Additionally, insurers are shifting toward value-based contracting in favor of volume-based agreements, particularly in the specialty drugs market. As payer influence continues to evolve and grow, market access leaders need to provide payers with the full picture of the value their brands bring to healthcare delivery. ### Real-world data: the game changer With healthcare costs under the microscope, pharmaceutical manufacturers have growing pressure to deliver clinical trial results in the real world. Real-world data (RWD) – data collected in the context of routine care delivery rather than with the controlled environment of a clinical trial – is playing a progressively more central role in drug decision-making. In today’s value-driven marketplace, RWD can be a gamechanger for pharmaceutical market access. Potential sources for RWD include: - Electronic health records (EHRs) - Administrative claims - Patient-reported outcomes (PROs) - Medical product and device registries - Condition-specific or disease registries - Environmental factors and social determinants of health Real-world evidence (RWE), which the FDA defines as “the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data," can bridge gaps in evidence not addressed by clinical trials. In December 2021, the FDA issued guidance for evaluating RWD to support marketing applications after drug approval, such as a new indication. While randomized clinical trials are still considered the gold standard for formulary decision-making, payers use real-world data to validate clinical trial results further and help make coverage decisions across therapeutic areas. Additionally, more and more payers are tying payment for treatment to both short- and long-term effectiveness measures. Health plans are also turning to RWD to gain insights into drug safety, utilization, costs, and value. ### Generating real world data insights that demonstrate value to payers Pharmaceutical marketers have been using RWD for decades to inform their decision-making, respond to external stakeholders, and improve their brands’ market positioning. With the evolution of data analytics, there are greater opportunities to provide RWD to payers around long-term efficacy, safety in real-world settings, head-to-head comparisons, cost analyses for formulary placements, medication use and adherence patterns, and patient-reported outcomes and experiences – ultimately demonstrating the actual value of a therapy. In a 2017 Deloitte survey, more than half of life sciences companies polled planned to increase their RWE capabilities significantly. According to the findings, access to the right RWD was a common issue, and new channels for data, including external partnerships, would be needed to improve overall capabilities. The authors of the study pointed out that the FDA’s push to expand the use of RWE and “the growing imperative for life sciences companies to demonstrate product value is helping to drive commercialization strategies that result in broader insurance coverage, optimal pricing, and optimal formulary placement." ### The bottom line Achieving real-world insight from the point of care throughout the patient journey is ideal for demonstrating how your medication can improve outcomes and reduce costs. Life sciences companies should consider a commercialization partner that provides high-quality, timely, and actionable RWD to ensure a brand's post-approval market access. With over 120 real-time data points across the patient access journey and customizable market access reports, Phil provides its life science company partners with RWD and insights to support their brand value to payers. Learn more about the Phil Platform here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Enhancing your Patient Access Hub to Drive Brand Success Source: https://phil.us/enhancing-your-patient-access-hub-to-drive-brand-success/ ## Enhancing your Patient Access Hub to Drive Brand Success By Catherine Wood Hill, Vice President of Marketing at Phil, Inc. Biopharma hubs should strive to ensure patients get access to the medications they need quickly and affordably, while easing the manual effort required by prescribers. A positive hub experience builds trust, promotes brand loyalty, and supports ongoing therapy adherence. At the same time, the hub should maximize insurance coverage, which helps manufacturers improve brand economics. In this ideal state, the hub is a strategic partner that drives access, gross-to-net, and outcomes. The reality is that most hubs do an excellent job in one area, such as making sure patients have access to affordability programs, but fall short in another area, such as failing to offer a solution to ensure high coverage rates. The result is dissatisfied patients, disenfranchised HCPs, and missed brand outcomes and goals – a likely contributing factor to why over 6 out of 10 brands launched between 2019 and 2021 underperformed expectations. Since manufacturers collectively poured $19 Billion into helping patients afford their brands in 2022 alone, optimizing hub performance should be be a top priority to ensure ROI and brand success. ### Common obstacles to hub adoption Issues on several fronts can impede hub adoption. The first is that historically, hub programs have involved manual enrollment processes. As a result, many HCPs are understandably hesitant to use a manufacturer's hub because they have had poor experiences dealing with lengthy enrollment forms that must be filled out by hand and faxed back. The second challenge comes from relying on outbound phone calls from a call center to engage patients – and upwards of 89% of life science company hubs use a call center. Most people today screen their calls and rarely pick up if they don't recognize the phone number. They want to avoid the interruption and risk of spending time on a phone conversation they haven’t planned. Lastly, incentive misalignment can keep sales representatives from driving prescription volume through the hub. Many pharmaceutical compensation plans pay reps the same for a covered script as an uncovered script, which disincentivizes promoting the hub. Getting an uncovered script is a lot less work: the rep has the HCP send the prescription to the local specialty pharmacy or retail, which is more likely to utilize the uncovered coupon or substitute the product, avoiding the prior authorization (PA) processes for the patient. ### The key to hub success Core teams commonly work in silos, pursuing goals that are not necessarily aligned with the brand’s overall objectives and can cause a breakdown from a hub optimization perspective. Hub success starts with high-level leadership and cross-functional unity on the “why” of their patient services program, the overarching goals, and everyone’s responsibility in the implementation process. For example, let’s assume the program sponsor is patient services, and that team’s leadership has excellent strategic relationships with the market access, brand, and sales leadership teams. This tight-knit collaboration translates to buy-in for driving coverage via the hub and accountability for the rollout across all teams… this is where hub success begins. At Phil, we have worked with life sciences companies that have seen a 30% increase in volume within two months after all the internal stakeholders started marching in the same direction. ### Optimizing the hub The optimization stage can begin once everyone is on the same page, and the field teams are trained to promote the hub. It’s important to differentiate maximizing adoption from optimizing the hub. Driving 100% of scripts through the hub is maximizing HCP adoption. However, if HCPs are not submitting the necessary PAs or patients are not enrolling, the hub is not optimized. In this case, patients and HCPs will have poor experiences with minimal treatment access, and the manufacturer will not see the brand outcomes they expect. The best approach to hub optimization is to analyze granular data to understand what is happening territory by territory in terms of new script volume, patient enrollment, prescriber engagement, and payer response. Then, field team management can identify opportunities to get more patients started on the branded therapy quickly and affordably. #### Action steps to boost hub enrollment and engagement After identifying key opportunities, stakeholder teams can take several steps to improve hub enrollment and engagement: - Field team education based on specific identified territory opportunities - Peer-to-peer coaching, where high-performing reps partner with low-performing reps - Creation of targeted marketing collateral to drive desired behaviors and outcomes - Strong alliance with a hub partner that has experience across a host of clients #### What to expect from Phil as your hub partner Life sciences companies working with Phil get a strategic partnership that focuses on optimizing patient access across the hub program to drive the company’s brand goals. Our consultative approach provides individualized recommendations and interventions based on real-time, granular data captured across the prescription journey, paired with our extensive experience helping specialty-lite brands achieve their access and bottom-line goals. Request a demo to tour the PhilRx patient access platform and learn how we can champion your brand's growth. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # For Pharmaceutical Brands, Pharmacy Matters Source: https://phil.us/for-pharmaceutical-brands-pharmacy-matters/ ## For Pharmaceutical Brands, Pharmacy Matters How to optimize prescription coverage at the counter Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # General Phil and Insurance Questions Source: https://phil.us/general-phil-and-insurance-questions/ ## General Phil and Insurance Questions Share this article on: --- # Harnessing the Power of Data to Drive GTN Performance Source: https://phil.us/harnessing-the-power-of-data-to-drive-gtn-performance/ ## Harnessing the Power of Data to Drive GTN Performance Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Healthcare Policy Updates Specialty Drug Manufacturers Need to Know Source: https://phil.us/healthcare-policy-updates-specialty-drug-manufacturers-need-to-know/ ## Healthcare Policy Updates Specialty Drug Manufacturers Need to Know The pharmaceutical industry is one of the most highly regulated industries in the United States. Despite many legal and regulatory obstacles, the U.S. has led the world in the number of new chemical and biological entity launches since the year 2000. To continue to innovate and flourish, life science companies must stay on top of and adapt to ever changing policies. Here are updates on three recent federal government policies that specialty drug manufacturers need to be aware of: ### Electronic prior authorization Prior authorization (PA) processes impose a burden on healthcare providers and can create considerable barriers to patient treatment access. According to an American Medical Association (AMA) survey, almost nine out of ten providers characterize the burden associated with PAs as “high” or “extremely high.” As of 2021, more than one-third of PAs were still fully manual – submitted via phone, fax, email, or mail. A manual process leads to care delays and abandoned treatment, negatively impacting patient outcomes. According to an independent data analysis of PAs commissioned by AHIP, automated electronic prior authorizations (ePAs) significantly reduce the administrative burden on providers and the time to therapy initiation. On December 6, 2022, The Centers for Medicare & Medicaid Services proposed a new rule that directs specific payers to move to ePA by 2026. The rule includes requirements that payers need to send decisions within 72 hours for urgent requests and seven days for standard requests, in addition to providing a specific reason for denials and publicly reporting PA metrics. PAs are a commonly employed utilization management (UM) measure that payers use to control specialty medication costs. As healthcare systems shift to fully automated PA processes, life science companies should seek a commercialization partner that offers a seamless, integrated ePA process that keeps their brand teams in the loop on how payers are treating their product. ### DIR Fees Direct and indirect remuneration (DIR) fees refer to the compensation pharmacy benefit managers (PBM) or Medicare Part D sponsors receive from pharmacies as much as a half year after the point of sale. This compensation includes rebates offered by manufacturers and concessions paid by pharmacies. These retroactive fees, also known as “claw-backs,” generate negative reimbursements for drugs that have already been dispensed. Between 2010 and 2020, the use of DIR fees grew by 107,400%. According to NCPA research, a typical community pharmacy pays around $81,000 annually in DIR fees. As these fees have exploded, so has their ambiguity and unpredictability, causing financial hardship for pharmacies and increasing patient out-of-pocket and nonadherence, ultimately diminishing brand performance. On April 29, 2022, CMS issued a final rule eliminating retroactive DIR fees by requiring that they be included in the negotiated price the patient pays at the pharmacy. The new rule will take effect in January 2024. This policy change should enable manufacturers to improve their gross to net while allocating more funds to patients to support patient access and care. ### Drug Pricing The Inflation Reduction Act (IRA), signed into law on August 16, 2022, includes several provisions to reduce prescription drug prices. Here’s a closer look at the provisions that will impact specialty drugs: 1) Pharmaceutical companies will have to pay rebates to the federal government if prices for single-source drugs and biologicals covered by Medicare Part B (effective in 2022) and most prescription drugs covered by Medicare Part D (effective in 2023) increase faster than the inflation rate. 2) Beginning in 2026, the federal government must negotiate prices for certain drugs with the highest total spending. This provision amends the “noninterference” clause with an exception that requires the Secretary of HHS to negotiate prices directly with pharmaceutical manufacturers for a limited number of single-source brand-name drugs or biologics that are covered under Medicare Part D and Medicare Part B. Some drug categories are excluded from this provision: - Drugs that have a generic or biosimilar competitor - Small-molecule drugs that are less than 9 years from their FDA-approval or licensure date and biologicals that are less than 13 years away - Drugs that account for less than $200M in Medicare spending in 2021 - Therapies that qualify as “small biotech drugs,” until 2029 - Treatments designated by FDA as orphan drugs - Plasma-derived products 3) In 2024, CMS will be able to cap out-of-pocket spending for Medicare Part D enrollees. Additionally, starting in 2025, Medicare’s liability for total costs above the spending cap will decrease significantly. This provision also requires manufacturers to provide specific price discounts on brand-name drugs and beneficiary premiums will be adjusted so that they do not increase by more than 6% from year to year. These changes are expected to substantially decrease out-of-pocket spending for beneficiaries who take specialty medications. The overall purpose of the new provisions is to improve affordability and access to innovative treatments, which not only benefits patients but also biopharmaceutical manufacturers. However, some of the requirements are expected to result in lost revenue for life science companies and negatively impact biopharma R&D investment levels, ultimately hurting innovation in the industry. ### Managing the ripples Every new healthcare policy has ripple effects for all stakeholders – both intended and unintended. As pharmaceutical markets, pipelines, and policies continue to evolve, life science companies of all sizes need an agile and flexible approach to optimize commercialization. Commercialization strategies are highly complex, costly, and cumbersome to execute – learn how PHIL can help your company here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How Biopharma Companies Can Support Patients with High Deductible Health Plans Source: https://phil.us/how-biopharma-companies-can-support-patients-with-high-deductible-health/ ## How Biopharma Companies Can Support Patients with High Deductible Health Plans In 2023, a growing number of patients are enrolled in high deductible health plans (HDHPs), which require members to pay healthcare costs out-of-pocket until they meet their annual deductible amount before the plan starts covering eligible costs. A recent analysis found that over half of American private-sector workers are now enrolled in HDHPs – a 14.5% increase from 2017. The current minimum deductible for an HDHP set by the IRS is $1,500 for an individual and $3,000 for a family. With actual deductibles averaging $6,013 for families, it should come as no surprise that patients with HDHPs often face significant hardship when paying the list price for their medications. It’s well established that high out-of-pocket costs are leading drivers of prescription abandonment and non-adherence which can have significant adverse consequences. Case in point: patients abandoned 94 million prescriptions in 2022 with increasing frequency as out-of-pocket grew. In recent years, biopharmaceutical companies have stepped up their efforts to support patients, spending over $80B over the last five years to help offset out-of-pocket costs for commercially insured patients. However, when it comes to supporting patients with HDHPs, it is not enough to simply have a patient support program in place – ultimately, it’s how these programs are designed and delivered that will make the most impact. #### Elevate awareness of your copay savings program Are patients and HCPs even aware that your brand has a copay support program? Unless your brand team has effective initiatives to promote awareness, it’s unlikely. A 2021 study of more than 6,300 patients revealed that almost 3 out of 5 patients have little to no knowledge of a branded patient support programs. Another survey found that 42% of HCPs lack a good understanding of pharma patient services programs. Considering that almost half of patients are willing to switch to a new medication to save money and less than 1 out of 5 look for a coupon when they can't afford their prescription, manufacturers should take steps to boost awareness of their savings programs and make it easy for patients to enroll in them. Brand and access teams can gain traction with their patient populations that have HDHPs by: - Leveraging field teams to educate HCPs on the value of their patient support programs - Offering real-time patient enrollment directly at the point of prescription - Integrating program promotion within patient and HCP marketing assets - Advertising the program within the EHR as a reminder to the physician when prescribing - Utilizing a hub partner that can develop differentiated dispense workflows based on copay amount - Optimizing their field teams with the program-aligned incentives. #### Leverage data to glean insights and develop responsive business rules Combining patient insights with business rules can help address individual patient needs while enabling life sciences companies to put their allotted access funding where needed most and optimize their gross-to-net (GTN). It makes sense to offer variable copay offers to align with insurance needs because patients with good prescription drug coverage may not have a need – or have a smaller need – for copay assistance. Designing a program that puts business rules in place to vary offerings based on coverage allows you to effectively spread your "bucket" of assistance funds over more patients. So, those patients with HDHPs who need more financial assistance over a more extended time to access their prescribed medication and stay adherent will receive it, while patients with a smaller out-of-pocket obligation will receive less. This approach will also help secure the long-term viability of your copay assistance program. Check out this infographic to discover five strategies that will ensure the long-term success of your patient support program. #### Provide transparency into the patient access journey Today’s patients want to be active consumers of healthcare services but typically lack the transparency needed to make informed decisions. This barrier is especially true when it comes to affordability. Recent surveys find that more than 5 out of 10 HCPs do not discuss medication costs with patients because they are unsure how much they will cost, and patients generally find that healthcare costs are unclear and confusing. Beyond medication affordability, the process for obtaining insurance approval and coverage tends to be murky at best. Transparency is critical to filling the information gaps that often exist across the patient access journey. Each touchpoint in this journey is an opportunity for pharmaceutical manufacturers to deliver more transparency and better support patients with HDHPs. With tech-enabled hub services, brand teams can meet patients where they are by delivering a frictionless, consumer-centric experience that offers more visibility around how to access and afford their prescribed treatment – including what their out-of-pocket will be –eliminating the sticker shock that all too often leads to prescription abandonment. #### Unlock access for patients with HDHPs For many life sciences companies, the upfront investment and opportunity cost relative to other commercial priorities often force trade-offs on program design that diminish access for a growing patient population with HDHPs. By partnering with Phil, you can eliminate this risk. The PhilRx platform sets the stage for a successful, modern hub services program that meets patients' individual needs by seamlessly connecting them with their prescribed therapy. Specialty-lite brands protect their GTN margins and unlock patient access by automating prior authorizations and ensuring manufacturer-driven copay coupon utilization with real-time insights across the prescription journey. Check out this resource to discover how Phil can help maximize your brand's unique value. Want to learn more about how to position your brand for long-term growth? Download our playbook for life sciences manufacturers: “Optimizing Patient Access for Sustainable Growth.” Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How can I (doctor) change my communication preferences? Source: https://phil.us/how-can-i-doctor-change-my-communication-preferences/ ## How can I (doctor) change my communication preferences? You can update your preferences by sending an email to the Phil HCP Support team (mdhelp@phil.us), or by calling Phil’s HCP Support team at 855-588-0387, Option 1. Share this article on: --- # How can offices change their default preference and frequency of receiving summary updates? Source: https://phil.us/how-can-offices-change-their-default-preference-and-frequency-of-receiving-summary-updates/ ## How can offices change their default preference and frequency of receiving summary updates? Offices can update this preference by sending an email to the Phil’s HCP Support team (mdhelp@phil.us), or by calling Phil’s HCP Support team 855-977-0975, Option 1. The frequency of the faxes can not be changed at this time, but HCPs can contact Phil’s HCP Support team any time if they need info on a script. Share this article on: --- # How Can Pharma Manufacturers Improve Patient Engagement in 2025? Source: https://phil.us/how-can-pharma-manufacturers-improve-patient-engagement-in-2025/ ## How Can Pharma Manufacturers Improve Patient Engagement in 2025? Patient engagement is a critical factor for brand success. Not only does patient engagement benefit patients by addressing unmet needs more effectively, but it has also proven to be a powerful driver of financial value. A groundbreaking study revealed that an investment of $100,000 in patient engagement could increase net present value and expected net present value by more than 500-fold the investment – the equivalent of accelerating a pre-phase 2 product launch by 2.5 years. By leveraging strong patient engagement strategies, pharmaceutical companies can enhance patient access to their specialty-lite and retail brands and experience improved program enrollment, medication adherence, and brand loyalty – ultimately driving better health outcomes and brand success. In this blog, we break down the top patient engagement initiatives that manufacturers should consider to strengthen outcomes. #### 1) Develop More Comprehensive Patient Support Programs The best way to implement a comprehensive patient support program is through a digital hub that meets patients’ expectations for digital healthcare. By integrating key services, including benefits verification, prior authorization, and adherence support, this technology-driven approach streamlines the patient journey by automating routine processes, providing real-time support, and enhancing patient access. It also allows manufacturers to meet each patient’s unique needs while optimizing resource allocation and generating valuable data and insights. #### 2) Deliver Clear Cost Information and Prescription Updates A user-friendly, digital experience helps patients manage their health and connect with their care teams more easily, which can lead to better access and adherence. For example, you can provide real-time transparency on prescription costs and status through automated text messages – if you’re interested in seeing what’s possible, check out how this works on PhilRx. Through direct communication channels, patients can understand out-of-pocket expenses, insurance coverage details, and available copay assistance programs. They can also track their prescriptions and manage refills, right on their phone. #### 3) Implement AI-Driven Communication Pharmaceutical commercialization teams can improve patient engagement by leveraging machine learning algorithms to tailor messaging and education content delivered through chatbots, mobile apps, and other digital channels which may boost overall patient satisfaction. #### 4) Expand Telehealth Services Connecting with healthcare providers through telehealth platforms improves patient engagement by enhancing accessibility, convenience, and continuity of care - particularly for those with mobility challenges, time conflicts, or who live in rural areas. Integrating with telehealth also enables brand teams to gather valuable data on treatment efficacy and patient experiences, ultimately fostering stronger patient relationships and potentially reducing healthcare costs. #### 5) Employ Gamification Strategies Pharmaceutical manufacturers can enhance patient engagement and access by integrating gamification into their support programs. Examples include offering: - Points for interacting with educational materials - Challenges that promote health behaviors - Social features for patient connection This approach can transform routine healthcare activities into interactive experiences that potentially increase patient engagement. In a retrospective analysis of a digital therapeutic mobile app that combined gamification, education, reminders, community, and incentives, participants demonstrated significant success in maintaining optimal medication adherence over time. #### 6) Adopt an Omnichannel Engagement Strategy By implementing a seamless omnichannel strategy, pharma companies ensure patients can engage through their preferred communication channels, whether it's through social media, email, texting, or in-person interactions. This approach allows for personalized, consistent messaging across multiple touchpoints, improving the patient experience. It also enables brand teams to reach a broader audience, provide timely information, and offer more convenient support, which may contribute to better brand outcomes and loyalty. This can also be integrated into a larger direct-to-consumer (DTC) program that brings together omnichannel marketing, telemedicine, and a digital patient and HCP experience that includes integrated pharmacy services and PA processing – watch this webinar for an in-depth guide to incorporating DTC into your brand strategy. ### Let’s Partner for Better Patient Outcomes Brand teams have unprecedented opportunities to enhance patient engagement, improve patient outcomes and drive financial value along the way. The PhilRx Digital Hub is a powerful solution designed for novel retail and specialty-lite brands. Book a demo today to see how PHIL can transform your patient support programs. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How do I send prescriptions to PhilRx? Source: https://phil.us/how-do-i-send-prescriptions-to-philrx/ ## How do I send prescriptions to PhilRx? You can use one of the following to send prescriptions to PhilRx: To eRx a RX on your EMR: 1) Selected the pharmacy type as RETAIL 2) Search exact spelling and spacing of the name PhilRx, LLC 3) Zip: 43235 4) NPI# 1487163598 To call in verbal RX: 1) Verbal Rx, Ph: 855-977-0975 To fax in a RX: 2) Fax# 888-975-0603 Share this article on: --- # How do I update my payment information? Source: https://phil.us/how-do-i-update-my-payment-information/ ## How do I update my payment information? You can log into your My.Phil account and upload a photo of your payment card - From the homepage, click on the person icon on the upper right-hand corner - Click the arrow next to the Payment Card Section - Select “Add Card” - Enter your card information (Card number, expiration date, CVV code) - Check the box if the payment card is an FSA, HSA, or HRA card - Confirm or add your billing address - Click "Save". Share this article on: --- # How Drug Manufacturers Can Evolve their Provider Engagement Model to Drive Brand Performance Source: https://phil.us/how-drug-manufacturers-can-evolve-their-provider-engagement-model-to-drive/ ## How Drug Manufacturers Can Evolve their Provider Engagement Model to Drive Brand Performance Evolving healthcare provider (HCP) needs and expectations have disrupted conventional customer engagement methods. The traditional reach and frequency model that had long been successful for pharma companies no longer delivers on brand goals. Several factors are driving this change. The transition to value-based payment models and growing emphasis on technological solutions have drastically altered workflows within healthcare practices. This shift is further compounded by health insurer-driven drug utilization management policies, such as prior authorization (PA) and step therapy. These requirements have introduced additional administrative burdens that impact patient care and contribute to HCP frustration and burnout. These changes, paired with staff shortages, constrain medical practice workflows and have significant implications for commercializing branded retail and specialty-lite therapies. As HCPs navigate these hurdles, there’s a risk that they may seek alternative therapies if they perceive difficulties in securing patient access to recommended treatments. In fact, one study found that more than 8 out of 10 providers avoid prescribing certain medications over half the time due to utilization management requirements. The bottom line is that today’s healthcare providers want more personalized, omnichannel interactions tailored to the needs of their entire practice in order to help them improve patient outcomes. To drive brand performance more effectively, life science brands should consider the following three approaches: #### 1) Consider a digital hub to engage HCPs across the prescription journey Providers expect life science companies to offer omnichannel solutions that lighten their workloads and assist them in meeting their patient’s needs. In one survey, 2 out of 3 physicians shared that they want more information about patient support from sales reps. Another survey found that about 60% of HCPs consider digital tools from pharmaceutical manufacturers important to support patient education, provide physician support, and manage patient care. These expectations represent a significant opportunity to build trusted relationships with HCPs by providing tools across various channels to facilitate patient access to therapy. A digital hub that integrates seamlessly into the prescriber’s workflow, modernizes the patient access experience, and helps patients get started on prescribed therapy quickly and affordably goes a long way toward engaging HCPs in the prescription journey for your brand. Your field team will be instrumental in driving scripts through the digital hub. That’s why optimizing the field team by educating them on how the digital hub facilitates success and benefits them and their customers while incentivizing them to promote hub engagement is crucial. #### 2) Equip your field team to deliver more value in every interaction Studies show that 89% of HCPs prefer personalized interactions with pharmaceutical companies. By tailoring information to address the specific needs of each healthcare stakeholder, field reps can position themselves as strategic partners in their customer’s decision-making process, bringing more value to every interaction. Equipping your field team with data is essential to making this happen. Here are two examples: - A PA has stalled due to missing data on a form. With the right data available from the brand’s digital hub, the field team steps in and assists the provider before frustration sets in, expediting the patient’s access to the branded retail therapy. - Each insurance company has its own coverage criteria for retail and specialty-lite brands, which often differ between plans within a specific payer, and the coverage rules are also subject to change at various times – a significant source of frustration for HCPs. Field reps can alleviate this by sharing data from the digital hub about how payers respond to your brand. #### 3) Employ dynamic segmentation for more meaningful engagement Life science manufacturers can use dynamic segmentation to engage more effectively with healthcare offices by leveraging data analytics and predictive modeling to continuously adapt their engagement strategies based on real-time insights into practice behaviors and preferences. This data-driven approach makes interactions with HCPs more meaningful and impactful, which can drive sales growth. However, most target lists are static and outdated. According to an IQVIA analysis, target lists are typically updated every 12 to 36 months even though up to 40% of HCPs change segments within six months. This lag can translate to lost engagement and sales opportunities. For retail and specialty-lite brands, real-time insight into how often and which providers are taking action to secure coverage such as PAs, appeals, and exceptions, is essential to identifying target lists and helping field teams take strategic steps to engage more effectively with practices. #### Optimize brand performance with a strategic partner Empower your marketing and sales teams to evolve their HCP engagement models to deliver more value with every customer interaction, engage more HCPs in the prescription journey, and employ more effective targeting strategies. To accomplish these goals, consider an integrated digital hub that offers retail and specialty-lite therapies a modern, alternative channel solution. The PhilRx Digital Hub seamlessly blends technology with proactive engagement to streamline the entire access journey for patients and HCPs. With comprehensive visibility into the drug channel, we equip commercial and access teams with tools, actionable insights, and real-time data to optimize brand performance. Request a demo to learn how to optimize provider engagement, field team enablement, and patient outcomes with PhilRx. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How Life Science Brands Can Successfully Navigate Retail Challenges Source: https://phil.us/how-life-science-brands-can-successfully-navigate-retail-challenges/ ## How Life Science Brands Can Successfully Navigate Retail Challenges In 2021, 3 out of 4 patients who tried to fill a launch brand were unsuccessful due to payer controls. As life science companies continue to launch innovative specialty-lite therapies, adopting a distribution strategy that ensures patients can access the brand as prescribed – efficiently and affordably – can mean the difference between a successful launch and failing to reach their expected value. As the primary channel for most brands, pharmacy networks play a pivotal role in the distribution, fulfillment, and reimbursement of medications, which means the brand's short- and long-term commercial success ultimately hinges on pharmacy performance. With a rapidly evolving pharmacy landscape, brand teams should need to have a strong understanding of challenges that they face in the retail channel and would be wise to carefully evaluate alternative pharmacy channels that can enable commercial success. ### An evolving pharmacy landscape Across industries, consumers increasingly demand convenient experiences beyond the traditional brick-and-mortar retail model. Moreover, patient preferences have evolved to prefer blended care models fueled by the COVID accelerated disruption across healthcare delivery systems. Ongoing labor shortages, inflationary pressure, and declining reimbursement make it difficult for traditional retail pharmacies to meet consumer demands in today’s environment. For more insights on the impact the pharmacy network can have on your brand’s coverage and access, read this white paper to uncover key trends, opportunities and challenges across the industry. While the U.S. pharmacy sector has lagged behind others in its adoption of e-commerce, it is quickly following the general retail industry as major pharmacy chains drastically reduce their footprint by permanently closing store locations across the country. Other pharmacy models are also picking up the slack. For example, tech-enabled hub providers are disrupting the status quo with consumer-centric, technology-driven approaches that support patients and healthcare providers across the prescription journey, enabling patients to access their medications conveniently and efficiently. ### The risks of relying on a traditional retail pharmacy network An ineffective distribution network can diminish patient and provider satisfaction, health outcomes, and gross to net. And strong market access, the ability of a pharmaceutical manufacturer to secure reimbursement and coverage for their products from payers, does not always translate to covered dispenses at the pharmacy level – particularly for specialty and specialty-lite therapies. That’s why brand teams must understand the following commercialization risks of relying solely on traditional retail networks in an evolving marketplace: - Limited influence – an open channel strategy offers few mechanisms to ensure a product is dispensed as intended at the retail pharmacy level. - Friction in the PA process – Robust payer utilization management requirements, most commonly prior authorization, introduce barriers to patients and healthcare providers that can reduce scripts and PA submission rates. - A fragmented patient experience – An experience that doesn’t align with consumer expectations can reflect negatively on the brand, leading to poor medication adherence and lower refill rates. - Lack of visibility – Limited access to key metrics around benefits verification, PAs, health plan PA behavior, and reimbursement rates inhibit manufacturers’ ability to steer commercialization more effectively. - High distribution costs – The cost of servicing national retail distribution is significant particularly for small and medium sized manufacturers already facing barriers to profitability. ### How to effectively assess your pharmacy network One of the primary contributors to brand success is a market access strategy – and execution – that enables affordable product fulfillment for appropriate patients. Commercialization teams need to understand the makeup and coverage implications of their dispense network so they can take proactive steps to maximize brand uptake and ROI. ##### Answering the following four questions will help you effectively evaluate your pharmacy network and implement strategies to challenges with ease: - What level of prescription coverage do we realize from the pharmacy network? Remember, market access does not necessarily equate to covered dispenses. Considering the influence of payers, PBMs, and network design is essential. - What percentage of health plans have contracts with our dispensing network? You should carefully evaluate if the pharmacy network has the contracts necessary to drive coverage effectively. - What are our pharmacy network’s PA processes and success rates? How efficiently and effectively pharmacies perform PAs can make or break your brand, so having this insight is critical. - How successful is our pharmacy network at driving prescription pull-through? It's crucial to assess the level of patient services program enrollments, brand switching, generic substitutions, and coupon utilization to assess brand pull-through at the pharmacy. - Does my network offer visibility into the prescription journey to inform business rules? In today’s dynamic environment, manufacturers should utilize data to map out friction points in the patient journey that limit access. To do so effectively, brands need timely access to prescription data from the time it's written to point of dispense and beyond. ### Ready to conquer retail challenges? Phil is an end-to-end pharmaceutical commercialization platform that helps brands conquer traditional retail challenges. By partnering with us, life science companies gain access to a nationwide pharmacy network with 98% plan coverage that allows patients to receive prescribed therapy quickly, conveniently, and affordably. Our digital-first platform helps more patients get started and stick to therapy, automates prior authorizations, and enables manufacturer-driven coupon utilization. Real-time insights give our manufacturer partners strategic visibility into the entire prescription journey. Read this case study to learn how one of Phil’s life science partners leveraged our nationwide pharmacy network and digital hub to achieve higher rates of prescription coverage, scripts dispensed as written, and refill adherence, significantly increasing net sales. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How Life Sciences Manufacturers can Meet HCP Expectations for Patient Access Support Source: https://phil.us/how-life-sciences-manufacturers-can-meet-hcp-expectations-for-patient-access/ ## How Life Sciences Manufacturers can Meet HCP Expectations for Patient Access Support With payer cost-containment measures continuing to escalate, patient access is top-of-mind for healthcare providers (HCPs) when deciding on prescribed therapy for their patients. Manufacturer-sponsored patient support programs are essential to helping patients get started and afford specialty and specialty-lite medications. A survey of 1,000 physicians found that HCPs believe these programs significantly positively impact their ability to practice medicine – yet, only 60% felt the pharmaceutical industry has robust patient support services. With the constraints of intricate utilization management requirements a significant factor for HCP prescribing decisions, conventional approaches are no longer enough. Life science companies can deliver value to their HCP customers by meeting their expectations when it comes to supporting patient access. ### Leverage Technology to Automate the Prior Authorization Process Time constraints and administrative demands that compete with patient care – exacerbated by growing prior authorization (PA) requirements and staff shortages – significantly contribute to physician frustration and burnout. When you consider that almost 9 out of 10 providers describe the burden associated with PAs as “high” or “extremely high,” it comes as no surprise that the vast majority refrain from prescribing certain medications over half the time due to drug utilization requirements. HCPs demand solutions that assist them in meeting their patient’s needs. According to a recent Bain & Company survey, around 60% of HCPs consider digital tools from pharma product manufacturers important to support patient education, provide physician support, and manage patient care. Biopharma manufacturers can provide immense value to HCP customers by taking a more customer-centric approach and offering digital solutions to streamline patient access workflows. A technology-enabled HUB that integrates seamlessly into the physician’s workflow and delivers the visibility they expect can help them effectively and efficiently manage the complexities of securing patient access to therapy. ### Provide Transparency into the Prescription Journey Drug utilization management programs, such as prior authorization (PA) and step therapy, often need more transparency for patients and their providers to make informed treatment decisions. Most physicians struggle to determine whether a prescription medication requires a PA. HCPs expect transparency from biopharma manufacturers, particularly regarding supporting patient access. Two-thirds of physicians surveyed said they want more information about patient support from sales reps. This expectation represents a significant opportunity to build trusted provider relationships by providing relevant and timely information on insurance coverage requirements and how they can facilitate patient access to therapy. A technology-enabled hub is critical to delivering the visibility providers expect to help them effectively and efficiently manage the complexities of patient access. Download this playbook to learn how to develop a digital hub that maximizes value for patients and providers. ### Offer a Modern Patient Access Experience Specialty and specialty lite therapy manufacturers should lean exclusively on hub solutions that offer a modern patient experience. They present the best option to address the access roadblocks and set the stage for brand success. A 2022 survey revealed that patients with positive experiences with a life sciences company’s services were 18 times more likely to enroll in a patient services program. Those with poor experiences were twice as likely to seek an alternative treatment option. A patient’s poor access experience often makes it back to the prescriber – it’s not unusual for the HCP to abandon that brand altogether based solely on the feedback from that one patient’s bad experience. Prescribers expect manufacturers to deliver patient access services that help them better serve their patients and: - Offer a frictionless, consumer-centric digital experience - Reduce time to therapy - Address prescription affordability concerns with copay support - Facilitate therapy access and maximize coverage - Provide flexible distribution channels, including home delivery options To learn more, check out this ebook: “Modernize the Patient Access Experience. Transform your Life Sciences Brand.” ### Help Support Medication Adherence Medication nonadherence is a long-standing problem that is linked to poor health outcomes. The issue is so prevalent that the American Medical Association (AMA) advises physicians to “consider medication nonadherence first as a reason a patient's condition is not under control.” Failure to stick with prescribed therapy is a substantial obstacle to physicians’ ability to deliver good patient outcomes and realizing the inherent value of pharmaceutical innovation. Drug utilization requirements, such as step therapy and PA, often disrupt treatment and impact adherence, with 88% of physicians reporting that PA interferes with continuity of care. HCPs today expect pharmaceutical manufacturers to provide tools and resources that help them monitor and support adherence. This can be accomplished through a digital hub that offers data-driven PA processes as well as simplified medication and refill management services. Read this case study to learn how PhilRx helped two neurology specialty-lite brands improve adherence. ### Start Meeting the Expectations of Your HCP Customers PhilRx is an innovative end-to-end commercialization platform that uses a modern, digital approach to help specialty-lite retail brands facilitate patient access, unlock coverage, and maximize reimbursement without compromising gross-to-net. By partnering with Phil, life sciences companies can meet provider expectations by offering a patient access solution that streamlines the prior authorization process, provides transparency into the patient journey, and delivers a modern experience that improves prescription adherence. Request a demo to learn more about how we can support your brand in unlocking patient access. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How long does it take for Phil to initiate the PA after receiving the script? Can this be started even before the patient completes their Phil registration? Source: https://phil.us/how-long-does-it-take-for-phil-to-initiate-the-pa-after-receiving-the-script-can-this-be-started-even-before-the-patient-completes-their-phil-registration/ ## How long does it take for Phil to initiate the PA after receiving the script? Can this be started even before the patient completes their Phil registration? Phil typically initiates the PA within minutes of confirming patient insurance. Phil will pre-locate/populate the patient’s insurance, and the patient will confirm insurance accuracy during registration. This ensures any recent insurance changes by the patient are fully captured, and the correct, payer-specific Prior Authorization is completed. Share this article on: --- # How long does it take for PhilRx to initiate the PA after receiving the script? Source: https://phil.us/how-long-does-it-take-for-philrx-to-initiate-the-pa-after-receiving-the-script/ ## How long does it take for PhilRx to initiate the PA after receiving the script? After a patient confirms their information, PhilRx verifies your patient's insurance, and pre-fills the prior authorization (PA), your office will receive a notification within 3.5 days that the PA is ready to review and submit. Share this article on: --- # How Manufacturers Can Improve Speed to Therapy: Overcoming Common Causes of Prescription Delays Source: https://phil.us/how-manufacturers-can-improve-speed-to-therapy-overcoming-common-causes-of/ ## How Manufacturers Can Improve Speed to Therapy: Overcoming Common Causes of Prescription Delays The timely initiation of a prescription therapy is critical to patients' health and quality of life and can often be a matter of life and death. Yet, a 2022 report revealed that more than 8 out of 10 patients encounter frustrating delays in accessing the medications they need to manage their health. Therapy delays not only have a profound impact on individuals' well-being but also significantly burden the healthcare system. Understanding the root causes of these delays is crucial for developing strategies that enhance patient care, streamline healthcare processes, and ultimately benefit patients and therapy outcomes. In this blog post, we will explore the most prevalent reasons why patients experience prescription therapy delays and delve into how pharmaceutical manufacturers can play a role in improving speed to therapy to improve outcomes for patients and their brands. ### 1) Getting an HCP appointment According to a recent survey, the average wait for a physician appointment is 26 days, with the wait times to see specialists typically even longer. Suppose the HCP determines that your specialty or specialty-lite medication will best treat the patient’s condition. In that case, the benefits verification and prior authorization processes can add more days to weeks to the time it takes to get started on treatment. Strategy to improve speed to therapy: Include a digital direct-to-consumer (DTC) channel, such as telemedicine, as part of your channel strategy. A well-executed DTC model will integrate a telemedicine channel with a digital fulfillment partner to offer an “e-commerce like experience” resulting in the patient having their appointment within a day or two and prescribed treatment in hand a few days later – slashing time to therapy from weeks or months to days. ### 2) Meeting step therapy protocols Step therapy – also known as step edits or fail first – is a common form of drug utilization management used by payers to control costs. This protocol requires that a lower-cost drug in the same therapeutic class be prescribed and fail before allowing coverage of a more expensive option. One study found that health insurance plans apply step edit protocols to nearly 40% of drug coverage policies. Many HCPs suggest that these policies don’t adhere to clinical guidelines. Additionally, the delays in prescribed treatment can be detrimental to patients. How to drive speed to therapy: Manufacturers should take a proactive approach to help HCPs meet step therapy protocols before a prior authorization expires(PA) resulting in a denial and erosion of confidence in your brand. The best way to accomplish this is to optimize the field team to be more responsive and relevant with HCPs, ensuring they are adequately informed on the insurance coverage requirements such as ICD-10 codes for their patient population. For a deeper dive on this topic, join our upcoming webinar with Fierce Pharma to learn how to optimize your field team to drive access. ### 3) Navigating prior authorization hurdles By design, the prior authorization (PA) process is a barrier to medication access – it can leave patients waiting for days, weeks, or even months for approval, and coverage denial may occur despite a therapy being appropriately prescribed. In an AMA survey, 94% of physicians reported patient care delays associated with PAs. The PA process presents a growing roadblock for HCPs trying to get a patient started on the prescription therapy they deem best. In an MGMA Stat poll, 79% of medical practices reported that PA requirements increased in 2022. How to drive speed to therapy: Considering that 72% of HCPs identify PAs as one of the biggest workflow issues to be solved with technological solutions, it only makes sense that the best way to accelerate access to therapy is to leverage technology to streamline the process. By making prescribing as easy as possible and simplifying the PA process, HCPs are more likely to write scripts and help patients get started on their prescribed therapy more quickly. ### 4) Removing financial barriers to therapy Out-of-pocket costs can be a significant factor in treatment delays. In a 2022 report, more than 1 out of 4 patients cited cost as the reason they experienced a delay in accessing their prescribed medication. The report also found that 79% of patients went to the pharmacy but found that the prescription cost was more than anticipated. And among patients facing affordability issues, 56% rationed their medication and 51% abandoned their medication. How to drive speed to therapy: A data-driven Hub solution with integrated transparency tools that help providers improve affordability conversations with patients so they can make the best decisions at the point of care will go a long way towards avoiding the delays related to cost concerns. For best results, it’s essential to take proactive steps to maximize enrollment in your patient services program and lay the foundation for covered dispenses. ### 5) Difficulties accessing a pharmacy A rapidly evolving pharmacy landscape is introducing new medication access challenges. With over 40% of counties in the U.S. considered “pharmacy deserts” as of 2021 and reports of numerous retail pharmacy closures in recent years, many patients – especially those with mobility issues – are at risk of delays filling their prescriptions due to logistical difficulties. How to drive speed to therapy: Partnering with a network of pharmacies that offers mail-order services to ensure that patients have uninterrupted access to your prescription therapy is a big part of the solution. You can take access one step further by working with a Hub digital hub with an integrated dispense network that functions as a liaison between the pharmacy and the patient. With business rules that triage each prescription to the pharmacy with the best coverage, you can accelerate access and improve the patient experience. Want to learn more about how to position your brand for long-term growth? Download our playbook for life sciences manufacturers: “Optimizing Patient Access for Sustainable Growth.” Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How many follow-up status emails will I get? Is there a more convenient way to get these updates? Source: https://phil.us/how-many-follow-up-status-emails-will-i-get-is-there-a-more-convenient-way-to-get-these-updates/ ## How many follow-up status emails will I get? Is there a more convenient way to get these updates? As a prescriber, you will receive a weekly summary fax/email on Monday mornings. You can update the preference for fax/email by sending an email to Phil’s HCP Support team (mdhelp@phil.us) or by calling Phil’s HCP Support team (855-977-0975, Option 1). Updates will continue as long as you have patients who are enrolled at Phil and they may at any time contact Phil to stop the updates. Share this article on: --- # How much will my prescription cost? Source: https://phil.us/how-much-will-my-prescription-cost/ ## How much will my prescription cost? While the final cost of your prescriptions will vary based on your insurance coverage and medication need, we offer lifetime free delivery to all Phil patients who maintain an active account. We never charge for shipping, making prescription management with Phil a completely free service! Share this article on: --- # How Non-Dispensing Pharmacies can Improve the Patient Access Journey Source: https://phil.us/how-non-dispensing-pharmacies-can-improve-the-patient-access-journey/ ## How Non-Dispensing Pharmacies can Improve the Patient Access Journey Patients struggling with complex medical conditions face a growing number of barriers to access, afford, and adhere to the innovative therapies their providers prescribe. In 2022, out-of-pocket costs led to the abandonment of 94 million prescriptions. And in a 2023 survey, 97% of medical practices said their patients had experienced care delays or denials due to increased prior authorization requirements. Life sciences manufacturers continue to seek new ways to improve the patient access journey to make it easier for patients to start on therapy. One model in particular, non-dispensing pharmacies, can be a powerful tool to break down barriers to medication access. These innovative pharmacy constructs do not hold inventory or dispense medications but instead focus on streamlining the patient access journey by serving as a bridge between the HCP and the dispensing pharmacy to benefit patients, HCPs, and manufacturers. ### Patients benefit from a better brand access experience Upon receiving the prescription, a non-dispensing pharmacy processes benefit verifications, prior authorizations, copay programs, and any other pre-fulfillment needs before transferring it to a dispensing pharmacy for adjudication and fulfillment. Additionally, since pharmacies are considered HIPAA Covered Entities, HCPs do not have to form a Business Associate Agreement (BAA) to share patient health information. This intermediary can be instrumental in simplifying the patient's treatment journey in an era where dispensing pharmacies are facing challenges on multiple fronts by enhancing their experience and improving access as follows: - Today's patients expect to be active consumers of healthcare services but often lack the transparency to make informed decisions about a prescribed treatment. Effective, non-dispensing pharmacies can deliver frictionless, consumer-centric experiences offering enhanced transparency that gives patients complete visibility into the status of their prescriptions, ensuringes they are aware of available patient services, and can seamlessly enroll in any copay programs they are eligible for. - The PA process frequently leaves patients waiting for extended periods of time for a coverage decision, and denials may occur for a host of reasons despite a therapy being appropriately prescribed. These therapy delays can profoundly impact individuals' health and often result in patients abandoning therapy. An integrated, non-dispensing pharmacy that is digitally equipped to manage PAs will help patients get started on their prescribed therapy more quickly and help them stay adherent. ### HCPs benefit from a seamless prescribing process Burdensome PA requirements and staff shortages exacerbate HCP time constraints and administrative demands. At the same time, six out of ten providers report that they are uncertain of the insurance benefits information needed to start patients on complex therapies. While many HCPs regularly use e-prescribing, many brands still require them to go to a website, download and fill out a form, and fax it to the brand’s hub. All of these factors can negatively impact the adoption of a branded therapy if providers anticipate patient access will be difficult. A tech-enabled, non-dispensing pharmacy can meet HCPs where they are by: - Integrating seamlessly into their current workflow - accepting e-prescriptions through electronic health records (EHRs) as pharmacies and eliminating the hassle of determining the right pharmacy to utilize based on a patient’s insurance - Smoothing the prescribing process by transferring relevant patient information from the EHR to ensure quality scripts that are more likely to get coverage - Alleviating the PA administrative burden by automating and managing the process from start to finish before transferring to the dispensing pharmacy ### Specialty-lite manufacturers need new models to influence brand performance Ineffective pharmacy networks can diminish a brand’s reputation, patient and provider satisfaction, health outcomes, and gross-to-net. And strong market access, the ability of a pharmaceutical manufacturer to secure reimbursement and coverage for their products from payers, does not always translate to covered dispenses at the pharmacy. Access partners that utilize non-dispensing pharmacies can help manufacturers navigate retail pharmacy challenges and eliminate the risks of relying on the traditional prescribing process by: - Decreasing prescription abandonment by ensuring the dispensing pharmacy is contracted with a patient's insurance plan - Increasing PA submission and approval rates by providing tech-enabled PA Support - Improving medication adherence and refill rates by supporting better continuity of care - Enabling better decision-making with more visibility into key metrics around benefits verification, PAs, health plan PA behavior, and reimbursement rates - Optimizing copay programs for financial sustainability by adhering to manufacturer business rules - Providing mechanisms to ensure a brand is dispensed as written at the retail pharmacy ### Discover the value of an integrated, digital hub platform Achieving strong market access for a specialty-lite brand does not guarantee that the patient can access the therapy reliably or affordably. This may explain why more than one of three new drug launches fall short of expectations. Integrated hubs with non-dispensing pharmacy models can break through these barriers. PhilRx is a scalable, end-to-end commercialization platform that helps specialty-lite brands protect their gross-to-net margins while facilitating access, unlocking coverage, and maximizing adherence. Our platform utilizes a non-dispense pharmacy that bridges our digital hub with an integrated nationwide pharmacy network to ensure patients receive prescribed therapy quickly, conveniently, and affordably. Our consultative approach is guided by real-time insights that provide strategic visibility across the prescription journey to improve brand performance. Book a demo of the PhilRx patient access platform today to discover first-hand how your brand can benefit. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How Pharmaceutical Manufacturers can Leverage Phil’s Technology to Improve Patient Access to Their Therapies Source: https://phil.us/how-pharmaceutical-manufacturers-can-leverage-phils-technology-to-improve/ ## How Pharmaceutical Manufacturers can Leverage Phil’s Technology to Improve Patient Access to Their Therapies Many patients struggle to navigate healthcare effectively, inhibiting access to prescribed therapies. Patrick Leary, Chief Commercial Officer at Phil, shares how technology can break down many of the barriers patients experience, enabling them to better afford and adhere to their medications. Q: What are the most significant challenges patients face today when affording the medications their providers prescribe? Pat: Over the last few decades, healthcare has shifted toward having patients take on greater financial responsibility for their medical services and products. I believe the impetus was to encourage patients to be better consumers; however, the shift hasn’t manifested in that way. It has often resulted in creating barriers to care. High coinsurance and high deductible health plans result in financial toxicity for many patients. Formulary requirements often dictate that patients use a “preferred” or generic brand to get coverage, even if a provider prescribes a “non-preferred” therapy that they think is best for a specific patient. Ultimately, there has just been a shift of cost from payers to patients, making it difficult for many people to afford the medicine they need to treat their health conditions effectively. Q: What role can technology play in easing the patient financial burden related to accessing their prescribed therapies? Pat: Technology helps reduce the financial burden in a couple of ways. First, from manufacturers and providers to payers and pharmacies, it can remove many administrative costs associated with processing prescriptions. These cost savings can be passed on to patients. Second, and quite frankly the biggest opportunity, is that technology can ensure that patients take advantage of any available copay programs to reduce out-of-pocket and utilize in-network pharmacies to maximize prescription coverage. Third, it can ensure that all of the administrative hoops required to gain payer approval for prescription coverage are addressed. It used to take an army of people calling payers, pharmacies, and foundations to determine what financial resources were available for patients and how they could take advantage of them. The same was often true related to gaining payer coverage of prescribed therapies. Now, by automating many of these processes, technology can efficiently and effectively funnel patients to the best financial outcome possible for their prescribed therapy. Q: Why is speed to therapy important? Pat: Speed to therapy is crucial for better outcomes. The faster a patient’s medical treatment initiates, the more likely it will be efficacious and prevent or slow down disease progression. With rare exceptions, that’s universally true for any disease state. Also, when patients must delay getting started – for example, while waiting for prior authorization – they get frustrated, and the likelihood of prescription abandonment escalates. This generally means a diluted patient experience and a reduction of brand loyalty. Another perspective is that of the providers. If they find getting their patient on therapy too time-consuming, they may decide to try another treatment even though it’s not optimal for that patient. Q: What hurdles slow the process of getting a patient started on their therapy? Pat: There are tremendous hurdles between patients and their prescribed therapies. I refer to them as hoops to jump through. Today, they are more like flaming hoops in the form of formulary and non-formulary lists, prior authorization requirements, and step therapy, where patients must first try and fail certain drugs. Payers have erected significant financial barriers for medications that are not preferred or off formulary. These barriers to therapy access are designed to steer patients away from specific therapies that payers deem too expensive. Q: How can pharmaceutical companies proactively increase speed to therapy? Pat: They need to make the prescribing process as easy, familiar, and light a lift as possible for providers and patients. That means meeting them where they are by modernizing the process. For patients, send texts with a link. Simplify forms by pre-filling the patient information you already have. For physicians, ensure the prior authorization process works within current workflows and attaches clinical information. Stay within their EHR so they don’t have to learn to navigate another website or portal. Make it as easy to prescribe your brand as a generic, and providers will do it more often. Suppose you can give providers an easy-to-use technology embedded in a familiar process that helps reduce patients’ financial burden. In that case, you will be able to get many more patients started on therapy more quickly. Q: Given the correlation between medication adherence and clinical outcomes, how can pharma manufacturers use technology to improve adherence? Pat: Manufacturers can use automated communication technology to make staying on therapy as easy as possible. For example: - Sending out messages that inform patients of the benefits of the therapy - Reminding them of how to take their medication and the potential side effects - Setting patients up with simple refill management - Informing of an upcoming refill and giving them the option to change the date It’s crucial to communicate with patients in the ways they prefer. Some people want to talk to a live person; others prefer a text reminder. When they sign up for therapy support, enable them to opt-in to receive text reminders. Give them choices to receive emails or phone calls. Then you can set up a cadence around the expectations for a particular therapy. Some nurse communications can be automated while allowing the patient to choose to talk to a nurse if they have additional questions. This approach will retain patients at a much higher level because they know what to expect, are more comfortable with the form of communication, and know they have resources when needed. Q: Can you share a real-world example? Pat: Absolutely! Phil is designing a technology-driven patient access program with a large pharma manufacturer. The program involves enrolling patients into the company’s nursing support program. We’re automating the front-end enrollment. With a large team of nurses making calls to enroll patients, the enrollment rates had been low. The underlying issue is that when people see an 800 number they don’t recognize, they don’t answer the phone. Our technology interacts with patients in ways they prefer, which results in much higher enrollment rates. Not only are patients happier, but so are nurses. And rather than calling and leaving messages all day, the nurses can focus on what they’re best at – helping patients adhere to their treatment. Q: How does the Phil Platform improve patient access to manufacturer’s brands? Pat: Phil reduces the friction many patients encounter when accessing their prescribed therapy. Our technology does all the things I’ve talked about and more: - For prescribers, utilizing the Phil hub platform and pharmacy network is as easy as prescribing a generic – they just go in, select “Phil Rx” in their EHR, and send it to us. - For patients, Phil captures all the relevant patient information from the EHR and prefills the electronic benefits verification form. The patient can confirm their insurance information on their mobile browser on their phone – we make that as simple as possible. If they don’t complete the mobile enrollment process (less than 5% of all patients) or want to talk to someone, we offer the opportunity to engage live via phone. They can call or request someone to call them. And this is all done in the patient’s preferred language. - If the prescribed therapy needs prior authorization, Phil takes care of it. The platform prefills the information into required PA forms and sends a fax to the prescriber’s office to have them verify, add any missing information, and electronically submit. - Every approved prescription is routed to a pharmacy that is best suited from a coverage perspective, meaning it has a contract with the payer. This eliminates out-of-network coverages. The platform automatically applies any manufacturer coupons or copay buydowns and collects credit card information to pay any difference. - Patients receive a text to opt-in to the support services program to receive adherence reminders, clinical messaging, and support. Phil’s enrollment rate is over 90% compared to 30% for prescriptions that go through the traditional retail process. - Opted-in patients are kept informed throughout the process, receiving updates about the status of their prior authorization, if they’ll be receiving some meds through a bridge program until approval, what their copay will be, etc. No more frustration because they are left in the dark about what is happening with their prescription. They can also choose to have their medication delivered to their home and to set up automatic shipments. The bottom line is that by streamlining the whole prescription process, the Phil platform achieves higher patient enrollment, more coverage for enrolled patients, and lower out-of-pocket. This trifecta translates to better medication access and adherence. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How to Choose the Best Commercialization Partner to Drive Patient Access Source: https://phil.us/how-to-choose-the-best-commercialization-partner-to-drive-patient-access/ ## How to Choose the Best Commercialization Partner to Drive Patient Access ### Is a pharmaceutical hub the best solution for commercializing your therapies? For well over a decade, pharmaceutical hub services have played a pivotal role in supporting patient access to life-saving and life-altering advanced drug therapies. Unfortunately, hubs tend to be a partner with low customer satisfaction rates and lower than ideal coverage and adherence. So, what is the best way to support patient access to critical therapies? Amid the shift to value-based care, patients’ prescription out-of-pocket burden has increased, particularly for specialty tier drugs. Out-of-pocket cost is a big factor in prescription abandonment and medication adherence. A 2019 Kaiser Family Foundation Health Tracking Poll revealed 1 in 5 patients did not fill a prescription and 3 in 10 did not take their medication as prescribed due to cost. Close to 60 percent reported they had difficulty affording $100 or more per month on prescriptions. In response to market changes, hub models evolved to consist of a broad array of services that support market and patient access across prescription drug tiers. When contemplating patient access services for your brand, it’s essential to consider the value of a commercialization partner, determine what level of services will offer the best fit, and evaluate five other key factors. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How to Make the Most of your Manufacturer-sponsored Financial Assistance Source: https://phil.us/how-to-make-the-most-of-your-manufacturer-sponsored-financial-assistance/ ## How to Make the Most of your Manufacturer-sponsored Financial Assistance Life science companies are acutely aware of the financial burden patients face when trying to access branded medications. With an estimated 3 out of 10 American adults not taking medications as prescribed due to cost, affordability is a leading barrier to patient access and something that manufactures have to take seriously if they wish to unlock significant adoption. With rapid initiation of therapy and medication adherence crucial to better patient outcomes and brand viability, making financial assistance programs timely and easily accessible is paramount. That's why most specialty and specialty-lite pharmaceutical manufacturers invest in a variety of financial support programs to support continuity of care. In 2021 alone, about 70% of patients on newly-launched specialty drugs were on some type of patient assistance program subsidized by the manufacturer. However, in today's healthcare environment, it can be challenging not only to ensure strong patient adoption of these programs but also to ensure that these programs don't deplete margins to the point that they are detrimental to the manufacturer's financial health. Taking the following steps will help ensure your brand's program design aligns with its economic objectives to drive lasting brand value: ### Address gaps in coverage appropriately Free drug and other financial assistance programs fill the gap created by delays during the insurance authorization process and ease medication access for patients with affordability issues. They are also a useful tactic to deploy when a drug is not yet on payer formularies to ensure that patients can access and benefit from therapies. The most common manufacturer sponsored programs include: - Quick Start – For new patients experiencing a delay due to the insurance approval process, a “first fill” – and potentially refills – of the medication is dispensed free of charge to expedite treatment initiation. - Bridge – Patients experiencing a lapse in coverage due to an expired prior authorization (PA) or change in insurance coverage receive a limited free prescription drug supply. - Patient Assistance Program (PAP) – For qualifying patients who are underinsured, uninsured, or denied coverage, this program provides a economic support to address affordability challenges often for a specified period of time or up to a specific amount. - Copay Assistance – Financial assistance in the form of a copay card or coupon used at the pharmacy counter to reduce or eliminate the out-of-pocket obligation typically for commercially insured patients. Manufacturers should be aware that patient financial assistance programs are subject to regulatory scrutiny, so manufacturers need to ensure that they avoid noncompliance sanctions and penalties. For example, if offering a program for government insured patients, it’s essential for manufacturers to collect patient attestations to ensure that they don’t bill their plan for the medication. In addition, copay programs can run the risk of overutilization by pharmacies and the application of copay accumulators and maximizers by payers, which can hurt the manufacturer’s gross net. While these programs facilitate patient access to therapy, establishing business rules that set guardrails to ensure sustainability is vital so that the right program is offered to the right patient at the appropriate time. ### Differentiate financial assistance based on payer behavior With 82% of physicians reporting that PAs lead to treatment abandonment at least some of the time and over 80% frequently refraining from prescribing a therapy because of insurance requirements, there’s no doubt that PA requirements constitute a significant hurdle for patients and healthcare providers. Integrating a differentiated financial assistance program based on how payers are responding to your product can help brands protect their margins by buying time for coverage while continuing to support patient access and provider experience. Manufacturers should leverage insights on individual payer behavior, such as average approval times and low approval rates, to refine their business rules to differentiate how financial assistance is applied. For example, if you know that a plan often takes a number of days to make a PA decision, you should offer a bridge fill for the patient to get started immediately and apply a PA approval to their subsequent refills to maximize the % of covered dispenses. Commercialization teams should also monitor payer accumulator and maximizer programs, which keep their manufacturer copay discounts from applying toward the patient’s deductible or out-of-pocket limits, shifting drug costs onto patients and manufacturers. By understanding the utilization of these programs, teams can adjust their financial assistance offerings to protect the bottom line more effectively while still supporting patients. According to the latest data from Drug Channels, approximately 40% of commercial plans have implemented these benefit designs. ### Mitigate the risk of uncovered coupon abuse Over the past decade, branded pharmaceutical manufacturers have increasingly turned to copayment coupon programs to help defray patients’ out-of-pocket cost-sharing obligations at the pharmacy to drive pull-through. From 2014 to 2016, these copay offsets increased by 32% across all retail brands. Reimbursement rates across different pharmacies vary substantially, incentivizing some pharmacies to rely on uncovered manufacturer coupons to compensate for scripts that are “underwater,” which will negatively impact the manufacturer’s gross-to-net (GTN). The key to mitigating this risk is to drive every dispense of your brand through an incentive-aligned pharmacy network in which the individual pharmacies get reimbursed at the highest rates and where you have complete control over when these programs are offered. Coupon usage should be 100% driven by the business rules your team determines which could include approaches like only offering them after a prior authorization has been started by the pharmacy. Check out this ebook to learn more about how to optimize prescription coverage at the pharmacy. ### Finding the right commercialization partner With Phil on your side, your team can accomplish these steps with ease with a data-driven approach that manages your financial assistance program in a way that ensures your budgeted subsidies support the patient as intended while protecting your margins. The PhilRx platform allows for 100% manufacturer control over your financial assistance programs and serves as a digital front door for all of your patient services. Request a consultation today to discover how you can unlock your unique value. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How to Streamline Pharmaceutical Commercialization Source: https://phil.us/how-to-streamline-pharmaceutical-commercialization/ ## How to Streamline Pharmaceutical Commercialization Developing a new drug is an incredibly costly, time-consuming, and high-risk venture. In the 21st century, it typically takes ten years and over $2.6 billion for a pharmaceutical manufacturer to move a drug from its initial discovery into the marketplace. While getting an innovative treatment approved for patient use is a major milestone, it’s just the beginning and certainly does not ensure the brand’s commercial success. It takes an extensive, coordinated effort to successfully take a new drug from FDA approval into patients’ hands. Given that a considerable investment has already been made to make the drug available to patients, it's up to the commercial team to develop a go-to-market model that delivers the best ROI possible. Pharmaceutical manufacturers would be wise to strategically reduce commercialization inefficiencies and improve margins through outsourcing, Lean initiatives, and data analytics. ### Outsource your drug commercialization As research and development costs continue to soar, life sciences companies are under increasing pressure to optimize revenue generation for their brands. Since go-to-market strategies can be complex, resource intensive, and expensive, outsourcing pharmaceutical drug commercialization to third-party experts can yield significant cost savings and operational efficiencies while enhancing the probability of commercial success. Pharmaceutical companies can avoid major infrastructure, software, and personnel investments by adopting vendor solutions that integrate their marketing and commercialization processes. This strategy enables them to focus their budget on building and maximizing the value propositions of their brands by: - Creating a seamless patient experience - Accelerating time-to-therapy - Improving medication adherence - Optimizing market access ### Apply a Lean approach to commercialization The successful implementation of “Lean Manufacturing” at Toyota inspired organizations worldwide to adopt a Lean management approach. The Lean Enterprise Institute describes the concept as “a way of thinking about creating needed value with fewer resources and less waste.” According to the Virginia Mason Institute, Lean healthcare is about “implementing processes that add value from a patient perspective - and eliminating or improving those that don’t.” The organization also points out that while “cost savings aren’t the focus of Lean management, they are often an outcome.” Many U.S. healthcare organizations have successfully executed lean management principles, reporting better patient outcomes, lower costs of care, higher patient experience scores, and improvements in productivity. The pharmaceutical sector, however, has been a late adopter of the approach, with many companies struggling to sustain their Lean initiatives. This challenge is partly because the focus has been primarily on manufacturing operations, and an entrenched silo mentality has limited the potential value of lean practice. By adopting Lean principles across the entire supply chain, pharma manufacturers can realize significant efficiency benefits that will give them a competitive edge. For emerging life science companies that want to commercialize their own products, using a Lean approach can help with identifying the best areas to focus internal resources and where it makes the most sense to outsource. ### Leverage technology and data analytics Pharma supply chains generate large volumes of data – historical sales data, supplier performance data, insurance coverage data, point of sale consumer data, and much more – from which commercialization teams can glean insights to drive down costs and increase revenue. However, these data sources are often underutilized. According to data from IBM, 84% of chief supply chain officers report that their biggest challenge is a lack of supply chain visibility. From drug discovery and development to manufacturing, distribution, and fulfillment, advances in digital technology and analytics are opening opportunities at every stage of the pharmaceutical product’s life cycle. When pharma and life science companies leverage the latest digital technologies to analyze their supply chain data in real-time, they gain a clearer picture of what’s happening across the supply chain. Greater visibility will enable teams to identify inefficiencies and opportunities to reduce costs. Leaders can then make informed decisions to improve efficiency, decrease waste, reduce operational risks, and enhance the experience for all stakeholders. ### Is your brand reaching its full commercialization potential? Excellent clinical trial results do not guarantee commercial success. You need a go-to-market strategy that optimizes your ROI and ensures your product reaches its full commercialization potential. Phil’s “channel-in-a-box” solution enables life science companies to optimize the commercialization of their drugs effectively and efficiently. For more information on partnering with Phil, visit phil.us/manufacturers. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Hubs, Digital Pharmacies, and Specialty Pharmacies: What Pharma Access Teams Should Know Source: https://phil.us/hubs-digital-pharmacies-and-specialty-pharmacies-what-pharma-access-teams/ ## Hubs, Digital Pharmacies, and Specialty Pharmacies: What Pharma Access Teams Should Know The evolution of healthcare consumer expectations and proliferation of expensive specialty and specialty-lite therapies have led to the rise of innovative solutions to clear an often onerous path to prescribed treatment. In 2022, specialty drugs accounted for 55% of the net spending in the pharmaceutical market, up from 28% in 2011. And an estimated 3 out of 4 patients who try to fill a new prescription for a recently launched brand are unsuccessful due to payer controls. Hub services, specialty pharmacies, and digital pharmacies have emerged to fill gaps in the patient access journey and are now standard fixtures in the complex pharmaceutical supply chain. The three are often confused because of their developing roles and overlapping functions. However, there are distinct differences, which life science manufacturers should be aware of as they build access strategies for their specialty and specialty-lite brands. ### What is a hub? The National Council for Prescription Drug Programs (NCPDP) defines hub services – also called Patient Services or Patient Services Support – as “manufacturer-sponsored programs that assist patients and prescribers in the areas of access, affordability and adherence services providing efficient distribution of medication improving patient compliance.” Pharmaceutical hub designs can be complex, and there really is no one-size-fits-all solution. Hub services may include distribution support, benefits investigation and verification, prior authorization assistance, financial assistance program management, patient education and adherence support, pharmacy dispensing support, data reporting, and more. In addition to creating support services in-house, pharmaceutical manufacturers can obtain hub services through a third-party vendor or choose a hybrid approach. Initially, call-center-based hubs were built around high-priced, highly complex specialty medications that treated smaller patient populations and required high-touch patient support services. While these “traditional” hub models are expensive, cumbersome, difficult to customize, and may be overkill for some therapies, a 2022 survey of life sciences companies found that most still invest in this type of hub. A newer tier of prescription drugs, called “specialty lite,” does not need the same level of one-on-one patient support and has a lower price point than specialty therapies. However, most patients still experience significant insurance hurdles when accessing these treatments. Technology-enabled hub platforms have emerged to streamline patient access, modernize the support experience, and enable manufacturers to leverage data and analytics to improve these services. ### What is a digital pharmacy? Difficulties accessing a brick-and-mortar pharmacy are a common cause of prescription delays. With over 40% of U.S. counties considered “pharmacy deserts” as of 2021 and reports of numerous retail pharmacy closures in recent years, many patients – especially those with mobility issues – are at risk of experiencing delays filling their prescriptions due to difficulties getting to a pharmacy. Additionally, many consumers today want to eschew traditional pharmacies, preferring a digital, Amazon-like experience to access their prescribed medications. Digital pharmacies, also called online pharmacies, fill these patient access gaps. Considered disruptors in the pharmacy market, digital pharmacies operate on a technology-driven, direct-to-consumer prescription fulfillment model, enabling patients to order prescriptions and schedule home delivery through a mobile app. These new entrants to the pharmaceutical landscape deliver the convenience, access, price transparency, and privacy patients seek. However, there is the drawback of a lack of counseling support provided by pharmacists at the point of dispensing, which can be a problem for the proper usage and adherence to a prescribed medication. ### What is a specialty pharmacy? Specialty pharmacies focus on dispensing medications for complex, chronic, or rare conditions, including advanced therapies involving intricate administration and ongoing monitoring. Key aspects of their role include: - Educating patients to help them understand how to take their medications properly, including dosage, administration techniques, potential side effects, and how to manage them - Collaborating with healthcare providers to monitor patient progress, which can involve regular check-ins, tracking of lab results, and assessing the patient's overall health condition - Helping patients navigate the complexities of insurance coverage, such as processing prior authorizations and accessing manufacturer-sponsored copay support programs - Offering adherence management support, such as refill reminders, counseling, and follow-up calls Specialty pharmacy is a rapidly expanding sector of the market – growing 315% between 2015 and 2021. Notably, PBM-owned specialty pharmacies represent about 75% of the total market in dispensing and revenues. Most specialty pharmacies are part of limited networks designed by PBMs, which gives payers more economic control over prescription fulfillment and can adversely affect the level of coverage a brand can expect. ### Is Phil a pharmacy or a hub? Neither! While Phil works with pharmacies to help brands navigate retail challenges and provides hub services to enhance and streamline patient access, our innovative solution does much more. PhilRx is a scalable, end-to-end commercialization platform that helps specialty-lite brands protect their gross-to-net margins while facilitating access, unlocking coverage, and maximizing reimbursement. Our manufacturer partners have access to an integrated, nationwide pharmacy network that helps patients receive prescribed therapy quickly, conveniently, and affordably. A consultative approach guided by real-time insights provides strategic visibility across the prescription journey. Learn how to position your brand for long-term growth by downloading this playbook for life sciences manufacturers. Want to learn more about how to position your brand for long-term growth? Download our playbook for life sciences manufacturers: “Optimizing Patient Access for Sustainable Growth.” Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Implementing an Effective Bridge Program: Laying the Foundation for Covered Dispenses Source: https://phil.us/implementing-an-effective-bridge-program-laying-the-foundation-for-covered/ ## Implementing an Effective Bridge Program: Laying the Foundation for Covered Dispenses A common challenge for specialty and specialty-lite brand commercialization teams is maximizing prescription coverage while minimizing free goods program overutilization. Patient bridge and quickstart programs, which provide temporary access to medications for patients experiencing coverage gaps or delays, are essential for therapy continuity and preventing financial burden on patients. However, these programs can negatively impact the manufacturers’ bottom line if manufacturers don’t implement the appropriate safeguards and requirements. At their core, these programs should be a tool to buy time for coverage and not a primary funding source for patient medications and pharmacies. Manufacturers should analyze their program design and consider the subsequent financial implications to ensure that they are effectively promoting patient access while managing their gross-to-net (GTN) performance to sustain the long-term viability of their branded therapies. Brand teams can use several approaches to optimize their bridge or quickstart programs: ### Evaluate the gross-to-net impact of your bridge program Most specialty and specialty-lite pharmaceutical manufacturers invest in various financial support programs to support continuity of care. With as many as 70% of patients on newly-launched specialty drugs using a patient assistance program subsidized by the manufacturer, commercialization teams must manage these programs the most of these programs effectively. When patients are unable to get their prescription covered due to an expired prior authorization (PA), lack of formulary placement or change in insurance coverage, a manufacturer-sponsored bridge or quickstart program provides a lifeline to patients to help them get started on a therapy that can improve their quality of life. Not only does this have benefits for speed to therapy, but it also has positive implications to brand loyalty amongst HCPs that can feel confident that patients can adhere to their intended care plan. Manufacturers rightfully view these programs as part of their commitment to patient care and access. Yet, if the program is not designed effectively (i.e. no requirement for a prior authorization submission for eligibility), a bridge program can impact the brand's GTN and bottom line as follows: - Increased buy downs: When a manufacturer has to buy down more prescriptions that get covered by insurers, they can significantly impact a manufacturers net revenue. These “rebates” are deductions from the list price, affecting the overall net revenue and profitability. - Higher hub or pharmacy fees: Implementing and administering patient bridge programs can incur additional operating costs, including program management, customer support, enrollment processes, and coordination with specialty pharmacies or distribution channels. These expenses can significantly impact the bottom line with overutilization particularly if the partner is utilizing an FTE staffing model. - Deferred revenue: Relying on a bridge program for an extended period may delay a patient's transition to full insurance coverage or alternative support programs. As a result, manufacturers experience prolonged periods of reduced or delayed revenue until patients secure proper coverage, diminishing cash flow and profitability. This can have significant implications on a brands ability to invest in growth to serve more patients. ### Ensure your access partner has tight integration with their pharmacy network Pharmacies can significantly impact pharmaceutical manufacturers' commercial success as crucial players in the prescription fulfillment process. A pharmacy network's contractual agreements and affiliations with payers, PBMs, and PSAOs can greatly influence coverage. A fragmented dispensing network diminishes a manufacturer's ability to deliver to patients and can hurt the bottom line by over-relying on free goods programs to fill coverage gaps. Many pharmacies that utilize mail order models are increasingly relying on manufacturer sponsored bridge programs as a key revenue stream when brands face significant obstacles to secure coverage as it presents an easy, less expensive path to revenue. Therefore, it is imperative to ensure your network has not only the contracts to deliver effectively and allows manufacturers to have tight control over the business rules surrounding their free goods programs. Stringing together your own network of pharmacies or specialty pharmacy partners is risky, operationally challenging, and often proves to be a costly mistake as the ability to be able to monitor them and make adjustments to business rules can be overwhelming. Without tight integration, you are likely to experience the same challenges with free goods overutilization. Working with a commercialization partner that integrates a robust and varied national network of pharmacies into its solution is ideal for maximizing plan contract coverage while minimizing bridge plan utilization. Check out this eBook for a deeper dive into how to optimize prescription coverage at the pharmacy. ### Implement an effective prior authorization strategy If your brand faces significant generic competition or is going to market with a significant list price, you are almost certain to face utilization management obstacles. The PA process is prone to errors and challenges, such as changing payer rules, lack of transparency, and the use of multiple utilization management measures, which can create gaps in coverage. However, brands must accept this and take a proactive approach to ensuring they have the right partner to facilitate submissions as well as structure their free goods program design to ensure that the only means to access it is if a prior authorization is submitted by the HCP. Brands should note that while many retail & specialty pharmacies assist with the PA process, most leave it up to the prescriber or patient. In many cases, pharmacists and pharmacy techs manually process PA requests, which is time-consuming and delays therapy initiation. While this is an ideal time for a quickstart program, it’s often difficult for manufacturers to implement business rules to deliver a parallel dispense approach effectively.. The key to getting (and keeping) patients off free goods programs and maximizing coverage is to implement a data-driven approach that streamlines the process from start to finish: - Employing user-friendly technology to simplify enrollment & BV processes - Educating patients and healthcare providers on alternative patient assistance programs - Using feedback loops to stay on top of evolving payer prior authorization requirements - Utilizing data that differentiates dispense workflows based on payer behavior - Providing full visibility into the prior authorization journey ### Let’s lay the foundation for covered dispenses of your brand Maximizing prescription coverage for branded therapies while minimizing reliance on patient free goods programs is a complex but crucial goal for pharmaceutical manufacturers. By understanding the gross-to-net effect of your program, partnering with a robust network of pharmacies, and modernizing your PA process, you can enhance coverage and ensure that patients have uninterrupted access to your prescription therapy. With Phil, you can access a nationwide pharmacy composed of retail, chain, and specialty pharmacies with 98% plan coverage. The data-driven PhilRx platform gives you complete control over your financial assistance programs – supporting patients as intended while protecting your margins – and serves as a digital front door for all your patient services. Get started by requesting a consultation today! Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Improving Access, Coverage, and GTN with a Digital Hub Source: https://phil.us/improving-access-coverage-and-gtn-with-a-digital-hub/ Upcoming Webinar ## Improving Access, Coverage, and GTN with a Digital Hub Feb 28, 2024 at 11am PST Your patient support services should drive quick, easy, and affordable access to your retail and specialty-lite therapies. If your approach isn’t delivering the outcomes that you (and your patients and providers) expect, consider an alternative channel strategy. With a strategic digital hub, you can offer an end-to-end patient and provider experience that drives access, coverage, and GTN for your retail and specialty-lite brands. On this webinar, you will learn: - Why branded retail and specialty-lite manufacturers are challenged to improve access and affordability through traditional support services - Key strategies for building a digital hub that supports patients and providers throughout the medication access journey - How brands are improving patient access, provider engagement, and brand outcomes with an alternative channel strategy Attend this webinar to discover the building blocks of a digital hub model that is designed to improve branded retail and specialty-lite outcomes. Hear from seasoned leaders at Phil as they share actionable takeaways to help you unlock the full potential of your access strategy. The registration window is now closed. Sign up to be notified about future events. ### Meet your Speakers Learn strategies and best practices from industry leaders at Phil ###### Nicole Grycan VP Commercialization, Phil Inc. Nicole brings over 20 years of experience in the pharmaceutical industry, supporting strategic client growth and partnerships. She recently joined Phil as VP Commercialization to oversee client-centric initiatives. ###### Catherine Wood Hill SVP, Marketing, Phil Inc. Catherine Wood Hill is a seasoned marketing leader with over 15+ years of experience in customer-centric demand generation and lifecycle marketing. As SVP Marketing, she helps life sciences companies improve access, engagement, and outcomes. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Improving Adoption of Your Patient Support Services Source: https://phil.us/improving-adoption-of-your-patient-support-services/ Playbook ## Improving Adoption of Your Patient Support Services An actionable playbook to achieving sky-high adoption of your patient support services Download PDF Life sciences teams are investing significant time, energy, and effort into their patient services programs, and most are not yielding desired results. It’s time to turn your patient services into a strategic force for brand growth. This white paper outlines how to overcome barriers to patient program utilization and key strategies to maximize patient adoption. #### In this playbook, you’ll learn about: - Evaluating the current state of patient services in the life sciences industry - Overcoming common barriers to patient services program utilization - Key strategies to maximizing adoption of your patient services programs #### Harness the power of your patient services Maximize the impact of your patient services. Schedule a call to discover how Phil can help you create a transformative patient access program. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Improving Prescription Coverage at the Pharmacy Source: https://phil.us/improving-prescription-coverage-at-the-pharmacy/ White Paper ## Improving Prescription Coverage at the Pharmacy A manufacturer’s guide to optimizing prescription coverage through strong pharmacy partnerships Download PDF Pharmacies play a pivotal role in brand success. Through strategically integrating your dispense network into your access strategy, you can successfully improve coverage and accelerate patient adoption. This white paper uncovers the pharmacy dynamics that underpin pharmaceutical brand growth, and outlines actionable strategies to help you build a strong pharmacy partnership that optimizes coverage at the counter. ### In this white paper, you’ll learn about: - Identifying key players in the pharmacy landscape that impact brand success - Actionable steps to evaluate the efficacy of your pharmacy network - Key strategies to maximize covered dispenses, adoption, and refills #### Optimize coverage at the counter Tap into the power of an access-driven pharmacy network. Discover how the PhilRx patient access platform can strengthen coverage, access, and GTN for your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Innovating Your HCP Engagement Model Source: https://phil.us/innovating-your-hcp-engagement-model/ Playbook ## Innovating Your HCP Engagement Model A manufacturer's guide to improving patient outcomes through the provider network Download PDF 9 in 10 providers expect pharmaceutical companies to help them address their challenges and concerns. Is your team leveraging the right strategy in the right channels at the right time to effectively educate and engage providers? This playbook unpacks the current state of HCP engagement for retail and specialty-lite brands, and offers a 4-point proven strategy for innovating the HCP engagement model through data and technology. #### In this playbook, you’ll learn: - Why traditional HCP engagement methods are no longer sufficient in today’s healthcare environment - Strategies to improve education and engagement across your provider network - How to optimize your field efforts to drive patient outcomes and brand performance #### Improve patient access, adherence, and advocacy Equip your team with the tools they need to drive provider adoption. Learn how PhilRx can help you create a seamless PA process and HCP engagement model fuelled by real-time data and insight. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Innovative Strategies to Streamline the Access Journey for Patients & Providers Source: https://phil.us/innovative-strategies-to-streamline-the-access-journey-for-patients-and/ Upcoming Webinar ## Innovative Strategies to Streamline the Access Journey for Patients & Providers Sep 10, 2024 at 9am PDT Putting patients and providers at the heart of every brand initiative is top of mind for all pharma teams. But, many manufacturers have large gaps and friction points in their access journey that are creating high barriers to access, engagement, and adherence. Join our webinar to dive into trusted strategies and best practices for designing a medication access experience that drives patient outcomes and provider engagement, based on learnings from Phil’s diverse portfolio of pharma brands. #### What you’ll learn on the webinar: - Identify the most prevalent challenges affecting today’s patients and providers - Adopt effective strategies that elevate your access journey, from appointment to refill - Empower your team with insights to boost access, engagement, and adherence Elevate your medication access experience for patients and providers. Register now. Registration is now closed. Sign up below to learn about future webinars. ### Meet your Speakers ###### Catherine Wood Hill SVP, Marketing, Phil Inc. Catherine Wood Hill is a seasoned marketing leader with over 15+ years of experience in customer-centric demand generation and lifecycle marketing. As SVP Marketing, she helps life sciences companies improve access, engagement, and outcomes. ###### Shyam Patel Director, Client Optimization, Phil Shyam Patel is a seasoned business operations professional with a strong background in strategy and analytics within the healthcare industry. He excels in optimizing program performance for our clients. ###### Neil Dean Director, Product Management, Phil Inc. Neil is a results-oriented Product Management professional with experience leading teams to launch emerging products & services to support strategic objectives. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Designing a Direct-to-Patient Program that Turns Cost Barriers into Accelerated Patient Success Source: https://phil.us/insights/case-studies/philrx-designs-transformative-telemedicine-channel-for-womens-health-brand/ Therapeutic area Women’s Health Lifecycle stage Mid-Cycle ## Designing a Direct-to-Patient Program that Turns Cost Barriers into Accelerated Patient Success Download PDF ### Key Takeaways #### Situation A women’s health brand sought to launch a Direct-to-Patient (DTP) channel for discreet, convenient care after FDA approval. #### Challenge Deliver an integrated digital patient access experience while addressing coverage gaps and gross-to-net improvement opportunities. #### Solution Partnered with PHIL to implement a flexible, API-integrated DTP program with telemedicine, tailored dispense options, and national pharmacy coverage. #### Outcomes The program delivered 35K new prescriptions, 91% patient enrollment, 91% HCP PA submissions, 2x pull-through, 5x refill adherence, and 4.1x net sales per patient. ##### 2x Pull Through ##### 91% HCP PA Submissions ##### 5x Patient Adherence Share TABLE OF CONTENTS ### Client Background A women’s health brand recently received FDA approval for a treatment indicated for hypoactive sexual desire disorder (HSDD) in women. Their target audience is middle-aged women seeking convenient and discreet healthcare solutions. ### Launch Goals - Launch a Direct-to-Patient (DTP) access channel on their website to align with evolving consumer preferences - Provide a seamless, discrete experience through telemedicine and home prescription delivery - Identify the right partner to execute this strategy successfully in the post-COVID digital healthcare era ### The Challenge As the brand laid the groundwork to launch a digital access channel to complement their retail strategy, they understood the following had to be true to ensure DTP success: - The digital access experience had to be transparent, convenient, affordable, and integrated to meet e-commerce-like expectations and maintain brand loyalty. - The brand needed a DTP and digital hub partner that could compliantly share patient health and prescription data to deliver a seamless, integrated experience and speed therapy access. - The DTP program required infrastructure to support brand coverage and sustainable growth by ensuring processes that convert formulary placement into a high percentage of covered dispenses. ### The Solution The brand recognized the opportunity in launching a DTP program but initially struggled to identify the right partners among similar vendors. They concluded that a modern patient access experience was essential but insufficient without addressing gross-to-net challenges. Therefore, they prioritized finding a digital hub partner that could improve prior authorization rates and maximize covered dispenses. After an extensive search, they chose PHIL as a partner due to our proven results, platform flexibility, and unique gross-to-net optimization capabilities. Our teams partnered to implement a responsive solution for this innovative women’s health product and together the organizations sought to: - Market the channel on the brand’s patient website for a consistent experience throughout the access journey. - Use API integration to share patient data between the telemedicine provider and digital hub for faster benefits checks and prior authorizations. - Design the program to enable seamless therapy access with tailored dispense options for different insurance statuses (copay, Bridge, PAP). - Offer patients the choice of home delivery or local pharmacy pickup. ### Bringing a Direct-to-Patient Strategy to Life PHIL collaborated with commercial teams to implement a responsive solution in a matter of weeks: 1. Direct Integration in Brand Assets Patients visiting the brand website could start a virtual visit to get a prescription today. 2. Multiple Options to Access Care Patients accessed disease-specific providers via synchronous or asynchronous visits, based on state regulations. 3. Digital Patient Enrollment After receiving a prescription, patients enrolled in the PHIL platform via a mobile text link. 4. Telemedicine PA Portal PHIL built a PA portal integrated with PA submission software for HCPs to easily manage payer requirements and submit prior authorizations. 5. National Dispense Network PHIL’s pharmacy network provided 98% coverage, ensuring patients could access covered home delivery. 6. End-to-End Visibility The brand team had full visibility into the Rx journey to optimize program performance. ### Driving DTP Success with PHIL ###### Strong Patient and HCP Engagement ##### 35k New Prescriptions ##### 91% Enrollment ##### 91% HCP PA Submissions ###### Improved Outcomes vs. Other Channels ##### 2x Pull Through ##### 5x Refill Adherence ##### 4.1x Net sales ### PHIL Quickly Maximized the Benefit of Formulary Wins #### Request a Demo Fill out the form below to request a discovery call with the PHIL team. ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. #### Featured Case Studies #### Engaging Providers to Overcome Adoption and Adherence Challenges to Deliver Brand Growth With data-driven insights and full visibility into the prescription lifecycle, this innovative ophthalmology brand achieved a successful flagship therapy launch. Read more #### Removing Barriers and Boosting Adherence to Drive Adoption and Growth With insight into the prescription lifecycle, this migraine brand launched a robust channel program that delivered a modern patient access experience Read more #### Overcoming Low Enrollment and High Abandonment Rates Through Seamless Patient Access Providing end-to-end visibility into the prescription lifecycle, this novel women’s health brand expanded covered dispenses and maximized reimbursement for patients. Read more View all case studies ### Get latest updates --- # Engaging Providers to Overcome Adoption and Adherence Challenges to Deliver Brand Growth Source: https://phil.us/insights/case-studies/philrx-drives-high-adoption-for-ophthalmology-brand/ Therapeutic area Ophthalmology Lifecycle stage New Launch ## Engaging Providers to Overcome Adoption and Adherence Challenges to Deliver Brand Growth Download PDF ### Key Takeaways #### Situation A biotech preparing to launch its flagship eye care therapy aimed to drive prescriber adoption, patient adherence, and sustainable growth. #### Challenge Competing brands, high prior authorization rates, cost barriers, and retail limitations required a modern patient access strategy. #### Solution Partnered with PHIL to deliver a digital-first program featuring seamless enrollment, bridge access, automated PA support, contracted pharmacy routing, and real-time insights. #### Outcomes 50% of prescriptions flowed through PhilRx in Year 1, driving high adoption, payer awareness, and supporting a successful acquisition by a major pharmaceutical company. ##### 90% Patient Enrollment ##### 5x Covered Dispenses ##### 6x Refill Adherence Share TABLE OF CONTENTS ### Client Background A biotech company preparing for FDA approval of its flagship eye care therapy in late 2021 aimed to leverage strong Phase 3 clinical results to drive results at launch. ### Launch Goals - Raise awareness with HCPs while offering a seamless PA submission process - Ensure patients faced no barriers to accessing and adhering - Protect GTN while delivering sustainable growth ### The Challenge Despite having a unique product with proven benefits, the team knew success required an effective patient access strategy to overcome key launch challenges. - Branded Competition Not first to market—needed best-in-class user experience to drive HCP prescribing. - Barriers to Patient Access Ensure affordable, quick therapy starts without cost burden with an effective bridge program. - Utilization Management Hurdles Specialty-lite category meant frequent prior authorizations (PA), even after winning formulary placement. - HCP Loyalty Build awareness and confidence in adherence amid generic and over the counter competition. - Retail Channel Retail presence was important but inadequate for evolving consumer behavior and PA needs. - Stakeholder Insights Monitor payer and HCP response during launch to guide timely strategy adjustments to business rules. ### The Solution The brand determined that retail distribution alone—and traditional specialty pharmacies—couldn’t meet modern patient expectations or address today’s channel complexities. To ensure launch success, they needed a partner that could deliver a seamless digital experience, eliminate access barriers, and manage gross-to-net by driving high PA submission rates and leveraging a fully contracted pharmacy network. They chose PHIL as a partner due to our proven success as a strategic digital hub partner and ability to convert market access into covered dispenses. ### Partnering to Bringing a Launch Strategy to Life - Offering a Frictionless Digital First Experience HCPs ePrescribe within existing workflows; patients enroll and manage prescriptions on their smartphones in minutes. - Complete Payer Awareness Amongst Payers PHIL would support PAs for all prescriptions received during the launch phase to create awareness amongst our extensive payer network with 98% plan coverage - Real-Time Business Rule Adjustments Our platform delivers real-time data and insights, enabling strategic access decisions to unlock sustainable growth. ### The Approach PHIL partnered with launch teams to provide strategic guidance and implement a customized access program powered by the PHIL Platform—fully integrated into brand assets and launch-ready within weeks. - Seamless Digital Enrollment Patients enroll via text in minutes after receiving a prescription. - Bridge Program Immediate low-cost therapy start while PHIL handles PAs in parallel. - Pharmacy Routing Prescriptions routed to contracted pharmacies after benefit verification. - “1-Click” PA Submissions Prepopulated forms from eRx allow quick HCP review and submission. - Simple Refills Patients opt into refills management with notifications for easy adjustments. - Business Rules Engine Real-time payer insights enable timely updates to access strategies. ##### This solution gave the brand access to ### The Results With a coordinated marketing effort, 50% of total prescriptions were sent through the PHIL in year 1! ##### 90% Enrollment 90% of patients receiving a prescription via the PHIL platform completed the digital enrollment process. ##### 1.5x Pull Through 1.5 times higher pull through vs. retail for patients prescribed a new prescription to PHIL. ##### 5x Covered Dispenses 5x more covered dispenses vs. retail for patients using the PHIL platform. ##### 6x Refill Adherence 6x higher refill adherence for patients using the PHIL channel. #### Request a Demo Fill out the form below to request a discovery call with the PHIL team. ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. #### Featured Case Studies #### Removing Barriers and Boosting Adherence to Drive Adoption and Growth With insight into the prescription lifecycle, this migraine brand launched a robust channel program that delivered a modern patient access experience Read more #### Designing a Direct-to-Patient Program that Turns Cost Barriers into Accelerated Patient Success Combining a modern patient experience with end-to-end visibility into the prescription lifecycle, PHIL maximized covered dispenses for this women’s health brand. Read more #### Overcoming Low Enrollment and High Abandonment Rates Through Seamless Patient Access Providing end-to-end visibility into the prescription lifecycle, this novel women’s health brand expanded covered dispenses and maximized reimbursement for patients. Read more View all case studies ### Get latest updates --- # Removing Barriers and Boosting Adherence to Drive Adoption and Growth Source: https://phil.us/insights/case-studies/philrx-launches-robust-channel-strategy-for-specialty-lite-migraine-brand/ Therapeutic area Neurology Lifecycle stage New Launch ## Removing Barriers and Boosting Adherence to Drive Adoption and Growth Download PDF ### Key Takeaways #### Situation A migraine therapy brand prepared for FDA approval in a crowded market dominated by major players. #### Challenge Needed a modern access solution to drive adoption, secure coverage, overcome PA hurdles, and gain real-time insights. #### Solution Partnered with PHIL to deliver seamless enrollment, tailored dispense workflows, intelligent routing, and actionable data. #### Outcomes Converted formulary access into covered dispenses with 90% enrollment, 1.5× first fills, 3× refill adherence, and 4× net sales. ##### 90% Patient Enrollment ##### 1.5x First Fills ##### 3x Refill Adherence Share TABLE OF CONTENTS ### Client Background As the brand prepared for FDA approval of its flagship migraine therapy in early 2021, it aimed to leverage strong clinical results and a novel fast-acting nasal delivery to stand out in a crowded market. Despite promising science, success was not guaranteed in a category dominated by major players with celebrity-backed campaigns. To drive adoption, coverage, and adherence, the team sought a differentiated go-to-market strategy and engaged commercial partners to overcome competitive and channel challenges. ### Launch Goals - Drive adoption with a differentiated go-to-market strategy - Secure coverage and ensure patient access - Boost adherence for sustainable growth ### The Challenge To support a successful launch, they needed a partner that could help them: - Deliver a Modern Patient Access Experience Eliminate friction points with a seamless, digital-first experience for patients and HCPs. - Lay the Foundation for Covered Dispenses Partner with a company that could convert formulary placement into covered dispenses. - Generate Lasting HCP Loyalty Build awareness and confidence in adherence with effective support and ecommerce like home delivery. - Provide an Alternative to Retail Avoid prior authorization challenges in the retail channel that could threaten adoption and erode Gross to Net. - Gain Actionable Insights Leverage real-time data during the launch phase to adjust business rules and unlock coverage and growth. ### The Solution The brand knew going it alone was risky and that legacy access partners couldn’t meet modern channel demands. Targeting a diverse patient population, they needed a solution that could tailor dispense workflows for Commercial, Government, and Uninsured patients. They chose PHIL as a partner due to our exceptional patient experience, integrated platform, and proven ability to drive new starts while converting formulary access into covered dispenses. Together, we set out to support a successful launch by: - Simplify HCP & Patient Access Journey Enable easy ePrescribing within existing workflows, smartphone-based enrollment, and full script visibility throughout the journey. - Neutralize Prior Authorization Obstacles Use real-time benefits checks, parallel workflows, and prepopulated forms for easy and quick PA submissions. - Leverage Channel Data Analyze HCP, patient, and payer behavior to support obtainment of formulary and adjust business rules to facilitate improved access. ### Partnering with PHIL to Commercialize Their Therapy PHIL partnered with launch teams to implement a customized patient access program powered by its integrated platform—fully embedded in brand assets and launch-ready within weeks. The launch solution included: - Seamless Digital Enrollment Patients enroll via text in minutes on their smartphone after receiving a prescription—often before leaving the doctor’s office. - Differentiated Dispense Workflows Tailored by insurance type, including uncovered options, patient assistance programs, and government waivers. - Intelligent Pharmacy Routing Prescriptions routed to pharmacies contracted with the patient’s insurance after eRx and benefit verification. - “1-Click” PA Submissions Platform auto-populates forms from eRx data for quick prior authorization and formulary exception submissions. - Simple Refills Patients opt into refill management and receive notifications to manage upcoming prescriptions. - Payer Coverage Data & Insights Manufacturers access real-time payer response data to inform market access strategies. ##### This solution helped the brand ### The Results The partnership with PHIL facilitated the conversion of formulary placement to covered dispenses positioning the brand for sustained growth. ##### 90% Enrollment 90% of patients receiving a prescription via the PHIL platform completed the digital enrollment process. ##### 1.5x First Fills PHIL successfully drove more 1.5x successful patient starts vs. retail with our customized dispense workflows to ensure new starts. ##### 3.5x Refill Adherence 6.5 average patient refills per patient for patients receiving a prescription via the PHIL channel – 3x higher than other channels. ##### 4x Net Sales 4x higher net sales than other pharmacy channels because of improved pull through, % Rx covered, and refill adherence. #### Request a Demo Fill out the form below to request a discovery call with the PHIL team. ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. #### Featured Case Studies #### Engaging Providers to Overcome Adoption and Adherence Challenges to Deliver Brand Growth With data-driven insights and full visibility into the prescription lifecycle, this innovative ophthalmology brand achieved a successful flagship therapy launch. Read more #### Designing a Direct-to-Patient Program that Turns Cost Barriers into Accelerated Patient Success Combining a modern patient experience with end-to-end visibility into the prescription lifecycle, PHIL maximized covered dispenses for this women’s health brand. Read more #### Overcoming Low Enrollment and High Abandonment Rates Through Seamless Patient Access Providing end-to-end visibility into the prescription lifecycle, this novel women’s health brand expanded covered dispenses and maximized reimbursement for patients. Read more View all case studies ### Get latest updates --- # Overcoming Low Enrollment and High Abandonment Rates Through Seamless Patient Access Source: https://phil.us/insights/case-studies/philrx-unlocks-90-dispense-coverage-for-womens-health-brand/ Therapeutic area Women’s Health Lifecycle stage Mid-Cycle ## Overcoming Low Enrollment and High Abandonment Rates Through Seamless Patient Access Download PDF ### Key Takeaways #### Situation Women’s health brand launched HSDD therapy but growth stalled despite strong formulary placement. #### Challenge Low enrollment (2%), poor coverage conversion (25%), and high drop-off threatened financial viability. #### Solution PHIL implemented a digital-first access program with seamless enrollment, 1-click PA, optimized routing, tailored workflows, and real-time insights. #### Outcomes 90% enrollment, +36% new scripts, 2× first fills, 5× total fills, 4× covered dispenses, 110× monthly net sales. ##### 90% Patient Enrollment ##### 4x Covered Dispenses ##### 5x First Fills Per Patient Share TABLE OF CONTENTS ### Client Background After FDA approval, a women’s health brand launched an HSDD therapy with a bridge program, specialty pharmacy network, and telemedicine integration. Despite strong formulary placement, growth stalled due to specialty pharmacy partner. ### Goals - Ensure seamless patient access through modern, digital-first workflows - Convert formulary placement into covered dispenses to drive adoption - Improve adherence and provider confidence for sustainable growth ### The Challenge They found their current partner was ill-equipped to address commonly experienced channel challenges resulting in: - Low Enrollment (2% of Patients) Automated calls and a lengthy process deterred patients; one year post-launch, enrollment remained in the low single digits, limiting PA success. - Poor Conversion of Market Access (25% of Eligible Rx) Despite 85% formulary placement, few covered dispenses due to poor UX, PA bottlenecks, and limited pharmacy network (60%). - Low Refill Adherence (1.5 Refills per Patient) Reliance on manufacturer financial support and high out-of-pocket costs after bridge program led to significant patient drop off. These factors threatened the brand’s financial future and prompted the commercial team to re-evaluate its strategy and channel partner. ### The Solution Facing stalled growth, the brand needed a partner to convert formulary access into covered dispenses, improve patient and financial outcomes, and gain visibility into payer behavior. After an extensive search, they chose PHIL as a partner due to our proven results, seamless integration with telemedicine, and the opportunity to build a configurable platform tailored to evolving business needs. ##### Partnership Goals: - Seamless Patient & HCP Experience Enable frictionless prescribing, PA processes, and easy patient access to therapy. - Convert Market Access to Covered Dispenses Streamline coverage approvals with tailored dispense programs based on payer behavior while leveraging intelligent pharmacy routing based on insurance plan. - Equip the Field Team Provide tools and data to help HCPs overcome PA bottlenecks and close access gaps. ### The Approach PHIL partnered with the brand’s commercial team to launch a customized solution in six weeks, integrating with their telemedicine partner and creating an access workflow that dispensed bridge prescriptions while pursuing PAs. We built a custom access program to solve the brand’s unique challenges that included: - Digital Enrollment Text-based smartphone enrollment—no app required. - 1-Click PA Submissions Auto-populated PA forms from eRx layered with PA submission software for fast submission. - Optimized Pharmacy Routing Prescriptions routed to contracted pharmacies for coverage. - Differentiated Dispense Programs Utilized business rules for tailored access based on payer PA behavior. - Adherence Support Ongoing digital and live support for therapy adherence. - Actionable Insights Access to real-time data points and field enablement dashboards. ##### This solution gave the brand access to ### The Results The brand experienced transformational results after 18 months. ##### Patient Engagement 90% enrollment in PHIL Platform and opted into easy refill management ##### Access & Adherence +36% Monthly new prescriptions 2x Successful first fills 5x Increase in total fills per patient ##### Financial Impact 110x net sales per month #### Request a Demo Fill out the form below to request a discovery call with the PHIL team. ### Streamline the Medication Access Experience Discover how the PHIL platform can help your brands maximize coverage, adherence, and commercial performance. #### Featured Case Studies #### Engaging Providers to Overcome Adoption and Adherence Challenges to Deliver Brand Growth With data-driven insights and full visibility into the prescription lifecycle, this innovative ophthalmology brand achieved a successful flagship therapy launch. Read more #### Removing Barriers and Boosting Adherence to Drive Adoption and Growth With insight into the prescription lifecycle, this migraine brand launched a robust channel program that delivered a modern patient access experience Read more #### Designing a Direct-to-Patient Program that Turns Cost Barriers into Accelerated Patient Success Combining a modern patient experience with end-to-end visibility into the prescription lifecycle, PHIL maximized covered dispenses for this women’s health brand. Read more View all case studies ### Get latest updates --- # Phil Inc - Events for Life Sciences Companies Source: https://phil.us/insights/events/ ## Resources/ Events Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Events ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### On-Demand Webinar: Capturing Actionable Metrics to Improve Patient & Brand Outcomes Market-leading manufacturers are embracing new models to improve visibility and insight into patient outcomes, provider, and brand performance. Watch this webinar as industry experts from Phil and Syneos Health explore gaps in today’s channel analytics environment, and offer strategic recommendations to help your team effectively leverage data to improve patient outcomes and brand performance. What you’ll learn on the webinar: Unpacking trends, challenges and opportunities for capturing the right channel metrics Building a strong data model, including which KPIs to track at the patient, provider, and program level Training your brand and field teams to optimize your patient and provider experience Lead with Insight Uncover a data-driven approach to optimizing patient and brand outcomes Watch now #### On-Demand Webinar: Innovative Strategies to Streamline the Access Journey for Patients & Providers Putting patients and providers at the heart of every brand initiative is top of mind for all pharma teams. But, many manufacturers have large gaps and friction points in their access journey that are creating high barriers to access, engagement, and adherence. On this webinar, dive into trusted strategies and best practices for designing a medication access experience that drives patient outcomes and provider engagement based on insights from Phil’s diverse portfolio of life sciences brands Watch now #### On-Demand Webinar: Delivering on Direct-to-Consumer: Exceeding Patient Expectations for Virtual Care Over 75% of patients have accessed care virtually as of 2024 – the primary reasons being for improved convenience and choice. As patient expectations for digital care continue to rise, the direct-to-consumer (DTC) movement should be top of mind for pharma manufacturers. Watch this webinar with seasoned leaders from Sun Pharmaceuticals and Phil to unpack the evolving landscape of digital care from the perspective of patients and providers, and its potential to improve prescription access, adherence and affordability Watch now #### On-Demand Webinar: Improving Access, Coverage, and GTN with Digital Hubs Your patient support services should drive quick, easy, and affordable access to your retail and specialty-lite therapies. If your approach isn’t delivering the outcomes that you (and your patients and providers) expect, consider an alternative channel strategy. With a strategic digital hub, you can offer an end-to-end patient and provider experience that drives access, coverage, and GTN for your retail and specialty-lite brands Watch now #### On-Demand Webinar: Designing a Digital Patient Access Journey With 90% of patients wanting to access healthcare through technology, a digital-first access program is now a must (Accenture). Discover the building blocks of a digital access journey that supports your patients from activation through adherence. Learn trusted strategies and best practices from our expert panel from Duchesnay Pharmaceutical Group, US Pharma Consulting, and Phil Inc Watch now 1 2 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Events for Life Sciences Companies Source: https://phil.us/insights/events/2/ ## Resources/ Events Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Events ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### On-Demand Webinar: Optimizing Your Field Team to Maximize Patient Access Field teams play a critical role in securing patient access. As a key player in your brand's success, your field team must command a mastery of your brand's strategic goals in order to effectively drive HCP loyalty and maximize patient access. In this webinar, you’ll learn how to design a modern field team model that mobilizes your field team to drive patient access with leaders from Phil and Real Endpoints Watch now #### On-Demand Webinar: Your Guide to Building An Exceptional Telemedicine Program All innovative therapies should consider a telemedicine strategy in order to meet patient demands and drive commercial success. On this webinar, you'll hear from industry experts at Phil and Prescribery as they share strategies and best practices for building and scaling a powerful telemedicine program that drives transformative brand outcomes. Watch this webinar to learn about: Evolving patient expectations for digitally-driven care Key components of a successful telemedicine program How to measure the impact and effectiveness of your telemedicine program Why you should watch: Patient expectations for virtual care have radically changed Watch now #### On-Demand Webinar: Patient Access Strategies to Drive Sustained Brand Growth In today’s complex channel environment, commercial teams must optimize their patient access strategy for sustainable brand growth. Tune in as seasoned industry experts, Patrick Coyle, Founder & CEO of Novus Proximus LLC and Daniel Johnson, Director of Product Marketing at Phil, share how you can develop an integrated patient access strategy that unites your hub, field team, and services programs into a supercharged growth engine. On this webinar, you’ll learn: Optimal commercial structure to respond to evolving channel dynamics Best practices for aligning field teams to promote organizational goals Understanding of the impact of financial barriers to patient success Key success metrics for a successful patient access program How to use data to optimize field and access program outcomes Watch now #### On-Demand Webinar: Improving Patient Access to Medications by Simplifying the Prescription Process Tune in as panelists will discuss the biggest challenges in the prescription process and implications to patients, as well as opportunities to improve medication access using technology. On this webinar, you will learn about: Current gaps in the patient access journey and implications Opportunities to improve medication access for patients How technology can streamline the prescription process Digital health tools that can be leveraged in the healthcare journey; and How simplifying access to medication will drive improved health outcomes Watch now #### On-Demand Webinar: Tech Enabled Patient Access Technology is the driving force behind transforming patient access. On this webinar, you'll discover trusted strategies and best practices for building a technology-enabled access strategy from seasoned leaders from Phil, Merck, Impel, Syneos Health, and Fierce Pharma. Watch this webinar to learn about: Why simplifying the patient access experience is critical to realize strong results What brands should look for in a commercialization partner How various pharmacy models impact a brand's strategic priorities What data is needed to respond the complexities of utilization management Transform your Patient Access Experience PhilRx is a seamless patient access platform designed to create a best-in-class experience for patients and providers Watch now 1 2 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Pharma Direct-To-Patient 2.0: From Experiment To Imperative Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access. The question is no longer if, but how. Read more #### Fierce Pharma: The Hidden GTN Drain: Why Specialty-Lite Brands Need To Streamline Their PA Process for Optimal Commercial Performance For retail and specialty-lite pharmaceutical brands, the path from prescription to profit has never been more treacherous. While commercial teams focus on market access negotiations and formulary wins, a critical revenue leak often goes unnoticed: the gap between prior authorization (PA) requirements and submission rates, creating a cascade of gross-to-net (GTN) erosion that threatens long-term viability. Read more #### BioPharma Dive: Redefining Commercial Success in Speciaty-Lite Specialty-lite products occupy a complex middle ground in pharmaceutical commercialization. Unsuitable for standard retail yet not requiring the full infrastructure of specialty pharmacies, these products face unique access barriers that traditional distribution models can’t address effectively. The solution Read more #### BioPharma Dive: Bridging Data Gaps that Impact Retail and Specialty-Lite Success Retail and specialty-lite brand teams are facing a paradox – they’re drowning in data yet struggling to gain actionable insight. While manufacturers collect vast amounts of information, most are still making critical business decisions based on incomplete data sets that fail to capture the full prescription journey. Read more #### Drug Channels: Harnessing the Power of Comprehensive Data to Drive GTN Growing market access barriers are compelling retail and specialty-lite pharmaceutical manufacturers to seek new approaches to optimize revenue and enhance patient access. Traditional data sources and siloed solutions are no longer sufficient to address the challenges of formulary exclusions and rising patient out-of-pocket costs. Success in today's market requires comprehensive visibility across the patient journey to drive meaningful improvements in gross-to-net (GTN) performance. Read more 1 2 3 4 5 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/10/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Implementing an Effective Bridge Program: Laying the Foundation for Covered Dispenses A common challenge for specialty and specialty-lite brand commercialization teams is maximizing prescription coverage while minimizing free goods program overutilization. Patient bridge and quickstart programs, which provide temporary access to medications for patients experiencing coverage gaps or delays, are essential for therapy continuity and preventing financial burden on patients. However, these programs can negatively impact the manufacturers’ bottom line if manufacturers don’t implement the appropriate safeguards and requirements Read More #### Launching a New Drug in a Category with Generic Alternatives Getting an innovative prescription drug approved for patient use is a significant milestone – however, it's only the beginning and certainly does not ensure the brand's commercial success. Considering it typically takes ten years and over $2.6 billion for a life sciences manufacturer to move a drug from its initial discovery into the marketplace, commercialization teams must employ effective launch strategies that differentiate their brand to get it into the hands of patients. Launching into a category with generic alternatives presents a unique challenge because payers often limit patients' access to the new entrant through utilization management tools that favor the lower-cost generics Read More #### What Makes Phil’s Prior Authorization Process Unique? The prior authorization process (PA) presents a significant (and growing) roadblock for healthcare providers trying to get a patient started on a prescription therapy they deem best. In general, a PA requirement affects patients' experience with their healthcare. It represents a length of time – and the associated frustration – they must wait to receive their medication or go without the treatment they have been introduced to by their provider and may desperately need Read More #### Transforming the Prior Authorization Process: How Feedback Loops can Improve Patient Access to Life Sciences Brands The use of prior authorization (PA) to control the utilization of prescription drugs, especially specialty medications, is growing, with 79% of medical practices reporting that PA requirements increased between 2021 and 2022. By design, the PA process is a barrier to medication access – it can leave patients waiting for days, weeks, or even months for approval, and coverage denial may occur despite a therapy being appropriately prescribed. The negative consequences of delaying treatment are well documented, yet more than 8 out of 10 patients still experience delays accessing their medications for reasons such as cost and insurance challenges Read More #### Prior Authorizations: What Pharmaceutical Manufacturers Need to Know As healthcare costs have escalated over the last several decades, public and private medical insurers have introduced different utilization management (UM) strategies to control healthcare expenditures. The proliferation of higher-cost specialty medications has accelerated the use of drug UM tools to control access, with prior authorization (PA) being the most common today. From the payer's perspective, PAs are necessary to improve quality of care and protect patients’ safety Read More 1 9 10 11 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/11/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Optimizing Life Sciences Field Teams in the Era of Drug Utilization Management A persistent challenge for life sciences manufacturers is growing access and affordability obstacles, exacerbated by hard-to-enter formularies and rigorous utilization management (UM) practices. Payers are tightening the screws year over year with new cost containment strategies. Where there used to be hoops, they are now on fire, making it more difficult than ever to ensure reimbursement at the pharmacy Read More #### Phil Inc Adds Additional Duchesnay USA Women’s Healthcare Product to PhilRx Patient Access Platform, Shares initial Access Improvements for Bonjesta® (doxylamine succinate and pyridoxine hydrochloride) In 2018, after launching Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), Duchesnay USA utilized a combination of retail and specialty pharmacies to support patient access to the medication. This channel strategy experienced challenges, particularly around patient experience and prescription coverage rates. In 2022, the Duchesnay team engaged Phil Inc looking for ways to address their patient experience and access challenges: Shipping time: Patients experienced delays to therapy after paying their out of pocket expenses Read More #### 3 Reasons to Work with a Commercialization Partner that has an Integrated Distribution Network The stakes are high for life science companies when establishing the “best fit” drug distribution and channel strategy for a brand across the lifecycle, particularly since strong market access is no longer a guarantee to ensure a high percentage of covered dispenses at the pharmacy. Many manufacturers know that a critical input into maximizing gross-to-net is the pharmacy network. A robust, and varied national network of pharmacies that combine retail, chain and specialty pharmacies is the best way to maximize plan contract coverage and reimbursement rates Read More #### How to Make the Most of your Manufacturer-sponsored Financial Assistance Life science companies are acutely aware of the financial burden patients face when trying to access branded medications. With an estimated 3 out of 10 American adults not taking medications as prescribed due to cost, affordability is a leading barrier to patient access and something that manufactures have to take seriously if they wish to unlock significant adoption. With rapid initiation of therapy and medication adherence crucial to better patient outcomes and brand viability, making financial assistance programs timely and easily accessible is paramount Read More #### PSAOs: What Life Sciences Commercialization Teams Need to Know Pharmacies can significantly impact pharmaceutical manufacturers’ commercial success as crucial players in the prescription fulfillment process. In addition to playing an essential role in the supply chain, pharmacies are the only consumer-facing entities. An ineffective distribution network can diminish a brand’s reputation, patient and provider satisfaction, health outcomes, and gross to net Read More 1 10 11 12 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/12/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Not Getting Traction with Your Patient Services Program? Here’s Why and What to do About it As life science companies continue to invest in and launch specialty and specialty-lite medications to help patients manage chronic - and sometimes debilitating or life threatening - conditions, they are tasked with developing patient support services programs to help patients access and stay on these therapies. Unfortunately, a poorly utilized program can undermine clinical efficacy and often hinders a brand’s commercial success. Despite pouring $5 billion each year into patient support programs, pharmaceutical manufacturers only get an estimated 3 percent of eligible patients to enroll and use their programs Read More #### Why Strong Market Access Doesn’t Always Translate to Covered Dispenses Strong market access, the ability of a pharmaceutical manufacturer to secure reimbursement and coverage for their products from payers and other decision-makers, does not always translate to covered dispenses at the pharmacy level – particularly for specialty and specialty-lite therapies. Manufacturers must also navigate a complex prescription fulfillment and payer utilization management landscape to overcome barriers to patient access. Here are the three biggest reasons why good market access does not guarantee coverage and what commercialization teams can do to overcome this challenge Read More #### Tech Enabled Patient Services: Do More With Less in 2023 More recently though, as life science companies strive to ensure improved access to their therapies and reduce operational costs, they are turning to disruptive technology platforms that offer the potential to break through barriers to medication. Unfortunately, some companies are still wrapped up in the old paradigm and spend millions of dollars on patient access solutions but get little in return. Here are four ways a technology-driven patient services solution can enable life science companies to achieve more in 2023: Automating workflows From the point of prescribing to driving therapy adherence, automated processes reduce friction across the patient’s medication journey Read More #### Phil Inc. Adds Duchesnay USA’s Women’s Healthcare Product to Its Patient Access Platform SAN FRANCISCO--(BUSINESS WIRE)--Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced that Duchesnay USA’s Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments, is now available to be prescribed via its patient access platform. It is not known if Bonjesta® is safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. The most common side effect of Bonjesta® is drowsiness.Phil’s customizable platform helps patients receive and refill medicines quickly, easily and affordably while giving life science companies unprecedented end-to-end visibility into the prescription life cycle Read More #### Healthcare Policy Updates Specialty Drug Manufacturers Need to Know The pharmaceutical industry is one of the most highly regulated industries in the United States. Despite many legal and regulatory obstacles, the U.S. has led the world in the number of new chemical and biological entity launches since the year 2000 Read More 1 11 12 13 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/13/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### 8 Metrics that Matter When it Comes to Measuring Your Patient Access Program For life science companies, patient support services have become as vital to a brand’s success as efficacy and price. A patient support services program has the potential to help break through barriers to medication access. That’s why it’s crucial to make sure it aligns with your business goals and delivers on your brand objectives while helping patients access their therapy as easily as possible Read More #### Developing a Distribution Strategy that Optimizes Gross to Net Downward pressure on net sales is an ongoing problem for pharmaceutical and life sciences companies. It’s crucial to understand the gross-to-net (GNT) challenges that manufacturers are facing and how they can leverage their distribution strategies to optimize GTN. Understanding the challenges surrounding GTN Numerous factors impact a life science company’s GTN, which is the difference between the wholesaler acquisition cost (WAC) – also known as the drug’s list price – and the manufacturer’s net sales Read More #### Are Traditional Hub Providers Keeping Pace with Today’s Consumers and Providers? The seismic changes in consumer behavior and expectations brought on by mobile devices and cloud computing seem to have happened overnight, but they’ve been years in the making. The popularity of user-friendly services offered by the likes of Amazon, Uber, and Apple Pay has driven innovation and disruption across industries. The COVID-19 pandemic further accelerated the shift to digital tools, especially in healthcare Read More #### Phil Patient Access Platform Capabilities Support Move to Digital Prescription Models SAN FRANCISCO, Calif. – November 7, 2022 – Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced its technology solution now offers expanded functionality for companies developing prescription digital therapeutics (PDTs). Using Phil’s platform, digital health companies can simplify the healthcare journey for patients with their prescription, manage both pharmacy and medical benefits processes and improve access to prescriptions Read more #### Tech Enabled Patient Access Webinar: Key Takeaways “Patient access begins at the moment that a drug is prescribed and encompasses everything that goes with getting a drug into a patient’s hand.” said Len Paolillo, CCO of Impel Pharmaceuticals, during last Thursday’s webinar focused on how the right technology can meaningfully improve the chances a therapy will actually be taken as prescribed. As the life sciences industry faces strong access headwinds in 2022 due to evolving consumer expectations and stricter payer utilization management requirements, the conversation was timely and important. Mr Read More 1 12 13 14 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/14/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Phil, Inc. Forges Strategic Partnership with Syneos Health SAN FRANCISCO, Calif. – October 25, 2022 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization with technology to improve patient prescription access, today announced an exclusive partnership with Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization. Through the strategic partnership, Phil will serve as Syneos Health’s hub partner, creating an end-to-end commercialization solution for life sciences organizations to ensure patients can seamlessly start and adhere to therapy and receive and refill medicines quickly, easily and affordably Read more #### How Pharmaceutical Manufacturers can Leverage Phil’s Technology to Improve Patient Access to Their Therapies Many patients struggle to navigate healthcare effectively, inhibiting access to prescribed therapies. Patrick Leary, Chief Commercial Officer at Phil, shares how technology can break down many of the barriers patients experience, enabling them to better afford and adhere to their medications. Q: What are the most significant challenges patients face today when affording the medications their providers prescribe Read More #### 3 Ways for Pharmaceutical Companies to Improve the Probability of Launch Success Launching a successful pharmaceutical brand is no easy task. It takes significant stakeholder alignment across many strategic fronts to successfully transition from FDA approval to product adoption and growth. And even with a sizable base and formulary placement, it doesn’t necessarily follow that a brand will overcome the “Coverage Hurdle'' that requires a brand to jump through hoops to convert market access to a high % of covered dispenses Read More #### Why Your Channel Strategy Matters Channel strategy underpins the deployment of a life science company’s overall commercialization strategy. A company’s channel strategy is the tie that binds the market access, patient access, marketing, trade, and sales strategies to meet brand goals effectively. Ideally, it tightly integrates the processes for managing the logistics of getting products from the manufacturer to patients, implementing services to support patient access and medication adherence, and capturing channel data to measure success and inform decision-making Read More #### 3 Ways Healthcare Technology is Improving Medication Adherence One of the most significant burdens on the U.S. healthcare system is nonadherence to drug therapy. Not only does this issue exact a severe toll on patients’ health and quality of life, but the related healthcare costs are also staggering Read More 1 13 14 15 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/15/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Where's the Data? The Healthcare Data You Need to Drive Commercialization What matters most for life sciences companies is not the amount of data but knowing how to use it. A Forrester report revealed that data-driven companies experience an annual average growth rate of over 30%. Pharma companies that invest in capabilities to capture and analyze the best data to make informed commercialization decisions will realize better business outcomes and a competitive advantage Read More #### How to Streamline Pharmaceutical Commercialization Developing a new drug is an incredibly costly, time-consuming, and high-risk venture. In the 21st century, it typically takes ten years and over $2.6 billion for a pharmaceutical manufacturer to move a drug from its initial discovery into the marketplace. While getting an innovative treatment approved for patient use is a major milestone, it’s just the beginning and certainly does not ensure the brand’s commercial success Read More #### Optimizing your Drug Distribution Model The primary objective of a drug distribution model is to ensure patients receive the medications they need when they need them. A manufacturer’s strategy for getting their product from manufacturer to patient – effectively and efficiently – is crucial to the success of a therapy. The complexity of the distribution process has been exacerbated as a result of the pandemic Read More #### Determining the Optimal Channel Strategy for Your Pharma Brand In this on-demand webinar, Patrick Leary, Phil’s Chief Commercial Officer, discusses challenges pharmaceutical brands are facing and how a well-thought-out channel strategy is essential to these key success factors: - Speed-to-therapy - Payer Coverage (Approvals of Rx) - Pull-through to First Fill - Adherence to Therapy - Reimbursement A fragmented commercialization strategy poses significant risks to brand growth and threatens things like the patient and prescriber experience, rates of prescription coverage and pull through, medication adherence, and ultimately, profit margins and commercial success. In this webinar, you’ll learn some of the market factors impacting channel strategy, such as payer cost control measures, out-of-pocket costs, and patient consumerization, along with seven important channel strategy considerations and eight components of channel partner evaluation. You will also see a case study on one brand’s successful launch where they exceeded their commercial and access targets with: A 95% enrollment rate 50% of Trx covered in the first month 3x average adherence vs other channels 4x + net sales vs other channels Read More #### Technology Trends Shaping the Future of the Pharmaceutical Commercialization Due to its highly regulated, high-risk environment, the pharmaceutical industry has traditionally been slow to adopt new technologies. A conservative approach to technology implementation means that pharma companies may be missing out on the advantages digital technologies offer and have lagged behind other industries in creating rich customer experiences; however, the Covid-19 pandemic significantly accelerated digital transformation throughout the industry. The latest healthcare technologies promise to transform the development and delivery of innovative pharmaceutical therapies and elevate the experience for patients and providers Read More 1 14 15 16 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/16/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Migraine - Post Approval Insights Migraine is a neurological disorder that affects approximately 1 in 6 Americans and leads to over 1 million emergency department visits in the US annually. Just like many neurological conditions, the treatment landscape of triptans, opioids and NSAIDs has fallen short of providing a sustainable solution for migraine patients with drugs that have subpar efficacy and intolerable side-effects. The condition has been difficult to study and characterize due to varying levels of severity, causes and symptoms and traditional therapies have not specifically addressed the disease pathology of migraines Read More #### 3 Patient Engagement Technology Myths A recent survey by Boston Consulting Group, exploring what patients want from pharma companies and how well companies are meeting those needs, revealed a deficiency in patient engagement. The growing demand for improved and more efficient communication between patients and healthcare entities has created an opportunity for pharmaceutical manufacturers to promote patient engagement through digital tools. However, three common myths may be holding them back Read More #### 6 Healthcare Trends Impacting Pharma Commercialization What commercialization strategies should life sciences companies focus on as they look ahead. It’s crucial to monitor trends closely to navigate the evolving healthcare landscape better and build winning strategies. Here are the top six healthcare trends affecting pharma commercialization today: 1 Read More #### Is Your Life Science Company Taking Full Advantage of Digital Technology? The pharmaceutical industry generates immense volumes of data, so it would make sense that pharma companies are ahead of the curve by leveraging the latest technologies to transform their operations across the value chain. However, historically, the pharmaceutical sector has been slow to embrace digital technologies. In a highly regulated, high-risk environment, it is no surprise that pharma companies tend to be risk averse Read More #### Is Your Pharma Product at Risk for a Mid-Life Cycle Crisis? Commercial launch is an expensive and risky endeavor, especially for small life science companies. According to a recent report, about half of all the drugs launched in the last fifteen years underperformed market expectations by more than 20%. In fact, over half failed to reach $250 million in peak U.S Read More 1 15 16 17 18 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/17/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Prior Authorization Hurdles Don’t Discriminate By Disease Experts have called for major reform to the existing prior authorization processes with suggestions such as: Streamlining of administrative steps Tighter turnaround times for prescription authorization Widespread automation and digitization of processes Integration of health and administrative systems Nationwide coverage The lack of standardization among current approval processes are resulting in treatment delays, poor patient and physician experiences, low adherence rates, script abandonment, and in many cases, increased healthcare spending as disease progression worsens. Below are some examples that illustrate the burden of prior authorizations within specific therapeutic areas. Cardiology The cardiovascular treatment landscape significantly expanded in 2015 with a new game-changing class of drugs, PCSK9 inhibitors, which are intended to manage cholesterol-related cardiovascular disease Read More #### How Small Pharma Manufacturers can Optimize Drug Commercialization through Outsourcing One of the most important considerations for any pharmaceutical manufacturer is determining the internal capabilities and capital needed to support drug commercialization. The reality is that small- and medium-sized life sciences companies lack the resources to match the commercialization strategies of big pharma. Fortunately, today, there are opportunities for small pharmaceutical companies to execute a go-to-market strategy through outsourcing Read More #### Is Your Market Access Strategy Meeting the Needs of Drug Formulary Decision Makers? Drug formularies are a driving force for patient access to prescribed medication. A pharmaceutical brand’s inclusion and positioning on drug formularies are often reflective of the market access strategy’s level of success. To remain competitive, pharma manufacturers must understand how formulary management and the influence of payers are evolving and take steps to optimize market access Read More #### Diabetes - Post Approval Insights According to the National Diabetes Statistics Report from the CDC, around 37.3 million people have diabetes in the US, while 96 million have prediabetes. Type 2 diabetes remains the most prevalent in the US (90-95% of diagnosis), while both subtypes represent chronic illnesses that require rigorous self management of therapies for effective disease control. The increased prevalence of diabetes over the last 20 years unleashed a multibillion dollar pharmaceutical market that has pushed drug developers to aggressively pursue life-saving treatments for both type 1 and type 2 diabetes Read More #### Does Your Pharmaceutical Brand’s Data Demonstrate Value to Payers? The traditional route to pharmaceutical market access focuses on successful clinical trials and meeting regulators' safety and efficacy data requirements. In the past, this same data was sufficient for payers to determine that the drug was worth covering at the price point set by the manufacturer. But times have changed Read More 1 15 16 17 18 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/18/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Antivirals - Post-Approval Insights Antiviral drug approvals over the last decade have been dominated by drugs aimed at treating Hepatitis C (HCV) and human immunodeficiency virus (HIV). An estimated 2.4 million to 4.7 million people are living with HCV in the US, while about 1.2 million people in the US live with HIV. While these are both huge markets that continue to attract big pharma development efforts, the competitive landscape has become multi-layered and complex with long-standing therapies being evaluated alongside newly approved combinations Read More #### Leveraging Data Analytics to Boost Pharmaceutical Market Access Specialty drugs comprise a growing share of the pharmaceutical market. According to an industry report by Drug Channels, total prescription revenues surpassed $500 billion in 2021, with specialty drugs accounting for almost 40 percent of outpatient prescription revenues and an even larger share of payers’ net prescription costs. Over the next five years, these therapies are projected to account for at least half of all revenue generated by the pharmacy industry Read more #### 3 Ways a Patient Access Platform Breaks Through Barriers to Medication There was a time when the path from a physician prescribing to the patient starting drug therapy was straightforward. With the rise of value-based healthcare and novel specialty treatments, that’s no longer the case. Today, rigorous payer requirements and increasing out-of-pocket obligations frequently hinder patient access Read More #### How to Choose the Best Commercialization Partner to Drive Patient Access Is a pharmaceutical hub the best solution for commercializing your therapies. For well over a decade, pharmaceutical hub services have played a pivotal role in supporting patient access to life-saving and life-altering advanced drug therapies. Unfortunately, hubs tend to be a partner with low customer satisfaction rates and lower than ideal coverage and adherence Read more #### Case Study: Defying the Mid-Cycle Curse for Specialty Pharma Mid-cycle specialty products often face challenges when it comes to reaching patients several years after launch. Case Study: Women’s Health Product Phil was able to assist our client with turning around a tumultuous post-approval journey. Reimbursement challenges led to poor uptake and the pharma manufacturer brought on a telemedicine company to help with the prescribing and authorization process Read More 1 15 16 17 18 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/19/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Meet Deepak Thomas, CEO & Founder of Phil Deepak Thomas is the founder and CEO of Phil. He started the company as patient zero after being diagnosed with a chronic illness in the late 90s and struggled to navigate his own care within the complex US healthcare system. Several years later, he applied his experience in tech to build a solution that expands and simplifies patient access to specialty drugs, while aligning economic incentives for therapy manufacturers Read More 1 15 16 17 18 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/2/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Meet Bob Schumaker, Vice President of Operations at PHIL As VP of Operations at PHIL, Bob Schumaker champions a collaborative approach that brings together healthcare stakeholders to improve patient care. Drawing from his extensive background, Bob has spent the last five years building and scaling PHIL's partnership operations with a laser focus on improving patients' lives. Can you tell us a little bit about what your role as VP of Operations entails Read more #### How Can Pharma Manufacturers Improve Patient Engagement in 2025? Patient engagement is a critical factor for brand success. Not only does patient engagement benefit patients by addressing unmet needs more effectively, but it has also proven to be a powerful driver of financial value. A groundbreaking study revealed that an investment of $100,000 in patient engagement could increase net present value and expected net present value by more than 500-fold the investment – the equivalent of accelerating a pre-phase 2 product launch by 2.5 years Read more #### 8 Patient Access Trends Pharma Leaders Should Consider in 2025 With a new year brings new brand goals. Retail and specialty-lite brand teams continue to face an evolving patient access landscape that's significantly impacting their commercialization strategies. From the expansion of direct-to-consumer (DTC) models to the growing importance of real-world evidence, these emerging trends are reshaping how patients interact with healthcare systems and access prescribed therapies Read more #### Meet Maria Klagos, VP People Operations at PHIL In our latest employee spotlight, we sit down with Maria Klagos, our new Head of People, who brings a wealth of experience in scaling HR functions at high-growth startups. We explore her unique background, her vision for PHIL’s culture, and the personal experiences that have shaped her professional journey. Please tell us a little bit about yourself and your new role at PHIL I joined PHIL as the VP of People Operations this past May Read more #### Transforming the Patient Experience with a Strong Direct-to-Consumer Program The pharmaceutical industry has undergone a digital transformation – as of 2024, over 75% of patients have accessed care virtually. Leading brands across the industry are embracing direct-to-consumer (DTC) programs to meet modern patient needs. If you’re not considering how this access strategy could benefit your stakeholders, you may be missing out on the opportunity to better serve your patients and providers while driving brand performance Read more 1 2 3 4 5 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/3/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Meet Chris Sweitzer, VP of Business Development at PHIL In this employee spotlight interview, we are excited to feature Chris Sweitzer, our new Vice President of Business Development at PHIL. With two decades of experience in the healthcare industry and a passion for enhancing patient access, Chris brings a wealth of knowledge and a unique perspective to our team. Please tell us a little bit about yourself and your role at PHIL Read more #### Integrating Telemedicine Into Your Pharmaceutical Brand’s DTC Strategy The popularity of direct-to-consumer (DTC) channels across industries has fueled patients’ expectations for convenience, cost savings, and improved access to healthcare services. While the COVID-19 pandemic cemented the idea that telemedicine can be a critical part of a pharmaceutical brand’s go-to-market strategy, it’s essential to recognize that it is just one piece of the puzzle. To truly transform the patient experience and improve brand outcomes, pharmaceutical brand teams need to integrate a telemedicine channel within a broader DTC strategy Read more #### Meet Jwalanta Shrestha, Director of Engineering, Data and Infrastructure, at Phil We recently caught up with Jwalanta Shrestha, our Director of Engineering, Data and Infrastructure, to get a behind-the-scenes look at his role in ensuring patients and our manufacturer partners have the right data when they need it. Please tell us about your time with Phil and your current Director of Engineering, Data, and Infrastructure role. I currently lead two different teams at Phil Read more #### 8 Strategies to Decrease Prescription Abandonment and Improve Medication Adherence An estimated 1 in 5 prescriptions are left at the pharmacy counter. This vexing healthcare challenge, known as prescription abandonment, is part of the broader concern of medication non-adherence, which also includes not taking medications as prescribed or failing to refill prescriptions. The issue is so prevalent that the American Medical Association (AMA) advises healthcare providers to "consider medication non-adherence first as a reason a patient's condition is not under control." Consequences of Prescription Abandonment Failure to stick with prescribed therapy is a substantial obstacle to a providers’ ability to deliver good patient outcomes and realize the value of pharmaceutical innovation Read more #### Is your Patient Access Hub a Strategic Partner? By Kelly Green, Vice President of Client Success at Phil, Inc. For patients prescribed a specialty or specialty-lite medication, getting started and staying on that therapy is typically a complex and expensive journey. That’s why many life science brands are increasingly turning to hub providers to support patient access and affordability Read More 1 2 3 4 5 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/4/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### The Case for an Alternative Channel Strategy in Specialty-Lite A major challenge for life science companies that manufacture specialty-lite therapies is finding a channel strategy that offers the level of access services patients and healthcare providers (HCPs) need at a price point that supports the brand's financial health. Typically, brand teams string together a network of brick-and-mortar retail or specialty pharmacies and either work with multiple vendors to build a traditional call-center-based hub or rely on the specialty pharmacies to provide these services. The result is that the brands' gross-to-net cannot sustainably support this channel strategy Read More #### How Non-Dispensing Pharmacies can Improve the Patient Access Journey Patients struggling with complex medical conditions face a growing number of barriers to access, afford, and adhere to the innovative therapies their providers prescribe. In 2022, out-of-pocket costs led to the abandonment of 94 million prescriptions. And in a 2023 survey, 97% of medical practices said their patients had experienced care delays or denials due to increased prior authorization requirements Read More #### Meet Haley DeCoy, Pharmacy Manager at Phil Haley DeCoy joined Phil right out of pharmacy school because she was interested in a non-traditional career path. Check out her employee spotlight to discover what motivates her and the major milestones she helps the pharmacy team achieve at Phil. Please tell us a little bit about yourself and your role at Phil Read more #### Proactive Steps to Overcoming the Top 3 Patient Access Barriers to Retail and Specialty-Lite Therapies Ensuring patients get started and adhere to their medications is critical to achieving optimal health outcomes. However, navigating the medication access journey is no longer straightforward. An estimated 1 out of 4 prescriptions are abandoned at the pharmacy, and a recent report found that more than 8 out of 10 patients encounter delays in accessing the medications they need to manage their health Read More #### Meet Abhyuday Polineni, Director of Engineering at Phil In this Employee Spotlight, Abhy, our Director of Engineering, shares a behind-the-scenes look at his role in helping to shape the PhilRx Digital Hub to impact health outcomes, along with the challenges and successes that come with ensuring that the platform runs smoothly. Please tell us a little bit about your role as Director of Engineering at Phil. I lead and manage our platform, and the team that handles everything that happens across the prescription journey, from when a prescription is written by the healthcare provider to Phil until it is shipped out to the patient Read more 1 2 3 4 5 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/5/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### 5 Ways PhilRx Meets Patients’ Expectations for Digital Healthcare From travel and entertainment to shopping and banking, digital experiences surround consumers daily. So, it should come as no surprise that they have high expectations for seamless and connected digital experiences in healthcare. And these expectations are driving demand Read more #### Meet Neil Dean, Director of Product Management at Phil Neil Dean joined our team as Director of Product Management because he wanted the opportunity to directly impact lives. In this employee spotlight, Neil shares what he likes most about his role, how he approaches challenges, and a project he’s passionate about. Please tell us a little bit about your role at Phil Read more #### Translating Data into Actionable Insights to Inform your Patient Access Strategy By Andrew Duncan, SVP of Business Operations, Pricing & Strategic Finance Pharmaceutical companies are embracing big data initiatives to drive their business objectives. For brand teams, data is valuable only when they have the right data to make informed decisions that improve access to their retail and specialty-lite therapies. Life science companies that invest in capabilities to capture, strategically analyze, and draw actionable insights from the most relevant data will realize better brand outcomes Read more #### How Drug Manufacturers Can Evolve their Provider Engagement Model to Drive Brand Performance Evolving healthcare provider (HCP) needs and expectations have disrupted conventional customer engagement methods. The traditional reach and frequency model that had long been successful for pharma companies no longer delivers on brand goals. Several factors are driving this change Read More #### The Evolving Role of Retail Pharmacies: What Branded Retail and Specialty-Lite Manufacturers Need to Know Branded retail and specialty-lite pharmaceutical manufacturers must be acutely aware of the changes occurring within the retail pharmacy channel because they directly impact access and commercialization efforts. The evolving landscape – marked by the transition of retail pharmacies into primary care providers, the reduction of chain pharmacy footprints, the rise of mail order and online pharmacies, and critical labor shortages – directly influences how branded prescription medications are distributed, accessed, and managed. The following retail pharmacy trends are strong indicators that manufacturers must consider and adopt an alternative channel strategy in 2024 and beyond Read More 1 4 5 6 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/6/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### 5 Trends Set to Impact Patient Access to Prescription Therapy in 2024 The pharmaceutical industry finds itself at the crossroads of innovative treatments and technological advancements redefining how patients access prescribed therapy. However, this tremendous innovation has also presented unique challenges in securing patient affordability and access to therapy. These five key trends should be considered and will influence how manufacturers should think about shaping their services programs heading into 2024 Read More #### Digital Health’s Role in Transforming How Healthcare is Delivered Editor’s Note: As the healthcare ecosystem continues to undergo significant digital transformations, life sciences companies would be wise to consider the impact of this evolution on one of their most important stakeholders - health care providers (HCPs). The fusion of the increased prevalence of blended care models, staff shortages, and higher utilization management requirements have resulted in an environment where HCPs find themselves more constrained than ever. This has made it more challenging for life sciences companies to effectively engage providers to ensure that patients can access their therapies Read More #### How Life Sciences Manufacturers can Meet HCP Expectations for Patient Access Support With payer cost-containment measures continuing to escalate, patient access is top-of-mind for healthcare providers (HCPs) when deciding on prescribed therapy for their patients. Manufacturer-sponsored patient support programs are essential to helping patients get started and afford specialty and specialty-lite medications. A survey of 1,000 physicians found that HCPs believe these programs significantly positively impact their ability to practice medicine – yet, only 60% felt the pharmaceutical industry has robust patient support services Read More #### Enhancing your Patient Access Hub to Drive Brand Success By Catherine Wood Hill, Vice President of Marketing at Phil, Inc. Biopharma hubs should strive to ensure patients get access to the medications they need quickly and affordably, while easing the manual effort required by prescribers. A positive hub experience builds trust, promotes brand loyalty, and supports ongoing therapy adherence Read More #### Leveraging Territory Performance Monitoring to Scale Hub Performance From ever-increasing payer utilization management requirements and declining gross-to-net margins, life sciences companies face complex commercialization challenges. Specialty and specialty-lite retail brands are increasingly leaning on hub services as a key component of their go-to-market strategy to elevate patient access and brand outcomes as conventional commercialization strategies continue to wain in their overall effectiveness. However, most manufacturers struggle to drive high adoption of and engagement with their patient services programs Read More 1 5 6 7 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/7/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Why Quality Scripts are Crucial to Ensuring Pharmacy Coverage for Your Brand When prescribing a specialty or specialty-lite therapy with hub services, a healthcare provider can often jumpstart getting their patient started on the treatment by sending the script directly to the hub. However, six out of ten providers report that they are uncertain of the insurance benefits information needed to start patients on complex therapies, and submitting the wrong information can hold up a prescription from the get-go. Health insurance plans typically have specific requirements that must be met before covering an expensive branded therapy Read More #### Hubs, Digital Pharmacies, and Specialty Pharmacies: What Pharma Access Teams Should Know The evolution of healthcare consumer expectations and proliferation of expensive specialty and specialty-lite therapies have led to the rise of innovative solutions to clear an often onerous path to prescribed treatment. In 2022, specialty drugs accounted for 55% of the net spending in the pharmaceutical market, up from 28% in 2011. And an estimated 3 out of 4 patients who try to fill a new prescription for a recently launched brand are unsuccessful due to payer controls Read More #### How Biopharma Companies Can Support Patients with High Deductible Health Plans In 2023, a growing number of patients are enrolled in high deductible health plans (HDHPs), which require members to pay healthcare costs out-of-pocket until they meet their annual deductible amount before the plan starts covering eligible costs. A recent analysis found that over half of American private-sector workers are now enrolled in HDHPs – a 14.5% increase from 2017. The current minimum deductible for an HDHP set by the IRS is $1,500 for an individual and $3,000 for a family Read More #### Revolutionizing Patient Access: Introducing the PhilRx Platform In the highly-competitive life sciences industry, optimizing access is key to success. Offering timely and affordable access to treatment can significantly improve your patients’ health outcomes, strengthen relationships with your provider network, and determine the overall success of your brand. Manufacturers at the top of the industry are streamlining medication access by modernizing the patient experience through breaking down utilization management barriers and strengthening workstreams with pharmacies and providers Read Now #### How Manufacturers Can Improve Speed to Therapy: Overcoming Common Causes of Prescription Delays The timely initiation of a prescription therapy is critical to patients' health and quality of life and can often be a matter of life and death. Yet, a 2022 report revealed that more than 8 out of 10 patients encounter frustrating delays in accessing the medications they need to manage their health. Therapy delays not only have a profound impact on individuals' well-being but also significantly burden the healthcare system Read More 1 6 7 8 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/8/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### 4 Commercial Practices Shaping the Future of Life Sciences Developing a new drug is an incredibly costly, time-consuming, and high-risk venture. In the 12-15 years it takes to move a prescription therapy from discovery into the marketplace, pharmaceutical manufacturers invest an average of $2.3 billion. Given the considerable investment to make the drug available to patients, it's critical for commercial teams to develop a go-to-market model that delivers an appropriate return on investment (ROI) Read More #### Meet Molly Fields, Director of Patient Support at Phil The next interview in our Employee Spotlight series is with Molly Fields, Director of Patient Support at Phil. We hope you enjoy learning more about Molly and her impressive experience in the health tech industry. Tell me a little bit about yourself I'm from San Diego, Carlsbad specifically, and I have 7 brothers and sisters Read More #### Setting the Stage for a Successful, Modern Hub Services Program This blog post was written by John Yu, Vice President, Patient Experience at Phil. Getting prescribed medications – especially those that treat more complicated, chronic conditions – into the hands of patients is like navigating a maze filled with roadblocks. Consider that out of all the products launched in 2019, only 1 out of 3 patients who tried to initiate a treatment could get it filled – with over half facing a formulary restriction and others abandoning due to cost Read More #### The Impact of Time Constrained HCPs on Life Sciences Commercialization and How Manufacturers Should Adapt Workflows within physician practices have drastically evolved over the last few decades. This shift is due to the transition to value-based payment models, technological advancements, and changing patient expectations for a modern access experience. Additionally, health insurer policies designed to manage growing healthcare resource utilization continue to disrupt the natural flow of patient care by introducing new administrative requirements that create challenges for providers Read More #### Conventional Biopharma Commercial Strategies are No Longer Enough In an era where life sciences companies face unprecedented costs to bring novel therapies to market and declining expected returns upon launch, conventional commercialization strategies are insufficient to deliver brand success. The traditional approach of driving demand to the top of the funnel through clinical differentiation, expensive media campaigns, and large field sales forces no longer guarantees adequate product adoption and long-term financial viability under the constraints of intricate utilization management requirements. Thus, a paradigm shift is in order – one that centers around an integrated commercial strategy that is laser-focused on patient access and underpinned by gross-to-net optimization Read More 1 7 8 9 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Blog Posts for Life Sciences Companies Source: https://phil.us/insights/phil-blog/9/ ## Resources/ Phil Blog Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Phil Blog ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Why Transparency is Critical in the Patient Access Journey The Healthcare system is notoriously complicated and opaque, making it arduous for patients to navigate successfully. That’s why there’s been a legislative push to increase transparency across through policies such as the No Surprises Act and Hospital Pricing Transparency rule. Getting access to prescribed therapies to treat complex medical conditions can be especially difficult and stressful for patients Read More #### How Life Science Brands Can Successfully Navigate Retail Challenges In 2021, 3 out of 4 patients who tried to fill a launch brand were unsuccessful due to payer controls. As life science companies continue to launch innovative specialty-lite therapies, adopting a distribution strategy that ensures patients can access the brand as prescribed – efficiently and affordably – can mean the difference between a successful launch and failing to reach their expected value. As the primary channel for most brands, pharmacy networks play a pivotal role in the distribution, fulfillment, and reimbursement of medications, which means the brand's short- and long-term commercial success ultimately hinges on pharmacy performance Read More #### Is Telemedicine Part of Your Brand’s Go-to-Market Strategy? Delivering an End-to-End Digital Experience is Essential The explosion of virtual healthcare during the COVID-19 pandemic fueled the rise of digital direct-to-consumer (DTC) channels in the life sciences industry. The realization that it’s possible for patients to have a compliant, clinical conversation to receive a prescription via a telemedicine platform linked to a brand’s website can be a game-changer. A well-executed DTC model provides a more responsive option for patients to meet them where they are in 2023 - online and on their phone Read more #### 3 Reasons Why Your Patient Services Program May be Falling Short on Medication Adherence Medication nonadherence is a long-standing problem linked to poor health outcomes, increased hospitalizations, and significantly higher healthcare costs. According to the CDC, out of the 3.8 billion prescriptions written in the U.S., one out of five are never filled. Even with good insurance and drug coverage, medication adherence rates for chronic conditions fall between 50-60%– a far cry from the 80% adherence rates medical experts say are necessary for optimal therapeutic efficacy Read More #### 4 Strategies to Maximize Enrollment in your Patient Services Program Low enrollment in manufacturer-sponsored patient services programs is rampant, so much so that many industry stakeholders have come to accept this as inevitable. This disappointing trend nearly always holds true if brands employ traditional “call center-based” hubs or specialty pharmacies that lack consumer-friendliness, creating unnecessary friction for patients and HCPs. These “clunky” programs typically result in enrollment rates between 20-30% Read More 1 8 9 10 19 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil - Press Release Source: https://phil.us/insights/press-releases/ ## Resources/ Press Releases Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Press Releases ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now January 8, 2026 #### Press Release: PHIL Invests in State-of-the-Art Cash Dispense Capabilities PHIL Inc. today announced a significant expansion of its cash dispense capabilities, a major strategic investment that positions the company to continue serving the rapidly growing direct-to-patient (DTP) market, helping pharmaceutical companies get medications in the hands of patients at scale. Read more January 8, 2026 #### Press Release: PHIL and Tenpoint Pharmaceuticals Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Read more January 8, 2026 #### Press Release: PHIL and Sprout Pharmaceuticals Expand Their Affordable Direct-to-Patient Access Program for Addyi(flibanserin) PHIL, the technology-powered patient access platform designed to help patients get easy and affordable access to their prescribed medications, and Sprout Pharmaceuticals, today announced that they have expanded Sprout's direct-to-patient program for Addyi (flibanserin). Read more September 22, 2025 #### Press Release: PHIL Launches Direct-to-Patient 2.0 Platform to Transform Access, Affordability, and Adherence in Pharma PHIL, a leader in patient access solutions for the life sciences industry, today announced the launch of PHIL Direct, its Direct-to-Patient (DTP) 2.0 platform, designed to help pharmaceutical brands meet evolving patient expectations while navigating affordability, compliance, and policy pressures. Read more July 8, 2025 #### Press Release: PHIL Secures $60M Growth Capital from K2 HealthVentures to Accelerate AI Integration Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas. Read more 1 2 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil - Press Release Source: https://phil.us/insights/press-releases/2/ ## Resources/ Press Releases Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Press Releases ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now July 6, 2023 #### Press Release: Phil and RedHill Biopharma Partner to Increase Access to Talicia® Talicia® is indicated for the treatment of Helicobacter pylori infection in adults Patients can now access RedHill’s Talicia® via the PhilRx Platform SAN FRANCISCO, Calif. – July 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform. The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting the moment the physician writes a prescription Read More June 6, 2023 #### Press Release: Phil and Teva Pharmaceuticals Launch New Program to Improve Access SAN FRANCISCO, Calif. – June 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma management Read More 1 2 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Resources for Life Sciences Companies Source: https://phil.us/insights/resources/ ## Resources/ Resources Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Resources ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Research Report: Bridging the Gap to Better Patient Outcomes: What HCPs Want from Pharma's Digital Access Channels New research from PHIL uncovers healthcare provider’s perspectives on direct-to-patient programs, and why this matters for pharma. Download #### Building Direct-to-Patient Programs that Exceed Today's Patient Expectations New research from PHIL uncovers patient's most pressing expectations for today's direct-to-patient programs, and why this matters for pharma. Download #### Setting the Stage for Commercial Success in 2025 and Beyond Numerous changes in the healthcare sector are impacting pharmaceutical manufacturers of retail and specialty-lite therapies and their patients, providers, and partners. In order to stay ahead, brand teams must become more agile, digitally-savvy, and patient-centric as they move into 2025. This eBook provides an in-depth guide for pharmaceutical brand teams to thrive in this evolving ecosystem through a laser-focus on patient outcomes and brand success Download #### Building a Direct-to-Consumer Program that Wins Pharma manufacturers are embracing direct-to-consumer models as they recognize its potential to improve patient outcomes, provider engagement, and brand performance. However, this transformation comes with challenges and considerations, as it represents a significant shift in how medications are marketed and accessed. If your team is looking to initiate or improve a DTC program as a key component of your channel strategy, this playbook will give you an in-depth overview and strategic roadmap for building an effective digital care initiative Download #### Innovating Your HCP Engagement Model 9 in 10 providers expect pharmaceutical companies to help them address their challenges and concerns. Is your team leveraging the right strategy in the right channels at the right time to effectively educate and engage providers. This playbook unpacks the current state of HCP engagement for retail and specialty-lite brands, and offers a 4-point proven strategy for innovating the HCP engagement model through data and technology Download 1 2 3 4 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Resources for Life Sciences Companies Source: https://phil.us/insights/resources/2/ ## Resources/ Resources Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Resources ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Key Success Factors to Drive Brand Excellence Your support services are critical to ensuring that your patients can start and stay on therapy, easily and affordably. With UM barriers increasing, a digital hub can be an effective channel solution, creating a seamless access experience that supports patients, providers, and manufacturer brand teams across the prescription journey. Download this playbook to learn about the core elements of a digital hub, and the five success factors you can optimize to accelerate the performance of your retail and specialty-lite brands Download #### Streamlining Access with PhilRx Medication access, affordability, and adherence challenges are no longer inevitable for retail and specialty-lite brands. Offer a digital access experience that meets patients and providers where they’re at while maximizing coverage and GTN with PhilRx. This one-pager uncovers how PhilRx can help you break through barriers and drive transformative brand outcomes Download #### Designing an Exceptional Life Sciences Hub Hub services represent a major touchpoint with patients and healthcare providers, yet many brands struggle to effectively drive engagement. To support today’s patients and providers, brand teams should consider a digital patient services model that maximizes patient access. Chart a new course with this playbook, where you’ll dive into the data behind digital hubs, learn key strategies for maximizing hub adoption, and read success stories from life sciences manufacturers that have successfully introduced a digital hub Download #### Optimizing the Field Team for Improved Brand Outcomes Life sciences manufacturers are facing significant access and affordability challenges. It’s time to evolve the traditional field model to a strategic approach that helps HCPs navigate patient access with ease. Read this white paper for innovative strategies and best practices to empower your field team to improve brand performance Download #### Strategies to Ensure the Long-term Success of Your Patient Services Programs Life sciences manufacturers face growing challenges with building patient support programs that are also financially sustainable. Discover key research findings and industry insights that offer a strategic approach to ensuring patient service programs drive long-term brand value. In this infographic, you’ll learn: The state of drug utilization management and how manufacturers are responding Key trends in optimizing patient support with a gross-to-net lens Strategies for building a sustainable patient services program Harness your patient access potential Ready to accelerate your access program Download 1 2 3 4 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Resources for Life Sciences Companies Source: https://phil.us/insights/resources/3/ ## Resources/ Resources Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Resources ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Optimizing Patient Access for Sustainable Growth Life science companies are often challenged to meet forecasts and maximize the growth of their therapies at any cost – with gross-to-net (GTN) often taking the biggest hit. In today’s market conditions, manufacturers can no longer afford to overlook GTN when building and scaling a patient access strategy. Read this white paper to discover the ultimate playbook for aligning the internal teams that have a stake in your brand’s success - including marketing, sales, market access, and patient services - to balance maximum patient access with a sustainable GTN Download #### Improving Prescription Coverage at the Pharmacy Pharmacies play a pivotal role in brand success. Through strategically integrating your dispense network into your access strategy, you can successfully improve coverage and accelerate patient adoption. This white paper uncovers the pharmacy dynamics that underpin pharmaceutical brand growth, and outlines actionable strategies to help you build a strong pharmacy partnership that optimizes coverage at the counter Download #### Streamlining Specialty-Lite Access with PhilRx Patient access challenges are no longer inevitable for specialty-lite brands. By combining a seamless user experience with digital hub services and an industry leading dispense network with 98% plan coverage, we can maximize patient access and optimize GTN for your brand. This guide uncovers how the PhilRx platform is designed to help you break through barriers and drive transformative brand outcomes Download #### Improving Adoption of Your Patient Support Services Life sciences teams are investing significant time, energy, and effort into their patient services programs, and most are not yielding desired results. It’s time to turn your patient services into a strategic force for brand growth. This white paper outlines how to overcome barriers to patient program utilization and key strategies to maximize patient adoption Download #### Successfully Navigating Prior Authorizations Most pharmaceutical manufacturers (and healthcare providers) are challenged with lengthy and manual prior authorizations. This creates a frustrating barrier to getting patients on the therapies they need to improve their health, quickly and affordably. Luckily, there’s a better path to access Download 1 2 3 4 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Phil Inc - Resources for Life Sciences Companies Source: https://phil.us/insights/resources/4/ ## Resources/ Resources Resources Type GTN Calculator Press Releases Resources Events Case Studies Phil Blog ##### Featured Press PR Newswire PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Drug Channels Harnessing the Power of Data to Drive GTN Performance Life Science Leader Pharma Direct-To-Patient 2.0: From Experiment To Imperative ### Resources ###### Calculate Your Brand’s GTN Potential with PHIL Use our GTN calculator to estimate your brand's commercial performance potential Try Now #### Modernizing the Patient Access Experience Patient expectations for digital-first care are at an all-time high. In response, pharmaceutical brands are delivering patient-centric access experiences that provide support at every stage of the prescription journey. This white paper unpacks key trends in patient engagement and key strategies for modernizing your patient services model Download #### Defining Success for Patient Support Services Life sciences brands aim to develop innovative therapies that improve patient health and wellbeing. Unfortunately, some brands struggle to reach this important milestone - this often occurs when they don’t have the right patient support services in place. This white paper offers key strategic questions you can ask to ensure your patient services programs are built to maximize brand access and growth Download 1 2 3 4 #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us ### Create a Path to Commercial Success Our expert team can build a tailored access program that drives your brand goals. --- # Pharmaceutical Commercialization and Hub Services Resources Source: https://phil.us/insights/search/ ## Resources ##### Filter By: 0 items found for "" ### Search No Result We're sorry. We cannot find any matches for your search term. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Integrating Telemedicine Into Your Pharmaceutical Brand’s DTC Strategy Source: https://phil.us/integrating-telemedicine-into-your-pharmaceutical-brand-dtc-strategy/ ## Integrating Telemedicine Into Your Pharmaceutical Brand’s DTC Strategy The popularity of direct-to-consumer (DTC) channels across industries has fueled patients’ expectations for convenience, cost savings, and improved access to healthcare services. While the COVID-19 pandemic cemented the idea that telemedicine can be a critical part of a pharmaceutical brand’s go-to-market strategy, it’s essential to recognize that it is just one piece of the puzzle. To truly transform the patient experience and improve brand outcomes, pharmaceutical brand teams need to integrate a telemedicine channel within a broader DTC strategy. #### The Role of Telemedicine in DTC Telemedicine has gained significant traction, accelerated by the COVID-19 pandemic and furthered in the recent rise of DTC programs in big pharma. For pharmaceutical manufacturers of all sizes, integrating telemedicine into their DTC models can help: - Improve access to therapy: With a telemedicine channel, patients can meet with a provider within a day or two, and have their prescribed treatment in hand soon after. - Meet the preferences of modern consumers: A telemedicine channel that is integrated with a digital hub platform offers the modern experience consumers want and expect – as close as they can get to an e-commerce-like access experience. - Reach more potential patients: Telemedicine can improve treatment access for those with mobility challenges, personal conflicts, and/or who live in rural areas. #### Why Pharma Brands Need a Comprehensive DTC Approach A comprehensive DTC model enables pharmaceutical manufacturers to boost brand adoption by enhancing access and engaging patients across the prescription journey. A disjointed access experience that requires patients to pick up prescriptions at their local pharmacy or prevents them from applying their insurance benefits, can fragment the patient experience and negatively impact gross-to-net. Your telemedicine channel should be seamlessly integrated into a broader DTC program that encompasses multiple touchpoints and services: - Multiple access channels: Offering flexible options for patients to connect with providers through in-person visits and telemedicine consultations enables pharmaceutical brands to expand their reach to underserved or remote populations, enhance convenience, and improve access to timely care. - Digital prescription platform: A digital platform can streamline the prescription process for patients and providers by streamlining medication management, refill processes, and communication between patients, providers, and pharmacies. By simplifying these processes, brands can break through access barriers and drive speed to therapy. - Simplified prior authorization (PA) process: Automating and simplifying the PA process can help alleviate the administrative burden on time-constrained HCPs while accelerating treatment initiation, improving patient satisfaction, and boosting treatment adherence. - Awareness, education, and support: Addressing barriers to program adoption is vital for increasing treatment awareness and adherence. Providing patients and providers with educational resources, support services, and clear information about the medication can enhance the treatment journey and mitigate potential concerns and misconceptions. - Real-time data and insights: Leveraging real-time data and insights down to a territory level enables pharmaceutical brands to rapidly identify trends and issues and equip their field teams to drive brand success. #### How to Leverage a Seamless DTC Experience that Drives Brand Growth A well-executed DTC model offers a highly responsive way to meet patients where they are - online and on their phones. Telemedicine alone is not enough – patients seeking treatment via this channel expect the entire process to be convenient, transparent, and affordable. Brand teams considering integrating a telemedicine channel into their go-to-market strategy should prioritize creating seamless, end-to-end experience that patients find in other, more digitally transformed industries. If your pharmaceutical brand team wants to initiate or improve a DTC approach, download our eBook, Building a Direct-to-Consumer Pharmaceutical Program that Works, to get a strategic roadmap for effectively navigating this paradigm shift. Ready to go DTC? The PhilRx Digital Hub seamlessly integrates with telemedicine to create a modern patient and provider experience that maximizes prescription coverage and gross-to-net. Get in touch today to learn how we can support your growth. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Is my information secure with PhilRx? Source: https://phil.us/is-my-information-secure-with-phil/ ## Is my information secure with PhilRx? Our fully HIPAA-compliant system protects your health data at all times. Your information is only seen by licensed pharmacy personnel and HIPAA-certified Patient Advocates. We take reasonable administrative, physical and electronic measures designed to protect the information that we collect from or about you (including your personally identifiable information and personal health information) from unauthorized access, use, or disclosure. When you enter sensitive information on our forms, we encrypt this data using SSL or other technologies. Share this article on: --- # Is Telemedicine Part of Your Brand’s Go-to-Market Strategy? Delivering an End-to-End Digital Experience is Essential Source: https://phil.us/is-telemedicine-part-of-your-brands-go-to-market-strategy-delivering-an-end/ ## Is Telemedicine Part of Your Brand’s Go-to-Market Strategy? Delivering an End-to-End Digital Experience is Essential The explosion of virtual healthcare during the COVID-19 pandemic fueled the rise of digital direct-to-consumer (DTC) channels in the life sciences industry. The realization that it’s possible for patients to have a compliant, clinical conversation to receive a prescription via a telemedicine platform linked to a brand’s website can be a game-changer. A well-executed DTC model provides a more responsive option for patients to meet them where they are in 2023 - online and on their phone. Commercial teams integrating a telemedicine offering into their go-to-market strategy would be wise to prioritize curating seamless, end-to-end user experiences that consumers experience in other more digitally transformed industries. Patients seeking medications via telemedicine expect the entire process to be convenient, transparent, and affordable. A fragmented telemedicine model that requires patients to pick up prescriptions at their local pharmacy or prevents them from applying their insurance benefits can dilute the patient experience and negatively impact gross-to-net. ### What does telemedicine with an end-to-end digital experience look like? For brand teams that have determined telemedicine should be a part of their go-to-market strategy, delivering a modern user experience across the access journey is essential. Here’s an overview of what an end-to-end patient journey would look like using telemedicine integrated with digital tools to access a branded prescription medication: - Online registration and assessment: The patient registers on the brand’s web page – typically after seeing an ad for the product – and takes an online assessment that includes describing symptoms and providing other relevant personal health and insurance information. - Appointment scheduling: Patient schedules a virtual appointment with a healthcare provider (HCP) via the telemedicine platform, which may offer different options such as video conferencing or a chat based engagement based on the nature of their condition and state regulations. - Telemedicine consultation: An HCP reviews the digital assessment, discusses symptoms and medical history, and asks follow-up questions to make an accurate diagnosis during the virtual visit. If the branded therapy is appropriate for the patient, they discuss the treatment plan, potential side effects, and additional questions. - E-Prescription: The HCP sends a prescription electronically to a partnered pharmacy or hub provider via an integrated patient services platform. Programs that lack the infrastructure to send prescriptions to a preferred channel and rely exclusively in retail are likely to encounter obstacles. - Patient services enrollment: The patient services platform messages the patient to complete digital enrollment and offers any appropriate financial support options. - Benefits verification (BV) and prior authorization (PA): If required, the patient services platform should automatically perform an eBV to determine initial coverage and initiate an ePA (if required) to share this information with the telemedicine provider for payer submission. - Prescription fulfillment: Patient applies a manufacturer’s copay or benefits from a cash and offer if they don’t have coverage at checkout. The patient should choose whether to have the medication delivered to their home or transferred to a local retail pharmacy. Integrated digital tools ideally should enable delivery tracking, providing estimated arrival times and facilitating communication with the delivery service. - Follow-up and refills: Patients can easily manage refills, receive periodic reminders, schedule follow-up appointments, and sign-up for other support. Check out this case study to see how PhilRx helped a women’s health brand achieve significant growth by implementing a digitally powered telemedicine channel strategy. ### How leveraging a seamless DTC experience drives brand growth By integrating your DTC channel with a comprehensive digital experience, your life science brand can respond to evolving consumer behavior to drive brand growth and realize a greater return on your DTC investment in the following ways: #### Speeding access to therapy In the traditional consumer-driven access channel, a prospective patient sees an advertisement for a therapy that treats their condition. The patient calls their doctor to schedule an appointment, which will likely be weeks or even months away – a 2022 survey found that the average wait for a physician appointment is 26 days. During the appointment, the HCP sends a prescription to a local pharmacy, which will do a BV. If a PA is needed, this can add days to weeks until the patient can get their medication. With a digitally enabled DTC channel, the patient will most likely have their telemedicine consult within a day or two and their prescribed treatment in hand two days later. #### Meeting the preferences of modern consumers Telemedicine integrated into an end-to-end digital medication fulfillment platform offers the experience consumers want and expect – as close to an e-commerce-like, prescription-drug shopping experience as they can get. They save time and gas by skipping the trip to the doctor’s office. They don’t have to take time off work or find childcare. They can skip waiting in line at a brick-and-mortar pharmacy by taking advantage of the convenience of prescription delivery. They can choose the communication channels they prefer – whether by phone, email, or text – so they aren’t left in the dark about the status of their prescribed therapy. #### Reaching more potential patients A DTC channel can be an effective way to reach patients who may have never learned about the benefits of your branded therapy, such as digital-first consumers and patients with limited access to in-person care or retail pharmacies. Additionally, telemedicine integrated with a national network of pharmacies improves treatment access for those with mobility challenges or who live in rural areas by optimizing affordability and providing covered home delivery of prescriptions. #### Promoting medication adherence Integrating telemedicine with a digital hub solution that leverages data analytics to identify patients at high risk of nonadherence and employs proactive interventions can significantly improve adherence to your branded therapy. Examples include: - Sending out personalized refill reminders via text messaging - Providing digital access to educational materials via a user-friendly patient portal - Facilitating and tracking BVs, PAs, and program enrollments - Monitoring access data across the prescription access journey #### Let’s unlock the full potential of your telemedicine strategy Phil offers a digital, end-to-end telemedicine and product fulfillment infrastructure that delivers a modern patient access experience while enabling brands to maximize prescription coverage – ultimately driving brand growth. Get in touch today to discover how partnering with Phil can help you successfully implement a DTC strategy. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Is there a difference between the AZ and OH pharmacies? Source: https://phil.us/is-there-a-difference-between-the-az-and-oh-pharmacies/ ## Is there a difference between the AZ and OH pharmacies? We have two locations; one in Columbus, OH and one in Scottsdale, AZ. Each location has a dedicated team to support different medications. However, regardless of which location you send the script to, it will be directed appropriately without impact to the patient experience. Share this article on: --- # Is there a place where I can proactively see all of the patients I've sent through PhilRx? If so, how do I get sign-up/access that information? Source: https://phil.us/is-there-a-place-where-i-can-proactively-see-all-of-the-patients-ive-sent-through-philrx-if-so-how-do-i-get-sign-upaccess-that-information/ ## Is there a place where I can proactively see all of the patients I've sent through PhilRx? If so, how do I get sign-up/access that information? We fax or email weekly updates to your office outlining all relevant patient and processing updates from PhilRx. Share this article on: --- # Is there one place where prescribers can see all the Rx they’ve written versus only the updates on where action needs to be taken? Source: https://phil.us/is-there-one-place-where-prescribers-can-see-all-the-rx-theyve-written-versus-only-the-updates-on-where-action-needs-to-be-taken/ ## Is there one place where prescribers can see all the Rx they’ve written versus only the updates on where action needs to be taken? We send a weekly HCP summary fax/email that will consist of the patient cases with a pending action (either from the patient or HCP) along with the scripts that have been successfully processed/shipped (at the bottom of the fax, may be on the 2nd or 3rd page). Share this article on: --- # Is your Patient Access Hub a Strategic Partner? Source: https://phil.us/is-your-patient-access-hub-a-strategic-partner/ ## Is your Patient Access Hub a Strategic Partner? By Kelly Green, Vice President of Client Success at Phil, Inc. For patients prescribed a specialty or specialty-lite medication, getting started and staying on that therapy is typically a complex and expensive journey. That’s why many life science brands are increasingly turning to hub providers to support patient access and affordability. The success of a hub program hinges on accomplishing three critical outcomes: - Maximizing the number of covered dispenses - Ensuring patients get started on therapy as quickly as possible - Driving medication adherence Unfortunately, many hub programs struggle to produce these outcomes. Although manufacturers pour billions each year into patient support programs, only 3 percent of eligible patients enroll and use these programs, and 3 out of 4 patients who try to fill a launch brand are unsuccessful due to payer controls. And even with good insurance and drug coverage, medication adherence rates for chronic conditions remain between 50-60%. Identifying the right hub partner translates to identifying a strategic hub partner that can deliver on the three critical outcomes. Patient access teams should consider several key factors that will enhance the value of their patient access program. At the same time, they need to recognize the red flags that may deter success and ultimately result in a poor return on investment. ### Considerations to achieving key hub outcomes It’s crucial to find a strategic hub partner that is flexible, insight-driven, and focused on the patient outcomes that truly matter. With an abundance of hub services providers in today’s market, it can be challenging to discern which is best for your brand. There are several vital factors patient access teams should be looking for: - An incentive aligned model that aligns the hub partner’s and brand’s goals. This approach ensures accountability, and when critical brand outcomes are achieved, it is a win-win-win for the patient, the manufacturer, and the hub partner. - Flexible design and implementation that supports agility in a dynamic drug channel by enabling brand teams to establish and easily alter program business rules to adapt to any changes, such as formulary wins, territory changes, payer response, and brand life cycle priorities. - Insights derived from real-time data that offer visibility into the patient journey enable manufacturers to ascertain whether their internal teams are aligned in promoting the hub, why certain key success indicators may be underperforming, and to measure the true impact of their patient access services to be more responsive to stakeholder needs and health plan requirements. - A consultative approach that ensures all internal stakeholders buy in to and are incentive-aligned with the patient access program from the beginning. ### How to identify the right strategic hub partner for your brand Selecting the right hub partner is critical to the successful trajectory of a brand’s access program. Brand teams should avoid getting locked into a one-size-fits-all model. With the many potential hurdles that exist in an ever-evolving patient access landscape, this approach risks poor hub outcomes and return on investment. A digital hub that enables a data- and metrics-driven approach integrated across the entire prescription journey can give manufacturers the insights they need to quickly adapt to changes, more effectively driving covered dispenses, speed to therapy, and medication adherence. Patient access teams should also be sure any hub partners under consideration are using emerging technology, especially digital channels, to provide a frictionless, consumer-centered experience. For example, embedding hub enrollment within the clinical workflow of HCPs improves the likelihood that they will prescribe a branded therapy and that patients will utilize support services to help them succeed. ### What Phil brings to the table that other hubs do not In addition to our incentive-aligned model, flexible design and implementation capabilities, and consultative approach based on data, the following differentiators set Phil apart from other hub solutions: - We are a lean organization with deep industry expertise and a technology-forward mindset currently managing 35 manufacturer programs - Our digital capabilities enable brands to have their digital hub program up and running in 6-weeks post contract signing, on average - Our digital hub offers seamless, mobile enrollment for patients, is embedded in HCP workflows, and makes it easy to refill prescriptions via our informed simple refill process - Ongoing, post-launch consultations involved meeting with clients regularly to share actionable data and make program recommendations based on the data we’re seeing - We put patients at the heart of our hub model, providing educational resources and ongoing support to ensure they get the medication they need quickly and affordably ### Ready to maximize the value of your hub? Our team helps specialty-lite brands unlock the full potential of their hub services. Book a demo of the PhilRx patient access platform and discover first hand how we can help strategically maximize coverage, access, and GTN. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Key Success Factors to Drive Brand Excellence Source: https://phil.us/key-success-factors-to-drive-brand-excellence/ Playbook ## Key Success Factors to Drive Brand Excellence A playbook for branded retail and specialty-lite manufacturers looking to create an optimal channel strategy that improves patient access, provider engagement, and brand outcomes Download PDF Your support services are critical to ensuring that your patients can start and stay on therapy, easily and affordably. With UM barriers increasing, a digital hub can be an effective channel solution, creating a seamless access experience that supports patients, providers, and manufacturer brand teams across the prescription journey. Download this playbook to learn about the core elements of a digital hub, and the five success factors you can optimize to accelerate the performance of your retail and specialty-lite brands. #### In this playbook, you’ll learn about: - Current access and affordability challenges affecting patients, providers, and brands - How digital hubs can help retail and specialty-lite brands improve performance - Key success factors for driving brand outcomes through a digital hub #### Optimize brand performance Your channel partner should be a strategic stakeholder in your brand success. With PhilRx, life sciences leaders are seeing 90% patient enrollment rates, 2x higher coverage, and 3x refill adherence compared to traditional approaches - book a demo to learn more. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Launching a New Drug in a Category with Generic Alternatives Source: https://phil.us/launching-a-new-drug-in-a-category-with-generic-alternatives/ ## Launching a New Drug in a Category with Generic Alternatives Getting an innovative prescription drug approved for patient use is a significant milestone – however, it's only the beginning and certainly does not ensure the brand's commercial success. Considering it typically takes ten years and over $2.6 billion for a life sciences manufacturer to move a drug from its initial discovery into the marketplace, commercialization teams must employ effective launch strategies that differentiate their brand to get it into the hands of patients. Launching into a category with generic alternatives presents a unique challenge because payers often limit patients' access to the new entrant through utilization management tools that favor the lower-cost generics. Given that considerable investment has already been made to make the drug available to patients, it's up to the commercial team to develop a go-to-market model that optimizes patient access by delivering the product at an affordable cost to patients and positioning it for a positive return on investment. To do so, it’s critical that the therapy receives placement on formulary and is covered at a high percentage when dispensed at the pharmacy. There are four strategic considerations that pharmaceutical commercialization teams should keep in mind – and technology-enabled patient access support can serve as a critical tool for an organization looking to establish its brand in a category with generic alternatives successfully. ### 1. Take stock of the current payer landscape In a recent webinar hosted by the IQVIA Institute for Human Data Science, a panel of experts agreed that “there was a call for smarter spending on medicines, not just more spending” and “there will be continued pressures to control costs of drugs, push the development of biosimilars, and reduce barriers for entry of generics.” It is imperative for pharmaceutical manufacturers preparing to launch a product to be aware of the impact these factors will likely have on the success of their brand. Life science companies can greatly enhance their chances of launch success by comprehensively analyzing the competition. Evaluating the strengths and weaknesses of existing generic alternatives enables commercialization teams to identify opportunities for differentiation and innovation, including filling gaps in the current treatment offerings. These unmet needs could range from efficacy limitations, to delivery methods, as well as adverse effects and patient adherence issues. Delivering on an unmet need is critical if the brand ultimately hopes to secure placement on a high percentage of formularies without offering astronomical reimbursements. An in-depth understanding of payer and provider dynamics is perhaps most important in today’s value-based, cost-sensitive environment. Knowing how different payers leverage formulary tools to influence market access in the therapeutic area is crucial. With this knowledge, brand teams can align their pricing strategies, develop compelling value propositions, and establish mutually beneficial partnerships with key stakeholders. ### 2. Differentiate the new branded therapy The stakes are high, with pharmaceutical manufacturers facing diminishing returns on research and development and increasing payer utilization management controls. Strategic product differentiation, particularly in competitive categories, is critical to mitigating risk and improving the probability of success. The promise of positive patient outcomes alone is insufficient. Payers require manufacturers to prove the real-world value of their brands, which means that patients need to be able to access and adhere to therapy. When data is an integral part of your strategy, you can better understand patient needs and show how yourbrand uniquely solves unmet problems, such as enhanced tolerability, convenience, greater safety, or reduced healthcare costs. Your channel strategy should underpin the deployment of the brand’s overall commercialization strategy by creating a post-launch infrastructure that substantiates its value beyond efficacy. Marketing and educational campaigns targeted toward healthcare providers and patients should create awareness of the therapy’s unique benefits and help position it as a valuable and preferred treatment option. ### 3. Forge strong relationships with key stakeholders By actively collaborating and communicating with key stakeholders throughout the drug launch and beyond, pharmaceutical manufacturers can build trust, credibility, and lasting partnerships, which will increase the chances of brand success. Here are several ways to forge strong relationships: - Approach payers and PBMs as partners in achieving better patient outcomes - Develop payer-centric value messages - Provide educational resources for providers and patients - Partner with healthcare providers through a dedicated field team - Support prescribers’ office staff on addressing UM requirements - Engage with patient advocacy groups and organizations - Offer patient-centered services to facilitate access and medication adherence ### 4. Optimize drug launch execution To ensure a successful launch of a brand in a therapeutic category with cheaper generic alternatives, commercialization teams should take the following steps: - Develop a targeted launch plan based on steps 1-3 - Implement competitive pricing and contracting strategies that maximize coverage - Make the most of your manufacturer-sponsored financial assistance program - Equip the field team to drive brand adoption and coverage - Leverage technology-enabled patient services - Establish metrics to monitor the launch and efficacy of your access program #### Realize the full potential of your therapy in a competitive marketplace Launching a brand is more challenging than ever, especially when competing against lower-cost alternative therapies. More than one of three new drug launches fall short of expectations – don’t let yours be one of them. By understanding the competitor and payer landscapes, strategically differentiating your product, building solid relationships with stakeholders, and optimizing launch execution, your brand can reach its full potential and expected value. The PhilRx Patient Access Platform is the first end-to-end pharmaceutical commercialization platform that helps brands unlock coverage and maximize reimbursement. Patients have access to a nationwide partner pharmacy network that allows them to receive prescribed therapy quickly, conveniently, and affordably. Additionally, our deep integration with our partner pharmacies allows us to ensure that branded therapies are dispensed as intended. PhilRx simplifies prior authorizations and supports manufacturer-driven coupon utilization. Real-time insights give our manufacturer partners strategic visibility across the prescription journey and enable you to make responsive changes to your business rules. Reach out today to learn more! Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Leveraging Data Analytics to Boost Pharmaceutical Market Access Source: https://phil.us/leveraging-data-analytics/ ## Leveraging Data Analytics to Boost Pharmaceutical Market Access Specialty drugs comprise a growing share of the pharmaceutical market. According to an industry report by Drug Channels, total prescription revenues surpassed $500 billion in 2021, with specialty drugs accounting for almost 40 percent of outpatient prescription revenues and an even larger share of payers’ net prescription costs. Over the next five years, these therapies are projected to account for at least half of all revenue generated by the pharmacy industry. To remain competitive in this space, manufacturers need to work with their channel and commercialization partners to access real-time data and meaningful insights to drive market- and patient access. ### The promise of data-driven insights Pharmaceutical companies have historically relied on data across the product life cycle to fuel decisions related to go-to-market approaches, resource allocation, marketing mix, pricing strategies, and customer segmentation. However, conventional data sources, such as claims, often lack critical details necessary to draw meaningful insights. Today, manufacturers should be expecting richer, more granular data sets. In a complex and rapidly evolving specialty marketplace, they need timely, relevant data that can be acted upon now. The quality of insights that can be gleaned from data today create value and bring tremendous opportunity for commercial strategies. In fact, a McKinsey analysis determined that leveraging advanced analytics can improve the EBITDA of pharmaceutical companies by anywhere from 45 to 75 percent. With the evolution of data analytics, life science companies can better understand stakeholder influences, preferences, and behaviors. The true potential of these data-driven insights lies in the ability to leverage them to improve care delivery, accelerate patient access and demonstrate real-world drug efficacy – and ultimately, patient outcomes. ### Metrics hold valuable insights for market access When implemented well, data capture and management offer visibility into the patient journey and insight into market activities around product movement and usage. Examples of data and metrics that hold valuable market- and patient-access insights for pharma manufacturers include: - Diagnosis and off-label use - The time between diagnostic test results and therapy selection - Prescriber affiliations with IDNs - Insurance coverage and reimbursement - Prior authorization requirements - Patient assistance program usage - Patient out-of-pocket obligations - Time to fill - Fill and refill rates - Referral and adjudication status - Denials and appeals - New medication starts - Medication stops and reasons why - Medication switching - Medication adherence - Adverse events The key to unlocking the value of captured data is to ensure it is translated into meaningful insights and actions that align with commercialization strategies while still complying with applicable regulations. ### Aligning data analytics with commercialization strategy Data has the power to help pharmaceutical companies identify gaps and opportunities with their current market- and patient-access efforts. To truly tap into this power, manufacturers must prioritize access to integrated data and insights that align with their market access strategies. Quality, real-time insights that accurately characterize the entire patient journey – from the provider visit to prescription processing to the patient receiving their medication from the pharmacy – will help manufacturers achieve their commercial objectives. Manufacturers can positively impact market access and minimize patient access barriers by employing advanced analytics to support: - Personalized patient engagement - Tailored provider and partner digital communications - Faster time to therapy - Medication adherence - Network and distribution optimization - Understanding of real-world clinical outcomes - Contract negotiations - Field force efforts A value-oriented data-driven approach can generate substantial returns, including a 5-10 percent net revenue improvement and 10-20 percent spend reduction/reallocation. ### Tapping into the full potential of pharma data analytics Pharmaceutical and life sciences companies have access to a vast amount of data but often lack the tools to tap into its full potential. Automated and secure data systems with next-generation analytics are vital to capitalizing on opportunities in the marketplace. Finding a commercialization partner to capture impactful data and then help leverage and scale the analytics to inform efficient and effective decision-making will drive your brand's success. As an end-to-end commercialization partner, Phil provides an integrated approach to data analytics across the patient journey giving manufacturers real-time visibility and control over their distribution channels. Get in touch today to discover how you can drive market access with deeper data insights. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Leveraging Territory Performance Monitoring to Scale Hub Performance Source: https://phil.us/leveraging-territory-performance-monitoring-to-scale-hub-performance/ ## Leveraging Territory Performance Monitoring to Scale Hub Performance From ever-increasing payer utilization management requirements and declining gross-to-net margins, life sciences companies face complex commercialization challenges. Specialty and specialty-lite retail brands are increasingly leaning on hub services as a key component of their go-to-market strategy to elevate patient access and brand outcomes as conventional commercialization strategies continue to wain in their overall effectiveness. However, most manufacturers struggle to drive high adoption of and engagement with their patient services programs. Far too often, brands struggle to sufficiently integrate their field teams with their hub. This ultimately results in gaps in healthcare provider (HCP) adoption, patient enrollment, and prior authorization submissions that hinder brand performance. As access teams look to scale their hub services to address these gaps, monitoring hub performance at the territory is essential to ensure strong outcomes nationally. Without question, biopharma field teams play an integral role in driving overall brand success. The visibility gained from benchmarking hub performance at the territory level enables field leadership and access teams to be more strategic with how they promote the hub and helps manufacturers operationalize brand goal alignment in the following ways: #### 1) Implementing more effective, responsive HCP targeting The traditional sales approach is to create an annual or biannual HCP target list for each territory focused on high-volume prescribers in the brand's therapeutic class. This strategy fails to address the current biopharmaceutical landscape's complex, competitive, and ever-changing nature. Territory data analysis enables a more dynamic – and effective – approach. By identifying patterns in HCP and payer behavior, targeting can be more strategic and dynamic so that field teams focus their efforts on the right HCPs at the right times with optimized messaging that positively impacts brand outcomes. #### 2) Driving hub enrollment and engagement A commercialization team’s best bet to getting their branded therapy into patients’ hands as a covered prescription is to ensure the hub is central to the brand’s go-to-market strategy, which also entails maximizing enrollment and engagement in the patient services program. Since the field team is instrumental in making this happen, management should make sure sales reps are: - Aligned to drive patient enrollment enrollment in the hub - Educated on why the hub is beneficial to them and their customers - Trained on how to efficiently and effectively promote the hub to HCPs - Equipped with the right resources and tools to educate HCPs and monitor their actions Just as importantly, manufacturers must continually monitor territory KPIs around HCP hub adoption and patient enrollment to gauge field performance. #### 3) Boosting prescription coverage by Improving Prior Authorization Outcomes In the long run, it doesn't matter how many scripts HCPs write if patients' insurance plans only cover a small proportion as the brand will have to over subsidize access to maintain brand loyalty. And something as simple as an administrative error, such as a wrong ICD-10 code, misspelled name, or omitted details, often results in a denied prior authorization (PA) request. Given that more than 9 out of 10 physicians report patient care delays associated with PAs, it's incumbent on manufacturers to improve speed to therapy and lay the foundation for covered dispenses by streamlining the PA process for HCPs. Empowering field teams with territory-level script quality insights and real-time data on the PA process empowers them to be more responsive and relevant with HCPs, ensuring brand prescribers are adequately informed on the insurance coverage requirements and submit outstanding PAs in a timely manner. #### 4) Pinpointing issues Territory-specific insights provide a granular understanding of various aspects of sales operations. By leveraging this information and feedback loops, manufacturers can pinpoint challenges, develop targeted strategies, allocate resources efficiently, and ultimately improve overall sales performance by: - Benchmarking and comparing performance metrics across territories that reveal underperforming regions or that require attention - Identifying high-performing and low-performing sales reps to implement targeted training, coaching, and support to enhance overall team performance. - Enabling process optimization and implementing best practices to yield a more streamlined and effective sales process. #### 5) Identifying areas of opportunity Territory performance data analysis equips biopharmaceutical sales and marketing teams with actionable insights to identify patient access opportunities. By understanding the unique characteristics and challenges of each territory, field teams can develop sales strategies and coordinate with internal brand teams to improve patient access by helping their HCP customers: - Streamline the PA process - Navigate retail challenges - Support patients on high-deductible health plans - Address their workflow challenges #### Let’s deliver more value to your HCPs Given the investment life sciences companies make in their hub programs, optimizing ROI by monitoring KPIs correlated with brand success makes sense. That means shifting away from the traditional operational measures not associated with patient access. Staying abreast of what is happening at a territory-by-territory level enables manufacturers to equip their field teams to drive brand success. With PhilRx, field teams can access real-time data on hub adoption and engagement, script quality, PA submissions, and payer responses. Phil’s proactive, consultative approach helps all internal stakeholders make the most of this data by providing actionable recommendations. Ready to get started with territory performance monitoring? Book a demo of the PhilRx patient access platform. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Is Your Life Science Company Taking Full Advantage of Digital Technology? Source: https://phil.us/life-science-company-digital-technology/ ## Is Your Life Science Company Taking Full Advantage of Digital Technology? The pharmaceutical industry generates immense volumes of data, so it would make sense that pharma companies are ahead of the curve by leveraging the latest technologies to transform their operations across the value chain. However, historically, the pharmaceutical sector has been slow to embrace digital technologies. In a highly regulated, high-risk environment, it is no surprise that pharma companies tend to be risk averse. A McKinsey analysis notes that “new technology often faces strong organizational barriers, such as mind-sets that resist IT change and conservative cultures that base decisions on perceived risks.” Digital transformation, which involves implementing new technologies, talent, and processes to improve business operations and meet stakeholder needs, accelerated across the pharma industry during the COVID-19 pandemic. Investments in digital innovation to ensure continued access to medications became the priority. Even those companies that had previously adopted technologies that failed to deliver the value promised needed to adopt digitally-enabled solutions to overcome the challenges posed by the pandemic. As life science companies look toward the future, it’s crucial to address the barriers to digital transformation so they can take advantage of the commercialization opportunities modern technologies have to offer. ### Barriers to digital transformation Many life science companies get bogged down by obstacles that keep them from achieving their digital transformation goals. These are the six most significant barriers: - Business silos: Many departments and functions work in silos, which impedes digital transformation. To reap the full benefits of advanced technology, cross-functional teams need to collaborate efficiently. - Company culture: A risk-averse culture is a significant barrier to technology adoption. A change management approach to digital transformation can help companies anticipate resistance, take steps to gain buy-in, and facilitate employee engagement. - Lack of tech talent and resources: A lack of technical expertise and appropriate funding can undermine the adoption of emerging pharma technologies. In a Deloitte survey of biopharma companies, 78% agreed they needed new leaders, and 54% said they needed more funding to succeed in the digital age. Only 20% revealed they are developing capable leaders to help in a digital environment. - Cybersecurity: As more companies become reliant on technology and more information moves to the cloud, data protection and security are foundational to successful technology implementation and digital transformation. - Legacy systems: Continuing to rely on outdated legacy IT systems, particularly if they do not integrate with advanced technologies, can prevent a company from realizing the value of new digital solutions. - Data quality: Access to timely and accurate data is essential to successfully executing technology transformation. Outdated, inaccurate information hampers informed decision-making and makes it difficult to measure progress on digital initiatives. ### Opportunities for tech-enabled commercialization From drug discovery and development to manufacturing, distribution, and fulfillment, advances in digital technology and analytics are opening opportunities at every stage of the pharmaceutical product’s life cycle. There are a plethora of commercialization opportunities for life science companies that adopt modern digital technologies, including: - Capturing meaningful post-launch real-world data on a drug’s efficacy, safety, and adherence - Finding new ways to support patients through their treatment journeys - Supporting value-based contracts with payers by demonstrating the value of your brand - Informing the drug lifecycle with deeper insights into disease progression, clinical characteristics, and outcomes - Providing personalized and relevant clinical and educational resources to meet patients where they are - Strengthening healthcare provider and payer engagement and relationships - Establishing a feedback loop that connects patient experiences with specific products - Facilitating targeted marketing campaigns The pandemic forced life science companies to pivot to digital innovation across every aspect of operations. Now, they need to ensure their digital transformation efforts bring a competitive advantage and drive their businesses forward. Many companies leverage external partners to support their digital initiatives for commercialization. Learn how Phi, Inc. can help you get closer to the patient with real-time visibility and control over your channels here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Designing an Exceptional Life Sciences Hub Source: https://phil.us/life-sciences-hub-design/ Playbook ## Designing an Exceptional Life Sciences Hub A playbook for speciality lite brands looking to offer a cutting-edge digital hub that maximizes value for patients and providers Download PDF Hub services represent a major touchpoint with patients and healthcare providers, yet many brands struggle to effectively drive engagement. To support today’s patients and providers, brand teams should consider a digital patient services model that maximizes patient access. Chart a new course with this playbook, where you’ll dive into the data behind digital hubs, learn key strategies for maximizing hub adoption, and read success stories from life sciences manufacturers that have successfully introduced a digital hub. #### In this playbook, you'll learn: - Why digital hub models are gaining popularity among biopharma brands - Strategies to help your brand maximize patient outcomes through your hub - How biopharma companies are successfully leveraging digital hubs #### Create a digital-first access experience The demand for digital access is at an all-time high. If you’re looking for expert guidance on how to build a successful digital hub, we’re here to help - book a demo of the PhilRx patient access platform for a personalized tour. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Is Your Market Access Strategy Meeting the Needs of Drug Formulary Decision Makers? Source: https://phil.us/market-access-strategy-drug-formulary/ ## Is Your Market Access Strategy Meeting the Needs of Drug Formulary Decision Makers? Drug formularies are a driving force for patient access to prescribed medication. A pharmaceutical brand’s inclusion and positioning on drug formularies are often reflective of the market access strategy’s level of success. To remain competitive, pharma manufacturers must understand how formulary management and the influence of payers are evolving and take steps to optimize market access. ### What is a drug formulary? A drug formulary is a list of pharmaceutical drug products – both generic and brand name – covered by payers. A multidisciplinary Pharmacy and Therapeutics (P&T) Committee, comprised of physicians, clinician prescribers, pharmacists, nurses, health plan administrators, and other medical experts, determines which medications are part of the formulary. Formulary selection involves the evaluation of a drug’s efficacy, real-world clinical performance, and cost. Based on the committee’s clinical judgment, those products that fail to show adequate clinical differentiation or benefit to justify the cost will have limited or no coverage. ### How do drug formularies work? Formulary lists are powerful tools used by insurers to influence which medications beneficiaries use. The structure of a formulary impacts the coverage provided for each drug and how much patients will have to pay out-of-pocket: - Closed Formulary: Prescription drugs not on the formulary list are not reimbursed by the payer. There may be exception policies based on medical necessity. Closed formularies have a stronger preference for generics over branded drugs. Often, the number of products in each drug class is limited. - Open Formulary: The payer reimburses for formulary and non-formulary drugs. Specific drug classes may be excluded from coverage, such as those for cosmetic use. Patients may have to pay additional out-of-pocket expenses for a non-formulary prescription, and physicians are encouraged to prescribe medications on the formulary. Many health plans use a tiered pharmacy benefit design. After clinical review, drugs are assigned a formulary ranking that correlates with the coverage level provided. A typical tiered plan would be as follows: - Tier 1 medications are the most cost-effective agents, usually generics, with the lowest out-of-pocket costs for patients. - Tier 2 medications are preferred brands that are still cost-effective but require a higher out-of-pocket obligation. - Tier 3 medications are non-preferred brands that offer either no coverage or the highest out-of-pocket costs. Managed care organizations (MCOs) often add utilization management measures to optimize patient outcomes and reduce unnecessary medication use and cost, particularly for higher-cost specialty drugs. The most common requirements are: - Prior authorization - Quantity limits - Step therapy - Mandatory generic substitution ### Trends impacting formulary coverage Clearly, payers have extensive influence on which pharma brands are covered and the level of coverage provided – staying competitive hinges on keeping up on what is happening in the market that will impact formulary selection and coverage. Here are four trends that are impacting a brand’s formulary selection and coverage. - Pharmacy benefits managers (PBMs) often serve as intermediaries, negotiating discounts and rebates from pharma manufacturers on behalf of insurers. The PBM market’s rapid consolidation is strengthening its negotiating power. Just three PBMs – OptumRx, Express Scripts, and CVS Caremark – control over 70% of the prescriptions processed in the U.S. - Formulary exclusions, which are the drugs that payers do not cover, have skyrocketed since 2014. In 2022, the three biggest PBMs collectively had excluded about 1,410 from their formularies. - Payers are adding higher tiers with cost-sharing formulas to defray costs related to specialty drugs. - Federal and state policies under consideration and intense public scrutiny around PBM pricing and rebate practices will likely force payers to make changes in their drug formulary structure. ### Optimizing market access Aligning your market access strategy based on payer priorities is the best bet for achieving desired formulary positioning. Steps your market access team can take include: - Understand how different payers leverage formulary tools to influence market access in your therapeutic area - Identify gaps in data sets and insights and find a commercialization partner that can fill those gaps - Approach and engage with payers as partners in achieving better patient outcomes and lowering costs - Implement value-based contracts for new medications and high-cost treatments - Develop payer-centric value messages - Use real-world data and evidence to demonstrate value and product differentiation in clinical outcomes - Offer patient-centered services to facilitate patient access and medication adherence - Differentiate your brand by highlighting how it boosts patient experience Ready to optimize market access? Our end-to-end commercialization solution helps pharmaceutical manufacturers support their brand value to payers while facilitating patient access to therapy with the lowest possible out-of-pocket costs. Learn more about the Phil Platform here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Abhyuday Polineni, Director of Engineering at Phil Source: https://phil.us/meet-abhyuday-polineni-director-of-engineering-at-phil/ ## Meet Abhyuday Polineni, Director of Engineering at Phil In this Employee Spotlight, Abhy, our Director of Engineering, shares a behind-the-scenes look at his role in helping to shape the PhilRx Digital Hub to impact health outcomes, along with the challenges and successes that come with ensuring that the platform runs smoothly. #### Please tell us a little bit about your role as Director of Engineering at Phil. I lead and manage our platform, and the team that handles everything that happens across the prescription journey, from when a prescription is written by the healthcare provider to Phil until it is shipped out to the patient. My team makes up the layer that supports the core infrastructure, interfacing with all stakeholders to ensure the platform runs smoothly and prescriptions are shipped on time. This includes all our external-facing applications, like the patient and provider portals, as well as the internal operations tools, such as the operations dashboard, dispensing pharmacy integrations, and other fulfillment-related functionality. #### What do you enjoy most about working here? Before Phil, I worked for several big companies, including Oracle and Microsoft. I was right out of college, and it was interesting to work on complex technical problems. After a couple of years, I wanted to work in a more intimate setting where the feedback loop with end users was tighter. I met Deepak Thomas and Puran Singh, Phil’s co-founders, and was sold on how they were approaching this complex problem of simplifying patient access to prescription medications. It was kind of a leap of faith – Phil was a startup in its early stages, but I have not had one regret since I joined. I’ve been here for nearly seven years, and it’s been a somewhat organic evolution for both the company and myself. Phil was the perfect blend of what I was looking for. We solve super complex problems, such as how to dispense prescriptions with a short turnaround time without having control over the entire value chain. It’s an ambiguous domain, and a lot of things can break. But at the same time, every line of code I write immediately impacts the people involved. #### What is the most challenging part of your job? What I love about the job can also be the most challenging, especially when the focus shifts toward operational issues and away from solving underlying engineering problems. The engineering team is like connective tissue for all stakeholders - patients, providers, manufacturers, pharmacies, and operations. Everyone plugs into the same platform, which needs to be orchestrated perfectly so that prescriptions seamlessly flow through the system. If something goes wrong, we must get that prescription back on track. One course of action can affect another stakeholder's experience, so we need to ensure that the platform gives everyone the right benefits and incentives. Another aspect that gets interesting and challenging is trying to stay connected to the real-world impact in the somewhat detached environment of software engineering. #### Can you share a recent project you are passionate about? We recently completed a re-architecture of the platform. We started it about two years ago when we realized that the way we were building things as a pure startup wouldn't scale once we gained additional volume and started supporting more clients. We had to rethink our approach, considering our core functionalities and how to make the platform a more configuration-driven system where engineers don't have to get involved daily in handling different stakeholder requests. With our new model, we drastically simplified the communication between our departments by having everyone working from the same source of truth. We also boosted the engineering team’s productivity significantly, freeing up our time to focus on scaling up the platform and addressing other technical problems. #### On a personal note, what do you like to do outside of work? I like traveling, reading books, and spending time with family. So outside of work, I mostly spend time in one of those three areas. Recently, I went with my family on a 10-day road trip through Idaho, Colorado, Utah, and Wyoming. I’m planning a similar trip this year. #### What’s something that you’ve always wanted to try or learn? I tend to be more of a reader, but I've always wanted to do something more physical with my hands. Recently, I decided to fix up my front yard, so I am learning how to excavate, level, and eventually add turf. There's been a learning curve… definitely different from writing code. I thought I'd be done in two weekends, but it's taking a lot longer than I expected. I'm enjoying the exercise and find it gives my family another opportunity to do something together. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Allison Laubenthal, Director of Client Success at Phil Source: https://phil.us/meet-allison-laubenthal-director-of-client-success-at-phil/ ## Meet Allison Laubenthal, Director of Client Success at Phil We are excited to feature Allison Laubenthal, our Director of Client Success, in this employee spotlight. Allison’s wealth of healthcare experience gives her deep expertise and understanding of our clients’ goals and challenges and how to navigate them. #### Please tell us a little bit about yourself and your role at Phil. My job as Director of Client Success is to cultivate and manage relationships with our biopharma manufacturer clients. This encompasses everything from program implementation and launch readiness, to serving as their primary consultant, providing highly targeted data, analytics, and insights. Ultimately, my team is focused on maximizing the value we offer our clients to help them reach their goals. #### Where or how do you think you can have the biggest impact in this role? I previously worked at CoverMyMeds, which prepared me well for this role because I worked in a similar space involving access, adherence, and affordability strategies. Prior to that I worked at AbbVie, supporting the Humira global marketing team, which at the time was the highest selling drug in the world. These roles have given me tremendous perspective into the pains and priorities of both large pharmaceutical brands as well as stakeholders in the healthcare tech space. #### What are some of the challenges that you’ve faced since joining the team? Our solutions are extremely customizable, meaning we can quickly change business rules and optimize our technology depending on the needs of our clients. It is not a one-size-fits-all solution. Factoring in the needs of our clients’ brands can be challenging as they range across several different therapeutic areas, requiring unique and targeted approaches. Another challenge is helping manufacturers, healthcare providers, and patients navigate a constantly evolving payer landscape. Our objective is to identify barriers to access and provide manufacturers with actionable insights that enable them to improve patient access to therapy. #### Can you share a recent project that you’re passionate about? We recently ran a pilot program with a regional focus, allowing us to document best practices and incorporate them in the nation-wide program. Working hand-in-hand with our client, we were able to identify gaps where additional resources, training and marketing were needed to execute a successful national launch. I'm most impressed with the speed at which we solve things at Phil. If a client has a challenge or an issue, teams across the company, from Product and Engineering to Client Success and Business Operations, have the mindset of "this is a priority and something we need to fix together." And within, sometimes as little as hours, it's solved. It's amazing to witness and be a part of. #### On a personal note, what would your perfect weekend look like? Sleeping in and waking up to sunshine. Spending time with family and friends, teaching a cycling class, trying new restaurants, and taking my dog on long walks! #### How would your best friend describe you in three words? Energetic, loyal, and fun! Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Andrew Duncan, SVP of Business Operations, Pricing, and Strategic Finance at Phil Source: https://phil.us/meet-andrew-duncan-svp-of-business-operations-pricing-and-strategic-finance/ ## Meet Andrew Duncan, SVP of Business Operations, Pricing, and Strategic Finance at Phil We recently caught up with Andrew Duncan, our SVP of Business Operations, Pricing, and Strategic Finance. Andrew shares how his personal connection with Phil’s mission is what he likes most about his role and a recent success that he is particularly proud of. #### Please tell us a little bit about yourself and your role at Phil. I lead the business operations team at Phil, which currently includes business operations, client optimization, strategic finance, and analytics engineering. I really enjoy what I do. My team's overarching goal is to help make sense of our data and apply it to make better decisions, whether that's related to pricing, forecasting, prioritization of our initiatives, or where we invest as a company. I came on board about 2 ½ years ago to build out this function, and now we're a proud team of seven. #### What do you enjoy most about working here? What I like most is my personal connection to what we do, which I can break down into two things: Phil's mission and the freedom this role provides. I think that most people in the US understand the pain of Utilization Management hurdles, and I can say from experience that calling them PAs doesn't really do it justice. Being on the receiving end of crazy bills because insurance says "no" doesn't feel good to me or anyone else. Having the opportunity to help people clear those hurdles so they can get the treatments they need at a reasonable price is truly work I can be proud of. We're doing something that is helping everyone across the pharma chain. I also really value the "just get your work done" aspect of our company’s culture. It allows me to balance work and personal life in a way that likely wouldn't be possible at many other companies. #### What is the biggest challenge you’ve faced since joining Phil? I think the biggest challenges are around scaling. Of course, this is a great problem to have because it means we're a growing company. As we’re expanding at breakneck speed, things are constantly changing. For example, outgrowing infrastructure that worked great six months ago, or discovering processes you thought were bulletproof that need to be rebuilt. On the flip side of the coin, this challenge also gets me up in the morning because it's exciting to solve these complex problems. I've learned that nothing works forever in a rapidly scaling company. You must always be on the lookout for what’s going to change, and be ready to jump in. #### Tell us about a recent success story that you’re proud of. I was really proud when we reached a milestone in 2023, where we could accurately predict our forecast in terms of volume within 5% of the actuals. The infrastructure we were previously using wasn’t working, and we are in the process of optimizing the system. It was a great success for our team. However, my lesson from significant accomplishments is that you can't rest on them. What we thought we did well no longer worked, and we needed to figure out how to build a new and improved model. In 6 to 12 months, it will likely change again because we won't be the same company we are today. Since I've been with Phil, there have been several distinct phases where one would not recognize the company it was just six months before, and that’s a good thing. #### What are your favorite hobbies or interests outside of work? Since my three- and four-year-old sons have come along, I've given up all of my previous hobbies and interests. Right now, besides spending time with my family, I'm part of an old man bowling league, which I didn't think I'd say at age 40, but here I am. We bowl once a week. Prior to children, and hopefully again in the future, I really liked playing basketball and golf, and going on road trips. #### What, if anything, are you currently binge-watching? Or reading? My wife and I just started The Gentlemen. We're only one episode in, so I don't know anything about it yet. I also like the really bad Bravo reality shows. You could say I'm a closet Bravo fan. So, my wife and I still watch Southern Charm, Vanderpump Rules, and Summer House. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Angie Stigliano, Operations Lead Pharmacist at Phil Source: https://phil.us/meet-angie-stigliano-operations-lead-pharmacist-at-phil/ ## Meet Angie Stigliano, Operations Lead Pharmacist at Phil This week, we had the opportunity to interview Angie Stigliano, Operational Lead Pharmacist, for our Employee Spotlight series. We hope you enjoy getting to know a little bit about her, and her experience at Phil. ### Tell me a little bit about yourself and what brought you to Phil I have been a pharmacist since 2016. In my pharmacist career I never worked for a startup, so that was one thing that really excited and interested me about Phil. Another thing that really drew me to the business was the mission statement of improving the lives of patients through focusing on better medication access. The second thing that drew me to this job was Gina Ilyasov, Phil’s former Pharmacist-in-Charge. I had an amazing interview experience with Gina and her team; my experience with everyone at Phil has been welcoming, collaborative, and open. Overall, a tech startup with an innovative concept, on top of working with a pharmacy network that really focused on prior authorizations, securing coverage, and driving access to difficult therapies was really interesting to me. ### What is your favorite part of the job? I honestly love my job! One of my favorite things about working at Phil is the collaboration and the culture of the pharmacy team and of the company. The culture is very welcoming, patient-centric, and open-minded to change. I really enjoy working with other departments to make noticeable, needle-moving changes that can make a difference to patients and providers, as well as our team internally. Also, I love how my role is centered around identifying gaps in the field and working with other departments to implement meaningful changes. Lastly, watching the fruits of our team’s labor come to fruition, through witnessing how our solution makes our client’s lives easier and offers patients and HCPs a better experience, is very rewarding. ### Great! So those are all really exciting things, what are things that are challenging for you? Challenging in this context is not negative, but rather a learning opportunity. One of the more challenging things for me is working on initiatives that are out of my depth of practice. For example, things that are more business related is not something I went to school for. For me, this offers an opportunity to figure out what's needed for patients, our clients, and the broader organization - so it’s a challenge in the way that you want to investigate and figure out the best possible solution. ### Shifting gears a little bit, what do you like to do outside of work? I have lots of different hobbies! I really love to do stuff outdoors. I'm a big runner. I like to do half marathon races once or twice a year. I love rockhounding, hiking, and natural medicine. That's been a big thing for my past. I also enjoy picking fresh things from the earth and making homemade chapsticks and lotions. I travel a lot with my friends and husband. and while I’m not necessarily a foodie, I enjoy trying new foods and dining experiences. I'm also a parakeet owner - I’m very interested in birds and I love to garden too. It’s a fun mix of activities! ### Who are some of your biggest influences? I would say in my personal life, it’s always been my dad and my mom when she was still alive, was a big influence on me. Both my parents were my best guides and advocates. Professionally, some of my pharmacy professors like my student advisor, Kelly Crucis. She was a huge help to me when I was going through school. I admired how calm and collected she was - nothing got under her skin. At Phil, Gina was a huge influence on me in terms of building my confidence as a leader and effecting change. She really opened my eyes that I have the skillset and opportunity to grow. My new manager, Pat Meyer (VP, Clinical Operations), has given me lots of helpful advice on interpersonal relationship building and business development best practices. Interested in learning more about Phil? Check out our company page to discover how you can help us improve the patient, provider, and pharmacy experience. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Bob Schumaker, Vice President of Operations at PHIL Source: https://phil.us/meet-bob-schumaker-vice-president-of-operations-at-phil/ ## Meet Bob Schumaker, Vice President of Operations at PHIL As VP of Operations at PHIL, Bob Schumaker champions a collaborative approach that brings together healthcare stakeholders to improve patient care. Drawing from his extensive background, Bob has spent the last five years building and scaling PHIL's partnership operations with a laser focus on improving patients' lives. #### Can you tell us a little bit about what your role as VP of Operations entails? I oversee the fulfillment side of the business, which has two main parts. First, we have a network of partner pharmacies that dispense medications to our patients. I work with our pharmacy partners to ensure they understand and follow our established rules, business agreements, and best practices. Second, I manage the wholesale arm of our business, supporting manufacturers with their patient access programs. I've been in this role for five years, and during that time, we've seen incredible growth – PHIL has grown more than twelvefold since I joined! #### What inspired you to join the Phil team? For me, it came down to two major factors – the work fit and the mission – that inspired me to join. I was really drawn to working in a managed marketplace or partner network where the interests of all parties – the patients, the partners, and the company – were aligned. I wanted to be part of an organization where stakeholders worked together seamlessly in a well-designed network. PHIL offered exactly that. As with any technology company, your core solution also has to work in order to be successful, and ours works exceptionally well. Most of all, I wanted to help people, and we do that by making patients' lives easier. #### You've transitioned from retail operations at companies like Target and Macy's to tech-enabled operations at PHIL. What key lesson from traditional retail has proven most valuable in the digital health space? The biggest lesson is to not be afraid of repetition. People are busy and there's a lot of information to process. Healthcare can be complex – when something's important, you need to be clear, consistent, structured, and often, repetitive. People often ask for guidance to navigate both healthcare itself and the operations behind it. For me, repetition means explaining something in a way that sticks, and doing the right things well, over and over again. Our job is to make people’s lives easier – we aspire to keep everything clear and accessible for patients, providers, and partners, and provide timely reminders throughout the process to ensure everyone stays informed. #### Have you had the opportunity to collaborate with your colleagues from different departments? If so, how would you describe the experience? Yes, in operations we always have opportunities to work with many different departments, and this is especially important in healthcare where there are several stakeholders – patients, HCPs, manufacturers, payers, pharmacies and more. PHIL does a great job of setting up subject matter experts for each of these stakeholders. Because of this structure, any patient journey requires working with a large team to ensure we're doing the right thing at each step. Having the chance to work with a significant portion of the company, I truly appreciate all the smart, talented people here who want to do good work and make things better for patients. It's valuable to work with colleagues who bring different perspectives because it prevents you from developing tunnel vision about your own processes. Everyone keeps the shared goal – helping patients access their prescribed medication more easily and affordably – in mind as we work through each step. #### On a personal note, how do you like to spend a day off when you have no plans or obligations? If my kids are off too, that definitely impacts how I'll spend my time! With a six-year-old and a three-year-old, it's pretty busy and attention-focused. If I have time to myself, I'll probably go for a hike and read a book, enjoy some quiet solitude. It really depends on who's around, but if the family's home, we'll spend the time together doing activities. #### If you could pick any superpower, what would it be and why? I would probably choose the ability to speak and understand every language. It would be incredibly useful, and bonus – it’s not the kind of power that would get me kidnapped by the government! Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Catherine Hill, VP, Marketing Phil Source: https://phil.us/meet-catherine-hill-marketing-vp/ ## Meet Catherine Hill, VP, Marketing Phil ### Catherine Hill Catherine Hill is the Vice President of Marketing at Phil. She joined the company at a pivotal time of growth. In this article Catherine shares what attracted her to Phil as a healthcare outsider and how her personal connection to healthcare drew her to the mission to get patients on life saving therapies. ### What was it about Phil that caught your attention initially? There were a few things, but initially my interest in Phil stemmed from personal experience as both a patient with chronic illness and watching my parents experience barriers with getting access to much needed treatment. I have spent most of my career in tech and I was starting to feel unfulfilled by the products I was working on. The prospect of a company built to benefit patient lives by assisting with access to critical therapies was really appealing. Phil offered a unique combination of excellent product-market fit, a strong mission and a world-class team. ### What inspired you to join a company in the healthcare industry given that you have a strong marketing background in industries outside of healthcare? I have seen “what good looks like” from a product-market fit and team perspective in the fast growth companies I had the privilege of working for in the past. And Phil has it. The combination of a product that is solving a real pain in the market with a team that is talented and passionate about the mission was incredibly appealing. I knew that my strong enterprise marketing background, combined with my experience marketing directly to consumers would allow me to build marketing programs that target the enterprise pharma manufacturers, as well as the consumers - prescribers and patients - in a really unique and robust way. ### What do you think makes a company “marketable”? Ultimately, a company is marketable when it is solving a real pain. When a company is solving a problem in a way that makes a noticeable difference in people’s lives, marketing is easier. Phil solves real problems for pharma manufacturers, physicians and patients. My job in marketing is to make sure those audiences know that there is a solution to their challenges. ### Is there a formula to how you approach marketing and are there any marketing strategies you will apply at Phil that are unique or new? I think there are best practices and structures that can be applied that cover about 80% of our marketing but there is a substantial portion that is unique to the situation at a given point in time. For Phil we have a demand-drives-demand strategy supported by a strong content marketing program. We will focus on driving awareness across all of our target audiences with thought leadership and industry focused content that will help make our sales and demand generation activities more efficient. ### Where do you see the marketing team at Phil in the next two years? We are in a period of fast growth as a company and we are building a marketing function to support that growth. My goal is to build a world class marketing team to communicate how Phil solves problems across all of our target audiences. In two years we will have learned a lot, done a lot of brand building, and worked with a lot of customers to build out case studies. I expect that we’ll be taking those learnings and scaling out the winners as we continue to test and iterate. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Chris Sweitzer, VP of Business Development at PHIL Source: https://phil.us/meet-chris-sweitzer-vp-of-business-development-at-phil/ ## Meet Chris Sweitzer, VP of Business Development at PHIL In this employee spotlight interview, we are excited to feature Chris Sweitzer, our new Vice President of Business Development at PHIL. With two decades of experience in the healthcare industry and a passion for enhancing patient access, Chris brings a wealth of knowledge and a unique perspective to our team. #### Please tell us a little bit about yourself and your role at PHIL. I'm thrilled to have recently joined the PHIL team as the Vice President of Business Development. Healthcare has been my passion for the past two decades, with the last 15 years specifically focused on market access and patient support. This isn't just a career for me – it’s a calling that stems from personal experience. Early in my professional life, I underwent surgery and was blindsided by a huge medical bill due to reimbursement challenges. As a young professional, I felt lost, unaware of the resources available to help me. This experience led me down the pathway to learning about the patient access world, the vendors that operate in this space, and how they can help support and advocate for patients. I made it my mission to understand the intricacies of this field and serve in this space. My journey has led me to PHIL, and I'm incredibly excited about the opportunity to grow with this organization and make a real difference in patients' lives. #### What inspired you to join the PHIL team? I was drawn to the patient access space because it allows me to help people while working in a rapidly evolving field where technology is transforming how patients engage with healthcare. Over the past decade, the emphasis on enhancing the patient experience has changed significantly, with a greater focus on leveraging the technology we use in our daily lives to improve the healthcare experience. I was looking to join an organization leading this field, and PHIL stood out with its best-in-class solution, commitment to patient-centric innovation, and entrepreneurial spirit. The company’s impressive growth over the past few years highlights the team’s effectiveness and increasing demand for their services, which is something I was really excited to be a part of. PHIL is not just participating in the patient access space; they are shaping it. I see tremendous potential for continued growth and impact, and I'm excited to contribute to an organization that is making a real difference in patients' lives. #### How have your past experiences prepared you for this role? Having operated extensively in the patient access space, I've gained valuable insights from multiple perspectives. My background as both a sales representative and a sales leader has given me a deep understanding of the connections and operations within the industry, spanning small, mid-sized, and large biotech and pharmaceutical companies. I can leverage existing relationships effectively to increase awareness and strengthen relationships across the sector. #### What do you see as the biggest opportunities for our business development in the next 1-2 years? I see our biggest opportunity in the next few years as significantly increasing PHIL’s brand awareness in the patient access space. While we have developed an impressive and effective solution that has skyrocketed over the past years, there's always more to do in terms of market recognition. This is an area where I believe I can make a substantial contribution to the team. Moreover, as the patient access space continues to evolve with an increasing emphasis on technology-driven, patient-centric solutions, PHIL is perfectly positioned to lead this transformation. Our challenge – and opportunity – is to ensure that key decision-makers in the pharmaceutical industry are aware of our capabilities and how our solution can help them improve patient outcomes and brand performance. #### Outside of work, what hobbies or interests do you enjoy? I have two children – a nine-year-old and a seven-year-old son – who keep us busy! They’re both very active in athletics and school activities, so our days are filled with gymnastics, baseball, and all the fun that comes with running them back and forth to their events. Outside of family time, I’m a big sports fan. I love following football, baseball, and basketball, and I enjoy catching games whenever I can. Recently, I’ve also taken up golf, which has been a great way to unwind and enjoy the outdoors. I find that spending time outside, whether it's on the golf course or out fishing, is a perfect way to recharge. #### What's a book, movie, or podcast that has significantly influenced your approach to business or life in general? The book that immediately comes to mind is The Oz Principle. If you're not familiar with it, the core principles focus on personal accountability and how that can influence every aspect of your life. This is something I've tried to embrace both professionally and personally. It encourages you to consider what you can do to control the situation and shape the narrative, which is ultimately all we can control in life – our perspective and mindset. The Oz Principle discusses essential leadership fundamentals, emphasizing the importance of personal accountability and how it can resonate throughout a team and an organization. It promotes a proactive problem-solving mentality, which I find invaluable in both business and everyday life. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Deepak Thomas, CEO & Founder of Phil Source: https://phil.us/meet-deepak-thomas-founder-of-phil/ ## Meet Deepak Thomas, CEO & Founder of Phil Deepak Thomas is the founder and CEO of Phil. He started the company as patient zero after being diagnosed with a chronic illness in the late 90s and struggled to navigate his own care within the complex US healthcare system. Several years later, he applied his experience in tech to build a solution that expands and simplifies patient access to specialty drugs, while aligning economic incentives for therapy manufacturers. Today, Deepak describes his journey in starting Phil as a “team of one” to working with some of the largest manufacturers such as Bausch Health. ### Why did you have the idea/vision to create Phil? In the late 90s, a few months after moving to the US, I was diagnosed with chronic Lyme disease and it was very difficult to navigate access to therapies. Even though Lyme disease is a complex condition to treat, I found it astounding how “stacked against the patient” the US healthcare system is when it comes to navigating care. I had to spend a lot of lunch hours calling doctors and insurers and paid several thousands of dollars out of pocket to fund therapies as I waited for insurance to kick in. As I progressed through my professional career, with more exposure to the tech sector, I saw an opportunity to create a platform that might alleviate patient burdens when accessing their meds. ### How did your professional background help navigate launching Phil? I come from a technology and business background and over the last decade it became clear that tech was creating significant consumer value across sectors. There was a clear opportunity for someone to come in and create a solution able to reduce consumer (patient) friction and deliver well-informed access to medications particularly for complex conditions. While the healthcare industry is complicated and can’t simply be fixed by “tech,” understanding the business and economic shortcomings of the healthcare industry spurred me to envision what a tech solution might look like. ### What were the initial steps to get the idea for Phil off the ground? The major challenge was getting a good understanding and perspective of the healthcare system in its entirety. At first I thought the major setback for the system was at the pharmacy level. I quickly came to the conclusion that the problem was far greater, and it was the disconnect between all the stakeholders involved in the process – the manufacturers, prescribers, insurers, pharmacies and patients. I thought “if only everybody involved knew what they needed to do at the appropriate point of time,” so that patients can receive therapies in a timely and painless manner. My goal was to create workflow efficiencies to connect the entire process and all the key players. Essentially that would involve the automation of certain processes to save time and money, combined with bespoke human intervention for troubleshooting and the more personal/one-on-one aspects of the care delivery process. I started the company as a team of one, I learnt how to code again and built a framework for the company over 8-9 months. From that point, I was able to raise funding and started building out the team, starting with my cofounder up to 155 employees today. ### What types of companies/products typically benefit from Phil’s offering? Specialty lite and specialty drugs are the niche that we serve across all therapeutic areas (TAs). Around 80% of drugs out there are generics and those don’t have significant access issues because they are not expensive. The more expensive therapies have significant hurdles to access and adherence. Right now Phil is breaking down access barriers for both specialty lite and specialty drugs in women’s and men’s health, dermatology, neurology, rheumatology, immunology, gastroenterology, infectious diseases, pediatrics, antiviral and cardiovascular indications among others and there is no aspect that ties Phil’s offering to a specific TA. See how Phil helped improve patient access to a women’s health drug. ### What are the main reasons (problems) spurring companies to seek Phil’s help? The patient experience is the main frustration for manufacturers. They have built cutting edge science, expended capital to create awareness among prescribers, but when it comes to getting patients on therapy, the system is failing the patient. Anybody who has walked into a retail pharmacy knows there is more to be desired from that experience. ### Where do you see the company in the next couple of years? Currently most of the manufacturers we work with are in the specialty lite segment, and we aim to strengthen our offering to manufacturers in the biologics and specialty segments. Those are tougher problems to solve, but our platform is built to work well across both segments. There is an expansion opportunity in specialty and biologics and we aim to have a strong presence there in the future. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Glenn Boyer, VP of Business Development at Phil Source: https://phil.us/meet-glenn-boyer-vp-of-business-development-at-phil/ ## Meet Glenn Boyer, VP of Business Development at Phil We are excited to introduce Glenn Boyer, VP of Business Development, who recently joined our team to support growth. In his interview, Glenn discusses his extensive experience in the pharmaceutical industry and why he believes Phil’s approach to digital hub transformation is the best approach. #### Please tell us a little bit about yourself and your role at Phil. I am a Vice President of Business Development at Phil. My professional journey in the pharmaceutical space began on the pharmacy benefit management side. I started out at Medco Health, which was bought by Express Scripts. I was subsequently recruited by the founder of CoverMyMeds (CMM), which was in the start-up stage and focused on solving prior authorization challenges.These roles gave me a unique perspective on the challenges that surround prior authorization, and how companies can help address them. At CMM, I was in a sales role and had the opportunity to partner with some of the largest pharma manufacturers in the United States. When CMM was bought out, I followed a trusted colleague to Redi.Health followed by AssistRx where my direct manager, Thomas Luby, joined Phil as current SVP Business Development. After talking to him, I ended up joining Phil as well. I’ve been working in business development in the pharma space for about 20 years and have built many meaningful relationships across the industry. I love what I do. #### What drew you to Phil? I appreciate that Phil’s approach to medication access is focused on digital hub transformation. The platform is intuitive and highly effective. I was also attracted to the company based on feedback from clients who were trying to reduce overhead and increase efficiency to help patients get access to their medications quickly and affordably. It was clear that clients are seeing strong results on PhilRx, so that was a big draw for me. #### What are you looking forward to accomplishing in this role? Phil is made up of an incredibly talented group of individuals, and I am excited about taking the company to new heights together. There's an opportunity to disrupt the model that exists right now. It's not working as efficiently or effectively as it could be, and Phil wants change that. I've seen several companies try to enter the patient access space and lose focus on what they're trying to accomplish. We are very specific about our mission to create an alternative channel solution that improves patient access. As big pharma companies face roadblocks with one-sided solutions, we want to be the go-to digital hub that streamlines the entire process of getting patients started and staying on medication quickly, easily, and affordably. #### What is the biggest challenge that you’ve encountered so far? The biggest challenge for me has been getting up to speed quickly on the systems and processes used within Phil. I believe in our product and know it works well, it’s simply a matter of getting fully dialed in. I’ve had a few professional transitions, and I find that the most daunting task is simply learning the internal workings of each organization to do my job most effectively. #### Have you had the opportunity to collaborate with your Phil colleagues from different departments? If so, how would you describe the experience? One of the main reasons I’m here is the people. Meeting folks from different areas within Phil has confirmed my belief that I am surrounded by a powerhouse of brilliant and driven individuals who are striving toward the same goal. These interactions have been very positive for me and have affirmed my decision to join the team because I get to work with great people every day. #### On a personal note, what do you enjoy doing outside of work? My partner and I are very active. She's a fitness enthusiast, so we like to play a lot of sports, go on runs, travel, and explore new areas. I frequent the parks around Columbus, Ohio, which has a wonderful park system. I have two daughters, aged 16 and 12, and we play a lot of board games as well as tennis and pickleball. My youngest rides horses, so I also spend a fair amount of time at the barn with her. #### What’s something that you’ve always wanted to try or learn? I want to get scuba diving certified. My partner is a master open-sea scuba diver, and we have visions of going to the British Virgin Islands and doing some sea diving. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Haley DeCoy, Pharmacy Manager at Phil Source: https://phil.us/meet-haley-decoy-pharmacy-manager-at-phil/ ## Meet Haley DeCoy, Pharmacy Manager at Phil Haley DeCoy joined Phil right out of pharmacy school because she was interested in a non-traditional career path. Check out her employee spotlight to discover what motivates her and the major milestones she helps the pharmacy team achieve at Phil. #### Please tell us a little bit about yourself and your role at Phil. I was born, raised, and educated in Ohio, so I have strong Midwestern roots. I earned my Doctor of Pharmacy degree at the University of Findlay in Ohio and have worked with Phil since becoming a licensed pharmacist. As Pharmacy Manager, I oversee the technicians and staff pharmacists at Phil’s Ohio and Arizona pharmacy locations. Our goal is to process prescriptions efficiently so patients can start their therapy as soon as possible. I also collaborate with internal teams to improve and streamline our pharmacy processes. #### What inspired you to join Phil? Throughout pharmacy school, I knew I wanted to pursue something different than the traditional pharmacist path of working in a chain store or hospital pharmacy. During my experiential years practicing in the field, I specifically chose unique internships that allowed me to see all the different avenues possible for a pharmacist career. Those experiences confirmed my desire to follow a non-traditional career path. After graduation, I learned about pharmacist opportunities in health tech, which led me to the Phil job posting in 2018. I’m very fortunate for the opportunities I’ve had to grow personally and professionally with the company. #### What motivates you most about working here? I love the people I work with! My team and their success really drive me. Every day is different, which I find motivating. Some days, I get to work on a compliance-based project, and on others, I may work on a process improvement or people management project. There are so many hands-on opportunities to become an all-around better pharmacist and manager. #### Tell us about a time when you felt proud of your work here and why it was significant. There’s one project I’m particularly proud of because it relied heavily on my team to make it happen. We realized that Phil needed to expand the licensing for its facilities. We had the Ohio pharmacy licensed in Ohio and the Arizona pharmacy licensed in Arizona. Phil was experiencing rapid growth, and to sustain that growth, we needed our pharmacies licensed in all 50 states. This was a complicated undertaking because each state board of pharmacy has its own rules. For example, some states require a staff pharmacist who works in the pharmacy location to be licensed as an individual pharmacist in that state. I coordinated with my team of staff pharmacists to delegate licensing. If there were 16 states where we needed a pharmacist to be licensed, we divided them up. I took on the first one when I was seven months pregnant, so I had to cram for the Multistate Pharmacy Jurisprudence Examination (MPJE), which is required to practice in other states. I passed three more within eight weeks of returning from maternity leave. At this point, my little one is likely eligible for his own license to practice. This project was a focus for our team for just over a year. The Ohio location is now licensed in nearly all 50 states. It was a major milestone for my team to play our part in bolstering the longevity of the company. #### On a personal note, what do you enjoy doing outside of work? Family has always been very, very important to me. I have a little one at home now, so if I had it my way, I’d spend every minute of every day with my family. I love watching my son experience the world around him. We have a goal this summer to spend 100 hours taking him outside to explore. Whether that be a new park, a playground, going for a walk, or just playing in the backyard, we want to spend as much time outside together as a family. #### What's one thing people don't know about you that they would be surprised to find out? Most folks would be surprised to know I am passionate about personal finance. I took a personal finance course as one of my electives as an undergraduate. That professor taught Dave Ramsey’s Financial Peace University. The curriculum immediately caught my interest and gave me a new perspective. Over the years, I've curated the financial content I'm reading and learning from to be applicable to my life. I’m specifically interested in personal finance for women in the workforce and full-time working moms and how investing can impact women and the type of lifestyle they want. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Johnny Yu, VP of Patient Experience at Phil Source: https://phil.us/meet-johnny-yu-vp-of-patient-experience-at-phil/ ## Meet Johnny Yu, VP of Patient Experience at Phil Next up in our Employee Spotlight series is Johnny Yu, VP of Patient Experience. Learn how Johnny’s enthusiasm, team-building skills, and drive to achieve the best patient experience make him a valuable asset at Phil. #### Please tell us a little bit about yourself and your role at Phil. I've been the VP of Patient Experience at Phil for a little over a year now. This role means a lot of different things. I oversee several operational departments across the company, namely Patient Support, Client Escalations, and PhilRx, our prescription processing arm. We have a great team here at Phil. At this point, we're pushing over 200 folks in the departments I oversee, and they're a fun group. Throughout my professional career, I’ve worked closely with customers. Before joining Phil, I spent most of the last decade in customer operations with Uber and a proptech startup. Before tech, I was in management consulting and also spent time in the Navy. #### What motivates you to come to work each day? There are a few things. One is Phil’s mission – it’s great to play a part in helping patients get their medications quickly and affordably. An even bigger motivator for me personally is the people – my team, my colleagues, and the leadership at Phil. You know how parents teach you that if you surround yourself with good people, good things are going to happen? That’s how I feel about the work environment at Phil. I wake up every day looking forward to talking to the team during our morning stand-up. Everyone has the right mindset, with their heart in the right place. I couldn’t ask for a better group of people to work with. #### What do you think has been your biggest contribution to the team so far? I would say scaling Phil operations has been my most significant contribution. Our PhilRx and Patient Support teams have more than doubled in the last three months. This type of growth forced us to revisit and revise existing processes and workflows while taking care of the normal day-to-day, which required our entire team to be resilient, flexible, and creative. On the more intangible side, I feel like we’ve created a culture of honest feedback and removed walls between operational teams. #### Is there a project you or your team has been involved in that you've been particularly proud of? One of our major focus areas in 2023 was improving processing quality so that every script gets to the patient faster and without inaccuracies. It took an all-hands-on-deck approach to execute this initiative. From Product to Engineering to Operations to Analytics, teams across Phil took ownership as problem areas were identified. We were able to reduce error rates to an exceptionally low level. This accomplishment was a proud moment across all the different teams. #### What is the most challenging part of your job? For me, the most challenging part of the job is also what makes it the most fun. Here at Phil, things are changing all the time. It's a very dynamic business, which is exciting and difficult at the same time. Recently we identified the need to staff up multiple teams quickly to meet extreme demand growth (a great problem to have!). The challenge for me operationally was ensuring the team was growing and executing the normal day-to-day priorities. And that wasn't easy. When you grow quickly, small gaps in any operational process are magnified and can quickly become disruptions. We must constantly rethink and revise our existing processes while operating under time-sensitive conditions. It's a challenging environment, but I wouldn't trade it for any other. #### On a personal note, what do you like to do in your free time? The simple answer is to get out of the house. I work remotely, so it’s easy to get lost in my work and realize I haven’t been outside to get a breath of fresh Seattle air. Living in the Pacific Northwest, I’m spoiled with what nature offers, so going on hikes with my wife and dog is a no-brainer. Also, I try to maintain some level of fitness, so getting to the gym is also a priority in my free time. #### If you could pick any superpower, what would it be and why? I think it would be the ability to travel in time. Knowing what the future holds would help me make the best decisions. I just spent weeks researching and buying the right TV. I'm just that type of guy. I really want to know and do all the research to make the best-educated decision. If I could teleport to my future self – a year or even a month from now – it would make my decision-making process so much quicker, easier, and more confident, eliminating all the anxiety and time spent making that final decision. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Jwalanta Shrestha, Director of Engineering, Data and Infrastructure, at Phil Source: https://phil.us/meet-jwalanta-shrestha-director-of-engineering-data-and-infrastructure-at-phil/ ## Meet Jwalanta Shrestha, Director of Engineering, Data and Infrastructure, at Phil We recently caught up with Jwalanta Shrestha, our Director of Engineering, Data and Infrastructure, to get a behind-the-scenes look at his role in ensuring patients and our manufacturer partners have the right data when they need it. #### Please tell us about your time with Phil and your current Director of Engineering, Data, and Infrastructure role. I currently lead two different teams at Phil. One oversees the cloud infrastructure for all the online patient services we offer, including MyPhil, client dashboards and databases. This team manages our code build pipeline. Engineers write code, but it needs to run somewhere – we are responsible for building out that system. Our overall focus is to ensure everything runs properly and efficiently, while increasing the platform's scalability so that as the business grows, our cloud infrastructure can handle the increase in volume. The other team handles data infrastructure. This system powers our Program Dashboard, our Field Portal, and all the data feeds that we share with clients and use internally. #### What inspired you to join Phil? I joined Phil about four years ago, right before the pandemic. At the time, I was working for a large e-commerce company. Coincidentally, both Deepak Thomas and Puran Singh – Phil’s co-founders – also worked there. I had known Puran since college, and he sold me on the idea of how Phil’s technology could address the unique healthcare challenge of helping patients access their prescribed medications more easily and affordably. Leveraging what I had learned as a developer in e-commerce to support Phil’s mission really appealed to me. I was thrilled about joining a dynamic startup where I could have diverse responsibilities and tackle innovative engineering challenges. This experience has been incredibly rewarding. We've encountered numerous opportunities to enhance our infrastructure and scalability, allowing us to continuously improve and optimize our systems. I'm proud to say that our team has consistently risen to these occasions, implementing robust solutions that position Phil for future growth and success. #### What do you like most about working here? The company-wide mindset of putting the patient first in everything we do is something I find noble and inspiring – it’s what I like most about working here. In addition, we have a great work-life balance here which is refreshing, coming from an e-commerce background where I had to be on alert 24/7. To top it all off, I get to work with brilliant and talented people, which makes the job all that much better. #### What do you find the most challenging about your job? The most challenging aspect of my job is ensuring our infrastructure scales seamlessly with the company’s rapid growth. We're constantly innovating and implementing proactive measures to stay ahead of our growth curve. This requires anticipating potential bottlenecks, optimizing our systems, and sometimes making anticipatory technology decisions. While it's demanding, seeing our infrastructure evolve and perform reliably is incredibly rewarding. Our team's forward-thinking approach and experience allow us to turn these challenges into opportunities for improvement, ensuring we maintain high performance and reliability for our partners. #### Can you share a project you or your team has been involved in that you've been particularly proud of or passionate about? I am particularly proud of two projects. When I first joined Phil, our entire cloud infrastructure was managed by a third-party company. We aimed to move the whole system in-house and manage it internally. To accomplish this, we built a new team from the ground up and successfully migrated that entire system to Amazon Cloud, making sure it was and remains highly scalable, secure and compliant. We also revamped our entire code-building pipeline, which is completely automated now. The other project was upgrading our data service. In the past, we generated a lot of data for the clients when requested, but the system was far from being scalable and reliable. If we had kept that system, it wouldn't have worked for us today. Our team built an entirely new platform called Data Service that is highly scalable and efficient. This system powers Phil's Program Dashboard, Field Portal, and the data feeds we send to our clients. I'm not only proud of how we worked together as a team to build this new system and what it accomplished for the company, but also how we coded and architected the entire system. #### On a personal note, what do you like to do in your free time? I have a two-year-old son, so the concept of free time is somewhat alien to me now. He keeps me busy. If I had some free time, I would like hiking, taking pictures, and traveling. If I'm not outdoors, I like hobbyist electronics, like tinkering with microcontrollers and electronics in general. #### What’s something that you’ve always wanted to try or learn? I’ve been trying to learn new things that don’t involve computers. Right now, I am exploring the world of espresso and coffee. I find the whole science and art behind it fascinating. For a long time I didn’t like to drink coffee. Now I have an espresso machine and am learning how to do latte art and other barista techniques. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Makena Zannini, Head of Business Optimization at Phil Source: https://phil.us/meet-makena-zannini-head-of-business-optimization-at-phil/ ## Meet Makena Zannini, Head of Business Optimization at Phil We’re delighted to introduce Makena Zannini, Head of Business Optimization at Phil. Discover Makena’s fascinating background and her analytical superpowers that help us move mountains. #### Tell me a little bit about yourself I grew up in a small town in Pennsylvania and ended up making my way to New York City. Now, I live in Portland, Oregon, with my husband and my 2 dogs. I've always been a math person, that kid who was doing dorky analyses and experiments with toys, for example. We went to Disney World when I was a kid, and I did this whole analysis of where we should stay based on what was important to us. I've just been very analytical my whole life and that's kind of how I got into doing what I'm doing. #### What do you do at Phil? At Phil, I lead biz ops for our main functional areas. I work closely with Product, Operations, and our client-facing teams. My team’s goal is to help drive better outcomes for our programs. So, that may involve analyzing how our clients or partners can optimize their programs in a way that they hadn't thought about. Or, examining data trends about a new product feature that we released to understand what we can learn and improve on. In a nutshell, it’s leveraging data and analysis to enhance outcomes for our clients, our partners, and our platform. #### What inspired you to join Phil? I’ve been working in Operations for awhile, and I was interested in doing this role at a smaller company. I think it's really exciting to be a part of an organization that’s building something from the ground up, and helping our team make a real impact in the industry. I got connected with Andrew, our Head of Business Operations, and he was a big influence on my decision to join. From our conversations, it was clear that the team had an important role in helping Phil be the best possible partner to our clients, and that goal excited me. Plus, the feeling that I had a strong team that would support me solidified my decision to join. #### What’s your favorite part of your job? I love navigating the intersection between the analytical and the subjective. I actually think that’s like my super power. I think it’s one thing to pull data. It’s another to be able to take that data and clearly identify how it interacts with what’s happening in the real world and all the potential implications on the clients, patients, and stakeholders involved. I always like to think about, what does the client care about, and what do patients care about, and how do I take that information and do something valuable with it? I really love storytelling through data, and using that skill to help influence people to take meaningful actions that improve outcomes. I think living in that world where you’re influenced by both the subjective and artistic as well as the analytical makes everything endlessly interesting and fun. #### What do you find the most challenging about your job? I think the most challenging thing is managing competing priorities at any point in time, especially at a small company. Our field is constantly changing, and we have an opportunity to make a real impact, so it’s important to triage based on a lot of different factors. I find it helpful to be in close communication with my team about our broader goals, to help contextualize what’s important and prioritize accordingly. #### What do you like to do outside of work? Pretty much anything outdoors. We're like the classic Portland people, always backpacking, hiking, or skiing. I just ran a marathon, and I just love being active and outdoors. We also foster dogs, which is a really fun thing that we've been doing for a while. We have 2 dogs of our own and it’s so rewarding and fun. I also have a slight obsession with house plants, which is sort of a problem. I started acquiring plants during Covid, when I had nothing else better to do, and it was great. #### What’s something you’re passionate about? One thing I care a lot about is DEI (diversity, equity, inclusion). That’s something I’ve been very involved in at previous companies, and it’s something I’m starting conversations about here at Phil as well - it matters to me that our company and leadership continues to represent different people with different backgrounds and demographics. I think it’s so important that we create a diverse environment for people who are coming into the company, as well as people who currently work here. It’s an area I’m really passionate about, and something that I hope to help lead at Phil in the near future. Interested in joining the Phil team? Check out our company page to learn more and explore our open job openings. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Maria Klagos, VP People Operations at PHIL Source: https://phil.us/meet-maria-klagos-vp-people-operations-at-phil/ ## Meet Maria Klagos, VP People Operations at PHIL In our latest employee spotlight, we sit down with Maria Klagos, our new Head of People, who brings a wealth of experience in scaling HR functions at high-growth startups. We explore her unique background, her vision for PHIL’s culture, and the personal experiences that have shaped her professional journey. #### Please tell us a little bit about yourself and your new role at PHIL I joined PHIL as the VP of People Operations this past May. I’m pleased my career path has led me here and am looking forward to the work ahead. Throughout my career, I've specialized in building people functions for rapidly growing startups. I typically join as the first HR hire, laying the groundwork for significant expansion. I've had the privilege of working with four startups as they achieved "unicorn" status, reaching valuations of over $1 billion. Two of them also went through their Initial Public Offering (IPO) processes during my time there. What I find most rewarding is developing the systems and processes that enable companies to scale effectively. In my past roles, I've helped facilitate 10x employee growth, which presents both challenges and opportunities. It's a dynamic environment that I find engaging and fulfilling. My approach involves getting hands-on with the work. I enjoy the process of building something from the ground up and navigating the complexities that come with rapid growth. At PHIL, I'm focused on building out our people team, which will encompass both recruiting and HR functions. My goal is to create an environment where our employees feel supported and empowered to do their best work. I'm genuinely excited about the potential here at PHIL and the impact we can make together. I look forward to applying my experience to help shape our company's future. #### What do you think sets PHIL’s company culture apart from others you’ve worked with? PHIL’s culture stands out in several key ways. First and foremost, there's a strong sense of mission-driven purpose. Employees feel deeply connected to their work because they, along with their friends and family, can directly benefit from PHIL’s services. This creates a palpable sense of impact, both on an individual and company-wide level. Secondly, there's a culture of mutual respect among employees. This manifests in efficient meetings, transparent communication, and a genuine appreciation for each other's time and ideas. Lastly, PHIL emphasizes work-life balance in a unique way. Rather than trying to make work feel like family, we encourage efficiency to allow flexibility for personal life outside of work. This approach to remote work is refreshingly forward-thinking. Instead of attempting to replicate an in-office environment remotely, PHIL is reimagining what a remote work culture can be. #### Can you share a memorable experience or achievement from your time here that you’re particularly proud of? In the months since joining PHIL, I've had the opportunity to make significant strides in our hiring processes, which I'm particularly proud of. When I arrived, I observed that our growing company had naturally developed diverse hiring approaches across different teams. This decentralized system reflected the entrepreneurial spirit of our managers but also presented an opportunity for streamlining. My focus has been on creating a unified, centralized hiring process that builds upon the strengths of PHIL’s existing practices. This new approach is designed to give time back to our hiring managers, allowing them to focus more on their core responsibilities. At the same time, we're enhancing the candidate experience by leveraging the expertise of our newly formed recruiting team. The results have been rewarding. We've created a more efficient and effective hiring system that benefits the entire organization. I find great satisfaction in organizing and optimizing processes like this. It's exciting to witness tangible improvements in our ability to hire faster and better, and I'm thrilled about the foundation we're laying for future growth. #### As PHIL continues to grow, what initiative(s) are you most excited about implementing? I'm excited to build upon PHIL’s culture by implementing processes that will enhance it and keep employees proud to work here. When I think about HR initiatives that truly matter to employees, retain high performers, and cultivate an effective culture, three key elements come to mind: - Great relationships with managers - Clear opportunities for growth within the company - Work that leaves employees feeling fulfilled and challenged These elements form the foundation of our upcoming initiatives. We're focusing on creating comprehensive manager training programs and providing toolkits to help managers give effective feedback to their teams. We plan to develop career ladders to help employees visualize their growth potential within the organization. Additionally, we're working on improving transparent communication to help employees better understand the company's goals and how their individual work contributes to these objectives. This understanding is crucial for helping people feel connected to their work every day. By starting with these fundamental areas, we can make significant improvements to PHIL’s cultural foundation and continue to build upon it as we grow. These initiatives will not only enhance our existing culture but also ensure we're well-positioned to support our rapid growth. #### On a more personal note, what's one thing people don't know about you that they would be surprised to find out? Well, I'm a bit of an Abraham Lincoln nerd. I grew up in Springfield, Illinois, which is known as the "Land of Lincoln." In this town, Lincoln isn't just a historical figure – he’s a part of everyday life. You see Abraham Lincoln everywhere, from murals on buildings to the names of streets and institutions. So, it’s only natural that my first ever job in high school was at New Salem, a reconstructed village where Lincoln lived when he first came to Illinois. I worked as a historical reenactor, wearing colonial dress and spending my days in a log cabin. I'd churn butter, spin wool, and talk to visitors about life in Lincoln's time. It was quite an experience, and it really deepened my knowledge and interest in Lincoln's life. The Lincoln enthusiasm in Springfield reached a peak around Lincoln's 200th birthday when the Abraham Lincoln Presidential Library and Museum opened. I remember how the whole town celebrated - we all flooded the streets wearing top hats in honor of our most famous resident. So, while it might not be obvious from my current work in HR, I've got a wealth of Abraham Lincoln facts tucked away. #### Who has been the most influential person in your life, and how have they shaped your personal or professional journey? The most influential person in my life is undoubtedly my husband. His journey over the past few years has been incredibly challenging, yet inspiring. In the summer of 2019, he suffered a fall that resulted in a traumatic brain injury. While he was still recovering from post-concussion syndrome, he contracted COVID-19 in March 2020, right at the beginning of the pandemic. Since then, he's been dealing with long COVID, which left him mostly bedbound for several years. Despite these enormous challenges, my husband has shown remarkable resilience. What truly amazes me is his ability to find joy even in such life-altering circumstances. His strength in the face of adversity has been a profound source of inspiration for me. Witnessing his journey has given me the confidence to grow and face my own challenges, both personally and professionally. He is, without a doubt, the strongest person I know. His unwavering belief in me motivates me to push my boundaries and strive to make a positive impact on the world. His resilience and support have shaped my approach to life and work, reminding me of the power of perseverance and the importance of finding joy, even in difficult times. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Molly Fields, Director of Patient Support at Phil Source: https://phil.us/meet-molly-fields-director-of-patient-support-at-phil/ ## Meet Molly Fields, Director of Patient Support at Phil The next interview in our Employee Spotlight series is with Molly Fields, Director of Patient Support at Phil. We hope you enjoy learning more about Molly and her impressive experience in the health tech industry. ### Tell me a little bit about yourself I'm from San Diego, Carlsbad specifically, and I have 7 brothers and sisters. I moved to Arizona in 2005 to work at a startup in the audio visual industry, and really enjoyed my time there. It allowed me to grow my operational skills and discover that I love finding process efficiencies and opportunities to decrease the cost of doing business by improving the systems through automation. I'm really dedicated to work. I am probably more dedicated than I should be, but it is in my blood. Aside from work, I also take my family and friends very seriously - I'm a very passionate person. I have a husband and 2 dogs, and while my husband and I have only been married for about 3 months, we've been together for 10 and a half years. ### You were in AV before your current role in the startup space. What inspired you to join Phil? After I left that job, I went to another startup in an adjacent industry for 2 years. A recruiter found my resume online and contacted me about a great opportunity in the health tech space. My first job was at a medical device startup, and I really loved it. I love startup companies. So when I learned more about the work that Phil was doing in the healthcare space, I was really interested. Plus, reading why Deepak started the company and the purpose of Phil really resonated with me in a way that I hadn't experienced since my first job in health tech. ### Can you tell us a little bit about what you do at Phil? Absolutely! I am the Director of Patient Support at Phil, which is currently a fast-growing, 40 person team that specifically works with patients regarding their prescription orders. I'm responsible for the functions within the patient support team. The opportunity to lead a team that works to ensure our patients have the support and resources is very rewarding. I also collaborate closely with other departments across the organization such as our product team, to improve our system functionality and efficiency to better our patient experience. ### What's your favorite part about your job? The people! Everybody that works for Phil is great. My team is equally fun and hard-working. I feel very grateful for the opportunity to mentor and shape the people on my team, and help them grow in their careers. I really love working at Phil. I love what we do. I love the challenge behind it. I love my coworkers. I wake up in the morning and want to work - that's the sign of a good work environment! ### What do you find challenging about your job? What I find challenging about my job is similar to what I find interesting and fun. Building our team and fostering relationships, offering great training and support to make sure they know why they're doing the things they're doing, while keeping everyone motivated all within a remote work environment is challenging. ### How does your team interact with patients specifically, and any outcomes or excitement that the team gets from those types of interactions? My team is excited when they help the patient get their prescription. Sometimes, the patient will reach out and say that their order has been delayed, and our team is able to identify why the order isn’t processing, and move the prescription to the next step. When a particular patient has experienced issues in the past, our team will set up a calendar reminder, and follow up on the refill to prevent issues and ensure the patient is having the best possible experience with Phil. I think our biggest triumph is when the patient doesn't know what's happening with their order, perhaps because they don't understand technology or they're not comfortable with the website, and our team is able to can make a phone call or send an email that offers a really helpful explanation of what's happened and what's going to happen next. It may sound small, but that effort makes a huge difference. ### What do you like to do outside of work? Pretty much anything outdoors. I'm not a huge water person, but besides that, I enjoy hiking, camping, and anything else we can take the dogs to do. Also, I love skydiving. It is an expensive habit, so we only go a couple of times a year, but that's actually how we got married! Curious about joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Neil Dean, Director of Product Management at Phil Source: https://phil.us/meet-neil-dean-director-of-product-management-at-phil/ ## Meet Neil Dean, Director of Product Management at Phil Neil Dean joined our team as Director of Product Management because he wanted the opportunity to directly impact lives. In this employee spotlight, Neil shares what he likes most about his role, how he approaches challenges, and a project he’s passionate about. #### Please tell us a little bit about your role at Phil. As Director of Product Management, I oversee Phil's patient, healthcare provider, and manufacturer experiences. From the moment the doctor writes a script to PhilRx and the patient signs up for support through the PhilRx Digital Hub, my job is to work closely with our internal teams to ensure a smooth and efficient medication access process. I also need to ensure our clients understand how the process is working and what actions they can take to improve it. #### What inspired you to join the Phil team? I was excited to have the opportunity to apply the product management and sales enablement skills from my previous work experience to make a direct impact on people’s lives. The timing was perfect to take on the level of problem-solving and intensity required for this role. These factors, and the fact that I found Phil’s track record of success mind-blowing, made the decision to join the team easy. #### What do you like most about the work we do here? It's twofold. From a conceptual standpoint, I really like that everything we do is in service of the patient. Even when we're figuring out ways to improve our clients’ experience, our ultimate goal is to make a difference in patients' lives and health outcomes by helping them access their prescribed therapies. That's the idea behind everything we do, and it's really core to the company's principles. From a day-to-day standpoint, we work in an immensely challenging space, which appeals to me. And by that, I mean it's very fast-paced, kind of gritty. Everything's not perfectly scaled out and pretty, so it's easy to see your own impacts and to be able to be in the fray. #### Could you describe a recent project at Phil you are passionate about? I'm working to automate our data entry process, which sounds unsexy from a project standpoint. However, from the perspective of the pharmacy tech, we're helping them spend more time helping patients face-to-face by automating daily repetitive tasks. I'm passionate about this because it builds on Phil's mission by empowering people to allocate their time in more impactful ways. The other aspect of this project I'm proud of is how we ramped it up rapidly and collaboratively. We worked closely with Engineering and the PhilRx pharmacy team - the whole process of figuring out and executing what we needed to do came together nicely. #### What is the biggest challenge that you’ve faced since joining the team? I've never worked in pharma before, and the space we work in is quite complex. Personally, the biggest challenge has been trying to learn a lot as I go. One of the principles at Phil is that the best way to learn is by doing. That means getting comfortable with being uncomfortable and fighting through that learning curve. Paradoxically, the challenge of learning as I go while making an impact is one of the things I find the most thrilling. It's demanding but super rewarding when you pull it off. One thing I'm getting out of this is learning how to keep a level head throughout what could otherwise be overwhelming and knowing everything else will feel much easier later down the line. #### On a personal note, what do you enjoy doing outside of work? Spending time with my family has become one of the most rewarding things I do. I have a 2 ½-year-old daughter and a son on the way. This definitely puts life into a new context. Aside from family time, I really enjoy running and swimming, mostly open-water swimming. And beekeeping is another hobby that I enjoy. #### What’s something that you’ve always wanted to try or learn? I want to learn Korean. My wife is Korean, and when we first started getting serious, I promised her grandmother that I would learn the language. So far, I’ve taken zero steps toward it, so that goal is dangling in front of me. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Nicole Grycan, VP Commercialization at Phil Source: https://phil.us/meet-nicole-grycan-vp-commercialization-at-phil/ ## Meet Nicole Grycan, VP Commercialization at Phil We are thrilled to have our VP of Commercialization, Nicole Grycan, share her personal journey with us in our next employee spotlight. Nicole’s industry expertise is instrumental in our mission to help people get their medications quickly, easily, and affordably. ### Tell me a little bit about yourself and what you do at Phil. I recently joined the Phil team as VP of Commercialization. I’ve spent 20 years in the pharmaceutical industry, which is wild because it feels like I just graduated from college! For 12 years, I worked on the agency side and then spent 8 years with Cover My Meds supporting prior authorization. At Phil, I play a big part in working with our clients to improve the end-to-end experience for patients, helping them get the therapies their doctors prescribe quickly and affordably. ### What inspired you to take on your current role? I was at a point in my life where I was ready for a change. In my previous role, I felt like I had accomplished the work that needed to be done. Phil’s mission of helping patients unlock access to therapy by ensuring the script written is the script dispensed really spoke to me. I was ready to step into a startup environment that’s still evolving, which I find exciting because not everything is set in stone so there’s room for growth and innovation. It was an opportunity to roll up my sleeves, try things, fail fast, and learn and grow from the experience. ### What do you like best about your job? Every day is different. It's exciting to feel like you are part of shaping something bigger than yourself. Everything hasn't been decided at Phil yet, which is appealing because there's an opportunity to put my stamp on it and grow and evolve with the company. The people are also a big part of that. There are a lot of smart people who work here, and I am proud to be among them. I love that we're driven to help patients, providers, and pharmaceutical companies work together to make it easier for patients to get started on therapy. There's something powerful in that. Our platform and the data we have access to allow us to provide actionable insights to pharmaceutical teams so they can strategically intervene to make the access process easier for patients and providers. ### What do you find challenging about your job? Finding the time to do all the things that I want to do! There's so much opportunity to do things here at Phil and do them well. I don't know how to spin it another way, but there are many exciting projects and not enough hours in the day to get to them all. ### On a personal note, how do you like to spend a day off from work? In my free time, I'm 100% about being outside, getting some fresh air, and spending time with my family, whether going for a walk, having a date night with my husband, or attending my kids' sporting events. ### Can you share a recent project or activity you've been passionate about? My passion is my kids, so my free time is consumed with whatever they're up to at the moment. For my daughter, it's swimming; for my son, it's hockey and basketball. Supporting my daughter's swim team this whole season has been incredibly inspiring. They started in the fall, and she set a goal for herself. And we've watched her exceed that goal. It's been amazing to sit back and be a swim mom and swim dad, and we're there volunteering and cheering her on. Her brother has also been really supportive, so we've all been in it together as a family. Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Meet Renee Kasun, VP of Business Development at Phil Source: https://phil.us/meet-renee-kasun-vp-of-business-development-at-phil/ ## Meet Renee Kasun, VP of Business Development at Phil Renee Kasun recently joined our team as Vice President of Business Development, bringing over 20+ years of sales experience. Discover how Renee plans to leverage her industry expertise to support growth at Phil. #### Please tell us a little bit about yourself and your role at Phil. I’m from Columbus, Ohio, and my professional background includes 20+ years in technology sales, including in data centers, managed services, and cloud services. I spent the last eight years with CoverMyMeds (CMM), working with pharmaceutical manufacturers to help support the prior authorization process. As Vice President of Business Development at Phil, I work closely with pharmaceutical manufacturers to understand their access challenges and determine how we can most effectively streamline patient access to their therapies through our digital hub. #### What inspired you to join the Phil team? I was impressed with the technology and the people behind it. The leadership team and people who built the PhilRx platform, seeing all they’ve accomplished, truly inspired me and made me want to be a part of this forward-thinking team. #### How do you think you will have the most impact in this role? I’m just a few months in, so I am still in the learning phase. I consider myself a lifelong learner, so I’m really enjoying the process of absorbing as much as I can from the insightful team at Phil. I expect to have an impact by growing and broadening the number of pharmaceutical manufacturers we work with. I have some strong relationships with manufacturers at different levels, so I’m excited to get the PhilRx platform in front of more potential partners to help them improve patient access and brand outcomes. #### What would you say is the biggest challenge you’ve faced since joining the team? I would say the biggest challenge right now is navigating the internal environment – learning the people and how different job roles intersect, the culture, the expectations, and the operational aspects. Everyone on the team has been very helpful and supportive in getting me up to speed. #### Can you share a recent project here at Phil that you’re excited about? Several great projects are in the works. I am particularly excited to dive into supporting access to mental health therapies. Historically, we have done a lot of work in the mental health space, and there’s even more opportunity to broaden this part of Phil’s portfolio. I’m looking forward to supporting this space because I believe there are significant challenges in the mental health space in terms of getting patients access to the right medications at the right time, and I’m eager to help create meaningful change. #### On a personal note, what are your favorite hobbies or interests outside of work? I’m into running, cooking, and traveling! I am very family-oriented, but my kids are all older now. My youngest is a college volleyball player, so we like to go watch her play. In my free time, I exercise as much as possible. I have two Australian Shepherds, and they’re my babies now – I enjoy walking them and taking them places with me. I grew up and have spent my whole life in Columbus, so I have an amazing network of friends who I enjoy spending time with. #### If you could pick any superpower, what would it be and why? My family used to joke that my superpower was that I could fall asleep at any moment. When my kids were little, and I had the opportunity to go to bed early, I could say, “Okay, I’m going to sleep,” and that would be it! That was a nice superpower, but I no longer have that one. So, if I could choose a new superpower, it would be to have the ability to read minds. That would certainly give me an extra edge at navigating discussions and driving value in my role at Phil! Interested in joining the Phil team? Check out our company page to discover our exciting job opportunities. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Mid-Cycle: 90% of Dispenses Covered Source: https://phil.us/mid-cycle-90percent-of-dispenses-covered/ ## Mid-Cycle: 90% of Dispenses Covered Learn how PhilRx unlocked payer coverage for 90% of this women's health brand’s dispenses on formulary transforming their brand trajectory Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Migraine - Post Approval Insights Source: https://phil.us/migraine-post-approval-insights/ ## Migraine - Post Approval Insights Migraine is a neurological disorder that affects approximately 1 in 6 Americans and leads to over 1 million emergency department visits in the US annually. Just like many neurological conditions, the treatment landscape of triptans, opioids and NSAIDs has fallen short of providing a sustainable solution for migraine patients with drugs that have subpar efficacy and intolerable side-effects. The condition has been difficult to study and characterize due to varying levels of severity, causes and symptoms and traditional therapies have not specifically addressed the disease pathology of migraines. However, due to the high disease burden impacting schools, workplaces, social settings and healthcare systems, pharmaceutical companies have prioritized the development of migraine therapies with a new class of drugs called calcitonin gene-related peptide (CGRP) antagonists. These CGRP antagonists were designed to target a substance that is elevated in the blood during migraine episodes and they can be administered to prevent migraine attacks. Several CGRP antagonists have been approved since 2018, with slight nuances in drug target, method of administration and dosing frequency. Clinical studies and meta-analyses have confirmed meaningful reductions in migraine headache days, yet the nuanced differences between CGRP antagonists requires a delicate assessment for individual patients. Meanwhile, these specialty medications come at a much higher price compared to existing standard of care options. The high price has meant that payers require migraine patients to jump through a number of medical and administrative hurdles before getting access to CGRP antagonists and this requires step therapy to prove no benefit on less expensive non-specialty agents, while prior authorization is required on the basis of migraine frequency and severity. For some clinicians and physicians, prior authorization hurdles to access CGRP antagonists can be a deterrent to the pursuit of these newer and more effective therapies as patients can't afford the wait times, while the stress of the authorization process can often be counterintuitive to the management of migraine symptoms. Manufacturers have the opportunity to work with Phil to improve market penetration of migraine therapies by offering an enhanced patient and clinician experience, detailed education on the nuanced benefits of these specialty medications, along with assistance in bypassing prior authorization hurdles. Here are some examples of recently approved CGRP antagonists and how they’ve fared on the market thus far. ### Aimovig Company: Amgen/Novartis Generic: erenumab-aooe Indication: For the preventative treatment of migraine Approval date: 17 May 2018 Analyst peak sales forecast: $1 billion by 2026 Full year 2021 sales: $313 million (US); $532 million (global) Market Reception: The first CGRP-antagonist to hit the market created a high demand among physicians and patients to gain access to the once-monthly injection. However, with first-to-market status also comes the burden of navigating uncharted payer waters. Aimovig was able to get onto some large formularies, but with the 2018 approvals of CGRP competitors from Teva and Eli Lilly, a three-way battle emerged for PBM coverage. Overall sales have steadily increased, with global 2018 sales of $119 million rising to $542 million in 2020. However, 2021 saw sales stagnate, possibly due to competitive pressure, particularly the approval of Biohaven’s Nurtec ODT as both a migraine prevention and a treatment. ### Ajovy Company: Teva Pharmaceuticals/Otsuka Generic: fremanezumab Indication: For the preventive treatment of migraine in adults Approval date: 14 September 2018 Analyst peak sales forecast: $536 million by 2023 Full year 2021 sales: $112 million (global) Market Reception: Ajovy became the second CGRP antagonist to hit the market, and this time offered patients with either quarterly or monthly doses. However, a new competitive landscape, combined with data showing no clear competitive edge, made it tough for Teva to compete with its rivals. After its approval, while Ajovy made it onto CVS's formulary, the drug suffered some large PBM setbacks, failing to make the preferred coverage lists of Express Scripts and OptumRx. The drug still requires failure on other cheaper therapies to be covered by any provider. Sales have been slower for Ajovy, making $164 million in 2020, only to see that drop by $40 million in 2021. ### Emgality Company: Eli Lilly Generic: galcanezumab Indication: For the preventive treatment of migraine in adults Approval date: 27 September 2018 Analyst peak sales forecast: $1.27 billion by 2025 Full year 2021 sales: $435 million (US); $577 million (global) Market Reception: While Lilly’s Emgality entered a three-way race with Amgen’s Aimovig and Teva’s Ajovy, Emgality produced some impressive clinical results combined with a convenient administration pen and offered patients a 12-month free drug program to speed-up access. The drug received coverage from all top 3 PBMs – Express Scripts, OptumRx and CVS – and in 2019, Emgality was able to hit $163 million in global sales, which was the highest first year of sales for a CGRP-antagonist. The drug also received an additional boost with a 2019 approval for cluster headaches in adults. ### Ubrelvy Company: Abbvie Generic: ubrogepant Indication: To treat acute treatment of migraine with or without aura in adults Approval date: 23 December 2019 Analyst peak sales forecast: $1.18 billion by 2026 Full year 2021 sales: $552 million (US/global) Market Reception: Originally discovered by Merck and later developed and registered by Allergan, Ubrelvy became the first oral CGRP approved to treat migraines as they happen. It received a favorable review in 2020 from US pricing watchdog ICER. However, despite a strong cost-effectiveness assessment, coverage still requires step therapy and prior authorizations. For example, some providers require therapy failure for a minimum of 30 days on two other triptans and authorization lasts for 12 months, requiring reauthorization thereafter. Ubrelvy generated $141 million in 2020, $552 million in 2021, while sales are expected to double in 2022. ### Nurtec ODT Company: Biohaven Generic: rimegepant Indication: To treat and prevent migraine Approval Date: 27 February 2020 (treatment); 27 May 2021 (prevention) Analyst peak sales forecast: $1.64 billion by 2025 Full year 2021 sales: $463 million (US/global) Market Reception: Nurtec is the first drug to receive approvals for both treatment and prevention, and as an oral once-daily option, it has commanded a clear edge over its CGRP competitors. The drug received a similar ICER cost-effectiveness assessment to Ubrelvy, however, during its 3Q21 earnings in November 2021, Biohaven said it had 57% of the oral GCRP market share vs Ubrelvy’s 43%. While Nurtec made $64 million in 2020, the drug saw stronger uptake in 2021, generating $463 million, but Nurtec still requires a similar step-therapy prior authorization process before coverage by many insurers, similar to Ubrelvy. In May, Pfizer announced a definitive agreement to acquire Biohaven for approximately $11.6 billion, a deal largely centered around the commercialization of Nurtec and Biohaven’s other CGRP assets. Innovative and new therapies will inevitably face access challenges as they launch. Patients face delays starting new therapies due to difficulties with prior authorization, reimbursement, and delivery. Phil works with migraine therapy manufacturers such as Impel Pharmaceuticals to improve patient outcomes by easing access to their prescribed medication. After achieving over a 90% enrollment rate and 3x better therapy adherence versus other dispensing channels, Phil holds the majority share of scripts for Impel’s acute migraine treatment, Trudhesa. For more information on how Phil works with manufacturers to streamline patient access, visit us at phil.us. Sales data taken from biomedtracker.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Modernize the Patient Access Experience, Transform Your Pharma Brand Source: https://phil.us/modernize-the-patient-access-experience-transform-your-pharma-brand/ ## Modernize the Patient Access Experience, Transform Your Pharma Brand Learn how Life Sciences companies can deliver a responsive consumer experience. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Modernizing the Patient Access Experience Source: https://phil.us/modernizing-the-patient-access-experience/ White Paper ## Modernizing the Patient Access Experience An executive’s guide to driving create an outstanding patient access experience that drives transformative brand outcomes Download PDF Patient expectations for digital-first care are at an all-time high. In response, pharmaceutical brands are delivering patient-centric access experiences that provide support at every stage of the prescription journey. This white paper unpacks key trends in patient engagement and key strategies for modernizing your patient services model. #### In this white paper, you’ll learn about: - Navigating the modern healthcare landscape and patient expectations for digitally-driven access - Key strategies for designing a patient-centric access experience that delights - How manufacturers have successfully transitioned to a modern access experience #### Elevate your access experience Build a modern access experience that delights your patients and providers. Book a tour of the PhilRx patient access platform for your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Not Getting Traction with Your Patient Services Program? Here’s Why and What to do About it Source: https://phil.us/not-getting-traction-with-your-patient-services-program-heres-why-and-what/ ## Not Getting Traction with Your Patient Services Program? Here’s Why and What to do About it As life science companies continue to invest in and launch specialty and specialty-lite medications to help patients manage chronic - and sometimes debilitating or life threatening - conditions, they are tasked with developing patient support services programs to help patients access and stay on these therapies. Unfortunately, a poorly utilized program can undermine clinical efficacy and often hinders a brand’s commercial success. Despite pouring $5 billion each year into patient support programs, pharmaceutical manufacturers only get an estimated 3 percent of eligible patients to enroll and use their programs. That’s a staggering missed opportunity. The key to turning things around is understanding the barriers to utilization and taking steps to maximize the adoption and the value of your program. ### The 3 biggest barriers to patient services program utilization There are three main reasons why eligible patients and prescribers fail to utilize a brand’s patient services program: - There’s a lack of awareness that the program exists. One study found that nearly 60 percent of patients have little or no knowledge of the medication support programs available. And while most patients rely on their physicians to provide information about prescribed treatments, a healthcare provider survey revealed that 42 percent don’t understand what support is available for their patients. - Providers and patients don’t see any benefit from participating in the program. If a healthcare provider does not perceive the value of a patient services program – for example, how it will save the practice administrative time by automating prior authorizations or improve patient adherence by making therapy more affordable, they are unlikely to adopt the program. In fact, 11 percent of HCPs believe that the time it takes to learn about patient service programs outweighs the value they offer. Almost half of patients think that pharma companies don’t understand what they need to manage their health, reducing the likelihood that they will trust that a sponsored program will help them. Without an understanding of how much the program will make it easier and more affordable to access their prescribed medication, they won’t be motivated to engage or even enroll in the first place. - The program is too complex or not delivered in a consumer-friendly way. A program that is difficult to access, understand, and navigate is bound to underperform. Provider practices are hectic and often understaffed, so they may not have the time to spend on helping patients enroll in a program or figure out how to use provider tools, such as benefits verification and prior authorizations. With 80 percent of patients preferring to use digital channels to communicate with HCPs and brands, they will undoubtedly be deterred from participating in a program that doesn’t give them the streamlined, “e-commerce-like” experience they’ve come to expect. ### How to maximize adoption of your patient services program Patient-support services programs are critical to clearing a successful trajectory for specialty-lite and specialty therapies. Life science brand teams can ensure uptake and utilization by taking the following steps to address the barriers to program adoption. - Educate HCPs and practice staff about your program. Make sure they understand how it works and will alleviate their pain points and benefit their patients. This can be accomplished through several communication channels, such as sales reps, conferences, emails, and your website. For example, Medical Economics, in its latest annual survey, reported that paperwork burdens, third-party interference (e.g., prior authorizations), and staff shortages were among the top ten issues physicians are facing. An AMA survey revealed that physicians and their office staff spend close to two business days per week completing PAs. Most physicians report that the PA process delays care and leads to treatment abandonment. If you can show them how your program will reduce the administrative burden of PAs and expedite access to therapy for their patients, you will gain a loyal prescriber and program advocate. - Make program enrollment and engagement across the patient journey as easy as possible. Today, more than ever, you need to meet patients where they are. That means providing them with a frictionless, digital-first customer experience. Patients are more likely to trust the program if the enrollment process automatically initiates at the point of prescribing. Send them a text with a direct link to an enrollment form already pre-filled with the relevant information pulled from the doctor's EHR. Allow them to choose the form of communication and engagement they prefer. And then be sure to make staying on therapy as easy as possible. This can be done through messages informing patients of their therapy's benefits and potential side effects and enabling them to easily set up refills. - Integrate the program within the physician's practice workflow. Your program should include easy-to-use tools that streamline the prescribing, benefits verification, and PA processes. Make sure the platform is configurable within current workflows and works within their EHR – enabling form auto-population, for example – which will save them significant time as they work to help patients access their prescribed therapy quickly and affordably. - Use data insights to evolve your program as needed. You can ensure your patient services program is living up to its promise by tracking the right metrics. With greater visibility into the prescription journey and how it impacts patients, you can make meaningful changes when necessary throughout your brand's lifecycle. The bottom line is that a patient services program in today's healthcare environment needs to streamline medication access and provide an integrated approach to data analytics across the patient journey in a digitally-driven way that accomplishes more with less. As an end-to-end commercialization partner, PHIL does just that. Check out this case study about a life science company that partnered with PHIL and achieved a 90 percent program enrollment and engagement rate, transforming the trajectory of its brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Capturing Actionable Metrics to Improve Patient & Brand Outcomes Source: https://phil.us/on-demand-webinar-capturing-actionable-metrics-to-improve-patient-and-brand/ ## On-Demand Webinar: Capturing Actionable Metrics to Improve Patient & Brand Outcomes Loading... Market-leading manufacturers are embracing new models to improve visibility and insight into patient outcomes, provider, and brand performance. Watch this webinar as industry experts from Phil and Syneos Health explore gaps in today’s channel analytics environment, and offer strategic recommendations to help your team effectively leverage data to improve patient outcomes and brand performance. #### What you’ll learn on the webinar: - Unpacking trends, challenges and opportunities for capturing the right channel metrics - Building a strong data model, including which KPIs to track at the patient, provider, and program level - Training your brand and field teams to optimize your patient and provider experience #### Lead with Insight Uncover a data-driven approach to optimizing patient and brand outcomes. Book a demo of the PhilRx Digital Hub to see how we can help you achieve your commercial goals with full visibility into the access journey. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Delivering on Direct-to-Consumer: Exceeding Patient Expectations for Virtual Care Source: https://phil.us/on-demand-webinar-delivering-on-direct-to-consumer-exceeding-patient/ ## On-Demand Webinar: Delivering on Direct-to-Consumer: Exceeding Patient Expectations for Virtual Care Loading... Over 75% of patients have accessed care virtually as of 2024 – the primary reasons being for improved convenience and choice. As patient expectations for digital care continue to rise, the direct-to-consumer (DTC) movement should be top of mind for pharma manufacturers. Watch this webinar with seasoned leaders from Sun Pharmaceuticals and Phil to unpack the evolving landscape of digital care from the perspective of patients and providers, and its potential to improve prescription access, adherence and affordability. #### Watch this webinar to learn about: - Key trends in the digital care landscape and the expected impact on patient outcomes, provider engagement, and brand performance - Analyzing the efficacy of DTC on patient outcomes across therapeutic areas - Strategies for developing a DTC model that meets patient needs for greater convenience, choice and transparency across their healthcare journey - How pharmaceutical manufacturers are introducing successful DTC programs #### Maximize access, adherence, and affordability Discover the building blocks of a seamless digital care experience that delights patients and providers. Book a demo of the PhilRx Digital Hub. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Designing a Digital Patient Access Journey Source: https://phil.us/on-demand-webinar-designing-a-digital-patient-access-journey/ ## On-Demand Webinar: Designing a Digital Patient Access Journey Loading... With 90% of patients wanting to access healthcare through technology, a digital-first access program is now a must (Accenture). Discover the building blocks of a digital access journey that supports your patients from activation through adherence. Learn trusted strategies and best practices from our expert panel from Duchesnay Pharmaceutical Group, US Pharma Consulting, and Phil Inc. #### Watch this webinar to learn about: - Effectively activating today’s patients in an evolving blended care environment - Leveraging technology to simplify the prescription process and maximize patient access - Overcoming leading medication adherence barriers through the use of digital tools #### Maximize hub adoption and engagement Enhanced hub services drive optimal patient outcomes. If you're looking for expertise to optimize your hub model, we can help - book an intro call with our seasoned access team. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Improving Access, Coverage, and GTN with Digital Hubs Source: https://phil.us/on-demand-webinar-improving-access-coverage-and-gtn-with-digital-hubs/ ## On-Demand Webinar: Improving Access, Coverage, and GTN with Digital Hubs Loading... Your patient support services should drive quick, easy, and affordable access to your retail and specialty-lite therapies. If your approach isn’t delivering the outcomes that you (and your patients and providers) expect, consider an alternative channel strategy. With a strategic digital hub, you can offer an end-to-end patient and provider experience that drives access, coverage, and GTN for your retail and specialty-lite brands. Hear from seasoned leaders at Phil as they share actionable takeaways to help you unlock the full potential of your access strategy. #### Watch this webinar to learn about: - Why branded retail and specialty-lite manufacturers are challenged to improve access and affordability through traditional support services - Key strategies for building a digital hub that supports patients and providers throughout the medication access journey - How brands are improving patient access, provider engagement, and brand outcomes with an alternative channel strategy #### Drive access with a best-in-class digital hub Leverage a digital hub that is designed to improve performance for retail and specialty-lite brands. Request a tour of the PhilRx Digital Hub. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Innovative Strategies to Streamline the Access Journey for Patients & Providers Source: https://phil.us/on-demand-webinar-innovative-strategies-to-streamline-the-access-journey-for/ ## On-Demand Webinar: Innovative Strategies to Streamline the Access Journey for Patients & Providers Loading... Putting patients and providers at the heart of every brand initiative is top of mind for all pharma teams. But, many manufacturers have large gaps and friction points in their access journey that are creating high barriers to access, engagement, and adherence. On this webinar, dive into trusted strategies and best practices for designing a medication access experience that drives patient outcomes and provider engagement based on insights from Phil’s diverse portfolio of life sciences brands. #### Watch this webinar to learn about: - Identifying the most prevalent challenges affecting today’s patients and providers - Adopting strategies to streamline every stage of the medication access journey - Empowering your team with insights to boost access, engagement, and adherence #### Elevate Your Patient and HCP Experience Create a seamless access journey that empowers your team to effectively measure and proactively drive success. Book a demo of the PhilRx Digital Hub. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Tech Enabled Patient Access Source: https://phil.us/on-demand-webinar-tech-enabled-patient-access/ ## On-Demand Webinar: Tech Enabled Patient Access Loading... Technology is the driving force behind transforming patient access. On this webinar, you'll discover trusted strategies and best practices for building a technology-enabled access strategy from seasoned leaders from Phil, Merck, Impel, Syneos Health, and Fierce Pharma. #### Watch this webinar to learn about: - Why simplifying the patient access experience is critical to realize strong results - What brands should look for in a commercialization partner - How various pharmacy models impact a brand's strategic priorities - What data is needed to respond the complexities of utilization management ### Transform your Patient Access Experience PhilRx is a seamless patient access platform designed to create a best-in-class experience for patients and providers. Book a call to learn more about how Phil can help your pharma brand thrive. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Determining the Optimal Channel Strategy for Your Pharma Brand Source: https://phil.us/optimal-channel-strategy-your-pharma-brand/ ## Determining the Optimal Channel Strategy for Your Pharma Brand In this on-demand webinar, Patrick Leary, Phil’s Chief Commercial Officer, discusses challenges pharmaceutical brands are facing and how a well-thought-out channel strategy is essential to these key success factors: - Speed-to-therapy - Payer Coverage (Approvals of Rx) - Pull-through to First Fill - Adherence to Therapy - Reimbursement A fragmented commercialization strategy poses significant risks to brand growth and threatens things like the patient and prescriber experience, rates of prescription coverage and pull through, medication adherence, and ultimately, profit margins and commercial success. In this webinar, you’ll learn some of the market factors impacting channel strategy, such as payer cost control measures, out-of-pocket costs, and patient consumerization, along with seven important channel strategy considerations and eight components of channel partner evaluation. You will also see a case study on one brand’s successful launch where they exceeded their commercial and access targets with: - A 95% enrollment rate - 50% of Trx covered in the first month - 3x average adherence vs other channels - 4x + net sales vs other channels Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Optimizing Life Sciences Field Teams in the Era of Drug Utilization Management Source: https://phil.us/optimizing-life-sciences-field-teams-in-the-era-of-drug-utilization/ ## Optimizing Life Sciences Field Teams in the Era of Drug Utilization Management A persistent challenge for life sciences manufacturers is growing access and affordability obstacles, exacerbated by hard-to-enter formularies and rigorous utilization management (UM) practices. Payers are tightening the screws year over year with new cost containment strategies. Where there used to be hoops, they are now on fire, making it more difficult than ever to ensure reimbursement at the pharmacy. Today, life science field teams need to command a mastery of what is occurring in the market specific to the payer landscape and their brands to communicate effectively with their core audience - HCPs. Market dynamics have required a shift from the traditional sales model focused on educating on the clinical efficacy of the product to one that centers on helping HCPs navigate the complex web of patient access. ### Why the traditional sales model needs to evolve The days of assuming access will come easily if an innovative treatment has high patient and provider demand and a motivated sales force are gone. Nowhere is this more evident than the lackluster performance of recent drug launches, of which over 60% between 2019 and 2021 underperformed expectations, including 24 out of 28 non-rare, non-oncology products. The reality is that patients who are prescribed specialty and branded retail therapies often face crippling access obstacles, including step therapy requirements, prior authorization hurdles, and high out-of-pocket costs, all of which create time-consuming tasks for providers and their staff. The impact on brands is typically acute and felt in the form of high rates of prescription abandonment, uncovered coupon overutilization, and the erosion of brand loyalty. Specialized roles beyond traditional, promotional sales are necessary to drive value for customers effectively. Without an integrated field team of sales representatives and reimbursement specialists that have access to real-time data and are focused on collaborative problem-solving to help get patients over the drug UM finish line, brand performance will suffer. ### How to optimize your field team to unlock coverage In this era of drug UM, field teams need to evolve their approach to be more responsive and relevant to customers. With the right information and tools, integrated field teams can drive brand performance and patient access more effectively. There are four keys to optimizing field teams: #### 1. Educate and get buy-in It's important to educate reps on the tools they have at their disposal, how these tools facilitate success, how the patient support program benefits them and their customers, and how any copay or bridge programs work. At a recent pharmaceutical sales meeting, the sales leadership made up fake checks and said, "If you had driven more scripts through the hub, this is what your bonus check would've been." It made an impression, cementing the buy-in of promoting the program because the sales reps could see how they would benefit. One of the things we do at Phil when working with a new life sciences partner is to hold weekly meetings with the sales leadership. We encourage bringing in some sales reps who will be early adopters of the platform and become champions, sharing their successes and helping to gain buy-in from the rest of the field team. #### 2. Align incentives Ensuring that field sales teams’ incentives align with corporate goals is crucial so everyone is rowing the boat in the same direction. Good sales reps are incentive -operated people who are resourcesful, so they will figure out what the bonus plan rewards and do what they need to do to earn that bonus. If the bonus plan incentivizes the generation of scripts, that’s poor alignment with what a manufacturer wants to accomplish in today’s world. The sales reps will get the number of scripts they need to make their numbers, but very few will be covered, so patients never get started on the therapy, and the manufacturer gets a poor return on their investment. The rep earns their bonus in the short term, but nobody wins in the long run. #### 3. Enable access to real-time data Working without real-time data is like being in a dark room with a candle – field team members can only see part of the situation – dimly, at best. To bring value to providers and patients and make the best decisions, they need a bright light – in the form of real-time data – to understand what is happening across the prescription journey. Whether a PA has stalled due to missing data on a form or the pharmacy has not done an electronic benefits verification, the field team can proactively assist the provider before frustration sets in and expedite the patient’s access to therapy. #### 4. Take a collaborative approach The field reimbursement specialist’s role is clearly defined. They help patients access their therapy, which involves educating and supporting the provider’s staff on addressing UM requirements, such as prior authorizations (PAs) and reimbursement resolution. Sales reps typically stick to the science, educating on clinical benefits and patient profiles. However, if they aren’t well versed on access and how to solve some of the hurdles, they’re caught in the past. Reps must be able to answer providers’ questions about whether a therapy is covered and the options for coverage. These are often the first questions practices ask today. A product could be the best science in the world, but the provider will not write for it if they don’t see a path for getting it covered. While sales reps can educate on reimbursement, they cannot participate in reimbursement resolution because HIPAA regulations prohibit access to protected health information (PHI). Ideally, the sales rep and field reimbursement specialist work in tandem to address PA and reimbursement issues that arise. With Phil’s solution, that collaboration is made possible. If an office has a problem, they can send a fax via a portal that conceals the patient’s PHI from the sales rep but allows the reimbursement specialist to see relevant information to help the office resolve the issue. ### Driving brand success By staying abreast of the shifts in the marketplace, health sciences companies can properly equip their field teams to drive brand success. With Phil, field teams have access to real-time data, enabling them to effectively collaborate to support healthcare providers with UM requirements and help patients access their prescribed therapies at the lowest cost as expediently as possible. Visit https://phil.us/life-sciences to learn more. Patrick Leary is Chief Commercial Officer at Phil, Inc. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Optimizing Patient Access for Sustainable Growth Source: https://phil.us/optimizing-patient-access-for-sustainable-growth/ Playbook ## Optimizing Patient Access for Sustainable Growth A playbook for life sciences manufacturers looking to build a best-in-class patient access program that drives sustainable brand growth Download PDF Life science companies are often challenged to meet forecasts and maximize the growth of their therapies at any cost – with gross-to-net (GTN) often taking the biggest hit. In today’s market conditions, manufacturers can no longer afford to overlook GTN when building and scaling a patient access strategy. Read this white paper to discover the ultimate playbook for aligning the internal teams that have a stake in your brand’s success - including marketing, sales, market access, and patient services - to balance maximum patient access with a sustainable GTN. #### In this white paper, you’ll learn: - Core elements, trends, and challenges of GTN growth for life sciences brands - Why GTN matters for your internal teams and aligning on shared vision of success - Key strategies to optimize patient access through a GTN lens - Success metrics to determine the efficacy of your access program on GTN #### Build a best-in-class access program Your GTN potential is only as strong as your access partner. We’ve helped dozens of brands optimize their commercialization plans, and we’d love to help your brand do the same. To learn more about how the PhilRx patient access platform can support your brand, book a meeting with our team. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Optimizing the Field Team for Improved Brand Outcomes Source: https://phil.us/optimizing-the-field-team-for-improved-brand-outcomes/ White Paper ## Optimizing the Field Team for Improved Brand Outcomes A playbook for life sciences manufacturers looking to educate, incentivize, and align their field teams to maximize access and gross-to-net Download PDF Life sciences manufacturers are facing significant access and affordability challenges. It’s time to evolve the traditional field model to a strategic approach that helps HCPs navigate patient access with ease. Read this white paper for innovative strategies and best practices to empower your field team to improve brand performance. #### In this white paper, you’ll learn about: - Evolving trends in UM and access barriers - Key strategies to optimize field teams for brand growth - Educating and aligning field teams to improve patient access - Tactics to drive brand adoption and loyalty with patients and providers #### Excel with an access partner Unlock your full brand potential with Phil. Discover how we can empower your field team to maximize access, coverage, and gross-to-net - connect with our team to learn more. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Optimizing your Drug Distribution Model Source: https://phil.us/optimizing-your-drug-distribution-model/ ## Optimizing your Drug Distribution Model The primary objective of a drug distribution model is to ensure patients receive the medications they need when they need them. A manufacturer’s strategy for getting their product from manufacturer to patient – effectively and efficiently – is crucial to the success of a therapy. The complexity of the distribution process has been exacerbated as a result of the pandemic. In addition to considering the range of physical, financial, and logistical challenges, life science companies would be wise to evaluate the needs and preferences of key stakeholders. Commercial teams can take the following steps to optimize their distribution process across a brand’s life cycle. ### Understand your distribution network options A pharmacy network is a group of pharmacies that a health plan contracts with to provide medication at a discounted price. The most impactful decision commercialization teams must make is whether to leverage an open or limited distribution pharmacy network, as this decision hinges on balancing market access with the cost of distribution. Here are the pros and cons of the two most common distribution networks: Limited distribution network: In a limited distribution network, a drug manufacturer contracts with only one or a very limited number of pharmacies. This option is commonly used for specialty therapies as it often presents a number of strategic advantages for brands. According to the 2019 State of Specialty Pharmacy Report, almost 85% of manufacturers manage some or all their products through this model. - Pros: More oversight over the distribution process and better medication adherence stemming from the high-toucher clinical care. This may also lower distribution costs. - Cons: Payer network coverage may be limited leading to lower coverage approval rates and over subsidization of medications to ensure patients can access Open distribution network: This is the traditional distribution option in which a pharmaceutical company makes its drug broadly accessible through a major wholesaler and various dispensing pharmacies, including retail, specialty, and mail order. A 2019 report by Deloitte estimates that 92% of total prescription drug sales go through wholesale distributors. - Pros: Larger geographical and health plan coverage, economies of scale, and reduced risk. - Cons: Less control over and visibility into distribution processes. Diluted patient experience and limited support for prior authorizations. ### Evaluate your distribution model for gaps The stakes are high for life science companies when it comes to establishing the “best fit” drug distribution model for a brand. Failure to develop an optimal distribution strategy can result in poor prescriber uptake, reduced speed-to-therapy, lower rx coverage approvals, prescription abandonment, poor medication adherence, inability to demonstrate value – and ultimately commercial failure. It’s not unusual for manufacturers to adjust distribution models as brands mature in the market. If your brand is in the middle of its lifecycle and underperforming, it may be time to evaluate your current distribution channel and consider transitioning to a different model that can help you achieve your business goals. The following six questions can help you identify gaps and weaknesses in your company’s distribution process: 1. Is your current distribution model enabling equal or better access to your brand vs. competitors? 2. Is your current process flexible, allowing your distribution to adapt to changes in the marketplace that may influence growth? 3. Does your return on investment justify the expenses you are incurring such as third-party logistics, transportation, limited distributor service fees, hub, and specialty pharmacy network? 4. Do you have visibility into channel data to inform critical commercial decisions? 5. Do you have the right level of pharmacy network coverage for the patient population size, geographical area, utilization patterns, and outcome goals? Does your pharmacy network have the contracts required to effectively drive coverage? ### Meet the needs of the four Ps A decade ago, a column in Reuters Events dubbed the customers that pharmaceutical companies should be focusing on as the “Four Ps”: prescribers, patients, payers, and pharmacies. The article made the point that “patients often have to make substantial co-payments and are increasingly informed and anxious to participate in the choice of their therapies, allotting them some of the prescriber and payer roles; Prescribers are suffering penalties for over-prescribing, making them payers to some degree; payers are involved in treatment guidelines, making them deciders... and so on.” The bottom line was that the four Ps determined the fate of pharma manufacturers’ drugs. Ensuring your distribution model meets the interconnected needs of these four key stakeholders is as relevant as ever today. Some relevant examples include: - Prescribers: Provide patient financial assistance programs, prior authorization support, and medication adherence support - Patients: Support medication access, adherence, education, financial assistance, and home delivery to deliver a seamless experience - Payers: Offer competitive pricing, contracting support, and outcomes reporting - Pharmacies: Support compliance management, patient education, reimbursement coordination, and billing assistance ### Streamline the product journey A seamless product journey is tantamount to optimizing your probability of success. All too often, life science companies find themselves entrenched in an overly complex and underperforming distribution model that lacks the flexibility to adapt to a changing marketplace and continue to meet the needs of stakeholders. Manufacturers can navigate distribution complexity by leveraging technology and data analytics to better connect patients to therapy. When life sciences companies partner with Phil, they gain access to a nationwide pharmacy network with 98% plan coverage that enables patients to receive their prescribed therapies quickly and effectively. Real-time insights ensure a consistent, predictable experience for providers and pharmacies across the network. This ensures that manufacturers are able to continue to grow their brands in a sustainable way. Read this case study to learn how one manufacturer partner changed its distribution model and transformed an underperforming mid-cycle specialty product into a successful brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Optimizing Your Field Team to Maximize Patient Access Source: https://phil.us/optimizing-your-field-team-to-maximize-patient-access-webinar/ ## On-Demand Webinar: Optimizing Your Field Team to Maximize Patient Access Loading... Field teams play a critical role in securing patient access. As a key player in your brand's success, your field team must command a mastery of your brand's strategic goals in order to effectively drive HCP loyalty and maximize patient access. In this webinar, you’ll learn how to design a modern field team model that mobilizes your field team to drive patient access with leaders from Phil and Real Endpoints. #### Watch this webinar to learn about: - Why the traditional sales model should evolve to include a focus on improving coverage and supporting adoption of your preferred channel - How to optimize your field team to unlock coverage through effective training, appropriate incentive alignment - The criticality of a data-driven approach that equips field teams with real-time insights on the prescription access journey #### Accelerate your field team transformation Ready to drive transformative outcomes through your field team? Discover our trusted approach for helping brands maximize access, coverage, and loyalty in our new white paper. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Partners in Patient Access: Drive Value for Your Biopharma Clients with PhilRx Source: https://phil.us/partners-in-patient-access-drive-value-for-your-biopharma-clients-with/ Lunch-and-Learn ## Partners in Patient Access: Drive Value for Your Biopharma Clients with PhilRx Jan 30, 2024 at 11am PST 90% of patients want to access healthcare through technology. We’ve designed an integrated, digital hub platform that helps specialty-lite and branded retail therapies maximize the metrics that matter - patient access and adherence, pharmacy coverage, and GTN. Join us for a conversational lunch-and-learn where we’ll offer a tour of the PhilRx digital hub platform and discuss how we partner with pharmaceutical consultants and agencies to drive brand success. #### Key takeaways from this session: - Our approach to breaking down barriers to access, coverage, and adherence - Core capabilities of the PhilRx digital hub platform for specialty lite brands - How we partner with biopharma partners to drive brand success together Join us for this 45-minute interactive discussion over coffee, and get your questions answered about how Phil can support your organization’s goals. The event window is now closed. Sign up below to be the first to know about our next event. ### Meet your Speakers Hear from industry specialists and product experts at Phil ###### Neil Dean Director, Product Management, Phil Inc. Neil is a results-oriented Product Management professional with experience leading teams to launch emerging products & services to support strategic objectives. ###### Scott Hughes VP Business Development, Phil Inc. Scott Hughes brings over 15 years of experience in business development in the life sciences industry with a proven track record of driving meaningful results for his clients. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Life Sciences Partners Program with PhilRx Source: https://phil.us/partners/ ### Accelerate Brand Success with PhilRx Drive growth for your life sciences clients with a digital hub partner trusted by industry-leading brands. ### Maximize Value for Your Biopharma Clients Help your biopharma clients overcome access, affordability, and adherence challenges. PhilRx offers a digital hub solution that is designed to improve access, coverage, and GTN. Loading... ### Hear from Happy PhilRx Patients #### Read reviews from our patient community Trustpilot ### Why Partner with Phil #### Modernize the Patient Access Journey Our platform allows brands to integrate an e-commerce-like journey for patients resulting in better access and adherence. #### Maximize Dispenses Covered by Payers We’ve built unique capabilities to ensure brands can capitalize on formulary placements to improve GTN. #### Enhance Insight into the Drug Channel Our platform generates comprehensive data that we translate into actionable insights to inform brand strategy. ### Partners We Work With #### Our solution can enhance your strategic objectives and offerings #### Expert Alliance Partners Life sciences consultants, marketing agencies, and full-service commercial organizations that offer support and advisory services to biopharma manufacturers. #### Technology Alliance Partners Health tech providers that offer solutions for biopharma manufacturers that are complementary to PhilRx, such as telehealth, adherence, or business intelligence. Get in Touch ### What Our Patients Say I wasn't able to afford a medicine that helped me ($1k+/month). Not through insurance, not online, not through manufacturer coupons. My doctor found it through Phil, I could continually purchase 3 months of this prescription at a time to receive a HUGE discount. It changed my life.” C Calra R. Patient The staff at PHIL are very customer-oriented, staying connected and providing guidance throughout the whole prescription process. They are knowledgeable in the service being provided and are friendly to engage with. The experience was very pleasant." R Ryan S. Patient I felt that my needs were being considered from the very beginning. That was so refreshing to me because it was out of the ordinary for a company to express such consideration, especially for a new customer like myself!" D Dawn M. Patient I wasn't able to afford a medicine that helped me ($1k+/month). Not through insurance, not online, not through manufacturer coupons. My doctor found it through Phil, I could continually purchase 3 months of this prescription at a time to receive a HUGE discount. It changed my life.” C Calra R. Patient The staff at PHIL are very customer-oriented, staying connected and providing guidance throughout the whole prescription process. They are knowledgeable in the service being provided and are friendly to engage with. The experience was very pleasant." R Ryan S. Patient I felt that my needs were being considered from the very beginning. That was so refreshing to me because it was out of the ordinary for a company to express such consideration, especially for a new customer like myself!" D Dawn M. Patient ### Partner Resources from Phil #### Webinar: Improving Access, Coverage, and GTN with a Digital Hub Discover the building blocks of a strong digital hub. Watch Now #### Blog Post: The Case for an Alternative Channel Strategy in 2024 and Beyond Learn how to strategically overcome common access challenges. Read More ### FAQs #### Is my information secure with PhilRx? #### Can I cancel my prescription? #### How much will my prescription cost? #### When will I receive my prescription? View FAQ ### Interested in Partnering? Get in touch with our team to learn how we can work together to help life sciences manufacturers achieve their full access potential. ### Get latest updates --- # Pharma Direct-To-Patient 2.0: From Experiment To Imperative Source: https://phil.us/pharma-direct-to-patient-2-0-from-experiment-to-imperative-2/ ## Pharma Direct-To-Patient 2.0: From Experiment To Imperative Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Is Your Pharma Product at Risk for a Mid-Life Cycle Crisis? Source: https://phil.us/pharma-product-mid-life-cycle-risk/ ## Is Your Pharma Product at Risk for a Mid-Life Cycle Crisis? Commercial launch is an expensive and risky endeavor, especially for small life science companies. According to a recent report, about half of all the drugs launched in the last fifteen years underperformed market expectations by more than 20%. In fact, over half failed to reach $250 million in peak U.S. sales. As the pharmaceutical market shifts toward value-based pricing, gaining market access and sustaining profitability have become more significant challenges. To mitigate the risk for stagnant growth post launch, it’s critical to understand and address the challenges of a product’s mid-life cycle. ### Pharma product mid-life cycle challenges The life cycle for a pharmaceutical product consists of a series of stages that begin at the drug’s conception and end when the brand is withdrawn from the market. There are three distinct stages of a pharmaceutical drug’s lifecycle: - The early or pre-marketing stage involves a pre-clinical discovery phase and three clinical trial phases required for FDA approval. It takes an average of ten years and over $2.6 billion for a manufacturer to move a drug from initial discovery into the marketplace. - The middle or commercialization stage is when a manufacturer can recoup the costs incurred during the early stage and start making a profit. Revenue generation for this stage is typically represented as a bell curve beginning with a product’s introduction to the market (launch) and moving through growth, maturity, and decline phases. This stage lasts about twelve to sixteen years for most brand-name drug manufacturers. - The late stage commences with a brand’s loss of market exclusivity as its patent expires and generic competition hits the market. The commercialization stage is fraught with risks that can negatively impact sales and market share growth, including increased competition, shrinking timeframe to hit peak sales, declining reimbursement, cost pressures, value-based pricing, and expiring patents. ### Small pharma hurdles Small life science companies are playing a larger role in the market. The share of drug launches by emerging companies more than tripled between 2006 and 2018, and in 2020, small biopharma companies originated and launched 40% of all new drugs. While small companies shine when it comes to innovating and developing novel treatments, they face more hurdles when it comes to commercializing their products. Unquestionably, the growing influence of payers, intense competition, and limited access to prescribers can make it difficult for life sciences companies with fewer resources to compete against big pharma. Recent findings from L.E.K. reveal that large companies have the advantages of size and scale when commercializing new products: - Average peak revenues are 50% higher for large pharma companies - Smaller biopharma companies are more likely to underperform market expectations - An even greater proportion of small manufacturers underperform in diseases driven by primary care channels ### Addressing mid-cycle commercialization challenges According to a Deloitte analysis, the top reasons product launches falter include limited market access, inadequate or incomplete understanding of the market and customer needs, poor product differentiation, and low prioritization and resource allocation. The report also notes that “if a product fails to meet launch year expectations, its probability of recovering revenue in subsequent years declines sharply.” Ensuring your product reaches its full commercialization potential requires innovative approaches to market intelligence and customer engagement to address the factors that lead to poor performance: - Seek early input to clarify the priorities and decision-making processes of payer drug formularies - Use post-launch data and services to differentiate your product from the competition - Invest in analytical tools to help you better understand key stakeholders and identify new market opportunities - Tap into real-world data insights to demonstrate value to payers - Leverage data analytics to boost market access - Employing data-driven, technology-based interventions to improve medication adherence - Consider the value of a commercialization partner ### Unlock the value of your product Superior clinical trial results do not guarantee commercial success. A robust clinical profile is no longer enough – you need a value proposition supported by real-time data and a go-to-market strategy that optimizes market access and patient and provider engagement. Read this case study to discover how a specialty brand overcame the mid-cycle challenge by adopting Phil’s commercialization platform. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Press Release: Phil and RedHill Biopharma Partner to Increase Access to Talicia® Source: https://phil.us/phil-and-redhill-biopharma-partner-to-increase-access-to-talicia-r/ ## Press Release: Phil and RedHill Biopharma Partner to Increase Access to Talicia® Talicia® is indicated for the treatment of Helicobacter pylori infection in adults Patients can now access RedHill’s Talicia® via the PhilRx Platform SAN FRANCISCO, Calif. – July 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform. The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting the moment the physician writes a prescription. HCPs can send an electronic prescription (eRx) for Talicia® to PhilRx directly from their electronic health record (EHR). The PhilRx Patient Access Platform simplifies the prior authorization process (PA) for physicians by allowing them to submit PAs for the medication with just one-click, streamlining the insurance coverage process for patients and increasing the chances of insurance reimbursement. The partnership between Phil and RedHill enables patients to receive Talicia® prescriptions quickly, easily, and affordably. Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records, and obtain assistance navigating insurance benefits. “RedHill is focused on advancing gastrointestinal and infectious diseases management through innovation, dedication, and a collective mindset of delivering on our promises. Our partnership with Phil will elevate our ability to eliminate access barriers to Talicia®,” said Ben Sloan, VP of Market Access at RedHill. “We are continually seeking ways to streamline prior authorizations and help patients navigate their insurance coverage, and the PhilRx platform will address and simplify these complex processes.” Talicia® is approved for the treatment of H. pylori, a common gastrointestinal (GI) bacterial infection that damages tissue in the stomach. While most people have H. pylori bacteria for years, many do not experience symptoms. In some cases, though, the infection can cause redness and swelling of the stomach lining. H. pylori is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. “H. pylori affects approximately 35% of adult Americans, and these conditions often go undiagnosed or untreated,” said Patrick Leary, Chief Commercial Officer, Phil. “Phil’s modern technology platform aims to improve the prescription process for life science companies, physicians, and patients – and working alongside RedHill to improve access to medication has the potential to transform their brand and positively impact patients.” Learn more about the PhilRx Patient Access Platform. #### About Talicia Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults. Talicia is the only low-dose rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address H. pylori's high resistance to other antibiotics. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based therapies and are a strong public health concern, as highlighted by the ACG, FDA and the World Health Organization (WHO) in recent years. In the pivotal Phase 3 study, Talicia demonstrated 84% eradication of H. pylori infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). Minimal to zero resistance to the key components of Talicia, was detected in RedHill's pivotal Phase 3 study. Further, in an analysis of data from this study, it was observed that subjects who were confirmed adherent to their therapy had response rates of 90.3% in the Talicia arm vs. 64.7% in the active comparator arm. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Talicia is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents which extend patent protection until 2034 with additional patents and applications pending and granted in various territories worldwide. ### TALICIA: IMPORTANT SAFETY INFORMATION Tell your healthcare provider about all of the medicines you take, including prescription or non-prescription medications or herbal supplements before starting Talicia. Talicia may affect the way other medicines work, and other medicines may affect the way Talicia works. Do not start any new medications while taking Talicia without first speaking with your healthcare provider. - You should not take Talicia if you are known to be sensitive to any of the components of Talicia (omeprazole, amoxicillin, rifabutin), penicillins, proton pump inhibitors or rifamycins. - You should not take Talicia if you are taking rilpivirine-containing products, delavirdine or voriconazole. Before you take Talicia, tell your healthcare provider about all of your medical conditions, including if you: - Are pregnant or plan to become pregnant. Talicia may harm your unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during your treatment with Talicia. - Have severe kidney disease or liver disease. When taking Talicia, do not crush or chew capsules. Do not take Talicia with alcohol. Call your healthcare provider immediately if while taking Talicia you develop: - New rash or other skin changes, muscle or joint pains, swelling of any area of the body, severe flu-like symptoms, difficulty breathing, fever, blood in your urine, increased or decreased urination, drowsiness, confusion, nausea, vomiting, ongoing stomach pain, bloody diarrhea, or if diarrhea continues after therapy is completed, weight gain or changes in your eyesight. What are the common side effects of Talicia? - The most common side effects of Talicia are diarrhea, headache, nausea, stomach pain, rash, indigestion, mouth or throat pain, vomiting, and vaginal yeast infection. Call your healthcare professional for medical advice about side effects. - Tell your healthcare provider if you experience tiredness, weakness, achiness, headaches, dizziness, depression, increased sensitivity to light, or pain when taking a deep breath. - Talicia may reduce the effectiveness of oral or other forms of hormonal birth-control. You should use an additional non-hormonal highly effective method of birth control while taking Talicia. - You may experience a brown-orange discoloration of your urine or tears while taking Talicia. - The information here is not comprehensive. Talk to your healthcare provider to learn more. ### APPROVED USE FOR TALICIA TALICIA is a prescription medicine for the treatment of a bacteria, Helicobacter pylori (H. pylori) in adults. Click here for the full Prescribing Information for TALICIA. You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at 1-833-ADRHILL (1-833-237-4455) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. #### About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of travelers' diarrhea in adults. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. Government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease. More information about the Company is available at www.redhillbio.com / twitter.com/RedHillBio. #### About Phil, Inc. Phil, Inc. revolutionizes life science product commercialization with technology to improve prescription access. Our patient access platform removes barriers to medication access and ensures patients can seamlessly start and adhere to therapy. Providing end-to-end visibility into the prescription life cycle, we unlock coverage and maximize reimbursement for brands while integrating into the lives and workflows of patients and providers. We combine a Silicon Valley mindset and deep pharma expertise with data insights and software-driven platform customization to improve provider experience and elevate brand value. #### Media Contacts Janine Bogris Evoke Canale for Phil Janine.Bogris@canalecomm.com Adi Frish RedHill Biopharma adi@redhillbio.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Source: https://phil.us/phil-and-sprout-pharmaceuticals-expand-affordable-direct-to-patient-program/ ## PHIL and Sprout Pharmaceuticals Expand Affordable Direct-to-Patient Program Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Press Release: Phil and Teva Pharmaceuticals Launch New Program to Improve Access Source: https://phil.us/phil-and-teva-pharmaceuticals-launch-new-program-to-improve-access-to-the/ ## Press Release: Phil and Teva Pharmaceuticals Launch New Program to Improve Access Loading... SAN FRANCISCO, Calif. – June 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma management. The goal of Phil and Teva Pharmaceutical’s partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably. Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records and obtain assistance navigating insurance benefits. The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting when the physician writes the prescription. Physicians can select the PhilRx Patient Access Platform directly from an electronic medical record (EMR) to submit a prescription for a Digihaler product. Then, physicians can determine if a prescription was filled and have the option to develop a personalized care plan based on the data provided. “As a global leader in generics and biopharmaceuticals, we are continually striving to improve and innovate around care delivery to help patients access their medication simply and affordably,” said Manny Montalvo, SVP, Digital Health & Innovation, Teva Pharmaceuticals. “With our integrated inhaler we are always looking for ways to enhance consumer experience as technology evolves, and Phil’s technology solution will help us build upon our efforts in a significant and meaningful way.” “There is incredible opportunity for pharma brands and physicians to better align outcomes, and Phil’s technology solution is patient-centric while seamlessly integrating into users’ workflows,” said Deepak Thomas, Founder and Chief Executive Officer, Phil. “We are pleased to work alongside Teva Pharmaceuticals to better meet consumers where they are in the health journey and improve access to medication.” Learn more about the PhilRx Patient Access Platform. ProAir Digihaler Indications and Usage ProAir Digihaler (albuterol sulfate) Inhalation Powder is a prescription medicine used in people ≥4 years of age for the treatment or prevention of bronchospasm in people who have reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. Important Safety Information About ProAir Digihaler - Contraindications: ProAir Digihaler (albuterol sulfate) Inhalation Powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose - Paradoxical Bronchospasm: ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs - Deterioration of Asthma: Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids - Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids - Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension - Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma - Hypersensitivity Reactions including Anaphylaxis: Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler - Coexisting Conditions: ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines - Hypokalemia: As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation - Most common adverse reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting - Drug Interactions: Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers Diuretics: Caution is advised in the coadministration of beta-agonists with non- potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy. AirDuo Digihaler Indications and Usage AirDuo Digihaler is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older. AirDuo Digihaler is not used to relieve sudden breathing problems from asthma and won't replace a rescue inhaler. AirDuo Digihaler contains a built-in electronic module that records and stores information about inhaler events. AirDuo Digihaler may be used with, and transmits information to, a mobile App. AirDuo Digihaler does not need to be connected to the app in order for you to take your medicine Important Safety Information About AirDuo Digihaler AirDuo Digihaler contains salmeterol. Long-acting beta 2 -agonist (LABA) medicines such as salmeterol when used alone increase the risk of hospitalizations and death from asthma problems. AirDuo Digihaler contains an inhaled corticosteroid (ICS) and a LABA. When an ICS and a LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems. - Do not use AirDuo Digihaler to treat sudden breathing problems from asthma. Always have a rescue inhaler with you to treat sudden symptoms. - Do not use AirDuo Digihaler if you have a severe allergy to milk proteins or if you are allergic to any of the ingredients in the product. Ask your healthcare provider if you are not sure. - Do not use AirDuo Digihaler more often than prescribed. - Do not take AirDuo Digihaler with other medicines that contain a LABA for any reason. - Tell your healthcare provider about all the medicines you take and about all of your health conditions. AirDuo Digihaler can cause serious side effects, including: - Fungal infection in your mouth or throat (thrush). Rinse your mouth with water without swallowing after using AirDuo Digihaler to help reduce your chance of getting thrush. - Weakened immune system and increased chance of getting infections (immunosuppression). You should avoid exposure to chickenpox and measles, and, if exposed, tell your healthcare provider right away. Worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or herpes infection of the eye (ocular herpes simplex) may occur. - Reduced adrenal function. This can happen when you stop taking an oral corticosteroid (such as prednisone) and start taking a medicine containing an inhaled corticosteroid (such as AirDuo Digihaler). During this transition period, when your body is under stress such as from fever, trauma (such as a car accident), infection, or surgery, adrenal insufficiency can get worse and may cause death. Symptoms of adrenal insufficiency include: feeling tired lack of energy weakness nausea and vomiting low blood pressure Sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine, stop using AirDuo Digihaler and call your healthcare provider right away. Serious allergic reactions. Stop using AirDuo Digihaler and call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction: rash hives swelling of your face, mouth, and tongue breathing problems Effects on heart - increased blood pressure - a fast or irregular heartbeat - chest pain - Effects on nervous system - tremor - nervousness - Bone thinning or weakness (osteoporosis) - Slowed growth in children. A child's growth should be checked often. - Eye problems including glaucoma and cataracts. You should have regular eye exams while using AirDuo Digihaler. - Changes in laboratory blood values (sugar, potassium, certain types of white blood cells) Common side effects of AirDuo Digihaler include: - Infection of nose and throat (nasopharyngitis) - thrush in your mouth or throat. Rinse your mouth with water without swallowing after use to help prevent this. - back pain - headache - cough These are not all the possible side effects of AirDuo Digihaler. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please see full Prescribing Information for AirDuo Digihaler. Armon Air Digihaler Indications and Usage ArmonAir® Digihaler® (fluticasone propionate) inhalation powder is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. Important Safety Information for Armon Air Digihaler - Contraindications: ArmonAir Digihaler is contraindicated in: Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures Patients with known severe hypersensitivity to milk proteins or any ingredients of ArmonAir Digihaler Deterioration of Disease and Acute Episodes: ArmonAir Digihaler is not indicated for the relief of acute bronchospasm. An inhaled, short-acting beta2-agonist, not ArmonAir Digihaler, should be used to relieve acute symptoms such as shortness of breath. Oropharyngeal Candidiasis has occurred in patients treated with ArmonAir Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation Immunosuppression and Risks of Infections: Patients who use corticosteroids, such as found in ArmonAir Digihaler are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use with caution in patients with the above because of the potential for worsening of these infections Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS. Taper patients slowly from systemic corticosteroids if transferring to ArmonAir Digihaler. Hypercorticism and Adrenal Suppression may occur with high doses of ICS, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such changes occur, discontinue ArmonAir Digihaler slowly. Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors: The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, ketoconazole) with ArmonAir Digihaler is not recommended because increased systemic corticosteroid adverse effects may occur. - Paradoxical Bronchospasm and Upper Airway Symptoms: Paradoxical bronchospasm may occur. if bronchospasm occurs treat immediately with an inhaled, short-acting bronchodilator discontinue ArmonAir Digihaler and institute alternative therapy - Hypersensitivity Reactions, Including Anaphylaxis: Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ArmonAir Digihaler. Discontinue ArmonAir Digihaler if such reactions occur - Reduction in Bone Mineral Density (BMD): Decreases in BMD have been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care when using ArmonAir Digihaler - Effect on Growth: ICS may cause a reduction in growth velocity, Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients receiving ArmonAir Digihaler. - Glaucoma and Cataracts: Long-term use of ICS, including fluticasone propionate, a component of ArmonAir Digihaler, may increase the risk for cataracts or glaucoma. Regular eye exams should be considered - Eosinophilic Conditions and Churg-Strauss Syndrome: Systemic eosinophilic conditions, such as Churg- Strauss syndrome, may occur when using ArmonAir Digihaler. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy - Adverse Reactions with ArmonAir Digihaler: Most common adverse reactions (greater than or equal to 3%) are: upper respiratory tract infection, nasopharyngitis, oral candidiasis, headache, and cough Please see full Prescribing Information for AirDuo Digihaler. About Phil, Inc. Phil, Inc. revolutionizes life science product commercialization with technology to improve prescription access. Our patient access platform removes barriers to medication access and ensures patients can seamlessly start and adhere to therapy. Providing end-to-end visibility into the prescription life cycle, we unlock coverage and maximize reimbursement for brands while integrating into the lives and workflows of patients and providers. We combine a Silicon Valley mindset and deep pharma expertise with data insights and software-driven platform customization to create exponentially better patient outcomes, improve provider experience and elevate brand value. Learn more at https://phil.us. About Teva Pharmaceuticals Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative medicines research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products. Learn more at www.tevapharm.com. About Digihaler® Asthma is caused by chronic inflammation of the lung airways and causes coughing, chest tightness, wheezing and shortness of breath. According to the Centers for Disease Control and Prevention (CDC), over 25 million Americans have asthma. Clinical data demonstrate the impact of the Digihaler System on asthma management resulting in a reduction in SABA use and increase in SABA-free days. The objective data support more timely patient-physician interactions versus standard of care. Patients may connect their inhaler to an app, which records inhalation data, and allows patients to securely share the data with a physician or care team to establish more personalized treatment plans. Media Contact: Katie Beach, Evoke Canale for Phil, Katherine.Beach@canalecomm.com PR Contact: Kelley Dougherty,(973) 832-2810, and Yonatan Beker, (973) 264-7378, Teva Pharmaceuticals Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa Source: https://phil.us/phil-announces-partnership-with-impel-neuropharma-in-support-of-trudhesa/ ## Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil Inc Adds Additional Duchesnay USA Women’s Healthcare Product to PhilRx Patient Access Platform, Shares initial Access Improvements for Bonjesta® (doxylamine succinate and pyridoxine hydrochloride) Source: https://phil.us/phil-inc-adds-additional-duchesnay-usa-womens-healthcare-product-to-philrx/ ## Phil Inc Adds Additional Duchesnay USA Women’s Healthcare Product to PhilRx Patient Access Platform, Shares initial Access Improvements for Bonjesta® (doxylamine succinate and pyridoxine hydrochloride) In 2018, after launching Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), Duchesnay USA utilized a combination of retail and specialty pharmacies to support patient access to the medication. This channel strategy experienced challenges, particularly around patient experience and prescription coverage rates. In 2022, the Duchesnay team engaged Phil Inc looking for ways to address their patient experience and access challenges: - Shipping time: Patients experienced delays to therapy after paying their out of pocket expenses. - Low insurance utilization: only 5-10% of scripts were being covered by insurance - Billing issues: inaccurate billing resulted in overcharges and double billing After an extensive search, Duchesnay USA decided to partner with Phil Inc and launched in January, 2023. Following launch, patients were seamlessly transferred from their prior specialty pharmacy to the PhilRx Patient Access Platform where they saw marked improvements in patient access and experience in just a few months. - Insurance Coverage: 4x increase in the percentage of dispenses covered by payers - Speed to Therapy: scripts shipping in less than 1 day making it easier to get started on therapy On the back of the Bonjesta® program success, Duchesnay USA is adding an additional therapy onto the PhilRx Platform, Osphena® (ospemifene). Osphena® is a prescription oral pill that treats moderate to severe painful intercourse and/or moderate to severe vaginal dryness, both symptoms of changes in the vagina due to menopause. Osphena® has a BOXED WARNING regarding Endometrial Cancer and Cardiovascular Disorders. Please keep reading below for Important Safety Information. By adding Osphena® to the PhilRx platform, Duchesnay USA seeks to improve patient access and adherence to the medication while improving the patient experience, and increasing the percentage of prescriptions covered by insurance. Indication: What is Osphena®? Osphena is a prescription oral pill that treats moderate to severe painful intercourse and/or moderate to severe vaginal dryness, both symptoms of changes in your vagina, due to menopause. Most Important Information you should know about Osphena® WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR DISORDERS Osphena® works like estrogen in the lining of the uterus (endometrium), but can work differently in other parts of the body. Taking estrogen alone or Osphena® may increase your chance for getting cancer of the lining of the uterus. Vaginal bleeding after menopause may be a warning sign of cancer of the lining of the uterus. Your healthcare provider should check any unusual vaginal bleeding to find out the cause, so tell him or her right away if this happens while you are using Osphena®. Osphena® may increase your chances of having a stroke or blood clots. You and your healthcare provider should talk regularly about whether you still need treatment with Osphena®. Call your healthcare provider right away if you have unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, and pains in your chest or legs with or without shortness of breath, weakness and fatigue. Who should not take OSPHENA? Osphena® should not be used if you have unusual vaginal bleeding, have had certain types of cancers, have or have had blood clots, had a stroke or heart attack, have severe liver problems, are allergic to Osphena® or any of its ingredients, or think you may be pregnant. Tell your healthcare provider if you are going to have surgery or will be on bed rest. POSSIBLE SIDE EFFECTS Serious but less common side effects can include: stroke, blood clots and cancer of the lining of the uterus. Less serious, but common side effects include: hot flushes or flashes, vaginal discharge, muscle spasms, headache, excessive sweating (hyperhidrosis), heavy vaginal bleeding (vaginal hemorrhage), night sweats Tell your healthcare provider about all of the medicines and supplements you take, as some medicines may affect how Osphena® works. Osphena® may also affect how other medicines work. Duchesnay USA encourages you to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please read accompanying Patient Information for Osphena®(ospemifene) tablets, including Boxed Warning in the U.S. Full Prescribing Information. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil Inc. Adds Duchesnay USA’s Women’s Healthcare Product to Its Patient Access Platform Source: https://phil.us/phil-inc-adds-duchesnay-usas-womens-healthcare-product-to-its-patient-access/ ## Phil Inc. Adds Duchesnay USA’s Women’s Healthcare Product to Its Patient Access Platform SAN FRANCISCO--(BUSINESS WIRE)--Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced that Duchesnay USA’s Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments, is now available to be prescribed via its patient access platform. It is not known if Bonjesta® is safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. The most common side effect of Bonjesta® is drowsiness.Phil’s customizable platform helps patients receive and refill medicines quickly, easily and affordably while giving life science companies unprecedented end-to-end visibility into the prescription life cycle. The platform offers a one-click system to submit prior authorizations and integrates seamlessly with technology systems already in place. Using the Phil platform, patients can easily access their prescription records, as well as receive assistance navigating insurance benefits.“Phil can help streamline the prior authorization process for prescribers, which can help increase pull-through rates. By investing in a technology solution like Phil’s patient access platform, it is possible to simplify a complex prescription ecosystem and deliver positive outcomes to all stakeholders,” said Tanya Carro, Executive Vice President & General Manager, U.S. Operations, Duchesnay USA. “We developed Phil’s technology platform to improve patients’ ability to navigate the complex systems related to prescription medications,” said Deepak Thomas, Founder and Chief Executive Officer at Phil, Inc. “We are proud to work with Duchesnay USA, a leading pharmaceutical company specializing in women’s health, as aligning our efforts to offer providers and patients a streamlined experience can lead to reduced costs and improved health outcomes.”Learn more about Phil’s patient access platform. About Bonjesta® is a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments. It is not known if BONJESTA® is safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. Women with this condition may need to be hospitalized. IMPORTANT SAFETY INFORMATION BONJESTA® is intended for use in pregnant women. It is not known if BONJESTA® is safe and effective in children under 18 years of age. Do not take BONJESTA® if you: - are allergic to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any of the ingredients in BONJESTA®. Please refer to the Patient Information leaflet for the complete list of ingredients; - take monoamine oxidase inhibitors (MAOIs). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including Marplan, Nardil, Emsam, Eldepryl, Zelapar, and Parnate. Before taking BONJESTA®, tell your healthcare provider about all of your medical conditions, including if you: have asthma; have eye problems called increased intraocular pressure or narrow angle glaucoma; have a stomach problem called stenosing peptic ulcer or pyloroduodenal obstruction; have a bladder problem called urinary bladder-neck obstruction; are breastfeeding or plan to breastfeed. BONJESTA® can pass into your breast milk and may harm your baby. You should not breastfeed while using BONJESTA®.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should you take BONJESTA®? - Talk to your healthcare provider about how much and when to take BONJESTA®. - Take BONJESTA® everyday as prescribed by your healthcare provider. Do not stop taking BONJESTA® without talking to your healthcare provider first. - Do not take more than 2 tablets (1 in the morning and 1 at bedtime) each day. - Take BONJESTA® tablets whole on an empty stomach with a glass of water. - If you take too much BONJESTA® (overdose), you may have the following symptoms: restlessness, dry mouth, the pupils of your eyes become larger (dilated), sleepiness, dizziness, confusion, fast heart rate, seizures, muscle pain or weakness, urination changes and build-up of fluid in the body. If you have these symptoms and they are severe, they may lead to death. If you take too much BONJESTA®, call your poison control center at 1-800-222-1222. ### What are the possible side effects of BONJESTA®? - The most common side effect of BONJESTA® is drowsiness. - Do not drive, operate heavy machinery, or do other activities that need your full attention unless your healthcare provider says that you may do so. - Do not drink alcohol, or take other CNS depressants such as cough and cold medicines, certain pain medicines, and medicines that help you sleep while you take BONJESTA®. Severe drowsiness can happen or become worse causing falls or accidents. BONJESTA® may cause an incorrect positive result for urine drug screening tests for methadone, opiates and PCP. These are not all the possible side effects of BONJESTA®. Call your doctor for medical advice about side effects.Keep BONJESTA® and all medicines out of the reach of children. Carefully read the storage instruction as detailed in the BONJESTA® Patient Information leaflet.Duchesnay USA encourages you to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. About Duchesnay USA is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay USA also commercializes a broad portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information, visit duchesnayusa.com. About Phil, Inc. revolutionizes life science product commercialization with technology to improve prescription access. Our patient access platform removes barriers to medication access and ensures patients can seamlessly start and adhere to therapy. Providing end-to-end visibility into the prescription life cycle, we unlock coverage and maximize reimbursement for brands while integrating into the lives and workflows of patients and providers. We combine a Silicon Valley mindset and deep pharma expertise with data insights and software-driven platform customization to create exponentially better patient outcomes, improve provider experience and elevate brand value. ### Contacts Katie Beach Evoke Canale for Phil Katherine.Beach@canalecomm.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil, Inc. Forges Strategic Partnership with Syneos Health Source: https://phil.us/phil-inc-forges-strategic-partnership-with-syneos-health/ ## Phil, Inc. Forges Strategic Partnership with Syneos Health SAN FRANCISCO, Calif. – October 25, 2022 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization with technology to improve patient prescription access, today announced an exclusive partnership with Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization. Through the strategic partnership, Phil will serve as Syneos Health’s hub partner, creating an end-to-end commercialization solution for life sciences organizations to ensure patients can seamlessly start and adhere to therapy and receive and refill medicines quickly, easily and affordably. Under the terms of the agreement, Phil will exclusively provide Syneos Health with HUB-related services. Syneos Health will serve as Phil’s preferred provider for outsourced services, including field teams, engagement center, market access, field reimbursement, nurse navigator, and other services. “We’re honored to partner with Syneos Health to modernize patient access to prescriptions with a solution that addresses the pain points of providers, insurers and biopharma companies,” said Deepak Thomas, founder and chief executive officer at Phil, Inc. “Our combined solution provides hands-on, high touch service, aided by the best Silicon Valley technology and tools, to remove friction from every step of the prescription process. By removing barriers to accessing medication, we can help patients receive and adhere to the prescriptions they need and create exponentially better health outcomes.” “Syneos Health is excited to collaborate with Phil to transform the patient experience for prescription management,” said Deanne Melloy, Chief Commercial Officer, Deployment Solutions, Syneos Health. “Leveraging our deep commercialization expertise and market knowledge, coupled with Phil’s proven platform, we can offer customers a new service that ensures patients get the therapeutics prescribed by their care providers, creating an end-to-end patient services unit that complements our long-standing offerings. ### About Syneos Health Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities. We bring together more than 29,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast. ### About Phil, Inc. Phil, Inc. revolutionizes life science product commercialization with technology to improve prescription access. Our patient access platform removes barriers to medication access and ensures patients can seamlessly start and adhere to therapy. Providing end-to-end visibility into the prescription life cycle, we unlock coverage and maximize reimbursement for brands while integrating into the lives and workflows of patients and providers. We combine a Silicon Valley mindset and deep pharma expertise with data insights and software-driven platform customization to create exponentially better patient outcomes, improve provider experience and elevate brand value. Contact Katie Beach Evoke Canale Katherine.Beach@canalecomm.com ### Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil Patient Access Platform Capabilities Support Move to Digital Prescription Models Source: https://phil.us/phil-patient-access-platform-capabilities-support-move-to-digital/ ## Phil Patient Access Platform Capabilities Support Move to Digital Prescription Models SAN FRANCISCO, Calif. – November 7, 2022 – Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced its technology solution now offers expanded functionality for companies developing prescription digital therapeutics (PDTs). Using Phil’s platform, digital health companies can simplify the healthcare journey for patients with their prescription, manage both pharmacy and medical benefits processes and improve access to prescriptions. PDTs deliver medical interventions that physicians prescribe directly to patients using evidence-based, clinically evaluated software intended to treat and manage a broad spectrum of diseases and disorders. At times, insurance plans don’t cover PDTs as a pharmacy benefit, making access to these innovative therapies difficult through traditional pharmacies and hubs. Unlike traditional prescription access tools, the Phil platform manages both pharmacy and medical benefits processes. Over time, the software learns, helping companies evolve business rules and provides data insights about the process, to ultimately ensure that patients have access to the PDTs that they were prescribed. “It is encouraging to work with a technology company like Phil to help deliver our treatment, Luminopia, to patients in need, as the company’s expertise in providing patients easy access to digital solutions helps to ensure an improved healthcare experience for patients and caregivers,” said Scott Xiao, Co-Founder and Chief Executive Officer of Luminopia, Inc. “As we see the industry evolve further with the development and coverage of PDTs, we are pleased to have even more opportunities to meet patients where they are at and leverage such an innovative platform to achieve our goals.” Referring to Regulora, metaMe Health’s PDT treatment for IBS pain, Chief Executive Officer Tim Rudolphi said, “Phil has made the prescription fulfillment process simple for us, but more importantly simple for our prescribers and their patients. We’re developing innovative prescription digital therapeutics to combat many common chronic conditions, putting the power right in the hands of patients -- and Phil’s digital-first approach supports patients in the very same way.” “Consumers expect a streamlined healthcare experience, much as they have grown accustomed to the experiences they have in travel and e-commerce. Especially as healthcare delivery methods have evolved due to the COVID-19 pandemic, more and more patients are seeking opportunities to connect virtually with providers, and we must also ensure that access to PDTs are convenient and affordable,” said Deepak Thomas, Founder and Chief Executive Officer at Phil, Inc. “We are pioneers in PDT commercialization, offering brands an innovative technology driven platform to prescribe, and helping to usher in new care delivery and prescription models.” Learn more about Phil’s patient access platform. About Phil, Inc. Phil, Inc. revolutionizes life science product commercialization with technology to improve prescription access. Our patient access platform removes barriers to medication access and ensures patients can seamlessly start and adhere to therapy. Providing end-to-end visibility into the prescription life cycle, we unlock coverage and maximize reimbursement for brands while integrating into the lives and workflows of patients and providers. We combine a Silicon Valley mindset and deep pharma expertise with data insights and software-driven platform customization to create exponentially better patient outcomes, improve provider experience and elevate brand value. Contact Katie Beach Evoke Canale for Phil Katherine.Beach@canalecomm.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Designing a Transformative Direct-to-Patient Program to Drive Brand Growth Source: https://phil.us/philrx-designs-transformative-telemedicine-channel-for-womens-health-brand/ Case Study ## Designing a Transformative Direct-to-Patient Program to Drive Brand Growth Read the success story behind an innovative women’s health introducing a successful direct-to-patient program with PHIL Download PDF A women’s health brand was on a mission to introduce a Direct-to-Patient program. Before partnering with PHIL, the brand identified an opportunity to improve access for their patient population through a digital channel. They were in search of a strategic partner that could drive coverage and access for patients, while providing data-driven insight across the prescription journey. PHIL and the women’s health brand worked together to achieve: - 91% patient enrollment - 2x pull through vs. retail - 5x refill adherence vs. retail #### Ready to elevate your access experience? PHIL is ready to serve as your strategic partner in brand success. Book a demo for a personalized tour of the PHIL patient access platform today. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Addressing Two Critical Issues: Prescriber Adoption & Patient Adherence Source: https://phil.us/philrx-drives-high-adoption-for-ophthalmology-brand/ Case Study ## Addressing Two Critical Issues: Prescriber Adoption & Patient Adherence Read the success story behind a trailblazing ophthalmology brand launching a retail plus distribution strategy that accelerated adoption with PhilRx Download PDF As an innovative ophthalmology brand was preparing to launch, they carefully prepared their channel strategy. The brand recognized that between fierce competition and a lagging retail channel, they needed a strategic partner that could help them maximize payer awareness, provider adoption, and patient access. #### PHIL and the ophthalmology brand worked together to achieve: - 90% patient enrollment - 5x covered dispenses vs. retail - 6x refill adherence vs. retail #### Ready to maximize brand adoption? PHIL is ready to serve as your strategic partner in brand success. Book a demo for a personalized tour of the PHIL patient access platform today. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Driving Adoption in a Crowded Market by Removing Access Barriers Source: https://phil.us/philrx-launches-robust-channel-strategy-for-specialty-lite-migraine-brand/ Case Study ## Driving Adoption in a Crowded Market by Removing Access Barriers Read the success story behind a novel migraine brand launching a robust channel program to deliver a modern patient access experience with PhilRx Download PDF As a speciality-lite migraine brand was preparing to launch, they began to develop a robust channel strategy. Before partnering with PHIL, the brand recognized that a successful launch in a highly competitive market would require an innovative approach to patient access. They needed a strategic partner that could help them deliver a modern patient experience while maximizing covered dispenses and provider loyalty. #### PHIL and the migraine brand worked together to achieve: - 90% patient enrollment - 1.5x higher first fills vs. retail - 3x refill adherence vs. retail #### Ready to maximize patient access? PHIL is ready to serve as your strategic partner in brand success. Book a demo for a personalized tour of the PHIL patient access platform today. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Overcoming Low Enrollment and High Abandonment Rates Source: https://phil.us/philrx-unlocks-90-dispense-coverage-for-womens-health-brand/ Case Study ## Overcoming Low Enrollment and High Abandonment Rates Read the success story behind a speciality-lite brand offering a seamless patient access experienced that skyrocketed coverage and GTN with PhilRx Download PDF An innovative specialty-lite women’s health brand was facing GTN challenges and needed to pivot to a multi-channel access strategy. Before partnering with PHIL, the brand was experiencing low program enrollment and poor market access conversions. They were in search of a strategic partner that could implement a seamless patient and HCP experience that would translate into more covered dispenses and GTN growth. #### PHIL and the women’s health brand worked together to achieve: - 90% patient enrollment - 4x lift in covered dispenses - 16% increase in GTN #### Ready to maximize brand growth? PHIL is ready to serve as your strategic partner in brand success. Book a demo for a personalized tour of the PHIL patient access platform today. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Edenbridge Pharmaceuticals Announces the Launch of DARTISLA ODT Source: https://phil.us/press/press/edenbridge-pharmaceuticals-announces-the-launch-of-dartisla-odt/ ## Edenbridge Pharmaceuticals Announces the Launch of DARTISLA ODT PARSIPPANY, N.J.–(BUSINESS WIRE)–Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, the commercialization partner and eHub for DARTISLA ODT, as well as in retail pharmacies throughout the country. To ensure access to patients in need, Edenbridge is sponsoring the DARTISLA ODT Copay Program, which allows eligible patients to obtain the product for as little as $0 when filled through Phil or $20 when filled at other pharmacies. “DARTISLA ODT is the first and only FDA-approved orally disintegrating tablet of glycopyrrolate, and we are excited to introduce this novel formulation of glycopyrrolate to patients and healthcare providers,” noted Daniel G. Worley Jr., Edenbridge’s Vice President of Business Development and General Counsel. “Further, Edenbridge is committed to ensuring patient access to this product, and we are pleased to be sponsoring the DARTISLA ODT Copay Program to facilitate getting DARTISLA ODT into the hands of people that need it most.” “Phil is proud to support Edenbridge’s commitment to providing broad access to this innovative therapy by simplifying the patient onboarding process allowing affordable, fast, broad-based distribution of Dartisla ODT,” said Deepak Thomas, Founder and CEO of Phil. The U.S. Food and Drug Administration (FDA) approved Dartisla ODT for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer on December 16, 2021. DARTISLA ODT is manufactured by Catalent (NYSE: CTLT) using their proprietary Zydis® orally disintegrating tablet delivery technology to create a freeze-dried tablet that disperses almost instantly in the mouth without water. For more information on the DARTISLA ODT Copay Program and available savings offers, visit www.dartisla.com/copay-card. Patients receiving the 2 mg dosage strength of another oral tablet dosage form of glycopyrrolate may be switched to the 1.7 mg dosage strength of DARTISLA ODT. DARTISLA ODT is not recommended for patients initiating treatment or receiving maintenance treatment with a lower dosage strength of another oral glycopyrrolate product (e.g., tablet strength of 1 mg). Patients who are at risk for anticholinergic toxicity due to various underlying medical conditions or who have hypersensitivity to glycopyrrolate or the inactive ingredients should not take DARTISLA ODT. Adverse reactions include blurred vision, drowsiness, decreased sweating, flushing, vomiting, constipation, dry mouth, tachycardia, and urinary retention. Please visit www.dartisla.com and consult the full prescribing information for additional important information. About Edenbridge Edenbridge is a specialty pharmaceutical company focused on identifying, developing, and marketing prescription pharmaceutical products. Edenbridge’s goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable, and accessible alternatives in the healthcare market. Edenbridge’s approach is to work with best-in-class and like-minded industry partners to deliver its products to physicians and patients everywhere. Founded in 2008, Edenbridge launched its first product in February 2010 and has sold its commercial products through every major channel of the U.S. prescription pharmaceutical supply chain. In addition, Edenbridge has a robust product development pipeline that includes 505(b)(2) NDAs, ANDAs, and foreign filings. For more information, visit www.edenbridgepharma.com or contact the Company directly at info@edenbridgepharma.com. About Phil Phil is a commercialization partner for innovative life sciences companies, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options. Through its digital stakeholder experiences, patient access services, market access solutions and distribution models, pharma manufacturers can provide patients with more affordable and timely therapy access. For more information on Phil, visit phil.us. ##### Contacts Edenbridge Contact Daniel G. Worley Jr. Vice President, Business Development & General Counsel 201-479-1336 dworley@edenbridgepharma.com Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole) Source: https://phil.us/press/press/lupin-announces-partnership-with-phil-inc-in-support-of-solosecr-secnidazole/ ## Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole) SOMERSET, N.J., Feb. 1, 2021 (GLOBE NEWSWIRE) – Lupin Pharmaceuticals Inc., announced today a partnership with Phil, Inc., which helps deliver cost-effective next-generation patient access solutions for patients prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet. [1] In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021. “Phil offers a systemic solution for a systemic problem,” Deepak Thomas, founder and CEO of Phil, Inc, said in a statement. “Because the underlying challenges in this space are experienced not just at the pharmacy but may extend to other stakeholders including prescribers and manufacturers, Phil aims to address these issues in their entirety.” Solosec was designed to be a single dose treatment for patients with BV. [1] Because Solosec is taken in one oral dose, it may be preferred by people who do not want to use a vaginal cream or take pills over multiple days. [1-3] Studies reveal that the longer and more complex a drug regimen is, the more it may lead to poor adherence and treatment failure. [4,5] The single dose of Solosec stays in the body and continues to treat BV for four days without an alcohol restriction; in vitro drug alcohol studies show Solosec does not inhibit the enzyme that metabolizes alcohol. [1] Solosec was shown not to interact with a common oral contraceptive: combination ethinyl estradiol and norethindrone. [1] “With the addition of Solosec to the Phil platform, we are able to provide a convenient channel for physicians to prescribe Solosec and enhance the patient experience,” said Jon Stelzmiller, President - Specialty, Lupin Pharmaceuticals, Inc. “We are proud that Lupin has been at the forefront of advancing affordable healthcare for women globally for decades, and we are committed to helping prevent and manage women’s health conditions, including BV.” ### Indication SOLOSEC® (secnidazole) 2 g oral granules is a 5-nitroimidazole antimicrobial agent indicated for the treatment of bacterial vaginosis in adult women. ### Dosage and Administration SOLOSEC is a single-dose therapy for oral use. The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt or pudding and consumed once within 30 minutes without chewing or crunching the granules. SOLOSEC is not intended to be dissolved in any liquid. ### Important Safety Information - SOLOSEC is contraindicated in patients with a history of hypersensitivity to secnidazole, other ingredients of the formulation, or other nitroimidazole derivatives. - Vulvo-vaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent. - Potential risk of carcinogenicity is unknown and has not been studied. Carcinogenicity has been seen in rodents chronically treated with nitroimidazole derivatives, which are structurally related to secnidazole. Chronic use should be avoided. - Breastfeeding is not recommended. Patients should discontinue breastfeeding for 96 hours after administration of SOLOSEC. - Most common adverse reactions observed in clinical trials (incidence ≥2%) were vulvovaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus. To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please click here for full Prescribing information ### About Lupin Pharmaceuticals, Inc. Lupin Pharmaceuticals, Inc. is the U.S. based wholly owned subsidiary of Lupin Limited, and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions. Together, all Lupin-owned entities combine to make up the 8th largest generic pharmaceutical company in the world by revenue size. Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality medications across many treatment areas. Lupin Pharmaceuticals Inc.’s branded pharmaceuticals division provides products designed to help prevent and manage women’s health conditions. ©2021 Lupin Pharmaceuticals, Inc. All Rights Reserved. Solosec® is a registered trademark owned by Lupin, Inc. NP-SOL-0176 ### About Phil Inc. Phil Inc., headquartered in San Francisco, California, is a leading provider of Digital Patient Access Solutions. By addressing patient access challenges using online technologies, as opposed to traditional call-center models, Phil Inc. partners with pharmaceutical manufacturers to deliver pioneering digital access to Specialty and Specialty-Lite therapies. Phil Inc’s access solutions may improve patient outcomes by lowering cost and improving speed to therapy, while freeing up prescribers and pharmacists to focus on delivering care. ### References - SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2019. - American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists, Number 215. Obstet Gynecol 2020:135(1):e1-e17. - Data on File, Physician Research. Advantage Healthcare, Inc. Prepared December 23, 2014. - Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678. e1- 678.e9. doi: 10.1016/j.ajog.2017.08.017. - Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis. 2004;31(8):488-491. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine Source: https://phil.us/press/press/phil-announces-partnership-with-impel-neuropharma-in-support-of-trudhesatm-dihydroergotamine-mesylate-nasal-spray-for-the-acute-treatment-of-migraine/ ## Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine SAN FRANCISCO – Sept. 28, 2021 – Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy. Trudhesa is indicated for the acute treatment of migraine with or without aura in adults. “Phil provides an efficient and value-driven experience for patients to get timely and affordable access to their medications,” said Deepak Thomas, founder and CEO of Phil. “The challenges in this space reach far beyond the patient, and our goal is to simplify this complex ecosystem to deliver positive outcomes for all stakeholders.” “Every step of our Trudhesa development program has been guided by the needs of people living with migraine,” said Adrian Adams, Chairman and Chief Executive Officer, Impel NeuroPharma. “That’s why we’re excited to partner with Phil on Trudhesa Direct™, a streamlined, customized, end-to-end process that will automatically enroll eligible, commercially-insured patients in a savings program to obtain and conveniently ship the medication straight to their home at no additional cost. This partnership will create a customized and seamless experience for patients who choose Trudhesa for rapid, sustained and consistent migraine relief.” ### About Trudhesa™ (dihydroergotamine mesylate) Nasal Spray Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) is approved by the U.S. Food and Drug Administration for the acute treatment of migraine with or without aura in adults in the U.S. Using Impel’s proprietary Precision Olfactory Delivery (POD®) Technology, Trudhesa gently delivers dihydroergotamine mesylate (DHE)—a proven, well-established therapeutic—quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and potential absorption issues, offering the potential for rapid, sustained, and consistent relief without injection or infusion, even when administered hours after the start of a migraine attack.¹ ### Trudhesa Indication and Important Safety Information ### Indication Trudhesa is used to treat an active migraine headache with or without aura in adults. Do not use Trudhesa to prevent migraine when you have no symptoms. It is not known if Trudhesa is safe and effective in children. ### Important Safety Information Serious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Trudhesa) and strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. As a result, these medications should not be taken together. ### Do not use Trudhesa if you: - Have any disease affecting your heart, arteries, or blood circulation - Are taking certain anti-HIV medications known as protease inhibitors (such as ritonavir or nelfinavir) - Are taking a macrolide antibiotic such as clarithromycin or erythromycin - Are taking certain antifungals such as ketoconazole or itraconazole - Have taken certain medications such as triptans or ergot-type medications for the treatment or prevention of migraine within the last 24 hours - Have taken any medications that constrict your blood vessels or raise your blood pressure - Have severe liver or kidney disease - Are allergic to ergotamine or dihydroergotamine ### Before taking Trudhesa, tell your doctor if: - You have high blood pressure, chest pain, shortness of breath, heart disease; or risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease or you are postmenopausal, or male over 40); or problems with blood circulation in your arms, legs, fingers, or toes. - You have or had any disease of the liver or kidney. - You are taking any prescription or over-the-counter medications, including vitamins or herbal supplements. - You are pregnant, planning to become pregnant or are nursing, or have ever stopped medication due to an allergy or bad reaction. - This headache is different from your usual migraine attacks. The use of Trudhesa should not exceed dosing guidelines and should not be used on a daily basis. Serious cardiac (heart) events, including some that have been fatal, have occurred following the use of dihydroergotamine mesylate, particularly with dihydroergotamine for injection, but are extremely rare. You may experience some nasal congestion or irritation, altered sense of taste, sore throat, nausea, vomiting, dizziness, and fatigue after using Trudhesa. Contact your doctor immediately if you experience: - Numbness or tingling in your fingers and toes - Severe tightness, pain, pressure, heaviness, or discomfort in your chest - Muscle pain or cramps in your arms or legs - Cold feeling or color changes in 1 or both legs or feet - Sudden weakness - Slurred speech - Swelling or itching The risk information provided here is not comprehensive. To learn more, talk about Trudhesa with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at www.trudhesa.com or 1-800-555-DRUG. You can also call 1-833-TRUDHESA (1-833-878-3437) for additional information. ### About Impel NeuroPharma Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. Impel, POD, Trudesa and Trudhesa Direct are trademarks of Impel NeuroPharma, Inc. ### About Phil, Inc. Phil is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options. Through its digital stakeholder experiences, patient access services, market access solutions and distribution models, pharma manufacturers are able to deliver affordable and timely therapy access to patients. For more information on Phil, visit phil.us. Contact Phil at: phil.us/manufacturers ¹ Impel Neuropharma. (2020). INP104-301. Table 3.8.2. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Phil Announces up to $100M Strategic Growth Investment from Warburg Pincus, Fred Hassan to join Board of Directors Source: https://phil.us/press/press/phil-announces-up-to-dollar100m-strategic-growth-investment-from-warburg-pincus-fred-hassan-to-join-board-of-directors/ ## Phil Announces up to $100M Strategic Growth Investment from Warburg Pincus, Fred Hassan to join Board of Directors Investment and board appointment to support accelerated growth and innovation within prescription management solutions Published: June 3, 2021 SAN FRANCISCO – June 3, 2021 – Phil, a software therapy deployment platform, today announced a $56 million Series D fundraise led by Warburg Pincus, a leading global growth investor. The investment is part of an arrangement for Warburg Pincus to invest up to $100 million and enables Phil to accelerate the development of innovative products while continuing to support the growth of its customers. As part of the investment, Fred Hassan, Director at Warburg Pincus, will join the company’s board of directors. Fred has a multi-decade career in pharmaceuticals, including roles as CEO of Schering-Plough and Pharmacia, as well as Board roles at Bausch & Lomb, Precigen, Valeant and Avon Products. He currently serves as a Director of Amgen. Specialty pharmaceutical products treat complex health conditions and constitute a significant portion of U.S. prescription medication spend. Despite the therapeutic potential of these products, patients and their care teams face substantial obstacles to access, affordability, and adherence. While these challenges have been traditionally addressed through call-center based ‘hub’ services, Phil’s team has developed a next-generation suite of software tools to streamline and simplify this complex, distributed workflow spanning patients, prescribers, pharmacies, insurers, and manufacturers. Phil’s solution drives efficiencies that result in up to 6x higher adherence and 33% improvements in patient affordability at 1/10th the cost of call-center based approaches, and is able to serve a wide range of therapies ranging from specialty ‘lite’ products to core specialty therapeutics. “As the only technology-powered, full-suite solution addressing the specialty pharmaceuticals market, Phil uniquely provides an integrated suite of solutions to replace the historically complex and cost-prohibitive process of deploying ‘hub’ services. With the goal to become the gold standard for pharmaceutical access, affordability, and distribution, this investment enables us to accelerate our growth at a rapid pace and serves as a well-deserved recognition of our entire team’s commitment over the past 6 years,” said Deepak Thomas, Founder and CEO of Phil. “Warburg Pincus has a stellar track record of investing and scaling innovative and category-defining healthcare and technology companies. Their operational and strategic support will be invaluable as we continue to grow our platform and relentlessly work to improve the experience of our customers and patients.” “The increasing demand for cost-effective, technology-enabled solutions, paired with the shift towards specialty medications in the go-forward pharmaceutical pipeline has enabled Phil to emerge as a disruptor in the space, providing a differentiated business model, grounded in modern technology,” said Andrew Park, Managing Director, Warburg Pincus. “We believe our investment will help advance Phil’s technology roadmap and are excited to partner with Deepak and the company in its next phase of growth,” added Pranav Verma, VicePresident, Warburg Pincus. “Phil is well-positioned to help pharmaceutical manufacturers address the challenge of efficient prescription management through its innovative platform that has been successfully deployed at some of the largest pharmaceutical companies across the United States,” said Fred Hassan, Director, Warburg Pincus. “I look forward to working with Deepak and the other board members to help Phil build and innovate its exciting pharmaceutical solution.” Warburg Pincus is a leading investor in healthcare and technology, with significant expertise in venture capital and growth investing. Since its inception, the firm has invested in excess of $12 billion and $22 billion into healthcare and technology companies, respectively. Current healthcare and healthcare IT investments include, Alignment Healthcare, Experity, Intelligent Medical Objects, Modernizing Medicine, Outset Medical, Qualifacts, Quantum Health, SOC Telemed, Summit Health and WebPT. ### About Phil, Inc. Phil is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options. Through its digital stakeholder experiences, patient access services, market access solutions and distribution models, pharma manufacturers are able to deliver affordable and timely therapy access to patients. For more information on Phil, visit phil.us. ### About Warburg Pincus Warburg Pincus LLC is a leading global growth investor. The firm has more than $60 billion in private equity assets under management. The firm’s active portfolio of more than 200 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 19 private equity funds, which have invested more than $90 billion in over 930 companies in more than 40 countries. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information please visit www.warburgpincus.com. ### Media Contact - Please send email to: press@phil.us Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Prior Authorization Hurdles Don’t Discriminate By Disease Source: https://phil.us/prior-authorizations-impacting-therapy-delivery/ ## Prior Authorization Hurdles Don’t Discriminate By Disease Experts have called for major reform to the existing prior authorization processes with suggestions such as: - Streamlining of administrative steps - Tighter turnaround times for prescription authorization - Widespread automation and digitization of processes - Integration of health and administrative systems - Nationwide coverage The lack of standardization among current approval processes are resulting in treatment delays, poor patient and physician experiences, low adherence rates, script abandonment, and in many cases, increased healthcare spending as disease progression worsens. Below are some examples that illustrate the burden of prior authorizations within specific therapeutic areas. ### Cardiology The cardiovascular treatment landscape significantly expanded in 2015 with a new game-changing class of drugs, PCSK9 inhibitors, which are intended to manage cholesterol-related cardiovascular disease. PA requirements were placed on PCSK9s (alirocumab and evolocumab) due to their high cost, and PA documentation is highly variable among insurance providers. National insurance data from 2017 suggested that coverage was denied at an 80% initial rejection rate, and appeals were able to get half of these prescriptions eventually approved, but not without heavy administrative burdens. A lack of understanding of the value of PCSK9s for high-risk groups led to negative implications on overall patient outcomes. A 2019 model study found improved approval rates for PCSK9 inhibitors with the adoption of a standardized evaluation process, proper documentation of insurance coverage, a transition from paper to electronic formats for insurance applications and improved communication with payors in response to denials. ### Dermatology For many dermatologists, prior authorizations have become a significant barrier to care with the number of dermatology drugs requiring PAs increasing and a greater variability in what documentation different insurers require for approval. Medications subject to prior authorisations include topical creams, retinoids, topical steroids, immunomodulators and biologics. Common indications affected by PAs include psoriasis, atopic dermatitis and acne. Patients with complex dermatologic conditions, often requiring off-label treatments, face particularly significant insurance barriers. One study found that the average time to a final PA decision was 9.4 days and medications requiring PAs had lower treatment initiation rates, while PA denials were associated with lower rates of disease improvement. ### Gastroenterology The treatment of inflammatory bowel diseases – including ulcerative colitis and Crohn’s disease – has been associated with delays in biologic therapy initiation as a direct result of denied prior authorizations. Most common biologics for both UC and Crohn’s disease include adalimumab and infliximab, among others. A recent pediatric study showed median biologic initiation time was 21 days, while PAs and complex PAs (requiring appeals, step therapy or peer-to-peer review) were associated with 10.2 day and 24.6 day increases in biologic initiation time, respectively. As a result, PA requirements and denials increased the likelihood of IBD-related healthcare utilization and a dependence on older generation therapies with side effects such as corticosteroids. ### Oncology The last decade has seen considerable advancement in the oncology field with the approval of several high cost medications. As a result, PA’s have been implemented for many aspects of cancer care including infusional and oral antineoplastic agents as well as supportive care medications. Experts have questioned whether PA’s are effectively reducing healthcare expenditures in oncology, particularly when delays to one treatment may lead to greater spending on other treatments or hospitalizations. Prior authorizations and coverage denials/appeals appear to be draining precious hours of oncologist’s time and PAs are the main reason for delays in oncology care. While there is more of a clear rationale to require PAs for newer cutting-edge medications such as immunotherapies, payers also require PA approval for supportive care or antineoplastic medicines that are cheap, clearly fit into ASCO treatment guidelines and have been on the market for a long time. These unnecessary barriers can substantially reduce adherence rates, promote therapy abandonment and worsen outcomes for oncology patients. ### Pulmonology Monoclonal antibodies (such as omalizumab, benralizumab, mepolizumab and dupilumab), have proven effective treatments for patients with severe allergic asthma. However, delays to treatment imposed by the prior authorization process has put patients at high risk of exacerbations during wait periods. One study revealed an average 44 day timeframe between prescription and first dose available for monoclonal antibody injection. This was composed of a mean 21.5 days days for insurance approval and 22.8 days for a specialty pharmacy to fill the medication. High risk patients required prednisone to reduce exacerbations while waiting for their biologic medications, which has side effects that could have been avoided with a more abbreviated timeline to treatment. ### How does Phil’s platform help with prior authorizations burdens? - Prescribers and patients have access to an integrated digital platform - Prescribers get alerts to log-in online for a digital PA submission - Field reimbursement teams are able to gain visibility into PA metrics real-time - National pharmacy network and wholesale supply offers shorter time to therapy - Real-time (PHI-blind) data allows manufacturers to better predict initiation, adherence and refills For more information on how Phil works with manufacturers to streamline the patient access channel, visit us at phil.us. ### References Cardiology https://pubmed.ncbi.nlm.nih.gov/31331186/ https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.118.314191 Oncology https://ascopubs.org/doi/full/10.1200/JOP.18.00428 Pulmonology https://pubmed.ncbi.nlm.nih.gov/33404389/ Dermatology https://www.jaad.org/article/S0190-9622(20)32296-9/fulltext#back-bib2 Gastroenterology (IBD) https://pubmed.ncbi.nlm.nih.gov/35190811/ General https://www.jacc.org/doi/pdf/10.1016/j.jaccas.2020.05.095 https://www.jfas.org/article/S1067-2516(19)30011-0/pdf Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Prior Authorizations: What Pharmaceutical Manufacturers Need to Know Source: https://phil.us/prior-authorizations-what-pharmaceutical-manufacturers-need-to-know/ ## Prior Authorizations: What Pharmaceutical Manufacturers Need to Know As healthcare costs have escalated over the last several decades, public and private medical insurers have introduced different utilization management (UM) strategies to control healthcare expenditures. The proliferation of higher-cost specialty medications has accelerated the use of drug UM tools to control access, with prior authorization (PA) being the most common today. From the payer's perspective, PAs are necessary to improve quality of care and protect patients’ safety. Conversely, healthcare providers report that the PA process often leads to delays in care which can cause patients to abandon their treatment and lead to adverse events. While there may be a patient-centric intent to the PA process, all too often, it creates an operational burden for providers, impairs patient experience, and negatively impacts health outcomes, ultimately increasing costs for all stakeholders. These issues have led to calls for PA reform. For pharmaceutical manufacturers, it's crucial to grasp how PAs affect patients’ access to their brands and what they can do to reduce friction in the process to ensure brand success. ### Understanding the PA process Prior authorization refers to a payer’s requirement for providers to establish the patient’s eligibility and obtain treatment approval to qualify for payment. This process allows the health plan to evaluate whether the prescribed therapy is medically necessary and meets coverage requirements. Standards for this review are often developed by the insurers themselves, presumably based on medical guidelines and cost and utilization factors. In general, the PA process involves the following steps: - Healthcare provider determines a patient needs a specific medication and writes a prescription. - The provider checks the patient’s health plan formulary to see if a PA is required. - If the provider’s office confirms that a PA is required, they need to: Obtain the insurance company’s PA form Complete all requested clinical and administrative information, including specifics relating to each CPT code that is applicable to the prescribed treatment Submit the form to the health plan Follow up with the insurance company until there is resolution of the PA request — an approval or denial. - If a provider sends a prescription to the patient’s pharmacy without knowing a PA is required, the pharmacy contacts the provider to obtain the needed information. - When the PA request is approved, the pharmacy dispenses the covered medication to the patient. - If a PA request is denied, providers and patients have the option to appeal – by law, all health plans must have an appeal process in place. - In many cases, a denial is due to incomplete information, and the PA is approved when submission errors are remediated. This complicated process is prone to error, not to mention frustration for providers and their patients, and generally takes a significant period of time, especially when conducted through outdated forms of communication, such as faxing and telephone calls, which all too often it is. ### Challenges with PAs In a 2021 press release, Susan Bailey, President of the American Medical Association (AMA), noted that "prior authorization remains a major obstacle to achieving optimal patient care." At the heart of the problem is the PA process's burden on physicians and the delays in care it causes for patients. The biggest challenges include: - Changing payer rules: Each insurance company has its own coverage criteria, and those criteria may differ between plans within a specific payer. The coverage rules also change at various times, so a provider's administrative staff could reference outdated criteria. To make matters worse, 74% of physicians find that PA criteria are only sometimes, rarely, or never based on evidence-based guidelines from national medical specialty societies. - Lack of transparency: A lack of clarity around the required documentation to obtain authorization leads to a time-consuming process that frustrates providers and patients and ultimately delays care. In fact, most physicians struggle to determine whether a prescription medication even requires PA. - Use of multiple UM tools: It's common for insurers to piggyback other drug UM tools onto the PA requirements, creating additional barriers to coverage. One example is step-therapy, also known as "fail-first," which requires patients to try and fail on one or more lower-cost drugs before obtaining coverage for the initially prescribed therapy. This requirement can delay proper treatment by weeks or months and has proven more expensive. Other commonly used tools include quantity limits, mandatory generic substitution, and tiered pharmacy benefit design. PAs aren't going away any time soon – their use as a cost-control tactic continues to expand. Today, even generics are susceptible to authorization, and pharmacy benefits management (PBM) organizations anticipate using price negotiations and UM tools to reduce spending by consumers and plan sponsors by more than $1 trillion through 2029. Time-consuming PA processes can result in high rates of medication nonadherence, hurting patient outcomes and, ultimately, manufacturers' gross to net. ### Improve patient access to your brand by reducing PA friction The market access role of payers translates to substantial impacts on treatment decisions. When you consider that healthcare industry stakeholders incur annual costs of $93.3 billion just navigating drug UM, it’s clear that pharmaceutical manufacturers should make every effort to reduce friction in obtaining PAs for their brands. An effective PA strategy includes the following: - Leveraging technology and automation to accelerate the PA process - Building solid relationships with healthcare providers and payers - Educating healthcare providers on the PA process - Monitoring and analyzing PA data Download our guide for life sciences companies for a more in-depth look at navigating PAs successfully. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Proactive Steps to Overcoming the Top 3 Patient Access Barriers to Retail and Specialty-Lite Therapies Source: https://phil.us/proactive-steps-to-overcoming-the-top-3-patient-access-barriers-to-retail/ ## Proactive Steps to Overcoming the Top 3 Patient Access Barriers to Retail and Specialty-Lite Therapies Ensuring patients get started and adhere to their medications is critical to achieving optimal health outcomes. However, navigating the medication access journey is no longer straightforward. An estimated 1 out of 4 prescriptions are abandoned at the pharmacy, and a recent report found that more than 8 out of 10 patients encounter delays in accessing the medications they need to manage their health. The issue of nonadherence is so prevalent that the American Medical Association (AMA) advises physicians to "consider medication nonadherence first as a reason a patient's condition is not under control." For life science companies, there are serious financial implications, including GTN challenges, related to patient access barriers. One study estimates that the pharmaceutical industry loses $250 billion in actual and potential revenue each year due to nonadherence in the U.S. alone. Whether due to knowledge gaps, prior authorization hurdles, or affordability concerns, there are proactive measures manufacturers can take to address these challenges and improve patient access. ### 3 top patient access barriers to retail and specialty-lite medications There are three main reasons why patients struggle to access the therapies they need to manage their medical conditions: #### 1) Patient and provider knowledge gaps Insufficient knowledge about specific medications, their benefits, available patient support programs, or how to navigate the healthcare system inhibits patients' ability to access and adhere to therapy. Health literacy issues lead to difficulties understanding medical information, including prescription instructions, which can cause improper medication use or nonadherence. #### 2) Prior authorization hurdles The rise of costlier retail and specialty-lite medications has accelerated the use of drug utilization management tools to control access, with prior authorization (PA) being the most common. By design, the PA process is a barrier to medication access – it can leave patients waiting for days, weeks, or even months for approval, and coverage denial may occur despite a therapy being appropriately prescribed. In a 2023 survey, 97% of medical practices said their patients had experienced care delays or denials due to increased PA requirements. #### 3) Affordability concerns Affordability is a leading driver of prescription abandonment and nonadherence. Out-of-pocket costs for retail brands climbed by $949 million from 2021 to 2022, and patients abandoned 94 million prescriptions with greater frequency as their copays grew. With over half of American private-sector workers enrolled in high deductible health plans (HDHPs) that require members to meet their annual deductible amount before coverage begins, affordability becomes an even bigger hurdle. ### Proactive steps life sciences companies can take to address these barriers Life science brand team can proactively clear the path to patient access by taking the following steps: #### 1) Educate key stakeholders in the patient access journey Educating key stakeholders about your medication, access options, and the patient services program is critical to overcoming knowledge gaps. A lack of knowledge about your brand's existence and its support programs will significantly chip away at new scripts, hub enrollment, adherence, and coverage. The field team plays an essential role in educating healthcare providers and their office staff about your patient support program and how it benefits them and their patients. Patients will not enroll or engage in a hub if they don't know it exists, how it will help them, and how to enroll – their most trusted source of information is their provider. According to a survey, 55% of patients expect to learn about support programs from their doctors Consequently, manufacturers should empower the field team to equip healthcare provider offices with the knowledge, messaging, and resources they need to leverage the program. Download our Key Success Factors to Drive Brand Excellence playbook to discover proven strategies for optimizing your channel strategy to improve patient access, provider engagement, and brand outcomes. #### 2) Streamline prior authorizations With 97% of HCPs reporting that they experience patient care delays or denials due to PA requirements, pharmaceutical commercialization teams should evaluate the toll PAs have (or potentially have) on their brands. While some retail pharmacies assist with the PA process, most leave it up to the prescriber or patient. An electronic solution does not necessarily have the desired impact as it still requires patients and HCPs to navigate required forms, albeit in a digital format. To streamline PAs, it’s crucial to look for a digital hub solution that ensures the PA process works within current HCP workflows, pre-populates required forms with clinical information, and monitors PAs for submission success. By making prescribing as easy as possible and simplifying the PA process, HCPs are more likely to write scripts and help patients get started on their prescribed therapy more quickly. Download this in-depth guide, Successfully Navigating Prior Authorization to learn how you can reframe your approaches to prior authorization through digital solutions that boost patient access. #### 3) Address financial concerns To make the most of manufacturer-sponsored financial assistance, an integrated digital hub solution with transparency tools can help providers improve affordability conversations with patients so they can make the best decisions at the point of care. This initiative will go a long way towards avoiding access issues caused by cost concerns. For the best results, it’s essential to lay the foundation for covered dispenses by maximizing coverage while minimizing reliance on free goods and ensuring your hub partner has a tightly integrated pharmacy network. For a deeper dive into how you can improve prescription coverage through strong pharmacy partnerships, download this informative guide for life sciences brands. #### Ready to drive patient access to your brand? PhilRx is a digital hub that sets the stage for modern support services, meeting patients' needs by seamlessly connecting them with their prescribed therapy and equipping commercial teams with actionable insights to optimize brand performance. Our platform enables retail and specialty-lite brands to protect their GTN margins and unlock patient access by automating PAs and supporting manufacturer-driven coupon utilization. Request a demo to see the PhilRx Digital Hub in action and learn how easy it is to get started. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Program FAQ Source: https://phil.us/program-faq/ ### Enrollment/EMR #### How does text enrollment work? #### How will PhilRx Pharmacy appear on EMR? #### If offices have issues with EMR, is there a service to contact for the help? #### Does PhilRx have a direct contact Line for EMR issues? #### Does the provider enter the patient's email address onto the EHR? If not, where? #### For the text messages to start, does the provider input the patient cell number into EHR? #### What happens if a patient does not want to receive text and not share their number? What is the phone number on file is a landline and not a mobile number? #### Won’t the patients ignore these text messages as spam? #### My HCP will not input insurance details when sending to a new HUB therefore in order to even start the process, will Phil not need to contact the patient for this info? #### What if the patient does not want text nor emails and only wants to communicate via Phone? How does the provider initiate this action? ### General Communications #### What means of communication does PhilRx use? Phone? Email? Text? #### General customer service support? Is there a live service to contact? #### How can PhilRx support additional language needs? #### What is the process for a patient that does not speak English? #### What is the process for a staff member that speaks limited English? #### What languages do we offer support? #### If a patient needs to be contacted by text or call in a different language, how is this facilitated? ### Pharmacy Network #### Which pharmacies does the actual Rx fill? #### Can the patient pick up their prescription from a Phil partner pharmacy in person? #### Can the patient pick a pharmacy that is not part of the Phil network? ### Patient Experience #### What is the refill process and procedure? Is PhilRx contacting patients when refills are sent or are they just automatically fulfilled with no notification? #### Does the patient text program provide any additional services besides enrollment? IE - adherence, reminders, tips, etc. #### When the script has no more refills, does PhilRx contact the office to get a new script? #### Does PhilRx accept any "transfers" of refills from other pharmacies? #### Does PhilRx fill non program scripts? #### In what timeframe will Phil contact the patient? #### What is the SOP for patients not opening or responding to the text messages? Will PhilRX call the patient? #### When will PhilRx contact the office about a patient who does respond to our messages? #### How long does it take for the Rx get to the patient? #### Once a Pharmacy receives the order, does the Pharmacy have a timeframe to get it out the door? #### If a patient has challenges receiving mail, is there another means to receive their prescription? #### Are refills triggered by the Hub or Pharmacy? ### Prior Authorizations #### Will PhilRx complete the PA process? If so, how long? What is the staff's role? #### Who is initiating the PA process? Pharmacist? PhilRx? Office? #### PhilRx reviews all documents submitted during the initial Rx submission, assuming this is done prior to the initial submission to payor? #### If the provider/staff includes documentation for the PA/SE in the notes section of initial submission, will Phil then input into CMM for them or will they still need to do it themselves (key code & notes)? #### What if the HCP/office prefers to do their own PA? #### What is the process if/when additional medical documents are needed for step edits? #### If additional documentation is needed from the provider's office, how will PhilRx communicate with the provider? Fax? Phone? Email? Portal? How many days goes by before PhilRx tries an alternate method or general reminder? #### Is there an HCP Portal available? #### PA process and documentation submission is done through CoverMyMeds™ (CMM). What if the office does not use CMM? Any alternate methods? #### Does PhilRx have a turnaround time frame to final review and approve everything after the provider submits everything accurately? Within the day? 24 hr? 48 hr? #### Let’s say the PA process is complete and it is determined that the patient hasn't met the steps needed. Will PhilRx fill this rx requirement and ship to patient or does patient fill in a traditional manner? #### How does PhilRx help manage step therapy that requires a specific duration? Will PhilRx follow up with patients after 2 months of the step therapy? Will they fill the step therapy? #### What does the appeal process look like for patients that get a denial, does the office need to request appeal or is automatically processed? #### How can PhilRx nationally support tough plans like XYZ for a specific indication? ### Copays/eBV #### Will patient’s out of pocket cost be strictly the copay? Shipping cost? #### After determining benefits investigation and applying copay program (if eligible), does the PhilRx Hub apply any other state/privately funded programs to aid with payment? Including LIS? #### Is Copay buydown automatically applied? What if copay needs to be “activated”? ### Payments/Shipping #### With initial fill, assuming the patient will determine the final OOP determined by the eBV to determine final cost? Are debit/credit cards accepted? Apple Pay? Venmo? Paypal? #### When refills are completed, does the patient have to input payment every time? Are credit/debit cards saved? Does the system allow patients to switch credit/debit cards? #### Does the patient input the shipping address during the initial Rx? Can this address be modified for subsequent refills? How? #### Will the provider get any notification that Rx has been successfully filled? #### How long does it take for an order to process? ### Portal and Provider Questions #### Why or why not should HCPs request/use the HCP Portal? #### Can offices have step by step instructions? #### For multi-physician practices, does the portal include the entire group and individual doctors? #### Can office customize portal during initial welcome call with champion? ### Client/Rep Communications #### What visibility will TMs and DMs have during this program? #### Can our TM compliantly discuss “PhilRx”? ### Data Capture #### How will the data be captured? Pharmacies report to IQVIA? ### Marketing and Branded Documents #### Is there a program-specific branded documentation/sheet? --- # PSAOs: What Life Sciences Commercialization Teams Need to Know Source: https://phil.us/psaos-what-life-science-commercialization-teams-need-to-know/ ## PSAOs: What Life Sciences Commercialization Teams Need to Know Pharmacies can significantly impact pharmaceutical manufacturers’ commercial success as crucial players in the prescription fulfillment process. In addition to playing an essential role in the supply chain, pharmacies are the only consumer-facing entities. An ineffective distribution network can diminish a brand’s reputation, patient and provider satisfaction, health outcomes, and gross to net. That’s why commercial teams need to evaluate the makeup and affiliations of the pharmacy networks that dispense their prescription therapies to ensure optimal access. One of the little-known pharmacy affiliations commercialization teams should be aware of are pharmacy services administrative organizations (PSAOs). ### What is the role of PSAOs? Because community, specialty pharmacies, and small independent chains lack the infrastructure and expertise of large pharmacy chains, contracting with a PSAO can help them stay competitive. This relationship is a lifeline for the vast majority of independent pharmacies, given that dispensing prescriptions drives more than 90% of their total revenue, and PSAO services facilitate access to pharmacy networks. The primary role of PSAOs is to provide a wide range of “back office” administrative, clerical, audit, and data support services to independent pharmacies for a fixed monthly fee. In most cases, they facilitate contract negotiations with PBMs, which may include reimbursements for prescription medications, dispensing fees, and participation within the PBM pharmacy network. They may also assist pharmacies with clinical support and regulation compliance. According to the Healthcare Distribution Alliance (HDA), PSAOs do not perform the following: - Dictating reimbursement rates - Setting Maximum Allowable Cost (MAC) rates - Determining formularies or patient coverage - Retaining any portion of pharmacy reimbursement - Establishing Direct and Indirect Remuneration (DIR) fees or retaining them - Creating networks or plan structures ### Understanding the current PSAO landscape As of 2012, the GAO reported there were at least 22 PSAOs. Today there are less than 10 in operation — a recent analysis estimated that the six largest PSAOs each have between 1,700 and 6,800 participating independent pharmacies. According to a report by the Pharmaceutical Care Management Association (PCMA), 83% of independent pharmacies contract with PSAOs, which operate under one of the two following models: - Wholesaler-integrated: The PSAO is a subsidiary of a drug wholesaler. In addition to supporting business administrative functions, it may also be involved in purchasing prescription drugs. Under this model, independent pharmacies may co-brand with the wholesaler through a membership or franchise. An estimated 75% of independent and small chain pharmacies contract with one of the “Big Three '' wholesalers: AmerisourceBergen, Cardinal Health, and McKesson. Examples include Elevate Provider Network and Health Mart Atlas. - Member-owned: Unaffiliated with a drug wholesaler, this is the traditional PSAO model. Under this model, the PSAO may be “wholesaler neutral” or have a preferred wholesaler contract arrangement. Some member-owned PSAOs, such as Arete Pharmacy Network or Epic Rx, are nationwide. Others have a specific geographic footprint, such as Community Independent Pharmacy Network. ### Key considerations for life sciences commercialization teams There are many considerations when planning to distribute and dispense a prescription therapy. One of a pharmaceutical manufacturer's most critical decisions is in influencing the pharmacies that will be part of their distribution network at launch. The long-term success of the ultimately brand hinges on the performance of those pharmacies. Unlike specialty pharmacies, almost all retail pharmacies are part of open networks, where the patient out-of-pocket is the same at every pharmacy across the network. However, the largest PSAOs are increasingly moving away from preferred networks meaning that some retail pharmacies may not have access to preferred networks in Medicare plans. In a preferred network, patients pay less out-of-pocket at a preferred pharmacy than if they go to a non-preferred network pharmacy. This can significantly influence prescription adoption. Limited networks – a common occurrence in specialty drug launches – limit coverage to designated pharmacies and give insurers more economic control over prescription fulfillment. In addition to evaluating a pharmacy network strategy, manufacturers must also consider the types of pharmacies they plan to include: independent, chain, specialty, pharmacy benefit manager-owned, etc. It's crucial to ensure you have the right level of pharmacy makeup to ensure coverage for the patient population size, geographical area, utilization patterns, and outcome goals. A pharmacy network's contractual agreements and affiliations with payers, PBMs, and PSAOs can influence coverage. You should carefully evaluate if the pharmacy network has the contracts necessary to drive coverage effectively. For example, while many specialty pharmacies may have 50 state dispensing capabilities, the fact that they utilize mail order models typically means that they are unable to contract with many state medicaid and regional health plans with requirements for in-state dispensing. When life sciences companies partner with Phil, they gain access to a nationwide pharmacy network with 98% plan coverage that enables patients to receive their prescribed therapies quickly and affordably. Real-time insights ensure a consistent, predictable experience for providers and pharmacies across the network. Our platform helps commercialization teams grow their brands in a sustainable way. Read this white paper to discover how your team can optimize prescription coverage at the pharmacy counter. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Research Report: Bridging the Gap to Better Patient Outcomes: What HCPs Want from Pharma's Digital Access Channels Source: https://phil.us/research-report-bridging-the-gap-to-better-patient-outcomes-what-hcps-want-from-pharmas-digital-access-channels/ Report ## Research Report: Bridging the Gap to Better Patient Outcomes: What HCPs Want from Pharma's Digital Access Channels New research from PHIL uncovers healthcare provider’s perspectives on direct-to-patient programs, and why this matters for pharma Download PDF New research from PHIL uncovers healthcare provider’s perspectives on direct-to-patient programs, and why this matters for pharma. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Calculate your GTN with PHIL Source: https://phil.us/resource-calculate-your-roi-with-phil/ ## Calculate your GTN with PHIL ###### Calculate Your Brand’s GTN Potential with PHIL Estimate Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Revolutionizing Patient Access: Introducing the PhilRx Platform Source: https://phil.us/revolutionizing-patient-access-introducing-the-philrx-platform/ ## Revolutionizing Patient Access: Introducing the PhilRx Platform Loading... In the highly-competitive life sciences industry, optimizing access is key to success. Offering timely and affordable access to treatment can significantly improve your patients’ health outcomes, strengthen relationships with your provider network, and determine the overall success of your brand. Manufacturers at the top of the industry are streamlining medication access by modernizing the patient experience through breaking down utilization management barriers and strengthening workstreams with pharmacies and providers. We’re on a mission to help branded retail and specialty-lite therapies achieve their full access potential. See the PhilRx patient access platform in action and discover how we can help your brand thrive. ### • Modern Access Experience The PhilRx platform is designed to make it as easy as possible for healthcare providers (HCPs) to prescribe treatments to their patients, and for patients to get quick and affordable access to their medications. It eliminates the traditional barriers associated with prescription enrollment, offering a seamless, end-to-end experience for everyone. ### • Maximized Covered Dispenses Phil works with an extensive, 50-state dispense network to ensure patients get on therapy quickly and affordably. Our network is curated to maximize covered dispenses with an industry-leading 98% plan coverage rate. ### • Simplified Prescription Process Sending and receiving a prescription through the PhilRx platform is simple. HCPs simply send prescriptions to PhilRx via their EMR system - no lengthy hub forms to fill out or software to download. Patients will receive a text from PhilRx to easily enroll and confirm their information, kicking off the benefits verification and fulfillment process. This streamlined process is key to ensuring more patients can access the treatments they need without unnecessary delays at the lowest possible price. ### • Enhanced Visibility and Insights The PhilRx platform includes a program dashboard that offers real-time visibility into the prescription process. This feature allows manufacturers to identify bottlenecks, address access challenges, and gain insight into the full prescription lifecycle. Phil continuously reviews program data to provide actionable insights and benchmark program performance, which can be leveraged to further optimize the patient and provider experience. ### Drive Affordable Access and Coverage The future of patient access is here. To learn more about how the PhilRx platform can accelerate your access experience, book a demo with our team. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Setting the Stage for a Successful, Modern Hub Services Program Source: https://phil.us/setting-the-stage-for-a-successful-modern-hub-services-program/ ## Setting the Stage for a Successful, Modern Hub Services Program This blog post was written by John Yu, Vice President, Patient Experience at Phil. Getting prescribed medications – especially those that treat more complicated, chronic conditions – into the hands of patients is like navigating a maze filled with roadblocks. Consider that out of all the products launched in 2019, only 1 out of 3 patients who tried to initiate a treatment could get it filled – with over half facing a formulary restriction and others abandoning due to cost. As PBM organizations plan to increase price negotiations and utilization management requirements to reduce pharmacy spending by more than $1 trillion through 2029, it's no wonder that many manufacturers shoulder patient access program investments of up to 60% of their gross-to-net (GTN) in the first year of a brand's launch to reduce financial barriers to adoption of their therapies. Pharmaceutical manufacturers with specialty and specialty-lite therapies lean heavily on the solutions offered by hub providers because, with the right design, they present the best option to address the roadblocks that may stop a prescription dead in its tracks before it ever gets to the patient. Setting the stage for your patient services program's successful launch entails three critical steps to ensuring a patient-centric experience that can optimize access to your therapy while maintaining a positive GTN. ### A positive experience: The difference between success and failure Whether you’re looking at the patient or healthcare provider (HCP), a poor experience can translate to a loss of brand loyalty. A 2022 survey revealed that patients with positive experiences with a pharmaceutical company’s services were 18 times more likely to enroll in a patient services program. Those with poor experiences were twice as likely to seek an alternative treatment option. Thus, it’s up to the brand to select the right channel partners that are capable of delivering an access experience that makes it as seamless as possible for patients to start and stay on therapy. Patients should not be left wondering about the status of their prescriptions or why they cost a certain amount. A responsive, digital hub partner can mitigate access barriers and keep patients in the loop, earning their trust and the level of program engagement essential to improving access and overall brand adoption. The HCP experience is also critical throughout the access journey. The prior authorization process tends to be clunky, with most still relying on antiquated paper-based communication systems and telephonic engagement. HCPs and their staff struggle with increasingly burdensome prior authorization requirements, which explains why more than 8 out of 10 avoid prescribing certain medications over half the time because of utilization management. The right hub partner should simplify the whole process by making HCP workflows more efficient to free up time to focus on treating patients, ultimately delivering a positive experience that will promote brand loyalty. Brands would be wise to remember that a patient’s poor access experience often makes it back to the prescriber; it’s not unusual for the HCP to abandon that brand altogether based solely on the feedback from that one patient’s bad experience. Effective hub services can ensure patients and HCPs have a positive experience with your brand, resulting in higher brand loyalty - something that is increasingly important in increasingly competitive therapeutic categories. ### 3 steps to ensure a successful launch of your Hub program ##### 1. Find a hub provider that uses a consultative approach A Hub partner should act as more than a "vendor". They should serve as an invaluable ally from a product's launch phase and throughout its commercial lifecycle. Hubs that leverage their expertise to take a consultative approach can cut through the complexity by helping recommend and ultimately deliver a tailored solution based on the manufacturer's business goals. Establishing a responsive workflow is critical for effectively streamlining patient access and addressing barriers to treatment for all patients - Commercial, Government, Underinsured, and Uninsured. For optimal results, Hub teams should actively collaborate with the manufacturer's internal teams, such as the market access team during pre-launch, the sales and marketing team leading up to launch, and the patient access team after launch. ##### 2. Harness the flexibility and scalability of a tech-enabled platform Improving access to specialty and specialty-lite therapies is a challenging problem to solve. Traditional hub partners have leveraged a people-driven, call-center approach to engage the appropriate parties, collect information, and facilitate actions to support coverage. The cost of running this type of program is astronomical from an operational standpoint and is not scalable. When you consider that industry benchmarks for enrollment rates for these programs are 20% or less, the ROI can be dismal with the lion share of fees going to outreach attempts to connect with stakeholders vs. getting patients started on therapy. A tech-enabled hub platform allows manufacturers to communicate with patients more efficiently and through the channels they prefer, such as SMS, boosting enrollment while automating the PA process to drive more submissions translating to higher rates of overall coverage. It also allows for a faster, more flexible, and cost-effective hub launch than traditional hubs. ##### 3. Ensure the Hub is dynamic enough to evolve quickly across the lifecycle To effectively balance speed to therapy and program cost, manufacturers need to implement business rules that set the parameters for their tech-enabled Hub services. These business rules should be constructed according to a manufacturer's goals, the drug's lifecycle, and their patient mix. For example, a newly launched novel drug may not have a favorable formulary placement or any formulary placement at all. The primary goal would likely be centered on volume adoption to get the therapy in the patient's hands, so business rules may favor shorter wait times for payer PA approval before a manufacturer-subsidized program kicks in. The focus may not weigh as heavily on overall gross-to-net or profitability quite yet. Once there's more product adoption, manufacturers can start evaluating payer-specific behavior and data to evolve their business rules based on new business goals and how the drug is performing in the market over time. ### Achieving your patient access objectives from the get-go At Phil, we are driven to help pharmaceutical manufacturers unlock patient access. Once we've determined your goals, we configure our platform based on your business rules and your patient access services program can be up and running in weeks. With enrollment rates in the 80-90% range, our digital Hub does an excellent job of streamlining patient access. As a data-driven tech company, we have the data to inform decisions around copay design, PA wait time thresholds, patient drop-offs at one cost vs. another, and numerous other variables. Along the way, we provide manufacturer teams with actionable insights to help them evolve their program and realize greater brand value. Our key differentiator is that we leverage our technology and data to partner in making a manufacturer's brand outcomes a reality. We lean in and say, "Hey, we've seen this data. Here are some proven proposals for you to implement based on the data we're seeing." Learn more about how we help leading life sciences brands modernize their hub services programs. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Setting the Stage for Commercial Success in 2025 and Beyond Source: https://phil.us/setting-the-stage-for-commercial-success-in-2025-and-beyond/ Playbook ## Setting the Stage for Commercial Success in 2025 and Beyond An in-depth guide to improving patient and HCP experiences, optimizing pharmacy services, and leveraging technology to drive commercial success in pharma Download PDF Numerous changes in the healthcare sector are impacting pharmaceutical manufacturers of retail and specialty-lite therapies and their patients, providers, and partners. In order to stay ahead, brand teams must become more agile, digitally-savvy, and patient-centric as they move into 2025. This eBook provides an in-depth guide for pharmaceutical brand teams to thrive in this evolving ecosystem through a laser-focus on patient outcomes and brand success. #### In this white paper, you’ll learn about: - The current state of commercialization in pharma, from policies to patient trends - Trusted strategies for enriching the patient and HCP experience - Recommended KPIs to track and optimize brand performance at the script, territory, and program level #### Master Your Commercial Strategy Set a strong foundation for your brand’s commercial efforts. Book a demo to learn how we can help build a tailored channel strategy that maximizes your patient outcomes, provider & field engagement, and brand success. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Sharpen Your Access and Commercialization Efforts Source: https://phil.us/sharpen-your-access-and-commercialization-efforts/ ### You’re One Step Closer to Simplifying Medication Access Our team will be in touch soon to discuss your access and commercialization goals, and how PHIL can help. We look forward to speaking with you! Loading... ### Sharpen Your Access and Commercialization Efforts Get the latest pharma insights, news, and events to elevate your patient experience, provider engagement, and brand performance. ### Get latest updates --- # 6 Considerations When Evaluating Patient Access Platforms Source: https://phil.us/six-considerations-when-evaluating-patient-access-platforms/ ## 6 Considerations When Evaluating Patient Access Platforms As life science companies strive to ensure easy and affordable access to prescription drugs, they are looking to disruptive technologies that offer the potential to break through barriers to medication. Unfortunately, some companies invest millions of dollars on patient access and advanced analytics solutions but get little in return. Here are six considerations to keep in mind when evaluating a potential patient access platform. - Easy access to meaningful data insights Data is of little value when it’s locked away in databases and unwieldy platforms. Users should not have to waste time sifting through complicated reports just to find outdated, inaccurate data. Poor data quality is a barrier to digital transformation that often leads to inadequate decision making. An effective patient access solution not only turns a wide spectrum of real-time data into insights that provide an accurate view of the patient journey, but also enables users to rapidly unlock these insights through intuitive, interactive dashboards. - Modern engagement Advanced digital communication tools fuel greater opportunities for pharmaceutical manufacturers to improve patient engagement, drive prescriber loyalty, and boost medication adherence. Today’s patients expect anytime-anywhere capabilities similar to the Amazon mobile experience, so it is important to consider the types of digital engagement a patient access platform offers. Examples of modern engagement include: Patient and healthcare provider portals Digital enrollment to eHub services Text reminders Digital notifications and alerts - Platform scalability Once a drug is launched, there are numerous variables – such as higher than expected volume, formulary expansion, and label changes – that could precipitate the need to scale the capabilities of your patient access platform. Scalability is defined as “the measure of a system’s ability to increase or decrease in performance and cost in response to changes in application and system processing demands.” When evaluating a patient access technology application, it’s crucial to investigate how easily the platform adapts to business changes. One of the biggest benefits of scalable technology is that it allows companies to be prepared for future growth with a lower up-front financial outlay. - Automated workflows Manual patient access workflows – such as benefits verification, prior authorizations, and program enrollments – are inefficient and extend the time to therapy. A technology platform that effectively streamlines patient access processes for all stakeholders involved from writing the prescription to receiving the therapy drives efficiency, responsiveness, agility, and transparency. - Integration capabilities A patient access platform should ensure connectivity to stakeholders across the prescription journey. Integration with providers, manufacturing, wholesalers, payers, pharmacies, nurse navigator programs, and fulfillment minimizes interruptions to medication access and improves patient experience. End-to-end integration not only gives pharmaceutical manufacturers more visibility across their channels, but also allows them to positively influence outcomes and prove value to payers. - Technology specifications It’s important to evaluate the following specifications of any enterprise healthcare technology prior to implementation to ensure success and minimize risk: Cybersecurity HIPAA compliance Flexibility Data backup and recovery IT support Interoperability There are many barriers that prevent patients from receiving their prescribed therapies. By adopting a technology-driven patient access platform, life science companies can minimize many of the factors that lead to prescription abandonment and medication non-adherence. A thorough evaluation of prospective solutions is crucial to identifying the right one that will bring your life science company the best results and the most value. Phil provides an integrated approach to data analytics across the patient journey that provides life science companies with real-time visibility into their distribution channels and supports efforts to drive medication adherence. Learn more about how the Phil platform facilitates patient access. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # How Small Pharma Manufacturers can Optimize Drug Commercialization through Outsourcing Source: https://phil.us/small-pharma-manufacturers-drug-commercialization-outsourcing/ ## How Small Pharma Manufacturers can Optimize Drug Commercialization through Outsourcing One of the most important considerations for any pharmaceutical manufacturer is determining the internal capabilities and capital needed to support drug commercialization. The reality is that small- and medium-sized life sciences companies lack the resources to match the commercialization strategies of big pharma. Fortunately, today, there are opportunities for small pharmaceutical companies to execute a go-to-market strategy through outsourcing. ### Market-driven opportunities Over the last decade, the pharmaceutical industry has changed – a lot. According to a McKinsey analysis, the share of drug launches by emerging life sciences companies more than tripled between 2006 and 2018. In 2020, small biopharma companies originated and launched 40% of all new drugs, according to an IQVIA report. Three key market factors have driven opportunities for small manufacturers to launch and commercialize their products: - Favorable business conditions: Strong economic growth, low-interest rates, and a wealth of venture capital investment combined with high valuations for life sciences companies have provided the monetary resources to launch independently. - More options for outsourcing: Technology advancements have opened the door for more vendors to provide sophisticated and specialized solutions that enable companies to effectively outsource commercialization capabilities to avoid investing in a large organizational footprint. - Shift to niche therapeutic areas: Over the next five years, specialty drugs are projected to account for at least half of all revenue generated by pharmacies. Most of these new therapies focus on treating rare – often referred to as “orphan” – diseases. Niche drugs do not require a substantial commercial scale because they benefit smaller, more targeted patient populations. ### The benefits of commercial outsourcing Smaller manufacturers are typically very lean organizations, which on the upside, enables them to be very agile and innovative. However, while large companies may turn to a service provider to fill a specific capability, capacity, or technology gap, smaller firms often need more comprehensive outsourcing support across the drug development and supply chain. And managing multiple vendors is complex and can be a challenge for lean companies. Traditionally, when emerging life science companies wanted to commercialize a pharmaceutical drug, they had two options: invest in and develop internal capabilities to go it on their own or license the product commercialization to large pharma. They have a third option now: outsource needed go-to-market capabilities to a third party. This approach can empower smaller drug companies to achieve commercial success on their own by leveraging external technology, infrastructure, and expertise. Strategic outsourcing can benefit the commercialization process by helping drug manufacturers: - Increase operational efficiencies and reduce costs - Scale up or down rapidly - Fill gaps in knowledge and skills - Gain visibility and control over distribution channels - Elevate brand awareness - Improve medication adherence - Optimize drug fulfillment - Demonstrate value to payers - Manage payer relationships more effectively ### Tips for outsourcing success Commercial outsourcing can create more challenges than it solves, including increasing risk and decreasing profits if not done well. Here are some five for getting it right: - Consider working with a third party that offers a broad range of commercialization solutions that can be customized for your needs to minimize the number of vendor relationships you need to manage. - Choose a vendor that approaches the relationship as an alliance and partnership that fosters trust and accountability. - Establish and track metrics to assess commercialization success and work closely with the vendor to course correct as issues arise. - Look for a partner with an integrated and flexible technology platform that provides a broad range of data and analytics capabilities. - Ensure your commercialization partner aligns with a nationwide dispense network and offers a high level of managed plan coverage, high reimbursement rates, and excellent compliance. ### Reaping the benefits of drug commercialization Commercialization strategies and efforts are highly complex, costly, and cumbersome to execute. As pharmaceutical markets, pipelines, and policies continue to evolve, life science companies of all sizes need an agile and flexible approach to optimize commercialization. Outsourcing drug commercialization to a third-party service provider can help emerging life science companies reap the benefits of successfully bringing their treatments to the market. The secret to success is to develop a strategic commercialization partnership. Phil’s “channel-in-a-box” solution enables lean and emerging life science companies to optimize the commercialization of their drugs effectively and efficiently. For more information on how Phil can help your company, visit us at phil.us/manufacturers. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Streamlining Access with PhilRx Source: https://phil.us/streamlining-access-with-philrx/ Guide ## Streamlining Access with PhilRx A one-pager for branded retail and specialty-lite manufacturers seeking to improve patient access and brand outcomes through the PhilRx Digital Hub Download PDF Medication access, affordability, and adherence challenges are no longer inevitable for retail and specialty-lite brands. Offer a digital access experience that meets patients and providers where they’re at while maximizing coverage and GTN with PhilRx. This one-pager uncovers how PhilRx can help you break through barriers and drive transformative brand outcomes. #### In this one-pager, you’ll learn about: - Overcoming access and affordability barriers in branded retail and specialty-lite - Key success factors that strengthen brand performance in the PhilRx digital hub - Proven steps to equip the field team to improve patient and provider engagement #### Meet your partners in patient access Ready to empower your brands with an alternative channel strategy? Book a demo for a tour of the PhilRx Digital Hub. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Streamlining Specialty-Lite Access with PhilRx Source: https://phil.us/streamlining-specialty-lite-access-with-philrx/ Guide ## Streamlining Specialty-Lite Access with PhilRx An in-depth guide to improving access, coverage, and GTN for speciality-lite brands through the PhilRx patient access platform Download PDF Patient access challenges are no longer inevitable for specialty-lite brands. By combining a seamless user experience with digital hub services and an industry leading dispense network with 98% plan coverage, we can maximize patient access and optimize GTN for your brand. This guide uncovers how the PhilRx platform is designed to help you break through barriers and drive transformative brand outcomes. #### In this guide, you’ll learn about: - Overcoming barriers to commercializing specialty-lite brands - Core capabilities of the PhilRx patient access platform - How speciality lite brands are partnering with Phil to drive incredible performance #### Meet your partners in patient access Our mission is to help speciality lite brands reach their full access potential. Book a demo for a personalized tour of PhilRx as your strategic access partner. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Succeeding with Alternative Channels: Drive Value for Your Pharma Clients with PhilRx Source: https://phil.us/succeeding-with-alternative-channels-drive-value-for-your-pharma-clients/ Lunch-and-Learn ## Succeeding with Alternative Channels: Drive Value for Your Pharma Clients with PhilRx Oct 8, 2024 at 9am PDT 90% of patients want to access healthcare through technology. We’ve designed a digital hub that helps retail and specialty-lite brands improve the outcomes that matter - patient access & adherence, provider engagement, covered dispenses, and gross-to-net. Join us for an interactive online session to learn about the PhilRx Digital Hub and how we partner with consultants and agencies to drive success for pharma manufacturers. #### Key takeaways from the session: - Our approach to breaking down barriers to access, coverage, and gross-to-net - Core capabilities of the PhilRx Digital Hub for retail and specialty-lite brands - How we partner with pharma consultants and agencies to support manufacturers Join us for this 30-minute conversational event and get your questions answered about how Phil can be a strategic channel partner to your organization and clients. Sign up for the event ### Meet your Speakers ###### Neil Dean Director, Product Management, Phil Inc. Neil is a results-oriented Product Management professional with experience leading teams to launch emerging products & services to support strategic objectives. ###### Thomas Luby SVP Business Development, Phil Inc. Tom brings 25+ years of experience of strategic sales leadership in the life sciences industry, including at McKesson, winning the President’s Club award 11 times, and at RelayHealth, achieving 5,500% growth in a new pharmaceutical segment. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Successfully Navigating Prior Authorization Source: https://phil.us/successfully-navigating-prior-authorization/ ## Successfully Navigating Prior Authorization Guide for Life Sciences Companies Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Successfully Navigating Prior Authorizations Source: https://phil.us/successfully-navigating-prior-authorizations/ White Paper ## Successfully Navigating Prior Authorizations An in-depth guide to creating a superior prior authorization process that improves provider adoption and patient access Download PDF Most pharmaceutical manufacturers (and healthcare providers) are challenged with lengthy and manual prior authorizations. This creates a frustrating barrier to getting patients on the therapies they need to improve their health, quickly and affordably. Luckily, there’s a better path to access. This white paper dives into the utilization management landscape, and how commercial teams can reframe their approach to create a seamless experience for providers, patients, and pharmacies. #### In this white paper, you’ll learn about: - Navigating the complex utilization management landscape in today’s economic climate - Key impacts of the traditional prior authorization process on your provider network - Creating a prior authorization strategy that drives provider adoption and patient access #### Transform your PA strategy Revolutionize your access approach with our advanced prior authorization process. Book a demo to learn about how the PhilRx patient access platform can streamline your access experience for providers and patients. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Tech Enabled Patient Access Webinar: Key Takeaways Source: https://phil.us/tech-enabled-patient-access-webinar-key-takeaways/ ## Tech Enabled Patient Access Webinar: Key Takeaways “Patient access begins at the moment that a drug is prescribed and encompasses everything that goes with getting a drug into a patient’s hand.” said Len Paolillo, CCO of Impel Pharmaceuticals, during last Thursday’s webinar focused on how the right technology can meaningfully improve the chances a therapy will actually be taken as prescribed. As the life sciences industry faces strong access headwinds in 2022 due to evolving consumer expectations and stricter payer utilization management requirements, the conversation was timely and important. Mr. Paolillo, alongside Deepak Thomas, Founder and CEO of Phil and Kim Plesnarski, VP, Market Access Solutions at Syneos Health, offered relevant insights for life science companies looking to improve their patient access strategy. The conversation touched on a range of hot-button topics ranging from the importance of timely channel insights to how tech, like the Phil Platform, has matured to the point where brands need to rely on it if they hope to reach their commercial goals. Here are key takeaways from the webinar for life sciences companies to consider: - Increasing channel complexity is driving a greater demand for patient support services, yet the legacy access model is broken “Basically every launch today requires investment in access and support services. That wasn’t the case just ten years ago.” said Ms. Plesnarski when unpacking why the industry is witnessing 16% yoy growth in patient support services. The consensus among the panelists was that the legacy solutions; expensive, call center driven HUB providers,and specialty pharmacy networks are ill-equipped to respond to this increasing complexity. According to Len Paolillo, brands must avoid falling into the trap of relying on their past launches and need to treat each launch as a fresh start to evaluate the current state of the channel and what needs to be done to drive access with each individual patient. If they don’t, it’s inevitable that they’ll see limited prescriber adoption and will over rely on subsidies to keep patients on therapy. - Patients are consumers and want the same purchase experience they’ve grown accustomed to in other industries - life sciences needs to deliver Mr. Thomas advised that brands would be wise to treat their target patient population first and foremost as consumers. Thus, they should be developing patient journeys that are responsive to consumer preferences and behavior in 2022 and on par with what consumers experience when making other significant purchase decisions. However, due to bolt on technology and the antiquated approaches of legacy access models, patients often feel like their pharma purchase experience is stuck in the past. This results in frustration, alienation of core constituents, and high rates of medication non adherence that contribute to poor health outcomes. Mr. Paolillo noted that one of the reasons he partnered with Phil to support Impel’s flagship launch in a competitive category was that the platform offered patients frictionless onboarding and refill experience that met patients where they are at - on their smartphone. He noted that “I was looking for a consistent patient experience that fit into their lives and stood out in its simplicity.” - Brands should have a realistic view of their payer timeline at launch and look for partners that can quickly respond to formulary wins The panelists agreed that strategic planning is paramount to ensure conversion of market access to covered dispenses - a must for brands looking to optimize their gross to net. Noting the impact that access partners can have on a brand’s overall commercial trajectory, Deepak shared his view that the choice of access partner at launch is perhaps the most important decision a brand has to make. He emphasized that brands would be wise to balance the patient experience with the pursuit of coverage as this can ultimately make or break a brands financials. Further noting that there is a key distinction between an access partner that can deliver on driving pull through and one that will sacrifice the pursuit of coverage for pull through at all cost. Len underscored that if brands want sustainable growth, that they need to have good insight into the channel data to be able to understand when payer lives are going to come on so that they can quickly roll them off free goods into reimbursement. Patients shouldn’t know and don’t care when quickstart ends and coverage begins, but it’s important for brands to be able to make these changes quickly to tightly manage their finances. - Life sciences companies need holistic pharmacy strategies that recognize that pharmacy incentives can be at odds with the patient & manufacturer Pharmacies typically have a singular mission and that’s to get patients on therapy noted Ms. Plesnarski. To succeed in today’s environment, brands can no longer rely on the notion that a pharmacy’s job is to help patients get on formulary. Brands should take a more strategic and proactive approach given that many pharmacies are not structured to deliver responsive patient experiences, or often do so at the expense of the manufacturer. As there are meaningful differences in the various pharmacy formats, brands would be wise to consider the value that pharmacies provide and whether or not their incentives are aligned with their own. Misaligned incentives have resulted in a growing gap between positioning on formulary and a brand’s ability to convert that access into payer coverage at the point of dispense.Thus, many brands find themselves over subsidizing patient access for much longer than they had anticipated at launch and falling into a mid cycle crisis. - If you don’t have clear, visible data into patient, physician, and HCP behavior, you won’t be able to adjust your access strategy effectively “Insights eat data for lunch”, Deepak quipped. All panelists were in agreement that timely data is essential to navigate the complexities of the drug channel in 2022. However, they were frank in suggesting that most access partners fall short in delivering the actionable insights brands need to be able to grow sustainably. Without insights there is not much a brand can do with the information. Mr. Paolillo underscored the value of data, noting that if you can’t map the data back to the friction points of key stakeholders, there is not much you can do to reduce abandonment and the data doesn’t have much value. He shared that one of the benefits of the Phil platform is that paired data and insights have allowed Impel to adjust business rules around copay and shipping to help patients start and adhere to therapy. The bottom line is that data & insights can be a key difference maker for brands. ### Unlock the value of your product Superior clinical trial results do not guarantee commercial success. A robust clinical profile is no longer enough – you need a value proposition supported by real-time data and a go-to-market strategy that optimizes market access and patient and provider engagement. If you are interested in learning more about what the Phil Platform can do for your brand, contact us to get started. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Tech Enabled Patient Services: Do More With Less in 2023 Source: https://phil.us/tech-enabled-patient-services-do-more-with-less-in-2023/ ## Tech Enabled Patient Services: Do More With Less in 2023 More recently though, as life science companies strive to ensure improved access to their therapies and reduce operational costs, they are turning to disruptive technology platforms that offer the potential to break through barriers to medication. Unfortunately, some companies are still wrapped up in the old paradigm and spend millions of dollars on patient access solutions but get little in return. Here are four ways a technology-driven patient services solution can enable life science companies to achieve more in 2023: ### Automating workflows From the point of prescribing to driving therapy adherence, automated processes reduce friction across the patient’s medication journey. According to the 2021 CAQH Index Report, automation has reduced the annual cost of healthcare administrative transactions – such as eligibility and benefit authorizations and prior authorizations (PAs) – by $166 billion. And there’s a significant opportunity to save an additional $20 billion simply by transitioning fully to electronic transactions. Embedding e-prescribing and patients services program enrollment within the clinical workflow of healthcare providers improves the likelihood that doctors will prescribe your therapy and patients will utilize support services that help them stay adherent. Simplifying this often cumbersome process can improve patient outcomes by ensuring that they access programs that can reduce out of pocket and accelerate therapy initiation. When you consider that healthcare industry stakeholders incur annual costs of $93.3 billion just navigating drug utilization management, it’s clear that pharmaceutical manufacturers should not overlook opportunities for partnerships that can support the prior authorization process for their brands. Time-consuming PA processes can result in high rates of medication nonadherence, hurting patient outcomes and, ultimately, manufacturers’ gross to net. Discover how to reframe your PA strategy with the support of digital solutions that boost patient access and brand success in this Guide for Life Sciences Companies. ### Delivering actionable insights Access to timely and accurate data is essential to executing data-driven patient services stratgies that are responsive to current needs. There is a wealth of data created throughout the prescription journey that can enable manufacturers to steer their patient support programs more effectively and efficiently; however, that data is of little value if it’s not timely or comprehensive. Outdated, inaccurate information hampers informed decision-making and makes measuring progress on patient access programs difficult. Technology can help commercial teams generate insights on key indicators of patient access such as new prescriptions, refills, adherence rates, coupon utilization, reimbursement rates, and patient engagement to design interventions that drive medication adherence and demonstrate value to payers. An effective patient access solution turns a broad spectrum of real-time data into insights that provide an accurate view of the patient journey. It enables users to unlock these insights through intuitive, interactive dashboards. You can learn more about the metrics that matter when measuring your patient access program here. ### Engaging patients Offering patient access and support services is the most tangible way for life sciences companies to connect and engage with patients. Each of the touchpoints along the patient’s journey can influence the likelihood of prescription abandonment, time to therapy initiation, and adherence to therapy. With more than $300B in estimated treatment value lost due to medication non-adherence, investing in services to help patients comply with their prescribed treatment is well worth the investment particularly as healthcare consumers increasingly expect seamless digital experiences on par with other industries. A wealth of evidence shows that patient support services positively impact adherence, clinical outcomes, and satisfaction while lowering overall healthcare costs; however, these services can only deliver value if patients use them and most do not. Traditional patient support HUB programs, which employ a call-center approach, tend to be misaligned with today’s consumers’ expectations resulting in suboptimal patient engagement - typically in the range of 10-20%. A technology-enabled approach to patient services should enable manufacturers to elevate patient engagement by: - Making it easy for patients to interact with value-added programs - Offering a frictionless, consumer-centric digital experience that meets patients where they are - Giving patients options for how to engage and receive communications to have complete visibility and control of their prescriptions Check out this eBook to learn more about modernizing the patient experience to achieve your brand’s commercialization objectives. ### Facilitating scalability Commercializing a medication, particularly a specialty drug, is fraught with risks across the product lifecycle that can negatively impact growth, including increased competition, shrinking timeframe to hit peak sales, declining reimbursement, cost pressures, value-based pricing, and expiring patents. In addition, numerous variables, such as higher-than-expected volume, formulary expansion, and label changes, can precipitate the need to scale the capabilities of a manufacturer’s patient access platform. Scalability, “the measure of a system’s ability to increase or decrease in performance and cost in response to changes in application and system processing demands,” should be a primary consideration when evaluating enterprise technology. One of the biggest benefits of scalable technology is that it allows companies to be more agile and more easily adapt to business changes with a lower up-front financial outlay. Technology driven patient services solutions that rely on software are better positioned to respond to unexpected changes in demand than models that rely exclusively on human capital to engage with patients. ### Ready to do more with less? Patient access platforms that automate workflows, deliver insights, engage patients, and enable scalability are vital to capitalizing on opportunities in the pharmaceutical marketplace. To ensure a better return on their investments in digital tools and solutions, life sciences organizations should seek partnerships with technology vendors to help them capture impactful data and help leverage and scale the analytics to elevate their brands. As an end-to-end commercialization partner, PHIL offers a digital platform that streamlines medication access and provides an integrated approach to data analytics across the patient journey. Request a consultation today to discover how you can unlock your unique value. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Technology Trends Shaping the Future of the Pharmaceutical Commercialization Source: https://phil.us/technology-trends-in-pharmaceutical-commercialization/ ## Technology Trends Shaping the Future of the Pharmaceutical Commercialization Due to its highly regulated, high-risk environment, the pharmaceutical industry has traditionally been slow to adopt new technologies. A conservative approach to technology implementation means that pharma companies may be missing out on the advantages digital technologies offer and have lagged behind other industries in creating rich customer experiences; however, the Covid-19 pandemic significantly accelerated digital transformation throughout the industry. The latest healthcare technologies promise to transform the development and delivery of innovative pharmaceutical therapies and elevate the experience for patients and providers. Digital transformation is “the process of using digital technologies to create new – or modify existing – business processes, culture, and customer experiences to meet changing business and market requirements.” Here are four of the biggest health technology trends shaping pharma's future. ### Automation From employee on-boarding and clinical-trial management to launch monitoring and sales operations planning, automated processes streamline workflows for pharmaceutical companies, saving them valuable time and money. Automated processes can also improve the patient experience in ways such as identifying all drug financial assistance programs for which patients are eligible and helping them successfully initiate and stay on therapy. According to the 2021 CAQH Index, automation has reduced the annual cost of healthcare administrative transactions, such as eligibility and benefit authorizations and prior authorizations, by $166 billion. And there’s a huge opportunity to save an additional $20 billion simply by transitioning fully to electronic transactions. ### Advanced analytics Advanced analytics, which also includes artificial intelligence (AI), machine learning, deep learning, and natural language processing, helps companies draw insights from their vast data to make more informed and strategic decisions. A recent report forecasts that the global healthcare analytics market is expected to grow at an annual rate of 28.8%, reaching $93.3 billion by 2027. The report attributes the rapid expansion to “the development of advanced analytical solutions tailored to the specific needs of healthcare organizations and facilities providing financial, operational, clinical, and administrative services.” Pharma companies sit on a wealth of data. With advanced analytics, they can make use of real-world data to analyze medication adherence rates, clinical outcomes, social determinants of health (SDOH), and cost savings that can inform how they respond to a rapidly evolving patient experience. This can empower pharma companies to employ personalized, data-driven interventions to drive medication adherence and demonstrate value to payers among other use cases. ### Digital platforms According to a recent report from Gartner, digital life science platforms will be mainstream within five to ten years, which will enable companies to “nimbly adapt their business and operating models in response to external disruption and change in business strategy.” A digital platform handles end-to-end business processes to optimize operations and improve the experience for both internal and external stakeholders. Ideally, it enables a data-driven ecosystem that cuts across organizational information silos and technology investments. In addition to enhancing patient engagement, digital platforms can help pharmaceutical companies: - Strengthen commercial and marketing operations - Deliver the experiences patients expect and demand - Optimize distribution and drug fulfillment channels ### Biosensors and wearable devices Driven by technological advances in mobile devices, remote patient monitoring, and disease detection and diagnosis, the global wearable biosensors market is expected to surpass $49 billion by 2027. The potential of wearable technologies to collect real-world data, enable personalized care, and improve patient outcomes presents significant opportunities for the pharmaceutical industry. McKinsey & Company gives an excellent example of how a digitally enabled approach to patient care using biosensor technologies may “improve outcomes to the extent that they could become a condition of reimbursement, particularly for expensive specialty drugs”: “A care plan for a Parkinson's patient might include a medication regimen with "chip on a pill" technology to monitor drug taking along with a smartwatch that monitors the patient's condition, sends him or her reminders to adhere to the prescribed treatment, and sends the neurologist compliance and health-status reports. The neurologist can then coach patients on lifestyle changes or even customize therapy remotely.” ### Are you ready for the future? Automated and secure data systems with next-generation analytics are vital to capitalizing on opportunities in healthcare. To ensure the commercial success of their life saving therapies, life sciences organizations would be wise to consider partnerships with technology vendors that can help them enhance their use of data to elevate the patient experience and drive overall brand value. As an end-to-end commercialization partner, Phil delivers a digital platform that streamlines medication access and adherence while providing an integrated approach to data analytics across the prescription journey. Get in touch today to discover how you can drive market access with deeper data insights. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # The Case for an Alternative Channel Strategy in Specialty-Lite Source: https://phil.us/the-case-for-an-alternative-channel-strategy-in-2024-and-beyond/ ## The Case for an Alternative Channel Strategy in Specialty-Lite A major challenge for life science companies that manufacture specialty-lite therapies is finding a channel strategy that offers the level of access services patients and healthcare providers (HCPs) need at a price point that supports the brand's financial health. Typically, brand teams string together a network of brick-and-mortar retail or specialty pharmacies and either work with multiple vendors to build a traditional call-center-based hub or rely on the specialty pharmacies to provide these services. The result is that the brands' gross-to-net cannot sustainably support this channel strategy. To mitigate this challenge and future-proof their specialty-lite brands, manufacturers should consider adopting an alternative channel strategy that is digital and integrated across the prescription journey. ### Long-established channel strategies are falling short In today's world, consumers increasingly demand seamless healthcare experiences and expect to receive their prescriptions conveniently and affordably. Retail and specialty pharmacies play a pivotal role in the distribution, fulfillment, and reimbursement of medications, yet may be limited in their ability to meet the expectations of patients facing access barriers. Retail pharmacies do not have the resources and are often too busy to pursue prior authorizations (PA) on behalf of patients and HCPs. Specialty pharmacies may not be incentivized to fill specialty-lite prescriptions because the prices are too low to justify providing the support services needed to obtain coverage. In either case, pharmacies may utilize uncovered manufacturer coupons as an easier, more profitable path to securing fulfillment. For manufacturers that go with a traditional call-center-based hub, this costly endeavor results in poor ROI for specialty-lite brands. It also fails to deliver the experience today's consumers want, diminishing patient access. ### Streamlining the patient access journey The patient and HCP experience with a manufacturer's access services is a significant differentiator for both specialty and specialty-lite brands. To be successful in this space, life science companies must work effectively with channel partners to employ digital solutions that integrate across the prescription journey, meeting patients – and providers – where they are today. An integrated digital channel helps manufacturers better meet the access needs of patients with the ability to: - Deliver a seamless and personalized patient experience that facilitates program enrollment and engagement, which boosts access. - Integrate into HCP workflows to streamline the PA process, which can lead to more covered prescriptions. - Provide more transparency around out-of-pocket costs, financial assistance, PA status, and prescription and refill status to support decision-making. ### Succeeding with an integrated digital channel in 2024 A digital channel with end-to-end integration allows manufacturers to leverage advanced analytics so brand teams can have a complete picture of the patient access journey – from the point of prescribing to the point of dispensing – and even down to the territory level. With this information in hand, they can evaluate the effectiveness of their commercialization efforts and adjust business rule parameters when needed to continuously improve covered scripts, affordability, and adherence while supporting the brand's financial health. By partnering with Phil, you gain access to a nationwide pharmacy network with 98% plan coverage that allows patients to receive prescribed therapy quickly, conveniently, and affordably. Our digital platform helps more patients get started and adhere to treatment, automates prior authorizations, and enables manufacturer-driven coupon utilization. Real-time insights give you strategic visibility into the entire prescription journey. Just as importantly, you can ensure your teams coalesce around driving the preferred channel for brand success. PhilRx generates real-time data down to the territory level, which allows field teams to have insight into how the digital channel increases HCP engagement and covered scripts. When the field teams' performance incentives align with the company's brand goals, they will be motivated to drive more scripts through that channel. To learn more about how to build an integrated digital channel for your specialty-lite brand, download our Life Sciences Hub Design Playbook. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # The Case for an Alternative Channel Strategy in Specialty-Lite Source: https://phil.us/the-case-for-an-alternative-channel-strategy/ ## The Case for an Alternative Channel Strategy in Specialty-Lite A major challenge for life science companies that manufacture specialty-lite therapies is finding a channel strategy that offers the level of access services patients and healthcare providers (HCPs) need at a price point that supports the brand's financial health. Typically, brand teams string together a network of brick-and-mortar retail or specialty pharmacies and either work with multiple vendors to build a traditional call-center-based hub or rely on the specialty pharmacies to provide these services. The result is that the brands' gross-to-net cannot sustainably support this channel strategy. To mitigate this challenge and future-proof their specialty-lite brands, manufacturers should consider adopting an alternative channel strategy that is digital and integrated across the prescription journey. ### Long-established channel strategies are falling short In today's world, consumers increasingly demand seamless healthcare experiences and expect to receive their prescriptions conveniently and affordably. Retail and specialty pharmacies play a pivotal role in the distribution, fulfillment, and reimbursement of medications, yet may be limited in their ability to meet the expectations of patients facing access barriers. Retail pharmacies do not have the resources and are often too busy to pursue prior authorizations (PA) on behalf of patients and HCPs. Specialty pharmacies may not be incentivized to fill specialty-lite prescriptions because the prices are too low to justify providing the support services needed to obtain coverage. In either case, pharmacies may utilize uncovered manufacturer coupons as an easier, more profitable path to securing fulfillment. For manufacturers that go with a traditional call-center-based hub, this costly endeavor results in poor ROI for specialty-lite brands. It also fails to deliver the experience today's consumers want, diminishing patient access. ### Streamlining the patient access journey The patient and HCP experience with a manufacturer's access services is a significant differentiator for both specialty and specialty-lite brands. To be successful in this space, life science companies must work effectively with channel partners to employ digital solutions that integrate across the prescription journey, meeting patients – and providers – where they are today. An integrated digital channel helps manufacturers better meet the access needs of patients with the ability to: - Deliver a seamless and personalized patient experience that facilitates program enrollment and engagement, which boosts access. - Integrate into HCP workflows to streamline the PA process, which can lead to more covered prescriptions. - Provide more transparency around out-of-pocket costs, financial assistance, PA status, and prescription and refill status to support decision-making. ### Succeeding with an integrated digital channel in 2024 A digital channel with end-to-end integration allows manufacturers to leverage advanced analytics so brand teams can have a complete picture of the patient access journey – from the point of prescribing to the point of dispensing – and even down to the territory level. With this information in hand, they can evaluate the effectiveness of their commercialization efforts and adjust business rule parameters when needed to continuously improve covered scripts, affordability, and adherence while supporting the brand's financial health. By partnering with Phil, you gain access to a nationwide pharmacy network with 98% plan coverage that allows patients to receive prescribed therapy quickly, conveniently, and affordably. Our digital platform helps more patients get started and adhere to treatment, automates prior authorizations, and enables manufacturer-driven coupon utilization. Real-time insights give you strategic visibility into the entire prescription journey. Just as importantly, you can ensure your teams coalesce around driving the preferred channel for brand success. PhilRx generates real-time data down to the territory level, which allows field teams to have insight into how the digital channel increases HCP engagement and covered scripts. When the field teams' performance incentives align with the company's brand goals, they will be motivated to drive more scripts through that channel. To learn more about how to build an integrated digital channel for your specialty-lite brand, download our Life Sciences Hub Design Playbook. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # The Evolving Role of Retail Pharmacies: What Branded Retail and Specialty-Lite Manufacturers Need to Know Source: https://phil.us/the-evolving-role-of-retail-pharmacies-what-branded-retail-and-specialty/ ## The Evolving Role of Retail Pharmacies: What Branded Retail and Specialty-Lite Manufacturers Need to Know Branded retail and specialty-lite pharmaceutical manufacturers must be acutely aware of the changes occurring within the retail pharmacy channel because they directly impact access and commercialization efforts. The evolving landscape – marked by the transition of retail pharmacies into primary care providers, the reduction of chain pharmacy footprints, the rise of mail order and online pharmacies, and critical labor shortages – directly influences how branded prescription medications are distributed, accessed, and managed. The following retail pharmacy trends are strong indicators that manufacturers must consider and adopt an alternative channel strategy in 2024 and beyond. #### Retail pharmacies are expanding their healthcare role In recent years, the role of brick-and-mortar retail pharmacies has been moving beyond the conventional practice of prescription dispensing. Pharmacists are now contributing to patient care through services such as immunizations, condition monitoring, and health screenings. Fueled by increased utilization during the pandemic, retail pharmacies have emerged as holistic healthcare centers, experiencing a 200% growth in clinic claims volumes from 2017 to 2022. Consumers are increasingly drawn to this one-stop-shop concept. A 2023 J.D. Power survey revealed that eighty-three percent of consumers want to receive health and wellness services at their local retail pharmacy. In response, major retail chain pharmacies like CVS, Walmart, and Walgreens are transitioning into health hubs, expanding their reach into primary care. In 2024 and beyond, a big challenge for pharmacists will be how to manage the demand of providing higher level patient care services while continuing to dispense medications. #### Brick-and-mortar pharmacies continue to reduce their footprint The U.S. pharmacy landscape is undergoing a significant transformation, with over 40% of counties labeled as "pharmacy deserts" in 2021, highlighting the widespread problem of limited access to pharmacies. In recent years, numerous retail pharmacy closures have been reported, contributing to this concern. Despite the earlier consolidation wave from 2010 to 2021 that saw CVS and Walgreens acquire nearly 5,000 pharmacy locations, there is a perceptible shift in focus more recently. The emphasis is now on improving operating margins, which has prompted large retail chains to announce plans to substantially reduce their footprint by permanently closing store locations across the country. Most recently, CVS announced it will be closing some of its pharmacies in Target stores as part of its “realignment strategy.” This approach appears to align with national chains exploring growth in healthcare services, primary care, and vaccinations. #### The revenue shift from traditional brand-name drugs to branded retail and specialty-lite therapies continues The revenue shift from traditional brand-name drugs to specialty-lite therapies is significantly impacting retail pharmacies, reshaping their business models and strategies. Branded retail and specialty-lite medications, which come at a lower price point than specialty therapies, but typically still require prior authorization (PA) and high copays, are a rapidly growing segment of the market. This shift has several implications for retail pharmacies: - Revenue dynamics: Traditional brand-name drugs, once a major source of revenue for retail pharmacies, are facing increased competition from generic alternatives and biosimilars, leading to a decline in revenue from these products. While specialty-lite therapies command higher prices, they come with operational and administrative challenges that are steering retail pharmacies toward diversifying their revenue streams. - Operational challenges: Branded retail and specialty-lite medications involve administrative processes, such as PAs, that require coordination with HCPs and payers. Retail pharmacies must invest in additional staff and training to manage the complexities associated with ensuring patients get insurance coverage and copay support for these medications. - Patient engagement and support: Branded retail and specialty-lite therapies often require additional patient support due to access challenges and potential side effects, prompting retail pharmacies to adapt by providing enhanced patient education and adherence support to ensure optimal outcomes for patients. #### There is an ongoing shortage of pharmacy personnel Labor shortages are exerting a notable impact on retail pharmacies, posing significant challenges to their operations. The shortage of qualified personnel, including pharmacists, pharmacy technicians, and support staff, is leading to increased workloads for existing staff, which are tied to burnout, more shortages, and disruptions in service. As demand for healthcare services, prescription dispensing, and patient care continues to rise, retail pharmacies are finding it increasingly challenging to adequately staff their facilities. The strain on the workforce affects various aspects of pharmacy operations, from fulfilling prescriptions and providing patient counseling to managing administrative tasks. The shortage also impedes the ability of retail pharmacies to expand service offerings or explore new avenues, creating a need for innovative solutions such as technology integration and workflow optimization to alleviate the impacts of the ongoing labor shortage. #### Digital hubs with integrated pharmacy services are gaining traction Consumers' awareness and acceptance of alternative pharmacy channels is growing as many choose to avoid traditional pharmacies, preferring a digital, Amazon-like experience to access their prescribed medications. This shift is consistent with the broader trend toward digital health solutions that offer convenience and a seamless experience. Consequently, digital hubs are emerging as significant players in the evolving retail pharmacy landscape, offering innovative solutions that reshape how consumers access medications. Considered disruptors in the pharmacy market, digital hubs with integrated pharmacy services operate on a technology-driven, direct-to-consumer prescription fulfillment model, enabling patients to order prescriptions and schedule home delivery through a mobile app. They also automate the benefits verification and prior authorization processes, freeing healthcare providers and retail pharmacists from this burden and enabling patients to access their prescribed medications faster and more affordably. #### Let’s navigate these changes together Phil is an end-to-end digital hub platform that helps retail and specialty-lite brands successfully navigate retail pharmacy challenges, enabling them to proactively shape their commercialization approaches, ensure optimal market access, and effectively meet the needs of patients and healthcare providers. The PhilRx platform utilizes a non-dispense pharmacy that bridges our digital hub with a nationwide pharmacy network to ensure patients receive prescribed therapy quickly, conveniently, and affordably. Ready to get started? Request a demo today! Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # The Impact of Time Constrained HCPs on Life Sciences Commercialization and How Manufacturers Should Adapt Source: https://phil.us/the-impact-of-time-constrained-hcps-on-life-sciences-commercialization-and/ ## The Impact of Time Constrained HCPs on Life Sciences Commercialization and How Manufacturers Should Adapt Workflows within physician practices have drastically evolved over the last few decades. This shift is due to the transition to value-based payment models, technological advancements, and changing patient expectations for a modern access experience. Additionally, health insurer policies designed to manage growing healthcare resource utilization continue to disrupt the natural flow of patient care by introducing new administrative requirements that create challenges for providers. According to U.S. Surgeon’s Office advisory, time constraints and administrative demands that compete with patient care – exacerbated by growing prior authorization (PA) requirements and staff shortages – are major contributors top hysician frustration and burnout. Time-constricted HCP workflows can negatively impact the commercialization of branded therapies as HCPs often seek alternative therapies if they lack confidence in patient access. Life sciences companies must adapt accordingly so their patients and branded therapies can thrive. ### How do current HCP workflows impact life sciences brands? Healthcare provider time constraints can reduce the effectiveness of sales efforts, leading to slow adoption at launch and throughout the product life cycle. Pharmaceutical sales representatives' access to physicians has become increasingly difficult over the last several decades. At least half of HCP practices restrict rep visits in some way – up from just a quarter in 2008. With physician practices experiencing growing administrative burdens and turnover, getting quality face-face time with providers to speak to the clinical efficacy of a product is more difficult than ever. The burden of utilization management requirements, such as PAs, is often negatively correlated with prescriber adoption of branded therapies . A 2022 national survey of physicians revealed that over 80% of providers refrain from prescribing certain medications over half the time due to utilization management requirements. And if the prescriber or patient has a poor experience during the PA process, brand loyalty will undoubtedly suffer, with the manufacturer risking the loss of a long-term prescriber. ### Adapting to HCP workflow challenges As life science companies face numerous challenges in the pharmaceutical marketplace, including adapting to HCP evolving workflows, conventional commercialization strategies are waning in their effectiveness. The following four approaches are highly effective in helping brand teams mitigate the negative impacts of provider time constraints to grow brand loyalty: #### 1. Optimize the field team A 2021–22 report found that 70% of HCPs feel that field reps “do not completely understand their needs and expectations,” and 62% say that the most significant area where pharma representatives can add value is by understanding their needs and sharing only relevant content with them to make the interactions more insightful. The key takeaway is that field teams need to evolve their approach to be more responsive and relevant in the limited time they have with HCPs. Life science companies should be educating reps on the tools they have at their disposal, how these tools facilitate success, how the patient access support program benefits them and their customers, and how any copay or bridge programs work. Sales reps must be able to answer questions about insurance coverage and work in tandem with the field reimbursement specialist to address any PA and reimbursement issues that arise. With the right information and tools in hand, integrated field teams can drive brand performance and patient access more effectively. #### 2. Engage with providers using their preferred channels Time constraints impact how physicians prefer to receive information. To build trust and engagement with a physician audience, it’s crucial to respect these preferences. Consider the following findings on HCP digital channel preferences: - 68% identified webinars or webcasts as their most preferred channel to receive information - 62% and 57% preferred to receive clinical and medical content on their computers and laptops, respectively. - 50% prefer to receive promotional content on their mobile or tablet - 47% prefer receiving communication through the marketing email channel. #### 3. Leverage technology to streamline the PA process for HCPs From the point of prescribing to driving therapy adherence, automated processes reduce friction across the prescription journey. According to a Deloitte survey, 72% of physicians identify PAs as one of the biggest workflow issues to be solved with technological solutions. Manufacturers can meet HCPs where they are by leveraging technology to improve patient access. Tech-enabled patient access services should ensure the PA process works within current HCP workflows, staying within the prescriber’s EHR, pre-populates required forms with clinical information, and monitors PAs for submission success. By making prescribing as easy as possible and simplifying the PA process, HCPs are more likely to write scripts and help patients get started on their prescribed therapy more quickly. #### 4. Use a data-driven approach To bring value to time-constrained providers, commercialization teams must understand what is happening across the prescription journey. Life science companies that invest in capabilities to capture and analyze the best data to make informed commercialization decisions will realize better brand outcomes and a competitive advantage. Tracking the right metrics enables greater visibility into the prescription journey and how it impacts HCPs and patients so meaningful changes can be made, when necessary, throughout the brand’s lifecycle. Whether a PA has stalled due to missing data on a form or the pharmacy has not done an electronic benefits verification, the field team can proactively assist the provider before frustration sets in and expedite the patient’s access to therapy. ### Let’s drive your brand’s success The impact of constrained HCP workflows can reverberate through the entire lifecycle of your branded therapy. The challenges are undeniable – limited physician access, utilization management hurdles, and dynamic communication preferences threaten brand success. By aligning your approach with the evolving needs of providers, you can secure your brand’s position in the market, foster brand loyalty, and ultimately maximize patient access. As an end-to-end commercialization partner, Phil helps life sciences companies deliver a tech-enabled, data-driven patient access experience, mitigating the burden of the PA process for physicians and their staff and empowering them to spend more time on patient care while facilitating therapy access and adherence. Download this prior authorization guide to learn how the PhilRx platform leverages technology to modernize the hub experience and streamline the payer utilization management process for physicians. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 3 Ways for Pharmaceutical Companies to Improve the Probability of Launch Success Source: https://phil.us/three-ways-for-pharmaceutical-companies-to-improve-the-probability-of-launch-success/ ## 3 Ways for Pharmaceutical Companies to Improve the Probability of Launch Success Launching a successful pharmaceutical brand is no easy task. It takes significant stakeholder alignment across many strategic fronts to successfully transition from FDA approval to product adoption and growth. And even with a sizable base and formulary placement, it doesn’t necessarily follow that a brand will overcome the “Coverage Hurdle'' that requires a brand to jump through hoops to convert market access to a high % of covered dispenses. With the stakes at brand launch at an all-time high as a result of soaring drug development costs and the prospect of slipping into a mid-cycle crisis an ever present reality - brands would be wise to adopt new paradigms at launch. While the need to adopt new launch models is essential, it remains to be seen whether such a paradigm shift is currently present in the marketplace.This question is particularly salient as it relates to smaller sized organizations whose share of launches has been increasing as % of annual new products introduced to the marketplace. Recent McKinsey research suggests their share of successful launches is well below that of experienced launchers: While this trend can’t be attributed to any one factor given all launches are dynamic and unique, one cause identified that is contributing to this disparity is that leaner organizations often rely on relationships with a few key opinion and trial-site leaders to inform their thinking on critical decisions like pricing, sales-force deployment, and partnerships. This should come as no surprise as smaller, capital constrained organizations inevitably have limited human capital to support commercial efforts. While larger companies typically deploy specialists in key areas such as marketing, access, and sales, it’s not uncommon for key executives at smaller organizations to serve as generalists that make decisions across these essential areas. In time constrained launch phases, commercial leaders often fall back on previously utilized partnerships and paradigms that are not necessarily fit to succeed in today’s dynamic drug channel. With insights gleaned from over 100 access programs across therapeutic areas, here are some of Phil’s key learnings that that can be applied to brand launches to help brand’s realize their unique potential: Prioritize Brand Loyalty over New Patient Starts - During a brand’s launch phase, commercial teams are often laser focused on generating a head of steam with HCPs and patients to get patients on therapy. From a tactical standpoint, this generally means a significant marketing effort directed at HCPs to educate them on the efficacy of their product and subsidizing access to therapy with a bridge program while the brand expands formulary placement. While getting patients on therapy is essential, generating a loyal base requires more than driving new prescriptions with manufacturer subsidies. To create lasting brand loyalty, brands must think holistically about their goals during a launch, and this should start with prioritizing the overall patient experience with their brand to ensure patients are able to easily access, afford, and adhere to therapy. If long term affordability and adherence are out of reach, brands will struggle to maintain loyalty over the long run even with a clinically differentiated product. This will result in diminished confidence with HCPs and patients which in return stunts their chances for sustained growth. Weight Market and Patient Access Equally - While most brands lack significant market access with top tier payers at launch, brands that have demonstrated differentiated clinical efficacy can reasonably expect to sign some major payor contracts. When this happens, the prevailing expectation is that these contracts will unlock patient access translating to meaningful coverage of dispenses. Commercial executives understand that this is essential for sustained growth as manufacturers can’t subsidize their brands with access dollars forever. Yet, it’s increasingly common for brands to be frustrated to find that their formulary placement isn’t flipping the script on the overall percentage of covered dispenses. The cause for this is typically related to challenges with prior authorization requirements as well as the misaligned incentives at the pharmacy counter that contribute to manufacturer coupon overutilization. Brands should shift their thinking further upstream from simply generating market access to orchestrating covered dispenses. This can be accomplished by choosing the right access partner to cultivate patient access strategies that facilitate a high probability of coverage success. Choosing the Right Access Partner is Critical - As pharmaceutical companies prepare for launch, they need to make critical decisions regarding their partner ecosystems that can help them realize commercial goals. There are two leading factors that have made this process more challenging for brands. First, as the size of the pharmaceutical market has expanded, so has the number of potential vendors. More choice has made the decision-making process more complex given that many solution providers look the same, talk the same, and make the same promises. Second, the complexities of the drug channel have increased dramatically, and the overall pace of change and disruption is increasing. This has translated into a need for larger partner ecosystems and diluted effectiveness of legacy access partners. Therefore, it’s essential for brands to ask the right questions when evaluating potential partners. Brands should press hard to determine if organizations are: - Positioned to respond to rapidly shifting consumer and HCP expectations - Structured to operate with aligned financial incentives - Able to corroborate their claims and results with robust data & references - Capable of making sense of data to provide actionable insights to inform strategy - Investing in innovation that will result in long term benefits in an evolving channel The bottom line is that launching a successful brand is a more challenging proposition than ever, particularly for smaller pharmaceutical companies. By prioritizing a more holistic and innovative approach that can be realized with the right partners, brands can meaningfully improve their probability of high adoption and reaching their expected value. Through its next-generation patient access platform, Phil partners with pharmaceutical manufacturers to remove barriers to medication access and adherence. A seamless patient experience allows those who need them to be able to benefit from their prescribed drug therapies. Visit our website to learn more. Share this article on: ##### Author Dan Johnson Director of Product Marketing, Phil Dan supports the organization’s growth by driving go to market strategy, crafting compelling content, and leading sales enablement. He has an extensive background in healthcare big and small and is passionate about the ability of technology to improve health outcomes. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # 3 Ways Healthcare Technology is Improving Medication Adherence Source: https://phil.us/three-ways-healthcare-technology-is-improving-medication-adherence/ ## 3 Ways Healthcare Technology is Improving Medication Adherence One of the most significant burdens on the U.S. healthcare system is nonadherence to drug therapy. Not only does this issue exact a severe toll on patients’ health and quality of life, but the related healthcare costs are also staggering. Studies show that up to 60% of patients struggle with medication adherence, and failure to take prescribed treatment causes an estimated 125,000 avoidable deaths and $100 billion in preventable healthcare costs each year. For years pharmaceutical companies have tried to address nonadherence by making medications more manageable and convenient to take through drug formulation and delivery method improvements. The latest technologies hold great potential to solve this deep-seated problem. By connecting siloed and fragmented data from key stakeholders, like providers, pharmacies, and payers, and using mobile applications to communicate with patients, the tech sector is stepping with data-driven applications to support and improve medication adherence. Here are three examples: 1. Reminders: Many patients have difficulties understanding and remembering how to take their medications correctly. Complicated medication schedules due to dosing or polypharmacy are common reasons for nonadherence. Patient-friendly mobile applications can use pharmacy data to send out timely automated reminders, such as push notifications, texts, and video messages that help patients stick to prescribed treatments. Additional reminders that a prescription is about to run out help patients stay proactive and further support adherence. 2. Patient education: An easy-to-access patient prescription information portal can offer educational materials on how a medication works, potential side effects, proper drug storage and administration, dosing, what treatment benefits to expect if taken as prescribed, and encouragement to contact their prescriber if anything unexpected occurs. Patient portal technologies can drive health literacy, which impacts treatment adherence and patient outcomes. 3. Motivation: Technology can help motivate patients to stick with their prescribed therapy. Consistent encouragement to complete various therapeutic steps combined with informative tools that drive a better understanding of how those steps pave the way to a meeting patients’ health goals can boost adherence. A 2017 study concluded that gamification – applying video game elements, such as virtual rewards for completing tasks, in a non-gaming environment – was a “valuable technique to motivate people to adhere to medication regimens.” In fact, the healthcare gamification market is forecasted to grow at an annual rate of 11.9% from 2019 to 2026. The bottom line is that personalized electronic correspondence promotes patient engagement and empowers patients to strive for therapy independence and self-management. Healthcare technology applications create opportunities to boost adherence to long-term therapies. While technology cannot replace the relationship between a patient and clinician, it can facilitate better partnerships between healthcare providers, pharmaceutical manufacturers, pharmacies, and patients to enhance outcomes. Through its next-generation patient access platform, Phil partners with pharmaceutical manufacturers to remove barriers to medication adherence. A seamless online experience empowers patients to access and benefit from their prescribed drug therapies. Visit our website to learn more. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Transforming the Patient Experience with a Strong Direct-to-Consumer Program Source: https://phil.us/transforming-the-patient-experience-with-a-strong-direct-to-consumer-program/ ## Transforming the Patient Experience with a Strong Direct-to-Consumer Program The pharmaceutical industry has undergone a digital transformation – as of 2024, over 75% of patients have accessed care virtually. Leading brands across the industry are embracing direct-to-consumer (DTC) programs to meet modern patient needs. If you’re not considering how this access strategy could benefit your stakeholders, you may be missing out on the opportunity to better serve your patients and providers while driving brand performance. A recent webinar hosted by Phil, in collaboration with Miten Soni, Associate Director of Brand Marketing at Sun Pharmaceuticals, sheds light on how pharmaceutical companies can define, analyze, and implement an effective DTC program in today’s virtual healthcare environment. #### Keeping Pace with Evolving Patient Expectations From online shopping to mobile food ordering to virtual learning, consumers have become accustomed to the increased speed, flexibility, and choice that technology offers. These advancements across industries have radically changed what patients want and expect from their healthcare experience. 4 in 5 patients want to use technology to manage their healthcare, and 60% of patients expect their digital healthcare experience to mirror that of retail. Top reasons that patients like digital access channels include the convenience, experience, and accessibility. The digital care environment is here to stay, and it’s the experience of the future. #### Defining DTC in Pharma The definition of direct-to-consumer can vary across organizations. At Phil, we define this as a digital access program with four distinct components: - DTC marketing strategy: a direct-to-consumer advertising strategy that is executed across multiple channels that are relevant to your patient population. - Telemedicine channel: an access channel that gives patients the option to see a provider and get prescribers through a telehealth appointment. - Digital patient experience & pharmacy services: a digital enrollment and prescription management platform for patients, including home delivery, text updates, and refills. - Digital HCP experience & PA process: an enhanced prior authorization (PA) and prescribing process for providers that keeps them in their existing workflows. If you’re interested in seeing how other manufacturers have approached DTC programs, we recommend this case study. #### Evaluating the Efficacy of DTC It’s important to keep in mind that direct-to-consumer programs will not be suitable for all brands. We suggest evaluating the following criteria when determining whether DTC may be a good potential fit for your brand: Patient population: analyze different aspects of your patient population to determine whether DTC is the right fit for a specific brand, such as: - Patient needs and preferences - Ideal medication access experience - Key education and engagement touchpoints Program strategy and design: consider the brand’s broader access strategy and whether a DTC program can support and integrate with these approaches, including: - Patient support strategy - Coverage and pricing strategy - Provider engagement strategy - Patient and provider education strategy Brand usage and requirements: evaluate the brand usage experience for the patient, and how this could impact a DTC program based on: - Role of pharmacist - Complexity of condition - Dosage requirements - Usage effects Regulatory compliance: consider the broader implications, as well as any condition-specific requirements, that could affect a DTC program, including: - Data privacy and security policies - Regulatory requirements - HIPAA compliance - Channel stipulations #### Building Blocks of a DTC Program DTC programs can (and should) differ based on the above factors, including but not limited to the brand’s goals, patient population, regulatory requirements, program strategy, and more. That said, there are several key components that most programs will benefit from: - Multiple access channels: gives patients the option to access care however works best for them, through telemedicine or in-office appointments. - Digital prescription fulfillment: offers digital prescription enrollment, fulfillment, and management for patients through a digital hub. - Simplified PA and prescribing process: automates parts of the PA process while keeping prescribers in their current workflows. In addition, the program equips the field team with digital tools to monitor script activity and proactively engage prescribers. - Tech-enabled education and support: provides digital and human-touch support programs that are tailored to patients, providers, and field teams. - Real-time data and insights: leverages digital hub insights and telemedicine integration to gain full visibility across the access journey at the script, provider, and territory level. For a deeper dive into developing an alternative channel strategy that supports your DTC program, check out this blog post. #### Transforming Patient Care with DTC Direct-to-consumer is the future of medication access. By offering more convenience, flexibility, and choice through a digital access program, pharmaceutical companies can pave the way to improved patient outcomes, provider engagement, and brand performance. Your success is our priority – we’ve designed the PhilRx Digital Hub to support manufacturers looking to build a best-in-class access experience for their patients, providers, and brands. Book a demo to see what we can help you achieve. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Transforming the Prior Authorization Process: How Feedback Loops can Improve Patient Access to Life Sciences Brands Source: https://phil.us/transforming-the-prior-authorization-process-how-feedback-loops-can-improve/ ## Transforming the Prior Authorization Process: How Feedback Loops can Improve Patient Access to Life Sciences Brands The use of prior authorization (PA) to control the utilization of prescription drugs, especially specialty medications, is growing, with 79% of medical practices reporting that PA requirements increased between 2021 and 2022. By design, the PA process is a barrier to medication access – it can leave patients waiting for days, weeks, or even months for approval, and coverage denial may occur despite a therapy being appropriately prescribed. The negative consequences of delaying treatment are well documented, yet more than 8 out of 10 patients still experience delays accessing their medications for reasons such as cost and insurance challenges. By implementing a PA strategy that integrates a feedback loop, life sciences manufacturers can improve the overall PA process for key stakeholders – ultimately accelerating time-to-therapy while increasing covered dispenses and gross to net (GTN) for their brand. ### The critical role of data in the PA process Data gleaned from the PA process, when analyzed appropriately can help pharmaceutical manufacturers improve access to branded medications and improve patient health outcomes. By tracking and analyzing this data, manufacturers gain insights into the utilization of their medications, payer reasons for denials or delays, how patients and prescribers respond to delays (i.e., prescription abandonment or writing a script for a different medication), and the impact of out-of-pocket costs and reimbursements. Pharmaceutical manufacturers can obtain a clearer picture of the PA process for their brands by leveraging a variety of data sources: - Prior authorization forms provide information about the patient and the reasons for the request. - Electronic health records (EHRs) and e-prescribing systems may give insights into the prescribing patterns of healthcare providers and the patient populations being treated with specialty therapies. - Payer claims data provide data on the number of PA requests submitted, approval rates, coverage outcomes, and reimbursements. - Hub providers can offer information on script quality, patient adherence rates, and barriers to access. - Field sales CRM systems provide data around the engagement levels with providers who are submitting PA requests, regional variances in PA activity, and how these factors impact sales performance. With a data-driven approach, commercialization teams can develop a comprehensive understanding of the PA process for their brands and can make more informed decisions on how to improve PA outcomes. Ultimately, manufacturers should look for a partner that brings together data from disparate sources to make it more accessible and actionable to improve overall brand outcomes. Brands that look to integrate data from a variety of divers providers will struggle to develop quality insights and make responsive changes in real time to drive growth. ### Using a feedback loop to enhance the PA process A feedback loop uses data output from a specific process to inform or adjust the execution of that process to reach a desired outcome or standard. Pharmaceutical manufacturers can apply the concept of a feedback loop to improve patient access to their brands by continuously using metrics to measure and analyze PA data across the patient journey at the territory level – from prescription to pharmacy dispense – and then using this data to adjust their approach to PAs. Examples of adjustments could include: - Educating prescribers on the importance of script quality and sending the right info like tried and fail information to pharmacies or hub providers - Communicating payer utilization management requirements to HCPs offices to reduce obstacles in the process and improve speed to therapy - Differentiating dispense workflows at the payer level to tailor the patient access experience and facilitate higher pull through - Identifying bottlenecks in real time to close gaps and submit outstanding PAs Brand teams can then measure the impact of each adjustment on their defined metrics to determine if further changes are needed. Only by taking an approach that prioritizes data driven optimization will brands be able to unlock patient access at scale. Read this case study to discover how an immunology therapy brand successfully integrated a PA feedback loop to overcome utilization management bottlenecks. ### Transform your brand’s PA process with Phil Unlocking the power of PA data should be at the forefront of every life science commercialization team’s effort to align brand goals with patient access. While a data-driven feedback loop can help companies quickly respond and adapt to patient access roadblocks, many teams find that getting a comprehensive – and timely – view of the PA process is a significant challenge. Phil is an end-to-end digital hub partner that provides an integrated approach to data analytics across the patient journey giving life science commercialization teams real-time visibility and control over their distribution channels. Get in touch today to discover how to leverage Phil’s data-driven software to transform your PA process and reach brand goals. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Translating Data into Actionable Insights to Inform your Patient Access Strategy Source: https://phil.us/translating-data-into-actionable-insights-to-inform-your-patient-access/ ## Translating Data into Actionable Insights to Inform your Patient Access Strategy By Andrew Duncan, SVP of Business Operations, Pricing & Strategic Finance Pharmaceutical companies are embracing big data initiatives to drive their business objectives. For brand teams, data is valuable only when they have the right data to make informed decisions that improve access to their retail and specialty-lite therapies. Life science companies that invest in capabilities to capture, strategically analyze, and draw actionable insights from the most relevant data will realize better brand outcomes. #### The value of complete and relevant patient access data Many pharmaceutical brand teams are experiencing data overload and are challenged to effectively use their data to solve for patient access issues, such as: - Constructing patient support program support amounts and criteria - Identifying HCP that could benefit from utilization management (UM) support - Analyzing GTN leaks in the patient access chain - Developing patient engagement strategies Then there’s the problem of missing data. Brands typically primarily rely on claims data, and to a lesser extent, data from prior authorization (PA) facilitation software, which leave out any prescriptions that are not taken to the pharmacy or switched out before processing the claim. It’s not uncommon for pharmacists to switch a non DAW-1 script for a branded retail product to a generic when a product is not on formulary. Sometimes, there are also economic reasons for switching. For example, if a pharmacist knows that a particular product is often severely under-reimbursed, they may switch to a generic to avoid losing money on that script. As a result, the manufacturer is often in the dark about the total number of scripts written and how many patients enrolled in their hub program or “went to the pharmacy”. They’re making decisions based solely on data that doesn’t reflect true patient dispense rated, or how well healthcare providers (HCPs) are clearing utilization management hurdles - or even whether they’re submitting PAs at all. Basing decisions on incomplete information derived from a subset of patients puts brand teams at risk of moving in the wrong direction. Working with a digital hub partner to help shepherd them through the data noise and ensure they see the complete patient access picture is critical to brand success. #### Informing field team efforts with a data-driven approach Equipping your field teams with the right data is key to improving patient access to your brand. Data can elucidate territory performance in terms of how effectively HCPs are clearing utilization management hurdles. This information allows field teams to be very targeted about who they engage with so they can be more efficient and see better results. For example, a field rep’s territory has an average PA submission rate of 80% for a specific brand; however, there is considerable variation across providers. Some HCPs have submission rates of 85-90% while others are 60-65%. It would make sense to target prescriber education to low submission offices, educating them on how to get their patients started on the medication as fast and affordably as possible. Data can also help identify trends, such as: - Changes in prescribing behavior. - PBMs that have more hurdles to coverage than negotiated or that your rebate would imply. - Reps who are generating a higher percentage of uncovered dispenses than others. These are all insights field leaders can use to pinpoint issues and address problem areas through education and support. #### The case for boosting your data analytics capabilities There are three major reasons why branded retail and specialty-lite brands need to boost their data analytics capabilities: - Data informs how to increase coverage, and more coverage translates to better patient access. It is challenging for mature brands to offer very generous uncovered programs. So, if a patient wants access to a product, the straight line is through coverage above all else. - The branded retail and specialty-lite space is unique in that it faces nearly all the same types of utilization management barriers as specialty products. However, HCPs are not usually as prepared to clear these hurdles effectively and specialty pharmacies that are well-versed in clearing them are not typically engaged. Working with a digital hub partner not only ensures that UM hurdles are understood, but the insights gleaned are funneled back to the sales team to better prepare their HCPs. - These drugs do not typically have the wholesale acquisition cost (WAC) to support traditional patient access programs. So, finding a strategic partner who can help clear those hurdles at a reasonable cost is critical. #### How partnering with Phil helps brands leverage their data more effectively First and foremost, Phil is a digital-first solution. The PhilRx Digital Hub natively captures every piece of information throughout the prescription process. We utilize a non-dispensing pharmacy to help maximize prescription coverage for patients. As the wholesaler, we purchase the product from the manufacturer and ensure that our network pharmacies maintain inventory levels to always have it in stock. We send them the scripts after a benefits investigation is run so we know whether the dispense is covered or uncovered and can ensure a smooth patient dispense experience. Phil uses every data point to design and continually refine our clients' patient access programs. Depending on the client's goals, this may include refining copay structures, targeting underperforming territories, or developing more effective payer strategies. With a hyper-targeted and data-driven approach, we help clients tailor their copay programs to ensure patients stay on therapy long enough to realize the full benefits of the medication and help determine how to balance GTN vs. total access and patient experience. Helping our clients see their patient access program as a continually evolving system rather than a copay card program with a static payment amount is critical to ensuring their program evolves along with the brand’s overarching strategy, GTN needs, and formulary coverage. Download Phil’s playbook, “Key Success Factors to Drive Brand Excellence,” to learn about our tailored approach to creating an optimal channel strategy for your brand. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Unlocking High Adoption of Your Patient Services Source: https://phil.us/unlocking-high-adoption-of-your-patient-services/ ## Unlocking High Adoption of Your Patient Services If you are struggling to capture a high % of patients in your support program, read this guide for actionable strategies to improve enrollment Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Upcoming Event: Partners in Patient Access: Drive Value for Your Biopharma Clients with PhilRx Source: https://phil.us/upcoming-event-partners-in-patient-access-with-philrx/ Lunch-and-Learn ## Upcoming Event: Partners in Patient Access: Drive Value for Your Biopharma Clients with PhilRx May 21, 2024 at 11am PDT 90% of patients want to access healthcare through technology. We’ve designed a digital hub that helps retail and specialty-lite brands maximize the metrics that matter - patient access and adherence, pharmacy coverage, and gross-to-net. Join us for an interactive online event to learn about the PhilRx Digital Hub and how we partner with pharmaceutical consultants and agencies to drive brand success. #### Key takeaways from this session: - Our approach to breaking down barriers to access, coverage, and gross-to-net - Core capabilities of the PhilRx Digital Hub for retail and specialty-lite brands - How we partner with biopharma consultants and agencies to improve outcomes Join us for this 45-minute conversational session over coffee, and get your questions answered about how Phil can support your organization and clients. The event registration window is now closed. Sign up to learn about future events. ### Meet your Speakers Hear from industry specialists and product experts at Phil ###### Neil Dean Director, Product Management, Phil Inc. Neil is a results-oriented Product Management professional with experience leading teams to launch emerging products & services to support strategic objectives. ###### Thomas Luby SVP Business Development, Phil Inc. Tom brings 25+ years of experience of strategic sales leadership in the life sciences industry, including at McKesson, winning the President’s Club award 11 times, and at RelayHealth, achieving 5,500% growth in a new pharmaceutical segment. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Delivering on Direct-to-Consumer: Exceeding Patient Expectations for Virtual Care Source: https://phil.us/upcoming-webinar-delivering-on-direct-to-consumer/ Upcoming Webinar ## Delivering on Direct-to-Consumer: Exceeding Patient Expectations for Virtual Care Jun 25, 2024 at 11am PDT Over 75% of patients have accessed care virtually as of 2024 – the primary reasons being for improved convenience and choice. As patient expectations for digital care continue to rise, the direct-to-consumer (DTC) movement should be top of mind for pharma manufacturers. Attend this webinar with industry leaders to unpack the evolving landscape of digital care from the perspective of patients and providers, and its potential to improve prescription access, adherence and affordability. #### What you’ll learn on the webinar: - Key trends in the digital care landscape and the expected impact on patient outcomes, provider engagement, and brand performance - Analyzing the efficacy of DTC on patient outcomes across therapeutic areas - Strategies for developing a DTC model that meets patient needs for greater convenience, choice and transparency across their healthcare journey - How pharmaceutical manufacturers are introducing successful DTC programs Discover the building blocks of a seamless digital care experience that delights patients and providers. Register now. The registration window is now closed. Sign up to receive updates about future webinars. ### Meet your Speakers ###### Jonas Boli Chief Product Officer, Phil With 15+ years of product management experience at large technology companies including Microsoft and Zillow, Jonas leads the Product Management department at Phil to support our company's mission to help patients get medications easily and affordably. ###### Miten Soni Associate Director, Brand Marketing, Sun Pharma Miten brings 10+ years of agency and brand marketing experience at small & medium pharmaceutical companies, including Pacira Biosciences and Sun Ophthalmics. Miten is currently the brand lead for Sun Pharma’s dry eye disease product, CEQUA. #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Upcoming Webinar: Optimizing Your Field Team to Maximize Patient Access Source: https://phil.us/upcoming-webinar-optimizing-your-field-team-to-maximize-patient-access/ ## Upcoming Webinar: Optimizing Your Field Team to Maximize Patient Access #### Upcoming Webinar: Optimizing Your Field Team to Maximize Patient Access Attend our upcoming webinar with Fierce Pharma to discover how to optimize your field team to drive patient access and gross-to-net. Attend our upcoming webinar with Fierce Pharma to discover how to optimize your field team to drive patient access and gross-to-net. Attend our upcoming webinar with Fierce Pharma to discover how to optimize your field team to drive patient access and gross-to-net. Attend our upcoming webinar with Fierce Pharma to discover how to optimize your field team to drive patient access and gross-to-net. Attend our upcoming webinar with Fierce Pharma to discover how to optimize your field team to drive patient access and gross-to-net. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Your Guide to Building An Exceptional Telemedicine Program Source: https://phil.us/upcoming-webinar-your-guide-to-building-an-exceptional-telemedicine-program/ ## On-Demand Webinar: Your Guide to Building An Exceptional Telemedicine Program Loading... All innovative therapies should consider a telemedicine strategy in order to meet patient demands and drive commercial success. On this webinar, you'll hear from industry experts at Phil and Prescribery as they share strategies and best practices for building and scaling a powerful telemedicine program that drives transformative brand outcomes. #### Watch this webinar to learn about: - Evolving patient expectations for digitally-driven care - Key components of a successful telemedicine program - How to measure the impact and effectiveness of your telemedicine program Why you should watch: Patient expectations for virtual care have radically changed. As of 2020, 93% of patients agree that they would use telemedicine to manage their prescriptions. In order to keep patients and providers happy, life sciences brands need a strong and successful telemedicine program. This webinar is suited for: Life sciences executives who are interested in building a best-in-class telemedicine program. If this sounds like you, we hope you’ll join us (and bring your insights and questions to the discussion)! #### Take telemedicine to the next level We've helped novel brands optimize patient access through telemedicine, and we can help your organization do the same. Book a call to learn more about how Phil can help. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # We can not find Phil in the EHR - what should we do? Source: https://phil.us/we-can-not-find-phil-in-the-ehr-what-should-we-do/ ## We can not find Phil in the EHR - what should we do? - To find Phil on the EHR, ensure you have selected the pharmacy type as RETAIL. - Search with the exact spelling and spacing of the name “PhilRx, LLC” - Search by NCPDP 3685508 - If you still can’t find PhilRx you can reach out to your EHR’s customer service line. - You can also prescribe to PhilRx via fax or phone: - Fax: (888) 975-0603 - Phone: (855) 977-0975 Share this article on: --- # We cannot find PhilRX in the EMR - what should we do? Source: https://phil.us/we-cannot-find-philrx-in-the-emr-what-should-we-do/ ## We cannot find PhilRX in the EMR - what should we do? To find PhilRx on the EMR, ensure you have selected the pharmacy type as RETAIL. - Search with the exact spelling and spacing of the name "PhilRx, LLC" - Search by NPI# 1487163598 - If you still can not find PhilRx you can reach out to your EHR’s customer service line. - You can also prescribe to PhilRx via fax or phone: - Fax: (888) 975-0603 - Phone: (855) 977-0975 Share this article on: --- # On-Demand Webinar: Improving Patient Access to Medications by Simplifying the Prescription Process Source: https://phil.us/webinar-improving-patient-access-to-medications-by-simplifying-the/ ## On-Demand Webinar: Improving Patient Access to Medications by Simplifying the Prescription Process Loading... Tune in as panelists will discuss the biggest challenges in the prescription process and implications to patients, as well as opportunities to improve medication access using technology. On this webinar, you will learn about: - Current gaps in the patient access journey and implications - Opportunities to improve medication access for patients - How technology can streamline the prescription process - Digital health tools that can be leveraged in the healthcare journey; and - How simplifying access to medication will drive improved health outcomes Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # On-Demand Webinar: Patient Access Strategies to Drive Sustained Brand Growth Source: https://phil.us/webinar-patient-access-strategies-to-drive-sustained-brand-growth/ ## On-Demand Webinar: Patient Access Strategies to Drive Sustained Brand Growth Loading... In today’s complex channel environment, commercial teams must optimize their patient access strategy for sustainable brand growth. Tune in as seasoned industry experts, Patrick Coyle, Founder & CEO of Novus Proximus LLC and Daniel Johnson, Director of Product Marketing at Phil, share how you can develop an integrated patient access strategy that unites your hub, field team, and services programs into a supercharged growth engine. On this webinar, you’ll learn: - Optimal commercial structure to respond to evolving channel dynamics - Best practices for aligning field teams to promote organizational goals - Understanding of the impact of financial barriers to patient success - Key success metrics for a successful patient access program - How to use data to optimize field and access program outcomes Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # What happens if a patient does not enroll with PhilRx after I send their prescription? Source: https://phil.us/what-happens-if-a-patient-does-not-enroll-with-philrx-after-i-send-their-prescription/ ## What happens if a patient does not enroll with PhilRx after I send their prescription? If a patient has not enrolled, PhilRx will send a series of SMS messages, we will call and leave voicemails to remind the patient to enroll. In addition, PhilRx will note on the HCP summary fax/email that arrives every Monday morning that the patient has not enrolled. Share this article on: --- # What if you could decrease time to therapy from 7 days to 1 day? Source: https://phil.us/what-if-you-could-decrease-time-to-therapy-from-7-days-to-1-day/ ## What if you could decrease time to therapy from 7 days to 1 day? The major issue with existing hub platforms is that they are based on multiple vendor tech programs that complicate and delay the patient access process. Many existing platforms are expensive to procure, clunky to work with and slow to launch. These factors not only impede patient access, but healthcare provider and manufacturer workflows as well. In the era of automation and same-day deliveries, there is significant room to improve the patient experience. Connecting the various players in the distribution chain seems to be necessary in order to solve these issues with the aim of improving the patient experience and speeding up time to therapy. This is why Phil was developed, to serve as a digital platform simplifying the patient and physician experience by streamlining administrative requirements to boost patient enrollment and adherence. Additional patient incentives include automated virtual copay programs that support affordability and further help with getting life saving therapies to patients in need. A simple and streamlined experience for all stakeholders directly translates to improved health outcomes for patients. By working with Phil, manufacturer partners are able to increase specialty pharmaceutical coverage and have more insight and control over their channels. Many leading manufacturers have adopted Phil to dramatically improve patient access and adherence, resulting in an average time to therapy from 7 down to less than two days. Manufacturers interested in learning more about Phil can contact us for more information. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # What is the PhilRx update cadence? Is there a way to adjust the frequency? Source: https://phil.us/what-is-the-philrx-update-cadence-is-there-a-way-to-adjust-the-frequency/ ## What is the PhilRx update cadence? Is there a way to adjust the frequency? The emails and faxes are weekly on Monday mornings and can not be customized at this point in time. We have found that this cadence provides a balance of giving you proper visibility and not overwhelming offices with information. You can call into Phil’s HCP Support team 855-977-0975, Option 1 or send an email (mdhelp@phil.us) if updates are needed more frequently. Share this article on: --- # What Makes Phil’s Prior Authorization Process Unique? Source: https://phil.us/what-makes-phils-prior-authorization-process-unique/ ## What Makes Phil’s Prior Authorization Process Unique? The prior authorization process (PA) presents a significant (and growing) roadblock for healthcare providers trying to get a patient started on a prescription therapy they deem best. In general, a PA requirement affects patients' experience with their healthcare. It represents a length of time – and the associated frustration – they must wait to receive their medication or go without the treatment they have been introduced to by their provider and may desperately need. If the prescribed therapy is not covered, this essentially precludes patients from being able to afford to start and adhere to a medication that could help them better manage a complex medical condition and improve their quality of life. Prescribers' biggest challenges are the level of manual effort required to complete prior authorization requirements and insufficient historical context with the health plan. For example, they are unfamiliar with the required forms – which vary from payer to payer – or unsure what pertinent information to include. Or, they are managing a large patient population and find it very difficult to address and complete prior authorizations at scale which can be tremendously diverse. Additionally, providers often struggle with conveying how the chosen therapy is clinically necessary to treat the patient's condition, flagging the payer that it should be covered. Providers have patients' best interests at heart and try their best to obtain coverage, so it's unfortunate that something simple – like missing patient data – keeps patients from the coverage they need. ### How manufacturers can alleviate PA challenges From the pharmaceutical manufacturer’s perspective, the more people take their medication, the more it can be studied in the population. When few people can afford the therapy because the pharmacy benefit manager (PBM) will not pay for it, pushing patients toward a cheaper treatment, manufacturers cannot get the real-life data they need for Phase IV trials or to demonstrate value to payers for formulary placement. Ultimately, this significantly jeopardizes brand success. Additionally, it also directly impacts their ability to recoup a return on their investment for the development of the therapy to continue to offer it to patients in a sustainable way. Demystifying the PA process for providers and patients and elimination points of friction are the best way for manufacturers to address the pain of utilization management roadblocks. Knowing what plans are asking for and presenting that information clearly and concisely is the best path for all stakeholders. When a brand hits the market, the manufacturer should have a good idea of what health plans will likely cover outright and what their targeted providers will need to do to get the product covered. The manufacturer must investigate, collaborate, and educate to alleviate PA challenges effectively. Providing as much context and information as possible to prescribers and patients can eliminate the opaqueness of the process, clearly set expectations, and result in higher adoption of their therapy. ### The value of streamlining the PA process It’s a well-accepted fact that a specialty or specialty-lite brand medication, especially when new to the market, will not be covered outright by most plans. Ideally, the best approach for the prescriber to get approval is to lean into the PA that’s required. Realistically, providers are very busy. The potential additional steps from a PA may not be worth their time from a cost-benefit perspective. Anything that delays the treatment or holds up the PA process might, in their mind, not be worth it when other treatments are on the market. And no provider loves to do the paperwork or see a claim get denied. Unfortunately, there’s no silver bullet to getting a medication approved and covered. Each plan has anywhere from one to five different forms required for submission to gain coverage and a variety of reasons why a drug is not covered. The following three knowledge factors must be present at the point of prescribing to maximize the chances of approval: - The patient has a good understanding of what their benefits may or may not cover - The prescriber knows which PA forms to send to the plan - The prescriber understands what information to include on the PA forms Manufacturers can support providers from the get-go, streamlining the PA process by thoroughly educating them on these knowledge points and partnering with a solution that can help improve submission rates. Additionally, manufacturers should also have a good sense of the impact of the obstacles that patients face when seeking therapies and explore programs (i.e. bridge, quickstart) that can help patients get on therapy quickly while seeking access to therapy. ### The essential role of technology and data analytics Technology and data analytics play a crucial role in improving the efficiency and accuracy of the PA process. Historical context regarding why PA requests were denied, what forms were used, and what information was needed for approval is vital to improving the process. At Phil, our platform tracks this information closely to provide this insight to manufacturers and inform our efforts. Technology enables us to gain historical context by looking at the PA data at a very granular level and using data analytics to extrapolate meaningful trends that can help providers submit more accurate PA forms and expedite the process. Our technology allows Phil's pharmacy team – the human aspect of all this – to guide the prescriber offices. For example, we can tell them, "This health plan always needs an ICD-10 code here. Please make sure you include one." Most PAs are electronic now, which is a big win for providers and patients. There's no need for doctors to call or fax the health plans anymore. Integrating Phil's system with the entities facilitating PAs allows us to help patients access their medication even faster. ### Phil’s secret sauce With many PA solutions on the market, there's one aspect that makes Phil stand above the rest – its secret sauce - and that's our human touch. Our PA specialty team does an excellent job of balancing Phil's technological capabilities which include prepopulation of forms, tracking outstanding submissions, and nudging prescribers. The human element allows us to open the lines of communication and build trust with our prescribers. Our research, data gathering, and nitpicking over PA forms enable us to help providers make more informed decisions so they can avoid wasting valuable time. Phil's technology also gives providers more visibility into where their patients' PAs stand and keeps patients informed each step along the way, taking our communications a step further. Even with these tools, our providers know there's always a human from Phil they can call. Visit https://phil.us/ to learn more about the PhilRx Patient Platform. Angela Stigliano, PharmD, is Subject Matter Expert for Pharmacy Operations at Phil, Inc. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # What to do if I receive a message indicating there is an issue with my insurance? Source: https://phil.us/what-to-do-if-i-receive-a-message-indicating-there-is-an-issue-with-my-insurance/ ## What to do if I receive a message indicating there is an issue with my insurance? In order to provide an accurate price quote, we need a photo of your prescription insurance card. This card should include the following info: ID, Rx BIN, Rx Group and PCN. 1. Text a photo of this card to 744-579. 2. You can log into your My.Phil account and upload a current photo - From the homepage, click on the person icon on the upper right-hand corner - Click the arrow next to the Insurance Section - Select “Add Insurance” - Select “Upload” and choose your photo - Select if you have commercial or government-sponsored insurance and click Save Common reasons we may have issues with your insurance include, but are not limited to: - We received your medical insurance when we need your prescription benefits information - Your coverage is no longer active - The information we have on file is invalid If you ever need additional assistance, you can always give us a call at 855-977-0975, option 3. Share this article on: --- # When will I receive my prescription? Source: https://phil.us/when-will-i-receive-my-prescription/ ## When will I receive my prescription? Your first fill is sent out via first class mail and should arrive within 1-5 business days. Refills are processed ahead of time and are shipped standard shipping to ensure you receive your prescription before your previous fill runs out. If you have any concerns or questions please contact us for assistance. Share this article on: --- # Where's the Data? The Healthcare Data You Need to Drive Commercialization Source: https://phil.us/where-is-the-data-the-healthcare-data-you-need-to-drive-commercialization/ ## Where's the Data? The Healthcare Data You Need to Drive Commercialization What matters most for life sciences companies is not the amount of data but knowing how to use it. A Forrester report revealed that data-driven companies experience an annual average growth rate of over 30%. Pharma companies that invest in capabilities to capture and analyze the best data to make informed commercialization decisions will realize better business outcomes and a competitive advantage. ### Understanding the value of data Data alone hold negligible value because it reveals very little meaningful information. The true value of data comes from analyzing the data to enable actionable insights. These insights can help pharma companies boost market access, improve business operations, and strengthen customer relationships. Using a data-driven approach for pharma commercialization can generate substantial returns, including a 5-10 percent net revenue improvement and 10-20 percent spend reduction/reallocation. By basing decisions on accurate information backed by validated data, pharma companies avoid moving in the wrong direction. Data-supported decisions eliminate political influence, bias, and following “gut feelings” that can lead to poor decision-making and waste valuable resources. Not all data is equal in its ability to contribute to sound business decisions. Data must be current and accurate when decisions are made. The healthcare environment is constantly evolving, so pharma companies should not rely on initial data sets that are likely to be no longer relevant. Continually collecting and analyzing data is key to effective commercialization strategies. Data sources for pharmaceutical commercialization There are various sources from which commercialization teams can leverage real-world data – post-launch data collected outside of a clinical trial – to make strategic, informed decisions, including: - Electronic health records (EHRs) and e-prescribing systems contain current, accurate patient-based data from prescribers. - Retail pharmacies collect a wide range of data on the prescriptions they fill and dispense, which offer a clearer picture of a patient’s medication use and barriers to adherence. - Supply-chain operations generate data across the entire product lifecycle, which can help identify vulnerabilities and bottlenecks that negatively impact market access. - Payer claims can provide medical claims data and data around enrollment and engagement in health plans and optional programs. - Patient-reported outcomes data comes from surveys in which patients independently report the status of their health conditions during treatment. - Digital devices and mobile health applications contain a wealth of patient-generated data on health habits and disease outcomes. - Disease registries collect data on patient populations diagnosed with specific conditions, which may reveal the quality of life and financial burden issues as well as other challenges not found in EHRs. - Customer relationship management (CRM) systems provide customer, customer engagement, and sales activity data that can drive commercialization objectives. ### 11 data-driven opportunities for pharmaceutical commercialization Data-driven decision-making offers many opportunities for pharmaceutical commercialization teams, including the ability to: - Demonstrate the value of treatments to payers - Enable outcomes-based pricing - Achieve a better formulary position - Drive medication adherence - Identify new opportunities for existing brands - Inform the design of patient services - Identify underdiagnosed patients - Grow sales and improve processes - Develop point-of-care clinical decision support - Strengthen provider, payer, and patient engagement - Harness the full power of digital technology investments ### Unlocking the power of data Unlocking the power of data should be at the forefront of pharmaceutical manufacturers’ efforts to align business goals and outcomes. Faced with an overwhelming amount of data and a complex healthcare ecosystem, many pharma commercialization teams find that getting a holistic – and timely – view of stakeholders is a significant hurdle. Data analytics can help companies quickly respond and adapt to market changes and obtain a competitive advantage with the right commercialization partner. Phil is an end-to-end commercialization partner that provides an integrated approach to data analytics across the patient journey giving life science commercialization teams real-time visibility and control over their distribution channels. Get in touch today to discover how you can drive market access with deeper data insights. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Why did my doctor send my prescription to Phil? Source: https://phil.us/why-did-my-doctor-send-my-prescription-to-phil/ ## Why did my doctor send my prescription to Phil? There are several reasons why Doctors choose to send your prescription to Phil: Pricing: We are able to get special pricing from the manufacturer on numerous commonly used, brand name medications. In addition to special pricing, we take the time to add any applicable manufacturer's coupons to bring pricing down as much as possible for you.- Prior Authorizations: We work with your Doctor to submit Prior Authorizations should they be required by your insurance for your prescription. Shipping: Shipping is always free! Your first fill is expedited at no cost to ensure medication can be started ASAP. Automatic Refills: Removing the hassle of remembering to pick up medications Support: Our Patient Advocate team is comprised of compassionate and enthusiastic problem-solvers who are here to help. We offer 365 days of support should you have any questions and need assistance! Share this article on: --- # Why Quality Scripts are Crucial to Ensuring Pharmacy Coverage for Your Brand Source: https://phil.us/why-quality-scripts-are-crucial-to-ensuring-pharmacy-coverage-for-your-brand/ ## Why Quality Scripts are Crucial to Ensuring Pharmacy Coverage for Your Brand When prescribing a specialty or specialty-lite therapy with hub services, a healthcare provider can often jumpstart getting their patient started on the treatment by sending the script directly to the hub. However, six out of ten providers report that they are uncertain of the insurance benefits information needed to start patients on complex therapies, and submitting the wrong information can hold up a prescription from the get-go. Health insurance plans typically have specific requirements that must be met before covering an expensive branded therapy. Those requirements start with the information on the script itself and include additional clinical information doctors must submit to meet utilization management requirements such as prior authorizations or step edits. Quality prescription intake is the first step to a smooth HCP and patient access experience and is crucial to ensuring your brand realizes the highest rates of adoption and coverage at the pharmacy as possible. #### What exactly is a “quality script”? At the most basic level, a prescription must include the following information to be considered valid for coverage of the prescribed brand: - Correct spelling of patient’s full name and date of birth - Right medication name, strength, dosage, and route of administration information - Instructions that comply with the drug’s approved indication - Quantity and refills on the prescription do not exceed the plan’s quantity limits - Specifies that medication should be “dispensed as written,” “brand name only,” or “no substitutions” When prescribing through a manufacturer's hub, the script must be submitted along with the insurance company's prior authorization request, if required. Providers will need to include specific clinical information that the insurance company needs to determine eligibility for coverage, which, at the least, typically includes: - The appropriate ICD-10 codes for the patient’s diagnosis - Prior therapy trial information that consists of the medication, strength, dosage, trial dates, and outcomes - CPT codes that correspond with the desired treatment #### 4 reasons why brands should monitor script quality Maximizing the number of quality scripts through the brand’s hub leads to: - Higher rates of prescription fulfillment: Missing or conflicting information will trigger a denial, which requires the provider’s office to either resubmit the prescription and PA or submit an appeal. When this happens, it’s more likely that the medication will never be dispensed due to the delay. Time-constrained HCPs may choose not to pursue an appeal, and the patient may decide to try an alternate therapy or simply abandon all together. In fact, 76 percent of physicians choose a different treatment when they encounter a barrier to prescribing a specialty or specialty-lite therapy therapy. - Improved speed to therapy: More than 8 out of 10 patients encounter frustrating delays when trying to access the medications they need to manage their health. And having the wrong patient information on the script is a common culprit. Manufacturers can take a proactive approach by ensuring HCPs are adequately informed on insurance coverage requirements such as ICD-10 codes for their patient population. - Higher rates of prescription coverage: High script quality correlates with coverage success for branded therapies. Discover how one specialty brand partnered with Phil and achieved a tenfold increase in prescription coverage by streamlining the PA process for prescribers and leveraging territory data on HCP behavior, payer responses, and script outcomes. - Better HCP and patient experiences: A poor prescribing experience translates to diminished brand loyalty, with the risk of losing a prescriber in the long run. A smoother prescription journey driven by a digital hub program can improve medication adherence. Evidence shows that switching to electronic prescribing increases first-fill adherence by 10% compared to traditional paper prescriptions. #### How to ensure high script quality for your hub program Physicians report that understanding the insurance requirements to get a patient started on a specialty brand is one of their most significant challenges. Field teams must be able to educate HCPs and their staff on how to properly submit scripts to the hub and address questions about insurance coverage and PA requirements so they can proactively send high quality script Life science companies should strive to closely integrate field teams with their hub, educating them on available hub tools, how the hub facilitates success, how the patient support program benefits them and their customers, and how any copay or bridge programs work. Hubs should deliver a PA process within current HCP workflows, pre-populate required forms with clinical information when available, and monitor the prescription journey to follow up to ensure the appropriate information is included in received prescriptions. With PhilRx, life science brands gain greater visibility into the prescription journey and can monitor performance at the territory level to optimize script quality nationally. With the right data at hand, they can deliver the appropriate interventions to drive meaningful changes. Whether a PA has stalled due to missing data on a form or prescribers continue to exclude ICD-10 codes on their prescription to the hub, the field team can proactively assist the provider to educate them to improve patient access. Ready to position your brand for long-term growth? Download this playbook on how life science manufacturers can get the most from their hub services. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Why should I send prescriptions to PhilRx? Source: https://phil.us/why-should-i-send-prescriptions-to-philrx/ ## Why should I send prescriptions to PhilRx? PhilRx simplifies the prescription process by assisting with prior authorization and transparency in prescription and cost tracking, ensuring your patients start and stay on the prescribed medication you provided. PhilRx helps patients receive the lowest out of pocket cost, free home delivery and refill reminders. Share this article on: --- # Why Strong Market Access Doesn’t Always Translate to Covered Dispenses Source: https://phil.us/why-strong-market-access-doesnt-always-translate-to-covered-dispenses/ ## Why Strong Market Access Doesn’t Always Translate to Covered Dispenses Strong market access, the ability of a pharmaceutical manufacturer to secure reimbursement and coverage for their products from payers and other decision-makers, does not always translate to covered dispenses at the pharmacy level – particularly for specialty and specialty-lite therapies. Manufacturers must also navigate a complex prescription fulfillment and payer utilization management landscape to overcome barriers to patient access. Here are the three biggest reasons why good market access does not guarantee coverage and what commercialization teams can do to overcome this challenge. ### There are coverage gaps in your pharmacy network There are many moving parts when it comes to market access and prescription coverage. Factors such as a pharma brand’s payer density, pharmacy plan contract footprint, and channel mix can greatly impact coverage at the pharmacy level. Most pharmacies participate in networks designed by pharmacy benefit managers (PBMs), who contract with health plans to obtain coverage for dispensed medications. However, these networks are dynamic often resulting in significant pharmacy plan contract gaps particularly amongst local and regional plans if pharmacies don’t have an in-state presence or utilize a mail-order model. Pharmacies may be part of open, preferred, or limited networks. Almost all retail pharmacies are part of open networks, where the patient’s out-of-pocket is the same at every pharmacy across the network. In a preferred network, patients pay less out-of-pocket at a preferred pharmacy than if they go to a non-preferred network pharmacy - a common tactic used by Medicare Part D plans to organize groups of pharmacies willing to accept lower reimbursement. Limited networks, which give payers more operational and economic control over prescription fulfillment, limit coverage to only designated pharmacies and are common for higher WAC specialty medications. According to an IQVIA report, tighter payer management is a growing trend causing “greater fragmentation of coverage across states and payer groups, as well as slower uptake of new products.” Manufacturers should consider the following factors when evaluating their channel strategy: - The percentage of payers the pharmacy network is contracted with – often driven by network design – corresponds with the level of coverage a brand can expect. - Payers prefer that specialty medications be distributed through limited channels, such as specialty pharmacies, which can impact patient access. - Geographical variations in patient population and health plan behavior can impact coverage decisions. - Shrinking pharmacy distribution networks are giving the largest contract entities more leverage while potentially leaving brands with no coverage in some areas. ### Your uncovered coupons are overutilized Over the past decade, specialty manufacturers have increasingly turned to copayment coupon programs to help defray patients’ out-of-pocket cost-sharing obligations at the pharmacy to drive pull-through. From 2014 to 2016, these copay offsets increased by 32% across all retail brands. In 2021, about 70% of patients on newly-launched specialty drugs were on some type of patient assistance program subsidized by the manufacturer. In general, pharmacy reimbursement rates are based on a discount percentage from the average wholesale price plus a dispensing fee minus the patient cost-sharing amount. Reimbursement rates can vary widely across pharmacy format types – i.e., central fill/mail order vs. retail. The variation in reimbursement rates can lead to under reimbursement on the pharmacy side and when scripts are “underwater” pharmacies may apply manufacturer subsidies and potentially lead to uncovered option over utilization (free goods & cash) and transfer outs. Pharmacies particularly like copay coupon programs because they can use them to help customers afford their medications without hurting the bottom line. However, an over-reliance on uncovered coupons negatively impacts the manufacturer’s gross-to-net (GTN). ### Pharmacies are substituting your brand with a generic equivalent Brand-to-generic substitution has long been a common pharmacy practice across all therapeutic areas. Beyond the fact that a brand’s market share and the manufacturer’s bottom line take a hit from this practice, it can potentially have unintended consequences, especially in some therapeutic areas. Several studies suggest that switching to a generic equivalent may negatively impact medication adherence, resulting in poorer outcomes, causing more adverse events, and increasing the total cost of care. The impetus for this practice has primarily been to reduce costs. However, while the price for a generic equivalent has been estimated to be anywhere from 30% to 85% less than the branded therapy, early evidence on specialty therapy substitutions suggests there may be little to no cost savings in these cases. In addition, since most of a pharmacy’s revenue comes from the reimbursements it earns for dispensing prescriptions – their gross margins average 42.7% for generics and only 3.5% for brand-name drugs, they have a significant financial incentive to substitute brands with generics when feasible. Brands should think carefully about their pharmacy strategy when they lose exclusivity to ensure that they are able to best serve patients and protect their economics. ### Take the reins to drive better coverage More than one of three new drug launches fall short of expectations – yours doesn’t have to be one of them. Good market access for a specialty and specialty-lite medication does not guarantee that prescriptions for that medication will be covered at the pharmacy level. By understanding the coverage implications of your brand’s dispense network and partnering with the right commercialization platform, your team can take the reins to drive better coverage. Phil is the first end-to-end pharmaceutical commercialization platform that helps brands unlock coverage and maximize reimbursement. Life science companies have access to a nationwide pharmacy network that allows patients to receive prescribed therapy quickly, conveniently, and affordably. Phil simplifies prior authorizations, and supports manufacturer-driven coupon utilization. Real-time insights give our manufacturer partners strategic visibility across the prescription journey and enable you to make responsive changes to your business rules. Check out our Ebook to learn how to optimize coverage of your specialty brand at the pharmacy counter. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Why the Pharmacy Matters: A Guide for Life Sciences Manufacturers Source: https://phil.us/why-the-pharmacy-matters-a-guide-for-life-sciences-manufacturers/ ## Why the Pharmacy Matters: A Guide for Life Sciences Manufacturers The pharmacy has an outsized impact on whether your brand is covered by payers and whether patients adhere to therapy - your access partner plays a key role in this process. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Why Transparency is Critical in the Patient Access Journey Source: https://phil.us/why-transparency-is-critical-in-the-patient-access-journey/ ## Why Transparency is Critical in the Patient Access Journey The Healthcare system is notoriously complicated and opaque, making it arduous for patients to navigate successfully. That’s why there’s been a legislative push to increase transparency across through policies such as the No Surprises Act and Hospital Pricing Transparency rule. Getting access to prescribed therapies to treat complex medical conditions can be especially difficult and stressful for patients. Drug utilization management programs, such as prior authorization (PA) and step therapy, often lack the transparency required for patients and their providers to make informed treatment decisions that enable patients to adhere to care plans. Recently, CMS proposed several new policy measures as part of the Interoperability and Patient Access final rule in an effort to make the PA process more efficient and transparent. Facilitating access to their branded specialty-lite therapies is a primary objective for life science commercialization teams. Here are four reasons why manufacturers should make transparency a core element of a brand’s patient services program. ### Building trusted relationships with patients and providers The pharmaceutical industry has a trust problem. A 2021 Accenture survey revealed that only 16% of consumers believe that pharmaceutical companies market their products in a trustworthy manner. Yet, nearly a third of respondents believe that providers work closely with pharmaceutical companies to inform health recommendations in their best interest. Research shows that trust in healthcare impacts treatment adherence, patient satisfaction, and health outcomes – all of which are crucial to a branded therapy’s success. One of the best ways to build trust is through transparency. Pharmaceutical manufacturers have a significant opportunity to build trusted relationships with patients and healthcare providers by enabling greater visibility during the prescription journey with tools that improve patient access. ### Delivering a consumer-centric experience The modern patient expects to be an active consumer of healthcare services, but often lacks transparency to make informed decisions. Multiple potential gaps exist in a patient’s prescription journey from diagnosis to treatment initiation to follow-up, with each touchpoint an opportunity for pharmaceutical manufacturers to enhance transparency. Patient access and support services are the most tangible ways for life sciences companies to connect and engage with patients. HUB services can meet patients where they are if they are driven by digital tools that deliver a frictionless, consumer-centric experience on par with what consumers experience in other industries. Tech-enabled patient services not only allow life science companies to do more with less but also support an enhanced transparency that: - Makes it easier for patients to access and afford their treatment - Gives patients options for how to engage and receive communications - Allows patients to have full visibility into the status of their prescriptions Check out this eBook to learn how to deliver a consumer-centric experience to achieve your brand’s commercialization objectives. ### Driving speed to therapy Ensuring patients have timely access to prescribed therapy is critical to better outcomes and, ultimately, a brand’s success in the pharmaceutical marketplace. Today’s reality for pricier retail and specialty-lite brands is that the PA process presents obstacles that inhibit access. In a 2022 survey by the American Medical Association, 80% of physicians reported that a PA can sometimes lead to treatment abandonment. When patients cannot begin treatment promptly, their health outcomes suffer. In the AMA survey, 94% of physicians reported care delays associated with PAs, and 89% believed the PA process had a negative impact on patient clinical outcomes. Furthermore, physician offices reported spending almost two business days on average completing PAs. Life science companies can drive speed to therapy by incorporating partnerships that deliver seamless electronic PA processes. Manufacturers should prioritize solutions with integrated transparency tools to help providers make the best decisions at the point of care, simplify the information gathering process, and keep everyone informed to avoid the typical delays that prevent patients from accessing their medications. Download this Prior Authorization Guide for Life Sciences Companies to discover how your team can reframe its approach to PA through digital solutions that boost patient access. ### Improving adherence It’s not unusual for patient services programs to fall short on medication adherence objectives, and a lack of transparency can be a culprit. Considering that one out of five prescriptions are never filled, and medication adherence rates for chronic conditions are only 50-60% - even with good insurance and drug coverage – pharmaceutical manufacturers should make every effort to help patients adhere to their prescribed therapies. By leveraging digital technology and data, brand teams can improve adherence by increasing transparency around the prescription journey for patients in the following ways: - Sending out personalized digital refill reminders - Providing education on proper administration, dosing, storage, and side effects - Facilitating communications through a user-friendly mobile application - Alerting nurse navigators to reach out to patients at risk of non-adherence - Offering real-time visibility into benefits verification, PA, program enrollment, and copay status ### How to provide patients and providers with a transparent prescription journey Life sciences companies face substantial hurdles to enabling access to their specialty-lite brands, and they cannot afford to miss a piece of the puzzle regarding their patient services programs. A technology-enabled HUB that delivers the visibility patients and providers expect will help them effectively and efficiently manage the complexities of patient access. Phil partners with pharmaceutical manufacturers to bring clarity to the prescription journey. Our patient support platform improves outcomes and experience by enabling speed to therapy with the lowest possible out-of-pocket burden. Learn more here. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Why Your Channel Strategy Matters Source: https://phil.us/why-your-channel-strategy-matters/ ## Why Your Channel Strategy Matters Channel strategy underpins the deployment of a life science company’s overall commercialization strategy. A company’s channel strategy is the tie that binds the market access, patient access, marketing, trade, and sales strategies to meet brand goals effectively. Ideally, it tightly integrates the processes for managing the logistics of getting products from the manufacturer to patients, implementing services to support patient access and medication adherence, and capturing channel data to measure success and inform decision-making. Getting your channel strategy is essential to ensure patients can access and adhere to therapy – here are four ways channel strategy can positively impact your brand’s success: #### 1. Differentiating your product With the pharmaceutical industry facing diminishing returns on development investment, and increased payer utilization management controls, the stakes are high. Strategic product differentiation, particularly in competitive categories is a must key to mitigate risk and improve the probability of success. The promise of positive patient outcomes alone is insufficient alone. Payers require manufacturers to prove the real-world value of their brands, which means that patients need to be able to access and adhere to therapy. Your channel strategy essentially creates a post-launch infrastructure to substantiate the value of a product beyond efficacy and when applied correctly can differentiate it from competing therapies that may struggle to generate significant adoption. When data is an integral part of your strategy, you can gain a deeper understanding of patient needs and show how your brand uniquely solves unmet problems, such as enhanced tolerability, convenience, greater safety, or reduced healthcare costs. #### 2. Improving patient experience Consumerization is one of the biggest healthcare trends impacting pharmaceutical commercialization today. Patients want the same experience they get from other industries, such as retail, consumer technology, and banking. At the same time, healthcare providers are busier than ever and under the gun to improve the quality of care and manage new blended care models. A poor prescriber experience often results in reduced brand loyalty. A well refined and modern channel strategy can improve patient and provider experience by minimizing the complexity associated with patient access, ultimately generating a stronger value proposition by: ● Improving outcomes by accelerating speed-to-therapy ● Limiting healthcare costs resulting from non-adherence ● Reducing the burden placed on prescribers to address lengthy PA requirements ● Minimizing poor outcomes due to prescription abandonment #### 3. Expanding coverage and reimbursement Getting a prescribed therapy from manufacturer to patient – effectively and efficiently – is crucial to hitting sales forecasts and, ultimately, brand success. Multiple studies have shown that broad payer coverage correlates with better outcomes, so it makes sense to ensure favorable coverage in today's value-based system. However, manufacturers would be wise to consider the fact that broad coverage doesn’t always translate into a high % of covered dispenses.A key element of a company's channel strategy is the design of its drug distribution model. Each plan's coverage, coding, and payment criteria determine whether a therapy is covered and at what price. Pricing and reimbursement systems are notoriously complex to navigate. Failure to optimize your distribution network can lead to poor coverage and reimbursement outcomes, undermining commercialization efforts even if your market access team has signed payer contracts.Life science companies – particularly those in certain therapeutic categories or that are smaller or startups – can generate a substantial competitive advantage and avoid a product mid-life cycle crisis with a streamlined distribution model that offers comprehensive coverage and high reimbursement rates. #### 4. Accelerating therapy starts Although the negative consequences of delayed therapy are well documented, medication delays are common. In a 2021 report, 82% of patients experienced delays accessing their medications for various reasons, including cost and insurance challenges.More and more payers are implementing utilization management measures, such as prior authorizations (PAs), to stem rising healthcare costs, especially related to specialty medications. In fact, 79% of medical practices report that PA requirements increased between 2021 and 2022. The PA process, by design, is a significant barrier to medication access – it can leave patients waiting for days or weeks for approval, and coverage can be denied despite being appropriately prescribed.A pharmaceutical company’s channel strategy can be instrumental in accelerating patient access to therapy. Integrating technology to simplify and automate the PA process for pharmacies and providers can effectively reduce medication access delays. ### Getting your channel strategy right Your channel strategy is essential to the patient journey and should be as unique as your product and the patients it treats. It can make or break your brand’s success. Watch Phil’s on-demand webinar to discover vital considerations for your channel strategy and how to evaluate channel partners so you can build a channel strategy that will have the most significant impact on your patients and your bottom line. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us --- # Terms of Service | PHIL Source: https://phil.us/terms/ ## Terms of Service Last Updated: July 15, 2026 Welcome to Phil, an online prescription management and delivery platform made available by Phil, Inc. (“Phil,” “we,” “us” or “our”). Please read these Terms of Service (the “Terms”) and our Privacy Notice (https://phil.us/privacy/) (“Privacy Notice”) carefully because they govern your use of the website located at https://phil.us/ and https://myphil.us (the “Sites”) and the online prescription management and delivery services provided by Phil that are accessible via the Sites, text messaging and email communications. To make these Terms easier to read, the Sites and our services are collectively called the “Services.” IMPORTANT NOTICE REGARDING ARBITRATION FOR U.S. CUSTOMERS: WHEN YOU CREATE OR LOG IN TO YOUR ACCOUNT WITH US, YOU AGREE (WITH LIMITED EXCEPTION) TO RESOLVE ANY DISPUTE BETWEEN YOU AND PHIL THROUGH BINDING, INDIVIDUAL ARBITRATION RATHER THAN IN COURT. PLEASE REVIEW CAREFULLY THE “DISPUTE RESOLUTION” SECTION BELOW FOR DETAILS REGARDING ARBITRATION. By accessing or using the Services in any way, including without limitation, browsing the Services, using any information, or submitting any content or personal information via the Services, you agree to and are bound by these Terms. If you don’t agree to be bound by these Terms, do not use the Services. IF YOU ARE HAVING A MEDICAL EMERGENCY, DO NOT USE OUR SERVICES – CALL 911. ### Privacy Notice Please review our Privacy Notice (https://phil.us/privacy/), which also governs your use of the Services, for information on how we collect, use and share your information. #### Who May Use the Phil Services You may use the Services only if you are eighteen (18) years or older, are capable of forming a binding contract with Phil and are not barred from using the Services under applicable law. #### Phil is a Prescription Management Platform Phil enables you to place an order for one (1) or more of your prescription medication needs (“Order”) and acts as a prescription management platform. You will only provide to Phil a valid prescription issued for a legitimate medical purpose by a medical professional acting in the usual course of his/her professional practice. The Services are not intended to be a substitute for professional medical advice, diagnosis or treatment, and do not constitute medical or other professional advice. Phil does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Services or by any other electronic means. Reliance on any information provided by Phil is solely at your own risk. The information provided through Phil’s Services is designed to support, not replace, the relationship that exists between patient/site-visitor and his/her physician. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on our Services. #### Telemedicine If you need a prescription, Phil may assist you by connecting you with a health care professional who will provide telemedicine services. These services are not provided by Phil and these Terms do not apply to such services. You should refer to the terms of service and privacy policies of telemedicine provider before using them. #### Order Fulfillment by Pharmacy When you place an Order through Phil, we work with pharmacies to process your Order and fill your prescriptions (each, a “Pharmacy”). Phil also is a Pharmacy and in some cases, Phil may fill your prescription. We verify that each Pharmacy that we work with is a licensed pharmacy. You also acknowledge and agree that, although we may select certain pharmacies to work with based on various metrics we apply, our decision to work with a specific pharmacy should not be deemed as an endorsement of, or a warranty regarding the quality of services provided by, such pharmacy. If, for any reason, you aren’t satisfied with the manner in which a Pharmacy processed your Order, you agree to address this issue with the Pharmacy directly. You also acknowledge and agree that Phil does not provide any medical advice, opinion, diagnosis or treatment, and that that no pharmacy-patient relationship (unless Phil is the Pharmacy that fills your prescription) or doctor-patient relationship is, or will be, established between Phil and you as a result of your use of the Services or otherwise. You should check product information (including package inserts) regarding dosages, precautions, warnings, interactions and contraindications before administering or using any medications. If you have any questions regarding your prescriptions, you should consult your healthcare professional or pharmacist, whose contact information may be listed on the prescription, the packaging of your prescription medicine or under your Account. #### Loaned Equipment If your prescription medicine requires a device or equipment to utilize, we may loan you such device or equipment. In this case, you will be provided the device or equipment with your prescription order and will be given information on how and when to return the device or equipment. If you do not return the device or equipment as instructed, you may be charged the cost of the device or equipment. #### Authorization to Transfer Prescription If your prescription was transferred to or originally filled by a non-participating pharmacy (not within Phil’s network) Phil may facilitate the transfer of your prescription to its participating pharmacy. By using Phil’s services, you authorize Phil to facilitate the transfer of your prescription to any participating Pharmacy. Phil has the sole discretion to determine which participating pharmacy fills your prescription. If the Pharmacy initially chosen by the Services is unable to fill your prescription(s), you expressly agree that Phil may transfer your personal information to another Pharmacy to do so. ### Changes to these Terms or the Services We may update the Terms from time to time at our sole discretion. If we do, we’ll let you know by posting the updated Terms on the Sites and/or may also send other communications. It’s important that you review the Terms whenever we update them or you use the Services. If you continue to use the Services after we have posted updated Terms it means that you accept and agree to the changes. If you don’t agree to be bound by the changes, you may not use the Services anymore. We’re always striving to improve the Services and, because our Services are evolving over time we may change or discontinue all or any part of the Services, at any time and without notice, at our sole discretion. #### Health-Related Content The health-related content you may find in the Services (“Health-related Content”) is broad in nature and in scope, describes only general principles of health care, and is neither specific instructions for individual patients nor appropriate or relevant to your personal situation. Health-related Content is not intended to be used to diagnose, treat, cure or prevent diseases or as a self-medication guide or substitute for consulting with your health professional or pharmacist. #### Registration and Your Information If you want to use certain features of the Services you’ll have to create an account (“Account”) via the Services. It’s important that you provide us with accurate, complete and up-to-date information for your Account and you agree to update such information to keep it accurate, complete and up-to-date. If you don’t provide us with accurate information (or do not update the information to keep it accurate, complete and up-to-date), we may suspend or terminate your Account. You agree to keep your Account password confidential and you’ll let us know immediately if there is any unauthorized use of your Account. Phil will not be responsible or liable for any loss or damage that results from your failure to comply with this security obligation. You are responsible for all activities that occur under your Account, whether or not you know about them, so please safeguard your Account password and other related information. #### SMS Text Messaging When using the Services, you may opt in to receive SMS text messages from us (“Text Messages”) by providing your express consent to receive Text Messages at the mobile number you provide regarding your account, Services, prescriptions, refills, order status, care-related reminders, and other service-related communications. Your consent is not required as a condition of purchasing any goods or services, including pharmacy products or services. You can cancel the SMS service at any time by replying STOP to any message or by using any other opt-out method we make available in the message content. If you want to opt in again, you may re-enroll in SMS notifications by following the identified opt-in process. By opting in, you authorize Phil to send Text Messages to the mobile phone number associated with your opt in, including by using an automatic telephone dialing system or other automated technology, as permitted by law. You confirm that you are the current subscriber or authorized user of the mobile number you provide and you are authorized to provide consent to receive Text Messages at that number. The frequency of Text Messages will vary depending upon the Services you receive and your interactions with us and your communication preferences. Message and data rates may apply. For help at any time, reply HELP to any Text Message, or contact us at privacy@usephil.com. Carriers are not liable for delayed or undelivered messages. We may change the short code or telephone number we use to send Text Messages. If we do, we will notify you as required by law. Please refer to our Privacy Notice for information on how we collect, use and disclose information, including information related to Text Messages. #### Additional Users of the Services You may add prescriptions for your family members, or others you are authorized to represent, as users of the Services on the following conditions: By adding a user over the age of eighteen (18) you acknowledge that you are acting as this user’s representative and have an express authorization from the patient to enter his/her personal information and have medications delivered to the address entered. If the additional user is under the age of eighteen (18) (a “Minor Child”), you represent that you are a parent or a guardian of the user. You recognize and acknowledge that there are certain risks of physical injury in connection with the administering of medication to a Minor Child. Such risks include, but are not limited to, failing to properly administer the medication, failing to observe side effects, failing to assess and/or recognize an adverse reaction, failing to assess and/or recognize a medical emergency, and failing to recognize the need to summon emergency medical services. You hereby fully release or discharge Phil and dispensing pharmacy from any and all claims from injuries, damages and losses your Minor Child may have, arising out of, connected with, incidental to, or in any way associated with the administering of medication. #### Delivery of Your Order If no one is present at your delivery address at the time of the delivery to receive your Order, the courier may leave your Order at your door or other secure location in accordance with the general guidelines issued by the delivery services, if the courier believes it is reasonable to do so. #### Feedback to the Phil Services Your opinion matters to us! We welcome feedback, comments and suggestions for improvements to the Services (“Feedback”). You can submit Feedback by emailing us at privacy@usephil.com. If you provide us any Feedback, you agree that we may use the Feedback you provide to us in any way, including in future modifications to the Services or in other services we may provide. You hereby grant to Phil a perpetual, worldwide, irrevocable, fully-paid, royalty-free, sub-licensable and transferable license to use, copy, modify, distribute, display, create derivative works of and otherwise exploit the Feedback for any purpose. #### Payment for Your Order through Phil When you submit an Order through Phil, the Pharmacy selected by the Services will calculate the total Order price, which will be based on: (i) the actual cash price charged by the Pharmacy for each medication, if you do not have health insurance coverage for prescription medications; (ii) a copay amount that you are required to pay for medications, if you do have health insurance coverage for prescription medications; and (iii) any applicable delivery and handling fee that we may charge for delivery of the medication to the address specified in your Order. After the Pharmacy determines the total Order price, we will send you an email to notify you of the Order Price. We will charge you only when you confirm the Order (using the appropriate button in the Service). For recurring Orders for medications that you take on an ongoing basis, you authorize Phil to initiate recurring non-refundable payments as set forth in this paragraph. If there is no change in the price or copay amount for the recurring Orders, we will process such Orders and charge you for the same price without sending you additional email for confirmation. If the price for a recurring Order has increased, we will send you another email to confirm the higher price or copay amount. If the price or copay amount for a recurring Order has decreased, we will charge you the lower price or copay amount without explicitly notifying you of the decrease. You may cancel recurring Order at any time through the Services before an Order is placed for that prescription. If you place an Order via the Services, you expressly authorize (i) Phil or Phil’s third party payment processing service provider to process and/or charge your credit card (and on a recurring basis for recurring medications) for verification, pre-authorization and payment purposes; (ii) to bear any additional charges that your bank or other financial service provider may levy on you as well as any fees or taxes that may apply to you, and (iii) that Phil may use your insurance information to run a test claim to determine the price of the medication and whether a Prior Authorization is needed. We may ask you to supply additional information relevant to your Order, including the expiration date of your credit card and your email and postal addresses for billing and notification. You represent and warrant that you have the legal right to use all payment method(s) that you provided to us to process your Order. You’ll receive a confirmation by email once the Pharmacy has completed processing your Order. If you have any concerns or objections regarding any charges, you agree to raise them first with Phil and you agree not to cancel or reject any credit card charges unless you have made a reasonable attempt at resolving the matter directly with Phil or the Pharmacy. By pressing the “Confirm” button for the listed charges in the Service, (i) you agree to the pricing, payment and billing policies applicable to such fees and charges, as posted or otherwise communicated to you, and (ii) you authorize us to provide your Payment Information and insurance information to third parties so we can complete your Order and to charge your payment method (plus any applicable taxes and other charges). You may need to provide additional information to verify your identity before completing your Order (such information is included within the definition of Payment Information). You represent and warrant that you will not dispute the payment with the credit card company so long as the transaction corresponds to the terms indicated on the payment page and in the Terms. You acknowledge that if any charges to the credit card are declined or charge backs are claimed against any outstanding amount, you will still be liable for payment pursuant to the Terms. If you authorize an Order or payment through a telephone interaction with a Phil agent or automated system, your verbal agreement during that call constitutes your authorization to charge the specified amount to your credit card on the same terms described above. You acknowledge that calls with Phil’s agents may be recorded, and that your verbal authorization carries the same legal effect as pressing the ‘Confirm’ button in the Service. Phil will confirm your authorization and Order details by email following any telephone interaction in which payment is authorized. #### Manufacturer’s Assistance Phil may apply manufacturers’ financial assistance, such as coupons, discounts, repayment, and other reductions in your out-of-pocket expenses in compliance with state and federal laws and regulations applicable to drug manufacturers’ assistance. Please note that manufacturers’ financial assistance is not available for government-sponsored plans, such as Medicare or Medicaid. #### No Refunds It is important that you carefully review any order or renewal for recurring prescriptions that you place. If you do not wish to receive a refill of a prescription, please remove the prescription from your account, cancel a refill before the order is placed or otherwise notify Phil directly. Once the medication has been shipped it cannot be returned and we offer no refund unless there was an error in the order or the medication is defective. If you experience an issue with your order, please contact Phil using the details below. #### Cancellation of Your Prescription or Refill You may remove a prescription from your Account or cancel a refill for a particular prescription at any time through the Services before an Order is placed for that prescription. #### Proprietary Rights Phil and its licensors exclusively own all right, title and interest in and to the Services, including all associated intellectual property rights. You acknowledge that the Services are protected by laws of the United States and any applicable jurisdictions. You agree not to remove, alter or obscure any copyright, trademark, service mark or other proprietary rights notices incorporated in or accompanying the Services. Neither these Terms nor your use of the Services transfers any right, title or interest in the Services, the content of the Services, or intellectual property rights to you, and Phil and its third party licensors retain all of their respective right, title, and interest to the Services and content. #### Rights Granted by Phil Subject to your compliance with these Terms, Phil grants you a limited, non-exclusive, non-transferable right to use the Services solely for your own personal and non-commercial purposes. Except as expressly permitted in these Terms, you may not: (i) copy, modify or create derivative works based on the Services; (ii) reverse engineer, decompile or disassemble the Services; or (iii) make the functionality of the Services available to multiple users through any means. Phil reserves all rights in and to the Services not expressly granted to you under these Terms. #### General Prohibitions By using the Services, you agree not to do any of the following: - Use, display, mirror or frame the Services, or any individual element within the Services, Phil’s names, any Phil trademark, logo or other proprietary information, or the layout and design of any page or form contained on a page, without Phil’s express written consent; - Delete, modify, hack or attempt to change or alter any content on the Services; - Attempt to access, tamper with, or use non-public areas of the Services, Phil’s computer systems or networks connected to any of our servers, or the technical delivery systems of Phil’s providers; - Attempt to probe, scan, or test the vulnerability of any Phil system or network or breach any security or authentication measures; - Avoid, bypass, remove, deactivate, impair, descramble or otherwise circumvent any technological measure implemented by Phil or any of Phil’s providers or any other third party (including another user) to protect the Services; - Attempt to access or search the Services through the use of any engine, software, tool, agent, device or mechanism (including spiders, robots, crawlers, data mining tools or the like) other than the software and/or search agents provided by Phil or other generally available third party web browsers; - Send any unsolicited or unauthorized advertising, promotional materials, email, junk mail, spam, chain letters or other form of solicitation; - Use any meta tags or other hidden text or metadata utilizing any Phil names, service marks, trademarks, logos, URLs or product names without Phil’s express written consent; - Use any material or information, including images or photographs, which are made available through the Services in any manner that infringes any copyright, trademark, patent, trade secret, or other proprietary right of any party; - Use the Services for any commercial purpose or for the benefit of any third party or in any manner not permitted by these Terms; - Forge any TCP/IP packet header or any part of the header information in any email or newsgroup posting, or in any way use the Services to send altered, deceptive or false source-identifying information; - Attempt to decipher, decompile, disassemble or reverse engineer any of the software used to provide the Services; - Use any device, software or routine intended to damage or otherwise interfere with, or attempt to interfere with, the proper functioning of the Services or servers or networks connected to the Services, or take any action that interferes with the access of any user, host or network, including, without limitation, uploading files that contain viruses, sending a virus, overloading, flooding, spamming, or mail-bombing the Services; - Collect, compile or store any information from the Services or personally identifiable information from other users of the Services without their express permission; - Provide false information, or impersonate or misrepresent your affiliation with any person or entity; - Defame, abuse, harass, stalk, threaten or otherwise violate the legal rights of any third party; - Violate any applicable law or regulation; or - Encourage or enable any other individual to do any of the foregoing; - You agree not to submit controlled substance prescriptions through the Services, except as expressly authorized by Phil in connection with specific programs or medications made available by Phil for which Phil has established applicable controls. A current list of controlled substances by DEA schedule can be found here. Although we’re not obligated to monitor access to or use of the Services, we have the right to do so for the purpose of operating the Services, to ensure compliance with these Terms, or to comply with applicable law or other legal requirements. We have the right to investigate violations of these Terms or conduct that affects the Services. We may also consult and cooperate with law enforcement authorities to prosecute users who violate the law. #### Links to Third Party Websites or Resources The Services may contain links to third-party websites or resources (“Linked Sites”). We provide these links only as a convenience and are not responsible for the content, products or services on or available from those websites or resources or links displayed on such sites. You should refer to the separate terms of use, privacy policies, and other rules posted on Linked Sites before you use them. Phil does not author, edit or monitor these Linked Sites, and is not responsible or liable for: (a) the availability of or content provided on such Linked Sites, nor does inclusion of any link imply endorsement of the Linked Sites by Phil, or vice versa; (b) third-party content accessible through such Linked Sites; (c) any loss or damage whatsoever you may incur from dealing with any Linked Site; or (d) your dealings with any third parties found on or through our Sites. You bear all risk associated with the use of the Linked Sites, third party services, and your correspondence or business dealings with advertisers other than us found on or through the Services. Phil does not control, makes no guarantees about, and disclaims any express or implied representations or warranties about the accuracy, relevance, timeliness, completeness, or appropriateness for a particular purpose of the information or the resources contained on the Linked Sites or any other Internet sites. We reserve the right to terminate such links at any time. The fact that we offer such links should not be construed in any way as an endorsement, authorization, or sponsorship of that site or its content, products, or services. #### Electronic Communications You agree that all agreements, notices, disclosures and other communications that we provide to you electronically shall have the same legal effect as if provided physically and shall satisfy any legal requirement that such communications be in writing. You understand that email communication has risk of third-party interception and may be transmitted to unintended parties. You expressly agree to hold Phil harmless for any damages associated with the security breach of your email or erroneous transmission. #### Mobile Security Most communication with Phil occurs through your mobile device. Therefore, your mobile device likely contains Protected Health Information (“PHI”), such as pictures of your prescriptions, medical insurance cards, and other vulnerable information. As a result, it is of utmost importance that you keep your mobile devices secure at all times. If you are using public Wi-Fi or email applications on mobile devices, you are likely using unsecure mobile networks, putting PHI at risk of interception. The best ways to protect mobile devices from security breaches is to maintain password protection, encryption, and/or to install a remote wiping/disabling program into them. A remote wiping/disabling program allows users to quickly clear and disable a lost or stolen mobile device, which can possibly prevent or reduce the magnitude of the breach. While Phil is HIPAA compliant and takes the utmost care in protecting your confidential information, it cannot protect information stored in your mobile device. By using Phil, you agree to hold Phil harmless of any data breaches occurring from theft/misplacement or any third-party intervention with your mobile device. #### Termination We may suspend or terminate your access to and use of the Services or deactivate or cancel your Account, at our sole discretion with or without notice, temporarily or permanently, for any reason or no reason, and without liability to you. You may cancel your Account at any time by sending an email to us at privacy@usephil.com. Upon any termination, discontinuation or cancellation of Services or your Account, all provisions of these Terms which by their nature should survive will survive, including, without limitation, provisions regarding loaned equipment, feedback, payment for your order, proprietary rights, third party websites or resources, warranty disclaimer, limitations of liability, governing law and forum and dispute resolution (including arbitration and class action waiver). Upon any termination, discontinuation or cancellation of the Services or your Account by you or us, you will continue to be obligated to pay all amounts owing under these Terms which are due and payable prior to such termination, discontinuation or cancellation. #### Warranty Disclaimers TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, THE SERVICES ARE PROVIDED “AS IS, WHERE IS” AND “AS AVAILABLE” WITHOUT WARRANTY OF ANY KIND. WITHOUT LIMITING THE FOREGOING, WE EXPLICITLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, SECURITY, ACCURACY AND NON-INFRINGEMENT, AND ANY WARRANTIES ARISING OUT OF COURSE OF DEALING, COURSE OF PERFORMANCE, OR USAGE OF TRADE. PHIL EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY FOR LOSSES ARISING OUT OF ANY ACTION TAKEN IN RELIANCE ON THE SERVICES AND/OR ANY CONTENT, TOOLS, APPLICATIONS, AND PRODUCTS PROVIDED ON THE SERVICES. PHIL MAKES NO WARRANTY THAT: (A) THE SERVICES WILL MEET YOUR REQUIREMENTS OR WILL BE AVAILABLE ON AN UNINTERRUPTED, TIMELY, SECURE ERROR-FREE BASIS; (B) THE CONTENT WILL BE UP-TO-DATE, COMPLETE COMPREHENSIVE OR ACCURATE; (C) THE QUALITY OF ANY RESULTS THAT MAY BE OBTAINED FROM THE USE OF THE SERVICES; (D) THE QUALITY OF ANY PRODUCTS, CONTENT, SERVICES, INFORMATION OR OTHER MATERIAL OBTAINED THROUGH THE SERVICES WILL MEET YOUR EXPECTATIONS; OR (E) THAT DEFECTS, IF ANY, WILL BE CORRECTED. WE MAKE NO WARRANTY REGARDING THE QUALITY, ACCURACY, TIMELINESS, TRUTHFULNESS, COMPLETENESS OR RELIABILITY OF ANY HEALTH-RELATED CONTENT OBTAINED AS A RESULT OF YOUR USE OF THE SERVICES. YOU UNDERSTAND AND AGREE THAT ANY CONTENT AND/OR DATA DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE SERVICES IS USED AT YOUR OWN RISK AND THAT YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER SYSTEM OR MOBILE DEVICE, OR FOR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF SUCH CONTENT, MATERIAL AND/OR DATA. IT IS SOLELY YOUR RESPONSIBILITY TO (1) ENSURE THAT YOUR ORDER WAS PROPERLY PROCESSED AND THAT YOU RECEIVED THE CORRECT MEDICATIONS (INCLUDING THE CORRECT DOSAGE(S) THEREOF), (2) CONSUME THE PROPER DOSAGE(S) OF YOUR MEDICATION(S), AND (3) STORE ALL MEDICATIONS PROPERLY AND IN ACCORDANCE WITH THE GUIDELINES PROVIDED BY THE PHARMACY AND/OR APPLICABLE MEDICATION MANUFACTURER(S). PHIL PROVIDES NO WARRANTIES REGARDING THE MEDICATIONS THAT ARE PROVIDED TO YOU BY THE PHARMACY AND ASSUMES NO LIABILITY FOR ANY MEDICATIONS (OR ANY INJURY OR DEATH RESULTING THEREFROM). PHIL EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, REGARDING A PHARMACY’S AND ITS PERSONNEL’S PROFESSIONAL QUALIFICATIONS, EXPERTISE, QUALITY OF WORK, OR ACCURACY IN FILLING YOUR PRESCRIPTION(S), AND ASSUMES NO RESPONSIBILITY FOR A PHARMACY’S COMPLIANCE WITH ANY APPLICABLE LAWS AND REGULATIONS (EXCEPT FOR PHIL IN THE CASES WHERE PHIL FILLS THE PRESCRIPTION). WITHOUT LIMITING THE FOREGOING, PHIL EXPRESSLY DISCLAIMS ALL LIABILITY FOR ANY PRESCRIPTIONS INCORRECTLY FILLED BY A PHARMACY, WHETHER AS A RESULT OF INACCURATE INFORMATION PROVIDED BY YOU OR OTHERWISE, ANY CANCELLED OR OTHERWISE UNFILLED PRESCRIPTIONS (OR ANY INJURY OR DEATH RESULTING THEREFROM), OR ANY ACT OR OMISSION OF ANY PHARMACY. #### Indemnity You will indemnify, defend and hold harmless Phil and its officers, directors, employee and agents, from and against any claims, disputes, demands, liabilities, damages, losses, and costs and expenses, including, without limitation, reasonable legal and accounting fees, arising out of or in any way connected with (i) your access to or use of the Services, or (ii) your violation of these Terms. #### Limitation of Liability TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL PHIL NOR ANY OTHER PARTY INVOLVED IN CREATING, PRODUCING, PROVIDING OR DELIVERING THE SERVICES, INCLUDING WITHOUT LIMITATION ANY HEALTH-RELATED CONTENT, BE LIABLE FOR ANY INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOSS OF DATA OR GOODWILL, OR THE COST OF SUBSTITUTE SERVICES ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OR FROM THE USE OF OR INABILITY TO USE THE SERVICES, OR FROM ANY COMMUNICATIONS OR INTERACTIONS WITH ANY PHARMACIES, WHETHER BASED ON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT LIABILITY), PRODUCT LIABILITY OR ANY OTHER LEGAL THEORY, AND WHETHER OR NOT PHIL HAS BEEN INFORMED OF THE POSSIBILITY OF SUCH DAMAGE, EVEN IF A LIMITED REMEDY SET FORTH HEREIN IS FOUND TO HAVE FAILED OF ITS ESSENTIAL PURPOSE. THIS LIMITATION OF LIABILITY APPLIES TO, BUT IS NOT LIMITED TO, THE TRANSMISSION OF ANY DISABLING DEVICE OR VIRUSES WHICH MAY INFECT YOUR EQUIPMENT OR SYSTEM, UNAUTHORIZED ACCESS, THEFT, BODILY INJURY, PROPERTY DAMAGE, OPERATOR STRIKES OR OTHER LABOR PROBLEMS OR ANY FORCE MAJEURE. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, SO THE ABOVE LIMITATION MAY NOT APPLY TO YOU. IN NO EVENT WILL PHIL’S TOTAL CUMULATIVE LIABILITY ARISING FROM ALL CLAIMS UNDER OR RELATED TO THESE TERMS, FROM THE USE OF OR INABILITY TO USE THE SERVICES, INCLUDING WITHOUT LIMITATION ANY HEALTH-RELATED CONTENT, OR FROM ANY COMMUNICATIONS OR INTERACTIONS WITH ANY PHARMACIES, EXCEED THE LESSER OF THE AMOUNTS YOU HAVE PAID TO PHIL FOR USE OF THE SERVICES OR ONE HUNDRED DOLLARS ($100). THE DISCLAIMER, EXCLUSIONS AND LIMITATIONS OF LIABILITY SET FORTH ABOVE ARE FUNDAMENTAL ELEMENTS OF THE BASIS OF THE BARGAIN BETWEEN PHIL AND YOU. ### Governing Law and Forum Choice These Terms and any action related thereto will be governed by the Federal Arbitration Act, federal arbitration law, and the laws of the State of Arizona, without regard to its conflict of laws provisions. Except as otherwise expressly set forth below in the paragraph “Dispute Resolution,” the exclusive jurisdiction for all Disputes (defined below) that you and Phil are not required to arbitrate will be the state and federal courts located in Maricopa County, Arizona and you and Phil each waive any objection to jurisdiction and venue in such courts. ### Dispute Resolution If you are a Phil patient who has a registered Phil account, then we each agree that any dispute, claim or controversy arising out of or relating to these Terms or the breach, termination, enforcement, interpretation or validity thereof or the use of the Services (collectively, “Disputes”) will be resolved solely by binding, individual arbitration and not in a class, representative or consolidated action or proceeding. You and Phil agree that the U.S. Federal Arbitration Act governs the interpretation and enforcement of these Terms, and that you and Phil are each waiving the right to a trial by jury or to participate in a class action. This arbitration provision shall survive termination of these Terms. As limited exceptions to the paragraph above: (i) we both may seek to resolve a Dispute in small claims court if it qualifies; and (ii) we each retain the right to seek injunctive or other equitable relief from a court to prevent (or enjoin) the infringement or misappropriation of our intellectual property rights. #### Conducting Arbitration and Arbitration Rules The arbitration between Phil patients with registered Phil accounts will be conducted by the American Arbitration Association (“AAA”) under its Consumer Arbitration Rules (the “AAA Rules”) then in effect, except as modified by these Terms. The AAA Rules are available at www.adr.org or by calling 1-800-778-7879. A party who wishes to start arbitration must submit a written Demand for Arbitration to AAA and give notice to the other party as specified in the AAA Rules. The AAA provides a form Demand for Arbitration at www.adr.org. Any arbitration hearings will take place in the county (or parish) where you live, unless we both agree to a different location. The parties agree that the arbitrator shall have exclusive authority to decide all issues relating to the interpretation, applicability, enforceability and scope of this arbitration agreement. Payment of all filing, administration and arbitrator fees will be governed by the AAA Rules, and we won’t seek to recover the administration and arbitrator fees we are responsible for paying, unless the arbitrator finds your Dispute frivolous. If we prevail in arbitration we’ll pay all of our attorneys’ fees and costs and won’t seek to recover them from you. If you prevail in arbitration you will be entitled to an award of attorneys’ fees and expenses to the extent provided under applicable law. Except as provided in in the second paragraph of this subsection above, the arbitrator shall determine all issues of liability on the merits of any claim asserted by either party and may award declaratory or injunctive relief only in favor of the individual party seeking relief and only to the extent necessary to provide relief warranted by that party’s individual claim. To the extent that you or we prevail on a claim and seek public injunctive relief (that is, injunctive relief that has the primary purpose and effect of prohibiting unlawful acts that threaten future injury to the public), the entitlement to and extent of such relief must be litigated in a civil court of competent jurisdiction and not in arbitration. The parties agree that litigation of any issues of public injunctive relief shall be stayed pending the outcome of the merits of any individual claims in arbitration. #### Class Action Waiver YOU AND PHIL AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN YOUR OR ITS INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING. Further, if the parties’ Dispute is resolved through arbitration, the arbitrator may not consolidate another person’s claims with your claims, and may not otherwise preside over any form of a representative or class proceeding. If this specific provision is found to be unenforceable, then the entirety of this Dispute Resolution section shall be null and void. #### Severability With the exception of any of the provisions in the paragraph above (Class Action Waiver), if an arbitrator or court of competent jurisdiction decides that any part of these Terms is invalid or unenforceable, the other parts of these Terms will still apply. #### General Terms These Terms constitute the entire and exclusive understanding and agreement between Phil and you regarding the Services, and these Terms supersede and replace all prior oral or written understandings or agreements between Phil and you regarding the Services. If any provision of these Terms is held invalid or unenforceable by an arbitrator or a court of competent jurisdiction, that provision will be enforced to the maximum extent permissible and the other provisions of these Terms will remain in full force and effect. Except where provided by applicable law in your jurisdiction, you may not assign or transfer these Terms, by operation of law or otherwise, without Phil’s prior written consent. Any attempt by you to assign or transfer these Terms absent our consent or your statutory right, without such consent, will be null. Phil may freely assign or transfer these Terms without restriction. Subject to the foregoing, these Terms will bind and insure to the benefit of the parties, their successors and permitted assigns. Any notices or other communications provided by Phil under these Terms, including those regarding modifications to these Terms, will be given by Phil: (i) via email; or (ii) by posting to the Services. For notices made by e-mail, the date of receipt will be deemed the date on which such notice is transmitted. These Terms apply only to Phil and you. These Terms are not intended to, and shall not, create any third-party beneficiary rights, except as expressly provided in these Terms. Phil’s failure to enforce any right or provision of these Terms will not be considered a waiver of those rights. The waiver of any such right or provision will be effective only if in writing and signed by a duly authorized representative of Phil. Except as expressly set forth in these Terms, the exercise by either party of any of its remedies under these Terms will be without prejudice to its other remedies under these Terms or otherwise. #### Contact Information If you have any questions about these Terms, the practices of Phil, or your dealings with the Services, or if you would like to update your personal information, please contact Phil at: Email: privacy@usephil.com Phone: (855) 977-0975, option 3 Phil, Inc. ATTN: Privacy Officer, 14500 Northsight Blvd, Suite 307 Scottsdale, AZ 85260 --- # Privacy Notice | PHIL Source: https://phil.us/privacy/ ## Privacy Notice Last Updated: July 15, 2026 This Privacy Notice (“Notice”) applies to the processing of personal information by Phil, Inc. and our affiliates (“Phil,” “we,” “us,” or “our”), including on our mobile application, our website available at www.phil.us, www.myphil.us, our associated site(s), our microsite(s), and our other online or offline offerings which link to, or are otherwise subject to, this Privacy Notice (collectively, the “Services”). Special Note to Phil Patients and Potential Patients: When you visit our website or inquire about or register for our Services, we may collect information that identifies you and relates to your past, present, or future physical or mental health, treatment and services received, and payment for such treatment and services. This information may be considered protected health information (“PHI”) by the Health Insurance Portability and Accountability Act of 1996 (as amended) and the Health Information Technology for Economic and Clinical Health Act. If you receive care from us, this Notice describes how we collect, use, and share your non-PHI personal information and is separate from and in addition to our HIPAA Notice of Privacy Practices describing how we use and disclose your PHI. Special Note to Consumers Residing in States with Laws Protecting Consumer Health Data or Sensitive Personal Information Privacy. For information on our processing of “consumer health data” or “sensitive personal information” subject to a consumer health data or other privacy law, please see Annex A – Supplemental U.S. Consumer Health Data Privacy Notice. - 1. UPDATES TO THIS PRIVACY NOTICE - 2. PERSONAL INFORMATION WE COLLECT - 3. HOW WE USE PERSONAL INFORMATION - 4. HOW WE DISCLOSE PERSONAL INFORMATION - 5. YOUR PRIVACY CHOICES AND RIGHTS - 6. INTERNATIONAL TRANSFERS OF PERSONAL INFORMATION - 7. DATA SECURITY AND RETENTION - 8. CHILDREN’S PERSONAL INFORMATION - 9. THIRD-PARTY WEBSITES/APPLICATIONS - 10. CONTACT US ### 1. UPDATES TO THIS PRIVACY NOTICE We may update this Privacy Notice from time to time in our sole discretion. If we do, we’ll let you know by posting the updated Privacy Notice on our website and/or by sending other communications where required by law. ### 2. PERSONAL INFORMATION WE COLLECT We collect personal information you provide to us, personal information we collect automatically when you use the Services, and personal information from third-party sources (see Section 4 below), as described below. #### Personal Information You Provide to Us Directly We may collect personal information you provide to us. - Account Information. We may collect personal information in connection with the creation or administration of your account. This personal information may include, but is not limited to, your name, date of birth, gender, email address, phone number, medical and health information, and other information you store when registering and maintaining your account. To fully utilize our Services, you may be required to fill out and submit forms containing additional personal information such as your postal address, social security number, and other personal information relevant to your health status, diagnosis, treatment, and insurance coverage. - Purchases. We may collect personal information and details associated with your purchases, including payment information. Any payments made via our Services are processed by third-party payment processors. We do not directly collect or store any payment card information entered through our Services, but we may receive information associated with your payment card information (e.g., your billing details). - Your Communications with Us. We, and our service providers, may collect the information you communicate to us, such as through email or our online chat tool. - Surveys. We may contact you to participate in surveys. If you decide to participate, we may collect personal information from you in connection with the survey. - Conferences, Trade Shows, and Other Events. We may collect personal information from individuals when we attend or host conferences, trade shows, and other events. - Business Development and Strategic Partnerships. We may collect personal information from individuals and third parties to assess and pursue potential business opportunities. - Job Applications. If you apply for a job with us, we will collect any personal information you provide in connection with your application, such as your contact information, educational and employment history, and CV information. #### Personal Information Collected Automatically We may collect personal information automatically when you use the Services. We use third-party customer relationship management, marketing automation, analytics, and data enrichment tools, including HubSpot and ZoomInfo, that collect or receive personal information when you visit or interact with our websites, emails, or other online content. - Device Information. We may collect personal information about your device, such as your Internet protocol (IP) address, user settings, cookie identifiers, other unique identifiers, browser or device information, Internet service provider, and location information (including, as applicable, approximate location derived from IP address and precise geo-location information). - Usage Information. We may collect personal information about your use of the Services, such as the pages you visit, you search for, the types of content you interact with, information about the links you click, the frequency and duration of your activities, and other information about how you use the Services. - Cookie Notice (and Other Technologies). We, as well as third parties (such as HubSpot), may use cookies, pixel tags, web beacons, and other technologies, collectively “Technologies”) to automatically collect personal information (such as IP address, device and browser information, and information about pages visited, links clicked, and other website activity) through your use of the Services. These Technologies may be used for analytics, marketing, lead generation, and business development purposes. Please note, if you become a Phil patient, such Technologies will collect personal information only as permitted by applicable federal and state laws. Cookies. Cookies are small text files stored in device browsers. Pixel Tags/Web Beacons. A pixel tag (also known as a web beacon) is a piece of code embedded in the Services collecting personal information about use of or engagement with the Services. The use of a pixel tag allows us to record, for example, that a user has visited, a particular web page or clicked on a particular advertisement. We may also include web beacons in e-mails to understand whether messages have been opened, acted on, or forwarded. See “Your Privacy Choices and Rights” below to understand your choices regarding these Technologies. #### Personal Information Collected from Third Parties We may collect personal information about you from third parties. For example, if you access the Services using a Third-Party Service (defined below), we may collect personal information about you from such Third-Party Service you have made available via your privacy settings. In addition, we and other third parties may upload or otherwise provide personal information about you (i.e., prescription fill date). We may receive business contact, professional, and company-related information about you from third-party data providers such as ZoomInfo. This information may include your name, business email address, business phone number, job title, employer, industry, and related professional information, and is used for sales, marketing, business development, and other purposes. ### 3. HOW WE USE PERSONAL INFORMATION We use personal information for a variety of business purposes, including to provide the Services, for administrative purposes, and to provide you with marketing materials, as described below. #### Provide the Services We use personal information to fulfill our contract with you and provide the Services, such as: - Managing your information; - Providing access to certain areas, functionalities, and features of the Services; - Delivering accurate and personalized recommendations through the use of artificial intelligence and machine learning capabilities; - Providing newsletters, advertisements, and other promotional communications (with your consent); - Answering requests for support; - Communicating with you; - Sharing personal information with third parties as needed to provide the Services; - Processing your financial information and other payment methods for products and Services purchased; - Processing applications if you apply for a job we post on our Services; and - Allowing you to register for events. Our Services are enabled and/or supported by machine-learning tools fundamental to our ability to provide real-time engagement, inform and document treatment approaches, and track progress. These machine-learning tools process natural language communications to support user experience and outcomes. #### Administrative Purposes We use personal information for various administrative purposes, such as: - Pursuing our legitimate interests such as direct marketing, research and development (including marketing research), network and information security, and fraud prevention; - Detecting security incidents, protecting against malicious, deceptive, fraudulent or illegal activity, and prosecuting those responsible for that activity; - Carrying out analytics; - Measuring interest and engagement in the Services; - Improving, upgrading, or enhancing the Services through activities such as data management, analytics, lead scoring, data quality, business intelligence, and internal reporting; - Analyzing, improving, upgrading, and/or enhancing the Services through the use of artificial intelligence and other methods; - Developing new products and services; - Creating de-identified and/or aggregated information. If we create or receive de-identified information, we will not attempt to reidentify such information, unless permitted by, or required to comply with, applicable laws; - Ensuring internal quality control and safety; - Authenticating and verifying individual identities, including requests to exercise your rights under this Privacy Notice; - Debugging to identify and repair errors with the Services; - Auditing relating to interactions, transactions, and other compliance activities; - Enforcing our agreements and policies; and - Carrying out activities required to comply with our legal obligations. #### Marketing We may use personal information to tailor and provide you with marketing and other content. We may provide you with these materials as permitted by applicable law. Additionally, with your consent, we may also use your information to contact you about goods and services that may be of interest to you. You may opt out of receiving such communications at any time by clicking the “unsubscribe” link at the bottom of these communications, by replying STOP to promotional text messages, or by contacting us as set forth in “Contact Us” below. We use marketing automation and customer relationship management tools, including HubSpot, to manage communications, measure content engagement, support marketing campaigns, and identify potential business opportunities. If you have any questions about our marketing practices, you may contact us at any time as set forth in “Contact Us” below. #### With Your Consent or Direction We may use personal information for other purposes clearly disclosed to you at the time you provide personal information with your consent, such as if you opt-in to participate in research studies and research and development activities, or as otherwise directed by you. #### Automated Decision Making We may engage in automated decision making, including profiling. Phil’s processing of your personal information will not result in a decision based solely on automated processing that has a legal or other similarly significant effect on you unless such a decision is necessary as part of a contract we have with you, we have your consent, or we are permitted by law to engage in such automated decision making. If you have questions about our automated decision making or to appeal a decision or finding made by such automated decision making, you may contact us as set forth in “Contact Us” below. ### 4. HOW WE DISCLOSE PERSONAL INFORMATION We disclose personal information to third parties for a variety of business purposes, including to provide the Services, to protect us or others, or in the event of a major business transaction such as a merger, sale, or asset transfer, as described below. Personal information collected through our SMS/text messaging program, including your mobile phone number and SMS consent status, will not be shared, sold, or rented to any third party, whether affiliated or unaffiliated with Phil, for that third party’s own purposes. #### Disclosures to Provide the Services We may disclose any of the personal information we collect to the categories of third parties described below. Service Providers. We may disclose personal information to third-party service providers assisting us with the provision of the Services. This may include, but is not limited to, service providers providing us with hosting, cloud storage, generative AI tools, customer service and relationship management, analytics, marketing automation and services, IT support and security, payment processing, system administration, data enrichment services (such as HubSpot and ZoomInfo), deployment of Technologies, chat features, and other related services. Please note, where required by law, we bind our service providers to privacy and security controls (including zero-day retention periods, where applicable). Where permissible by law, certain service providers collect or receive personal information through Technologies and, depending on configuration, may use such personal information for their own business purposes (such as improving their products, services, and datasets) subject to their terms and privacy notices. - Some of the service providers we may engage include: Google Analytics. For information about how Google uses your personal information, please visit Google Analytics’ Privacy Notice. To learn about how to opt-out of Google Analytics’ use of your personal information, please click here. HubSpot. For information about how HubSpot uses your personal information, please visit HubSpot’s Privacy Policy. To learn how to opt out of its use of your personal information, please click here. LinkedIn Analytics. For information about how LinkedIn uses your personal information, please visit LinkedIn Analytics’ Privacy Policy. To learn about how to opt-out of LinkedIn’s use of your information, please click here. ZoomInfo Co-Pilot. For information about how ZoomInfo uses your personal information, please visit ZoomInfo’s Privacy Policy. To learn how to opt out of its use of your personal information, please click here. - Third-Party Services You Share or Interact With. The Services may link to or allow you to interface, interact, share information with, direct us to share information with, access and/or use third-party websites, applications, services, products, and technology (each a “Third-Party Service”). Any personal information shared with a Third-Party Service will be subject to the Third-Party Service’s privacy policy. We are not responsible for the processing of personal information by Third-Party Services. - Business Partners. We may share your personal information with business partners to provide you with a product or service you have requested. We may also share your personal information with business partners with whom we jointly offer products or services. Once your personal information is shared with our business partner, it will also be subject to our business partner’s privacy policy. We are not responsible for the processing of personal information by our business partners. - Affiliates. We may share your personal information with our corporate affiliates. Advertising Partners. We may share your personal information with third-party advertising partners. These third-party advertising partners may set Technologies and other tracking tools on our Services to collect information regarding your activities and your device (e.g., your IP address, cookie identifiers, page(s) visited, location, time of day). These advertising partners may use this information (and similar information collected from other services) for purposes of delivering personalized advertisements to you when you visit digital properties within their networks. This practice is commonly referred to as “interest-based advertising,” “personalized advertising,” or “targeted advertising.” Some of the advertising Technologies we may use include Google, HubSpot, and LinkedIn. #### Disclosures to Protect Us or Others We may access, preserve, and disclose any information we store associated with you to external parties if we, in good faith, believe doing so is required or appropriate to: comply with law enforcement or national security requests and legal process, such as a court order or subpoena; protect your, our, or others’ rights, property, or safety; enforce our policies or contracts; collect amounts owed to us; or assist with an investigation or prosecution of suspected or actual illegal activity. #### Disclosure in the Event of Merger, Sale, or Other Asset Transfers If we are involved in a merger, divestiture, restructuring, acquisition, financing, reorganization, bankruptcy, dissolution, receivership, purchase or sale of assets, transition of service to another provider, or other similar corporate transaction, your personal information may be disclosed, sold, or transferred as part of such a transaction. ### 5. YOUR PRIVACY CHOICES AND RIGHTS #### Your Privacy Choices. The privacy choices you may have about your personal information are described below: - Email Communications. If you receive an unwanted email from us, you can use the unsubscribe functionality found at the bottom of the email to opt out of receiving future emails. Note that you will continue to receive transaction-related emails. We may also send you certain non-promotional communications regarding us and the Services, and you will not be able to opt out of those communications (e.g., communications regarding the Services or updates to this Privacy Notice). - Text/SMS Messages. If you receive an unwanted promotional text/SMS message from us, you may opt out of receiving future text/SMS messages from us by following the instructions in the text/SMS message you have received from us or by otherwise contacting us as set forth in “Contact Us” below. - Do Not Track Signals, Global Privacy Control, and Universal Opt-Out Mechanisms. Some browsers, browser extensions, and devices transmit automated “opt-out preference signals,” such as the Universal Opt-Out Mechanisms (“UOOMs”) (including the Global Privacy Control (“GPC”)), to indicate a user’s preference to opt out of certain data practices. These signals must typically be enabled through your browser settings or through a supported extension. You can check and adjust your settings by going to the “Do Not Sell or Share My Personal Information” link in the footer of this website. We recognize and process UOOMs in the states where applicable law requires such recognition and, when required by law, we treat a valid UOOM signals as a request to opt out of the sale or sharing of personal information and/or targeted advertising, as applicable in that jurisdiction. Where not required by law, we may (but are not obligated to) process UOOM signals as a best-effort opt out of the sale or sharing of personal information and/or targeted advertising. In such jurisdictions, any such best-effort honoring will apply only to the extent supported by our systems and may not affect all data flows, disclosures, or cookies. For a comprehensive opt-out, please use the “Do Not Sell or Share My Personal Information” link in the footer of this website. Some browsers also send “Do Not Track” (“DNT”) signals. Because DNT signals are not yet standardized and no law currently requires their recognition, we do not respond to DNT signals. - Cookies. You may stop or restrict the placement of Technologies on your device or remove them by adjusting your preferences as your browser or device permits. However, if you adjust your preferences, the Services may not work properly. Please note that cookie-based opt-outs are not effective on mobile applications. However, you may opt-out of certain tracking on some mobile applications by following the instructions for Android, iOS, and others. The online advertising industry also provides mechanisms that may allow you to opt out of receiving targeted ads from organizations that participate in self-regulatory programs. To learn more, visit the Network Advertising Initiative and the Digital Advertising Alliance. Please note you must separately opt out in each browser and on each device. #### Your Privacy Rights. In accordance with applicable law, you may have the right to: - Confirm Whether We Are Processing Your Personal Information. - Request Access to or Portability of Your Personal Information. - Request Correction of Your Personal Information. - Request Deletion of Your Personal Information. - Request Restriction of or Object to our Processing of Your Personal Information. - Request to Opt-Out of Certain Processing Activities including, as applicable, if we process your personal information for “targeted advertising” (as “targeted advertising” is defined by applicable privacy laws), if we “sell” your personal information (as “sell” is defined by applicable privacy laws), or if we engage in “profiling” in furtherance of certain “decisions that produce legal or similarly significant effects” concerning you (as such terms are defined by applicable privacy laws); and - Withdraw Your Consent to our Processing of Your Personal Information Please note that your withdrawal will only take effect for future processing and will not affect the lawfulness of processing before the withdrawal. Please note that if your request relates to protected health information (PHI) maintained in connection with prescription or pharmacy services, those rights are governed by HIPAA and our Notice of Privacy Practices rather than applicable state consumer privacy laws. If your request relates to information held by one of our partner pharmacies, we will notify you and assist in directing your request to the appropriate party. If you would like to exercise any of these rights, please click HERE and follow the instructions on that page or by emailing us at: privacy@usephil.com. We will process such requests in accordance with applicable laws. Only you, or someone legally authorized to act on your behalf in certain jurisdictions, may make a request to exercise the rights listed above regarding your personal information. If your personal information is subject to a law that allows an authorized agent to act on your behalf in exercising your privacy rights and you wish to designate an authorized agent, please provide written authorization signed by you and your designated agent using the information found in “Contact Us” below and ask us for additional instructions. To protect your privacy, we will take steps to verify your identity before fulfilling requests submitted under applicable privacy laws. These steps may involve asking you to provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Examples of our verification process may include asking you to confirm the email address we have associated with you. Some laws may allow you to appeal our decision if we decline to process your request. If applicable laws grant you an appeal right, and you would like to appeal our decision with respect to your request, you may do so by informing us of this and providing us with information supporting your appeal. #### Consumer Health Privacy Laws If you are a consumer residing in a U.S. state with a consumer health data privacy law, or a comprehensive consumer privacy law defining “sensitive personal information” to include health or medical information (or related data), please review our Annex A – Supplemental Consumer Health Data Privacy Statement for our privacy practices related to consumer health data. ### 6. INTERNATIONAL TRANSFERS OF PERSONAL INFORMATION All Services are controlled and operated by us from the United States and are not intended to subject us to the laws or jurisdiction of any state, country, or territory other than those of the United States. All personal information processed by us may be transferred, processed, and stored anywhere in the world, including, but not limited to, the United States or other countries, which may have data protection laws different from the laws where you live. ### 7. DATA SECURITY AND RETENTION We employ reasonable physical, technical, and administrative safeguards designed to keep personal information secure; however, no data collection, storage, or transmission including over the Internet or other network can be guaranteed to be 100% secure. Therefore, despite these safeguards, we cannot and do not guarantee the security of any personal information transmitted to us. Additionally, take steps to protect against unauthorized access to your password, phone, tablet, and computer by, among other things, signing off after using a shared device, choosing a robust password nobody else knows or can easily guess, and keeping log-in information and passwords private. We are not responsible for any lost, stolen, or compromised passwords or for any activity on your account via unauthorized password activity. Where required by applicable law, you may request access to information about our security policies and procedures by contacting us as described in “Contact Us” below. We store the personal information we collect as described in this Privacy Notice for as long as you use the Services, or as necessary to fulfill the purpose(s) for which it was collected, provide the Services, resolve disputes, establish legal defenses, conduct audits, pursue legitimate business purposes, enforce our agreements, and comply with applicable laws, unless you ask us to delete or transfer such information by contacting us as set forth in “Contact Us” below. To determine the appropriate retention period for personal data, we may consider applicable legal requirements, the amount, nature, and sensitivity of the personal data, certain risk factors, the purposes for which we process your personal data, and whether we can achieve those purposes through other means. ### 8. CHILDREN’S PERSONAL INFORMATION The Services are not directed to children under 18 (or other age as required by local law outside the United States) and we do not knowingly collect personal information from children. We may collect information from employers about members of all ages to determine eligibility for our services. If you are a parent or guardian and believe your child has uploaded personal information to the Services in violation of applicable law, you may contact us as described in “Contact Us” below. ### 9. WEBSITES/APPLICATIONS The Services may contain links to other websites/applications and other websites/applications may reference or link to our Services. These third-party services are not controlled by us. We encourage our users to read the privacy policies of each website and application with which they interact. We do not endorse, screen, or approve, and are not responsible for, the privacy practices or content of such other websites or applications. Providing personal information to third-party websites or applications is at your own risk. ### 10. CONTACT US If you have any questions about our privacy practices or this Privacy Notice, or to exercise your rights as detailed in this Privacy Notice, please contact us at: Phil, Inc. ATTN: Privacy Officer 14500 N Northsight Blvd, Suite 307 Scottsdale, Arizona 85260 Phone: (855) 977-0975; Option 3 Email: privacy@usephil.com --- # HIPAA Notice | PHIL Source: https://phil.us/hipaa/ ## HIPAA Notice THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. This Notice of Privacy Practices (“Notice”) describes the privacy practices of PHIL, Inc. and its affiliates (“PHIL”). PHIL is required by the Health Insurance Portability and Accountability Act (HIPAA) of 1996 and implementing regulations to protect the privacy of protected health information (“PHI”) about you. PHIL is also required by law to provide you with this Notice of Privacy Practices (this “Notice”) explaining its legal duties and privacy practices with respect to PHI. PHIL is legally required to follow the terms of this Notice currently in effect. PHIL is required by law to notify affected individuals following a breach of unsecured PHI. PHIL may change the terms of this Notice at any time. PHIL reserves the right to make changes and to make the new Notice effective for all information that PHIL maintains. Changes to the notice will be posted to the website. Copies of the most current Notice are also available upon request from our Privacy Officer. This Notice: - discusses how PHIL may use and disclose medical information about you. - explains your rights with respect to medical information about you. - describes how and where you may file a privacy-related complaint. ### Permissible Uses and Disclosures Without Your Written Authorization PHIL may use and disclose your PHI in the following ways without your written authorization. This list is not exhaustive. Your PHI may be stored and shared in paper, electronic, or other formats, and PHIL limits such use and disclosure to the minimum necessary to accomplish the intended purpose. Treatment: PHIL uses and discloses your PHI to provide treatment to you. For example, PHIL may use and disclose your PHI to fill prescriptions and coordinate care with other providers involved in your treatment. In addition, PHIL may contact you to provide information about treatment alternatives or other health-related benefits and services that may be of interest to you. Payment: PHIL may use and disclose your PHI to obtain payment for equipment and services provided to you. For example, PHIL may use and disclose PHI to claim and obtain payment from your health insurer, HMO, or other company that arranges or pays the cost of some or all of your healthcare (“Payors”), to verify that Payors will pay for healthcare rendered or for eligibility inquiries. Health Care Operations: PHIL may use and disclose your PHI in performing a variety of business activities referred to as “health care operations.” These activities allow PHIL to improve the quality of care provided and reduce healthcare costs. For example, PHIL may use PHI to evaluate the competence of its pharmacists and other healthcare workers and to arrange for legal services. PHIL may also disclose PHI to other entities covered by HIPAA to conduct certain health care operations, such as quality assessment and improvement activities, or for healthcare fraud and abuse detection or compliance. We may also make incidental disclosures of limited PHI to the extent permitted by law. Disclosure to Relatives, Close Friends and Other Caregivers: PHIL may use or disclose your PHI to a family member, other relative, a close personal friend or any other person identified by you when you are present for, or otherwise available prior to, the disclosure, if: (1) PHIL obtains your agreement; or (2) you do not object to the disclosure. If you are not present, or the opportunity to agree or object to a use or disclosure cannot practicably be provided because of your incapacity or an emergency circumstance, PHIL may exercise professional judgment to determine whether a disclosure is in your best interests. If PHIL discloses information to a family member, caregiver, other relative or a close personal friend, PHIL will disclose only information that it believes is directly relevant to the person’s involvement with your healthcare or payment related to your healthcare. PHIL may also disclose your PHI in order to notify (or assist in notifying) such persons of your location, general condition or death. If the patient is a minor, PHIL may disclose PHI about the minor to a parent, guardian or other person responsible for the minor except in limited circumstances. As Required by Law: PHIL will use and disclose your PHI whenever required by law. For example, PHIL is required to disclose PHI to the U.S. Department of Health and Human Services if requested to determine HIPAA compliance. Public Health Activities: PHIL may use or disclose your PHI for public health activities, such as the following: (1) to report health information to public health authorities for the purpose of preventing or controlling disease, injury or disability or aiding in disaster relief; (2) to report child abuse and neglect to public health authorities or other government authorities authorized by law to receive such reports; (3) to report information about products and services under the jurisdiction of the U.S. Food and Drug Administration; (4) to alert a person who may have been exposed to a communicable disease or may otherwise be at risk of contracting or spreading a disease or condition; (5) to report information to your employer as required under laws addressing work-related illnesses and injuries or workplace medical surveillance. Victims of Abuse, Neglect or Domestic Violence: If PHIL reasonably believes someone is a victim of abuse, neglect or domestic violence, PHIL may disclose PHI to a governmental authority, including a social service or protective services agency, authorized by law to receive reports of such abuse, neglect, or domestic violence. Health Oversight Activities: PHIL may disclose your PHI to a health oversight agency that oversees the healthcare system and is charged with responsibility for ensuring compliance with the rules of government health programs such as Medicare or Medicaid. For example, a government agency may request information while investigating possible insurance fraud. Judicial and Administrative Proceedings: PHIL may disclose your PHI in the course of a judicial or administrative proceeding in response to a legal order, subpoena or other lawful process. Law Enforcement Officials: PHIL may disclose your PHI to the police or other law enforcement officials as required or permitted by law or in compliance with a court order or a grand jury or administrative subpoena. Decedents: PHIL may disclose your PHI to a coroner or medical examiner as authorized by law and as necessary for these entities to carry out their lawful duties. Organ and Tissue Procurement: PHIL may disclose your PHI to organizations that facilitate organ, eye or tissue procurement, banking or transplantation. Research: PHIL may use or disclose your PHI for research if conducted in accordance with applicable law, such as pursuant to a privacy waiver or for activities preparatory to research. Threat to Health or Safety: PHIL may use or disclose your PHI to prevent or lessen a serious and imminent threat to a person’s or the public’s health or safety. Specialized Government Functions: PHIL may use or disclose your PHI for certain government functions, including but not limited to military and veterans’ activities; correctional institutions; national security and intelligence activities; or to the police or other law enforcement officials as required or permitted by law or in compliance with a court order or a grand jury or administrative subpoena. Workers’ Compensation: PHIL may disclose your PHI as authorized by and to the extent necessary to comply with state law relating to workers’ compensation or other similar programs. Business Associates: PHIL may disclose your PHI to third parties, known as business associates, that perform services on PHIL’s behalf. Business associates are required to agree to protect all PHI. De-Identification: PHIL may (directly or by permitting its business associates to do so) use or disclose PHI to create information that is de-identified in accordance with applicable law, including the HIPAA safe harbor and expert determination methods. Any disclosures of de-identified information, including for commercial purposes, will be conducted in accordance with applicable law and the HIPAA de-identification standards. Limited Data: PHIL may remove most identifiable information from a set of data and use and disclose this data set for research, public health and health care operations, provided the recipients of the data set agree to keep it confidential. Health Information Exchanges: PHIL may participate in one or more Health Information Exchanges (“HIEs”) and may electronically share your PHI for treatment, payment, healthcare operations and other permitted purposes with other participants in the HIE. HIEs allow your health care providers to efficiently access and use your PHI as necessary for treatment and other lawful purposes. Fundraising: PHIL does not use your PHI for fundraising purposes. If this practice changes, PHIL will update this Notice and provide you with an opportunity to opt out of receiving fundraising communications. ### Uses and Disclosures Requiring Your Written Authorization Other uses and disclosures of PHI not described above in this Notice will be made only with a written authorization signed by you or your representative. Subject to compliance with limited exceptions, PHIL will not use or disclose psychotherapy notes, use or disclose your PHI for marketing purposes, sell your PHI, or use or disclose genetic information for underwriting purposes unless you have signed an authorization. If you or your representative authorizes PHIL to use or disclose your PHI, you may revoke that authorization in writing at any time to stop future uses or disclosures. However, your decision to revoke the authorization will not affect or undo any use or disclosure of your PHI that occurred before you notified PHIL of your decision to revoke your authorization. Uses and Disclosures of Your Highly Confidential Information: In addition, federal and state law requires special privacy protections for certain highly confidential information about you (“Highly Confidential Information”). To the extent applicable to PHIL and required by law, PHIL will comply with such special privacy protections which may cover subsets of PHI that are viewed as sensitive, such as PHI that: - is about mental health and developmental disabilities services; - is about alcohol and drug abuse prevention, treatment, and referral; - is about HIV/AIDS testing, diagnosis, or treatment; - is about venereal disease(s); or - is about genetic testing. Substance Use Disorder Information: Federal law (42 CFR Part 2) (“Part 2”) provides additional protections for records of substance use disorder diagnosis, treatment, or referral for treatment. PHIL will not use or disclose Part 2-protected records without your written consent, except as expressly permitted or required by Part 2. Such consent may be revoked in writing at any time, except to the extent action has already been taken in reliance on it. Part 2 records may not be used to investigate or prosecute you without specific legal authorization. Any disclosure made with your consent must include the following notice: “This information has been disclosed to you from records protected by federal confidentiality rules (42 CFR Part 2). The federal rules prohibit you from making any further disclosure of this information unless further disclosure is expressly permitted by the written consent of the person to whom it pertains or as otherwise permitted by 42 CFR Part 2.” ### Your Rights Regarding Your Protected Health Information Right to Inspect and Copy Your Health Information: You may request access to or receive copies of your medical records, billing records and other records used to make decisions about you or direct PHIL to send a copy of your electronic information to another person designated by you in writing. There is a fee for obtaining copies of your records that is consistent with HIPAA and applicable state laws. Under limited circumstances, PHIL may deny access requests. If you desire access to your records, please submit a written request as described below under “For Further Information.” Right to Request Restrictions: You may request restrictions on PHIL’s use and disclosure of your PHI: (1) for treatment, payment and healthcare operations; (2) to individuals (such as a family member, other relative, close personal friend or any other person identified by you) involved with your care or with payment related to your care; or (3) to notify or assist in the notification of such individuals regarding your location and general condition. While PHIL will consider all requests for restrictions carefully, it is not required to agree to a requested restriction, except that it must agree to a restriction relating to a disclosure of PHI to a health plan for the purposes of carrying out payment or healthcare operations in which the PHI pertains solely to a healthcare item or service for which it has already been paid out of pocket in full and the disclosure is not required by law. If you wish to request restrictions, please submit a written request to Patient Relations (see address below). A form to request restrictions is available upon request as described below under “For Further Information.” Right to Receive Confidential Communications: You may request to receive your PHI by alternative means of communication or at alternative locations. PHIL will accommodate all reasonable, written request from you. Right to Revoke Your Authorization: You may revoke any written authorization obtained in connection with your PHI, except to the extent that PHIL has taken action in reliance upon it, by delivering a written revocation statement to PHIL (see address under “For Further Information” below). Right to Amend Your Records: You have the right to request PHIL to amend your PHI. If you desire to amend your records, please send a written request for the amendment, including the reason for the amendment, to Patient Relations (see address below). You may obtain a form to request an amendment as described below under “For Further Information.” PHIL will comply with your request unless it believes that the information that would be amended is accurate and complete or other special circumstances apply. Right to Receive an Accounting of Disclosures: Upon request, you may obtain an accounting of certain disclosures of your PHI made by PHIL during any period of time prior to the date of your request provided such period does not exceed six years. Right to Receive Paper Copy of This Notice: Upon request, you may obtain a paper copy of this Notice, even if you have agreed to receive such notice electronically, by contacting PHIL as described below under “For Further Information.” PHIL will make a good-faith effort to obtain your written acknowledgment that you have received this Notice. If acknowledgment cannot be obtained, PHIL will document the reason. Right to Receive Notification of a Breach: You have the right to receive timely notification if PHIL discovers that your unsecured PHI has been accessed, used, or disclosed in an unauthorized manner. PHIL will notify you of any such breach in accordance with applicable law. Personal Representatives: If you have given another individual a medical power of attorney, if another individual is appointed as your legal guardian or if another individual is authorized by law to make health care decisions for you (known as a “personal representative”), that individual may exercise any of the above rights listed for you. If you are unable to exercise your rights due to incapacity or an emergency, PHIL will use professional judgment to act in your best interests with respect to your PHI until a personal representative is available to act on your behalf. ### For Further Information or Complaints If you desire further information about your privacy rights, wish to submit a request related to your patient rights, are concerned that PHIL has violated your privacy rights or disagree with a decision that has been made about access to your PHI, you may contact PHIL at: PHIL, Inc. Phone: (855) 977-0975; option 3 Email: HIPAA@phil.us ATTN: Privacy Officer, 14500 N Northsight Blvd, Suite 307, Scottsdale, AZ 85260 For restriction requests and amendment requests, you may also contact Patient Relations at the address and phone number listed above. You may also file a complaint with the Office for Civil Rights of the U.S. Department of Health and Human Services (OCR) at: Website: www.hhs.gov/ocr Phone: 1-800-368-1019 TTY: 1-800-537-7697 PHIL will not retaliate against you if you file a complaint with us or with OCR. If you have questions about this Notice or about PHIL’s privacy policies, procedures, or practices, please contact us using the information above. ### Effective Date of This Notice This Notice is effective as of February 10, 2026. Last Revised: July 15, 2026. Version 26.2 --- # Supplemental U.S. Privacy Notices | PHIL Source: https://phil.us/annex/ ## Supplemental U.S. Privacy Notices ### Annex A – Supplemental U.S. Consumer Health Data Privacy Statement This Supplemental Consumer Health Data Privacy Statement (“Consumer Health Data Privacy Statement”) supplements Phil’s Privacy Notice and applies only to personal information we process that is defined to be “consumer health data” subject to the Washington My Health My Data Act (“MHMDA”), Nevada Consumer Health Data Privacy Law (“NVCHDPL”), Connecticut Data Privacy Act (“CTDPA”), or other applicable state consumer health data privacy law. Terms used in this Supplemental Consumer Health Data Privacy Statement defined in MHMDA or NVCHDPL will have the meaning set forth in those laws to the extent such laws are applicable. #### Consumer Health Data We Collect Under the MHMDA, “consumer health data” is defined as “personal information that is linked or reasonably linkable to a consumer and that identifies the consumer's past, present, or future physical or mental health status.” Under NVCHDPL, “consumer health data” is defined as “personally identifiable information that is linked or reasonably capable of being linked to a consumer and that a regulated entity uses to identify the past, present or future health status of the consumer.” Under the CTDPA, the definition of “sensitive data” includes data “revealing . . . mental or physical health condition or diagnosis.” As amended the definition of “sensitive data” was expanded to include “consumer health data” defined as any personal data “used to identify a consumer’s physical or mental health condition or diagnosis, including gender-affirming health data and reproductive sexual health data.” Because consumer health data is defined very broadly, many of the categories of personal information we collect under our Privacy Notice may also be considered consumer health data. Examples of consumer health data you may provide to us, or that we may otherwise collect, may include: - Information that could identify your attempt to seek health care services or information, including services that allow you to assess, measure, improve, or learn about your or another person's health. For example, we collect your search queries on the Services, which may include queries or other information concerning medical conditions or other health-related topics. - Information about your health-related conditions, symptoms, status, diagnoses, disease, testing, or treatments. - Information about social, psychological, behavioral, and medical interventions. - Information about use or purchase of prescribed medication(s). - Information about measurements of bodily functions, vital signs, symptoms, or characteristics including photographs. - Information about diagnoses or diagnostic testing, treatment, or medication. - Information about surgeries or other health-related procedures. - Reproductive or sexual health information. - Information about gender-affirming care. - Biometric information. - Genetic data. - Information about your access to healthcare, including precise location information that could reasonably indicate an attempt to acquire or receive health services or supplies. - Information processed to associate or identify an individual with the data listed above derived or extrapolated from non-health information. - Information related to the precise (geo)location information of a consumer used to indicate an attempt by a consumer to receive health care services or products. - Other information that may be used to infer or derive data related to the above or other consumer health data. #### Sources of Consumer Health Data We collect consumer health data that you provide to us, consumer health data we collect automatically when you use the Services, and consumer health data from third-party sources, as described in our Privacy Notice and below. #### Why We Collect and Use Consumer Health Data We collect and use consumer health data for the purposes and in the manner described in the “How We Use Personal Information” section of our Privacy Notice. Primarily, we collect and use consumer health data as reasonably necessary to provide you with the products or Services you have requested or authorized. This may include delivering and operating the products or Services and their features, personalization of certain product or Services features, ensuring the secure and reliable operation of the products or Services and the systems that support them, troubleshooting and improving the products and Services, and other essential business operations that support the provision of the products and Services (such as analyzing our performance and meeting our legal obligations). We may also use consumer health data for other purposes for which we give you choices and/or obtain your consent as required by law. #### Sharing of Consumer Health Data We may share each of the categories of consumer health data described above for the purposes described above and in the “How We Use Personal Information” section of our Privacy Notice. In particular, we may share consumer health data, with your consent or as reasonably necessary to complete any transaction or provide any product or Service you have requested or authorized, as described above. We only share or disclose your consumer health data as needed to provide you with the products or services that you request, or with your explicit consent or authorization. We may share or disclose any or all the above categories of consumer health data to the following entities that may use the data only as permitted for the purposes set forth above, and within the bounds of our contracts with them: - Business Collaborators (including pharmaceutical manufacturers, biotechnology companies, specialty pharmacies, and other healthcare industry partners with whom Phil collaborates to provide patient access, pharmacy, or therapy support services) - Product co-promotion partners - Product co-development partners - Marketing and Advertising Agencies - Social Media Companies and Platforms - Service Providers (including those hosting or analyzing data on our behalf, those assisting with fraud prevention, those assisting in program administration, those assisting in incident management and reporting, those administering our call center and websites, and those who assist with our information technology and security programs) - Emergency Personnel - Authorized/legal representatives, family members, and caregivers - Third parties (including those with whom Phil has joint marketing and similar arrangements, those who provide marketing and data analytics services, those who provide program enrollment or product fulfillment, payment, and authorization, other third parties as necessary to complete transactions, provide products/services, protect our rights or the rights of others, or where required by law) - Parties to a corporate transaction - Phil lawyers, auditors, and consultants - Legal and regulatory bodies In addition, we may share or disclose consumer health data as permitted or required by law, such as (i) to an acquiring organization if we are involved in a sale or a transfer of all or a part of our business, (ii) as needed to prevent, detect, protect against, or respond to security incidents, identity theft, fraud, harassment, malicious or deceptive activities, (iii) in situations that may involve violations of our terms of use or other rules, (iv) to protect our rights and the rights and safety of others, (v) as needed to support external auditing, compliance and corporate governance functions, (vi) as needed to preserve the integrity or security of our systems, or (vii) to investigate, report, or prosecute those responsible for any action that is illegal under applicable state or Federal law. #### How to Exercise Your Rights State consumer health data privacy laws provide consumers with certain rights with respect to consumer health data. For example, under MHMDA, consumers have the right to: (i) confirm whether Phil is collecting, sharing, or selling consumer health data and to access such data; (ii) withdraw consent from Phil’s collection and sharing of consumer health data; and (iii) request Phil delete consumer health data. Under NVCHDPL, consumers have the right to: (i) confirm whether Phil is collecting, sharing or selling consumer health data; (ii) have Phil provide the consumer with a list of all third parties with whom Phil has shared consumer health data relating to the consumer or to whom Phil has sold such consumer health data; (iii) request that Phil cease collecting, sharing, or selling consumer health data relating to the consumer; and (iv) request that Phil delete consumer health data. The rights afforded to consumers under applicable state consumer health data privacy laws are subject to certain exceptions. Depending on the Services offered, you can access and make choices about your consumer health data through our product controls within the Phil website. You may also exercise your rights by following the instructions found under the “Your Privacy Choices and Rights” section of our Privacy Notice. Phil will not discriminate against you for exercising any of your rights. We will make reasonable efforts to respond promptly to your requests in accordance with applicable laws. Please allow 45 days for a response. We may, after receiving your request, require additional information from you to authenticate your request and verify your identity. Please be aware that we may be unable to afford these rights to you under certain circumstances, such as if we are legally prevented from doing so. If your request to exercise a right under a consumer health data law is denied, you may appeal that decision by contacting us at: privacy@usephil.com. If your appeal is unsuccessful and your consumer health data is subject to MHMDA, you may raise a concern or lodge a complaint with the Washington State Attorney General at www.atg.wa.gov/file-complaint. #### Disclosure Regarding Third Party Collection of Consumer Health Data Under NVCHDPL This Supplement applies to Nevada consumers for purposes of providing additional disclosures required by NVCHDPL. We collect, use, process, and share consumer health data for the purposes and manners described above in our Consumer Health Data Privacy Notice. ##### Third Party Collection of Consumer Health Data on Phil Websites. We limit third party collection of consumer health data over time and across different Internet websites or online services when Nevada consumers use our websites or online services. We do this by disabling certain cookies or by ensuring that entities whose cookies, web beacons, pixels, and other online trackers we use on our websites and online services are our service providers or processors under applicable U.S. state privacy or consumer health data privacy laws. Nonetheless, please note that other third parties may still be able to process consumer health data from you over time and across different websites depending on your browser, browser settings and add-ons, and associated permissions you have set on your device. This collection of consumer health data by those third parties is unrelated to Phil processing of consumer health data from you, and we encourage you to review your browser settings and review those third parties’ privacy notices for more information about their consumer health data practices. ##### Review and Revision of Consumer Health Data. If you would like to review and/or revise your consumer health data, you may submit a request to us via any of the methods listed in this Notice. #### Updates to This Supplemental Consumer Health Data Privacy Statement We may update this Supplemental Consumer Health Data Privacy Statement from time to time in our sole discretion. If we do, we’ll let you know by posting the updated Supplemental Consumer Health Data Privacy Statement on our website, and/or we may also send other communications. ### Annex B – Consumer Health Data Authorization We and our partners use and share cookies and other tracking technologies (“cookies”) to improve your experience, measure website performance, and personalize marketing to you. Under certain state privacy laws, cookies are considered to include personal information and our sharing of cookies may be considered a “sale” or “sharing” for behavioral or “targeted” advertising. To opt out, click here . By clicking "Accept” or otherwise opting into personalized marketing, you authorize Phil to “sell” or “share” your "consumer health data” in accordance with our Consumer Health Data Authorization: This Consumer Health Data Privacy Authorization (“Authorization”) supplements Phil’s Privacy Notice and Supplemental Consumer Health Data Privacy Notice, and applies only to “consumer health data” subject to the Washington My Health My Data Act (“MHMDA”), Nevada Consumer Health Data Privacy Law (“NVCHDPL”), Connecticut Data Privacy Act (“CTDPA”), or other applicable state consumer health data privacy law (as applicable). Terms used in this Authorization defined in MHMDA, NVCHDPL, CTDPA, or other applicable state consumer health data privacy law will have the meaning set forth in those laws to the extent such laws are applicable. If you opt-in to “personalized marketing” through the www.phil.us cookie banner , you allow Phil to “sell” your consumer health data as described below: - Specific consumer health data intended for “sale”: Consumer health data collected via cookies and similar technologies including but not limited to browsing activity on www.phil.us; however, consumer health data does not include PHI of current or potential Phil users. - Purpose of the “sale” of consumer health data: To tailor and deliver personalized advertisements to you. - How consumer health data purchasers gather and use the data: Consumer health data purchasers will gather the data via cookies and other tracking technologies when you visit the Phil website. These purchasers may use the data to assist us to deliver personalized advertisements to you and in accordance with their privacy policies linked below. - Consumer health data purchasers’ contact information: Google. For more information about Google’s use of your personal information, please visit Google’s Data Policy. To opt out of Google’s use of your information, please click here. - Contact information for Phil: privacy@usephil.com #### Please note: - The provision of goods or services may not be conditioned upon you accepting the terms of this authorization. - Purchasers may redisclose the consumer health data sold under this authorization and such data may no longer be protected by the MHMDA, NVCHDPL, CTDPA, or other applicable state consumer health data privacy law. - You may revoke this authorization at any time through the Phil cookie banner . To do so, please be sure the box next to “Personalize Marketing” is unchecked and click “Save my preferences.” You may also click “Reject Optional Cookies” to decline our use of all cookies not required to operate our website. - A revocation will not impact previously sold consumer health data. In addition, if you use different browsers or devices, you must indicate your choices on each browser/device used to access www.phil.us. If you have any questions about how to revoke your authorization, please contact us at privacy@usephil.com. This authorization will expire one (1) year after accepting it. To learn more about how we use and share personal information including cookies, please review our Privacy Notice. ### Annex C – Supplemental U.S. Privacy Notice This Supplemental U.S. Privacy Notice supplements our Privacy Notice and only applies to our processing of Personal Information from U.S. consumers residing in a state with a comprehensive privacy law. #### Notice at Collection At or before the time of collection, U.S. consumers residing in a state with a comprehensive privacy law have a right to receive notice of our privacy practices. Such consumers can find this information below. - Personal Information Collected. See the section of this Supplemental U.S. Privacy Notice titled “Overview of Personal Information Collected, Disclosed, Sold and/or Shared” for a list of personal information which may be collected. If we have previously collected personal information in the past 12 months, we may collect that personal information from you. - Uses of Personal Information. See the section of this Supplemental U.S. Privacy Notice titled “Uses of Personal Information” for a list of the purposes for which we use personal information. - Is Personal Information “Sold” or “Shared” for “Cross-Context Behavioral Advertising”? Yes. See the section of this Supplemental U.S. Privacy Notice titled “Overview of Personal Information Collected, Disclosed, Sold and/or Shared” for more details. If we have previously “sold” personal information or “shared” personal information for “cross-context behavioral advertising” in the past 12 months, we may “sell” or “share” that personal information if collected from you. See the section of this Supplemental U.S. Privacy Notice titled “Right to Opt Out of ‘Sales’ of Personal Information and/or ‘Sharing’ for ‘Cross-Context Behavioral Advertising’” for instructions on how to opt-out of these activities. - Personal Information Retention. To determine the appropriate retention period for personal information, we may consider applicable legal requirements, the amount, nature, and sensitivity of the personal information, certain risk factors, the purposes for which we process your personal information, and whether we can achieve those purposes through other means. - Additional Information. For more information on our privacy practices, please review this Supplemental U.S. Privacy Notice and our Privacy Notice. Importantly, the section of our Privacy Notice titled “Your Privacy Choices and Rights” includes important details about how you can exercise some of the rights which you have under U.S. privacy laws. #### Categories of Sources From Which Personal Information Is Collected We collect personal information that you provide to us, personal information we collect automatically when you use the Sites, and personal information from third-party sources. #### Overview of Personal Information Collected, Disclosed, Sold, and/or Shared U.S. consumers residing in a state with a comprehensive privacy law are provided with the right to know what categories of personal information Phil has collected about them, whether Phil disclosed that personal information for a business purpose (e.g., to a service provider), whether Phil “sold” that personal information, and whether Phil “shared” that personal information for “cross-context behavioral advertising” in the preceding twelve months. U.S. consumers residing in a state with a comprehensive privacy law can find this information below: Category of Personal Information Collected Category of Third Parties To Whom Personal Information is Disclosed to for a Business Purpose Category of Third Parties To Whom Personal Information is Sold and/or Shared IdentifiersA real name, alias, postal address, unique personal identifier, online identifier, Internet Protocol address, email address, account name, Social Security number, or other similar identifiers. - Service providers - Business partners - Emergency personnel - Service providers - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Legal and regulatory bodies and other third parties as required by law - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Personal information categories listed in the California Customer Records statute (Cal. Civ. Code § 1798.80(e))Height, weight, hair/eye color, age/date of birth, gender, race/ethnicity, citizenship status, religion, information concerning sexuality/sex life, disability, personal characteristics and preferences, marital and family status, languages spoken, and other similar data elements - Emergency personnel - Service providers - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Legal and regulatory bodies and other third parties as required by law - Business partners - Advertising partners including those providing program enrollment and product fulfillment services - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Health Insurance DataPolicy number, reimbursement data, co-pay data, coverage amount data, health values, sensor reading data (e.g., HBA1C, blood glucose, etc.), subscriber or account identification number, claims history, benefits information, Medicare/Medicaid number, other government payer number - Service Providers, including to companies assisting in program administration - Healthcare providers (including specialty pharmacies) - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - Business partners - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Commercial informationRecords of personal property, products or services purchased, obtained, or considered, or other purchasing or consuming histories or tendencies; propensity scores obtained from third parties, such as likelihood you may be interested in certain purchases or may be experiencing life events; products or services you have purchased; records of products or services purchased, obtained, reviewed, or considered; records of program enrollment and activity - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Authorized/legal representatives, family members, and caregivers - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Personal information that reveals consumer’s genetic dataInformation derived from genetic testing, such as DNA sequences, gene mutations, chromosomal information, and inherited traits obtained through various methods including blood tests, saliva samples, and other biological specimens; information about a consumer’s predisposition to certain medical conditions, carrier status for genetic disorders, and responses to specific medications - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Legal and regulatory bodies and other third parties as required by law - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Biometric information that is processed for the purpose of uniquely identifying a consumerPhotograph, fingerprint, voice print, retina or iris image, or other unique physical representation (such as your digital or electronic signature on a patient consent form or program enrollment form) - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Legal and regulatory bodies and other third parties as required by law - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Internet or other electronic network activityBrowsing history, search history, information on a consumer's interaction with an internet website, application, or advertisement - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Geolocation dataPrecise location data, geofencing data - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Sensory dataSmart device records, health values and sensor readings data (such as steps taken, movement information, data collected by our mobile apps, blood glucose levels, heart rate, and blood pressure), recording of a customer service call, recording from a CCTV camera in our facilities - Service providers - Business partners - Emergency personnel - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Legal and regulatory bodies and other third parties as required by law - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Clinical research organizations - Clinical trial sites - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms - Clinical research organizations - Clinical trial sites Professional or employment-related informationEmployer and job title, medical license, employer location, information from a resume or CV, including education and certification credentials, information included in an IRS 1040 form - Service providers - Business partners - Emergency personnel - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Legal and regulatory bodies and other third parties as required by law - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Non-public education information (per the Family Educational Rights and Privacy Act (20 U.S.C. Sec. 1232g, 34 C.F.R. Part 99))Records relating to academics, health/medical, discipline, special education, attendance, and standardized test scores. - Service providers - Business partners - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Legal and regulatory bodies and other third parties as required by law - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Inferences drawn from other Personal Information to create a profile about a consumerProfile reflecting a consumer's preferences, characteristics, psychological trends, predispositions, behavior, attitudes, intelligence, abilities, and aptitudes - Service providers - Emergency personnel - Healthcare providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Personal information that reveals a consumer’s social security, driver’s license, state identification card, or passport number - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Personal information that reveals a consumer’s account log-in, financial account, debit card, or credit card number in combination with any required security or access code, password, or credentials allowing access to an account - Service providers - Business partners - Emergency personnel - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - Consumer reporting agencies - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - N/A Personal information that reveals a consumer’s racial or ethnic origin, religious or philosophical beliefs, or union membership - Service providers - Emergency personnel - Healthcare providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Authorized/legal representatives, family members, and caregivers - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Personal information that reveals the contents of a consumer’s mail, email, and text messages unless Phil is the intended recipient of the communication - Service providers - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Authorized/legal representatives, family members, and caregivers - Our lawyers, auditors, and consultants - Legal and regulatory bodies and other third parties as required by law - N/A Personal information collected and analyzed concerning a consumer’s healthInformation about physical or mental health, disease state, medical history or medical treatment or diagnosis, medicines taken; name/contact of a patient’s healthcare providers; general disease or product interest; health insurance company Insurance account number; information on payment for healthcare services (EOB forms, HSA statements, claims data, claims assistance records); health plan beneficiary names/numbers; information needed to accommodate disabilities; information about workplace accidents and occupational safety, medical record information, such as medical diagnosis, disease information, and treatment history; health values and sensor readings data, such as steps taken, blood glucose levels, heart rate, and blood pressure; drug allergies, prescriptions and dosing; medical appointment dates - Service providers - Business partners - Emergency personnel - Service providers - Healthcare providers - Health insurance companies (health plans) and other payors - Authorized/legal representatives, family members, and caregivers - Legal and regulatory bodies and other third parties as required by law - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms Personal information collected and analyzed concerning a consumer’s sex life or sexual orientation - Service providers - Business partners - Affiliates - Advertising partners - Internet service providers - Data analytics providers - Operating systems and platforms - Business partners - Advertising partners - Other third parties with whom you interact - Internet service providers - Data analytics providers - Marketing technology providers - Data enrichment providers - Operating systems and platforms #### Uses of Personal Information We may use and disclose the personal information that we collect for the following business and commercial purposes: - Providing the Sites as further described in our Privacy Notice; - Processing for administrative purposes as further described in our Privacy Notice; - Processing to improve the Sites and develop new products and services, as further described in our Privacy Notice; - Processing to operate our business, as further described in our Privacy Notice; - Processing for marketing purposes as further described in our Privacy Notice; - Processing with your consent or direction as further described in our Privacy Notice; - Auditing related to counting ad impressions to unique visitors, verifying positioning and quality of ad impressions, and auditing compliance with this specification and other standards; - Helping to ensure security and integrity to the extent the use of personal information is reasonably necessary and proportionate for these purposes; - Debugging to identify and repair errors that impair existing intended functionality; - Short-term, transient use, including, but not limited to, non-personalized advertising shown as part of your current interaction with Phil; - Maintaining or servicing accounts, providing customer service, processing or fulfilling orders and transactions, verifying customer information, processing payments, providing financing, providing analytic services, providing storage, or providing similar services; - Providing advertising and marketing services; - Undertaking internal research for technological development and demonstration; - Undertaking activities to verify or maintain the quality or safety of a service or device that is owned, manufactured, manufactured for, or controlled by Phil, and to improve, upgrade, or enhance the service or device that is owned, manufactured, manufactured for, or controlled by Phil. #### Right to Opt Out of “Sales” of Personal Information and/or “Sharing” for “Cross-Context Behavioral Advertising” We don’t “sell” personal information as most consumers typically define the term “sell” or “sold.” However, our Sites use advertising and analytics tools provided by third parties (such as HubSpot) that may constitute a “sale” or “sharing” of personal information under certain state laws. We “share” your personal information for “cross-contextual behavioral advertising” to provide you with “cross-context behavioral advertising” about Phil’s products and services. U.S. consumers residing in a state with a comprehensive privacy law may have the right to opt out of the “sharing” of personal information for “cross-context behavioral advertising.” To exercise these rights, please click HERE and follow the instructions on that page or by emailing us at: privacy@usephil.com. We will process such requests in accordance with applicable laws. #### Disclosure Regarding Individuals Under the Age of 18 Phil does not have actual knowledge of any “sale” of personal information of minors under 18 years of age. Phil does not have actual knowledge of any “sharing” of personal information of minors under 18 years of age for “cross-context behavioral advertising.” #### Disclosure Regarding Sensitive Personal Information Phil only uses and discloses sensitive personal information for the following purposes: - To perform the services or provide the goods reasonably expected by an average consumer who requests those goods or services. - To prevent, detect, and investigate security incidents that compromise the availability, authenticity, integrity, and or confidentiality of stored or transmitted personal information. - To resist malicious, deceptive, fraudulent, or illegal actions directed at Phil and to prosecute those responsible for those actions. - To ensure the physical safety of natural persons. - For short-term, transient use. - Maintaining or servicing accounts, providing customer service, processing or fulfilling orders and transactions, verifying customer information, processing payments, providing financing, providing analytic services, providing storage, or providing similar services. - To verify or maintain the quality or safety of a product, service, or device that is owned, manufactured, manufactured for, or controlled by Phil, and to improve, upgrade, or enhance the service or device that is owned, manufactured by, manufactured for, or controlled by Phil. - For purposes that do not infer characteristics about individuals. #### Non-Discrimination California residents have the right not to receive discriminatory treatment by us for the exercise of their rights conferred by the CCPA. #### Notice of Financial Incentive This Notice of Financial Incentives aims to inform you about any programs, benefits, and other financial incentive offerings, including price or service differences (collectively, “Incentive Offerings”), that we may provide in connection with the collection of your personal information so that you may make an informed decision on whether to participate in our Incentive Offerings. Such Incentive Offerings may be deemed “financial incentives” under the CCPA. The material aspects of any Incentive Offering, along with the personal information collected in connection with an Incentive Offering, will be described at the time you are presented with the Incentive Offering. Examples of our Incentive Offerings may include: - One-Time Discount. We may offer you a discount on your first order if you provide us your email address and agree to receive marketing emails in exchange for a one-time discount. - Refer-a-Friend Program. We may offer a discount on your future purchase when you provide your personal information along with your friends' or colleagues' personal information, and they make a purchase. The referred party may also receive a reward in the form of a discount on the first order and/or a free service for making a purchase through your referral. You can opt-in to an Incentive Offering by following the instructions that accompany the presentation of the Incentive Offering. If you subsequently wish to withdraw from the Incentive Offering, you may request such withdrawal by contacting us as set forth in “Contact Us” above. Each Incentive Offering may be based upon our reasonable and good-faith determination of the estimated value of such offer to our business, taking into consideration the value of the offer itself and the anticipated revenue generation that may be realized. --- # I’ve been Phished. What do I do now? Source: https://phil.us/smishing/ ## I’ve been Phished. What do I do now? In today's world, you likely receive SMS messages from a variety of organizations, including your bank, auto insurance provider, or subscription services like Netflix. Cyber criminals have found ways to send phishing messages using these well-known and trusted brands, making it even harder for you to detect a phishing scam. If you believe you've fallen for a phishing attempt, don't panic. Here's what to do next: - Disconnect your device: If you've responded to the phishing message, immediately disconnect your device from the internet. This will prevent any further damage and will stop the cyber attacker from accessing your device or personal information. - Change your passwords: If you entered any sensitive information in response to the phishing message, change your passwords right away. If you've used the same password for other accounts, change those as well. Use strong, unique passwords for each of your accounts. - Contact the organization: If you received the phishing message from an organization, such as Phil, reach out to them and let them know what happened. This will allow them to investigate the breach and put protective measures in place to prevent future scams. - Monitor your accounts: If you believe your personal information was accessed, monitor your account activity and credit reporting. Remember, this was just a test exercise by the Phil Security Team, and not a real phishing attempt. However, it's important to be cautious when receiving any SMS messages and to always verify the authenticity of the message and sender. If you're unsure about a message, reach out to the sender directly to confirm its legitimacy. Share this article on: #### Ready to learn more? Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance. Contact us